

C. Michael Gibson, M.S., M.D. Curriculum Vitae

Date Prepared: May 14, 2019
Name: C. Michael Gibson, M.S., M.D.
Office Address: Beth Israel Deaconess Medical Center
330 Brookline Ave, OV 540
Boston, MA 02215
Home Address: 116 Eliot Street
Natick, MA 01760
Work Phone: 617-307-5572
Work E-Mail: mgibson@perfuse.org
Work Fax: 617-975-9955
Place of Birth: Tulsa, Oklahoma

Education

1982	BA Phi Beta Kappa	Biological Sciences	University of Chicago
1984	MS	Arts and Sciences Basic to Human Biology and Medicine	Pritzker School of Medicine, University of Chicago
1986	MD Graduation with Honors, Alpha Omega Alpha	Medicine	Pritzker School of Medicine, University of Chicago

Postdoctoral Training

07/86-07/87	Intern	Medicine	Brigham and Women's Hospital
07/87-07/89	Resident	Internal Medicine	Brigham and Women's Hospital
07/89-07/90	Chief Medical Resident	Internal Medicine	West Roxbury Veteran's Administration, Boston, MA
07/89-07/92	Fellow	Cardiology	Beth Israel Hospital
07/92-07/93	Chief Medical Resident	Internal Medicine	Brigham and Women's

Hospital

Faculty Academic Appointments

07/91-07/95	Instructor	Medicine	Harvard Medical School
07/95-07/98	Assistant Professor	Medicine	Harvard Medical School
07/98-07/99	Professor	Medicine	Medical College of Pennsylvania/Hahnemann University School of Medicine
07/99-07/01	Associate Professor	Medicine	University of California San Francisco
07/02-11/12	Associate Professor	Medicine	Harvard Medical School
09/10-01/14	Consulting Professor	Medicine	Duke Medical School
11/12-	Professor	Medicine	Harvard Medical School

Appointments at Hospitals/Affiliated Institutions

Past

07/93-07/94	Associate Physician	Medicine	Beth Israel Hospital
07/94-07/98	Associate Physician	Medicine	Brigham and Women's Hospital
07/98-07/99	Associate Physician	Medicine	Medical College of Pennsylvania/Hahnemann University School of Medicine
07/99-07/01	Associate Physician	Medicine	University of California San Francisco

Current

07/01-	Associate Physician	Medicine	Beth Israel Deaconess Medical Center
--------	---------------------	----------	---

Other Professional Positions

1999-2001	Consultant	Genentech
2000-2010	Board Member	National Registry of Myocardial Infarction

2001-2004	Consultant	Millennium Pharmaceuticals
2001 -	Consultant	Boston Clinical Research Institute
2002	Consultant	Angel Medical Systems
2003-	Chairman, Medical Advisory Board	Angel Medical Systems
2005-	Consultant	Schering Plough Corporation
2007-2008	Consultant	Atrium Medical Corporation
2007-2010	Consultant	Heartscan Technologies, Inc.
2007-	Consultant	Sanofi-Aventis Pharmaceuticals
2007-	Consultant	Archemix Corporation
2007-	Consultant	The Medicines Company
2008	Consultant	Acusphere, Inc.
2008	Consultant	Cardica, Inc.
2008-	Consultant	Ascenta Therapeutics
2008-	Consultant	Bayer Corporation
2008-	Consultant	Johnson & Johnson Corporation
2008 - 2008-2010	Consultant Consultant	Janssen Pharmaceuticals Medicure, Inc.
2008-2010	Consultant	Novartis Pharmaceutical Corporation
2008-	Consultant	Portola Pharmaceuticals, Inc.
2008-	Consultant	St. Jude Medical
2008-	Consultant	ICON Medical Imaging
2008-	Consultant	Jim Moran Heart and Vascular Research Institute

2010-	Consultant	Novo Nordisk
2012 -	Consultant	Cardiovascular Research Foundation
2012 -	Consultant	Amarin Pharma Inc.
2013 -	Consultant	WebMD
2013 -	Consultant	St. Francis Hospital
2014 -	Consultant	Eli Lilly and Company
2014 -	Consultant	Regado Biosciences, Inc.
2014 -	Consultant	Roche Diagnostics Operations
2015 -	Consultant	Gilead Sciences, Inc.
2015 -	Consultant	Pfizer Pharmaceuticals, Inc.
2015 -	Consultant	CSL Behring
2015 -	Consultant	Pharma Mar
2015 -	Consultant	Merck & Co.
2015 -	Consultant	Takeda Pharmaceutical Company, Limited
2016 -	Consultant	Amgen
2016 -	Consultant	Shanghai MicroPort Medical (Group) Co, Ltd.
2016 -	Consultant	Astra Zeneca Pharmaceuticals
2016 -	Consultant	InCada
2016 -	Consultant	Plexuus, LLC
2016 -	Consultant	Somahlution, LLC
2016 -	Consultant	BSP Biological Signal Processing LTD
2016 -	Consultant	Portola Pharmaceuticals
2017 -	Member, Cardiovascular & Renal Drugs Advisory Committee	The Food and Drug Administration
2018 -	Consultant	Impact Bio LTD
2018 -	Consultant	MedImmune
2018 -	Consultant	Medtelligence
2018 -	Consultant	PERT Consortium
2018 -	Consultant	Pharma Mar
2018 -	Consultant	Vereseon Corporation
2018 -	Consultant	Duke Clinical Research Institute
2018 -	Consultant	Chiesi
2018 -	Consultant	Boston Scientific
2018 -	Consultant	Boehringer Ingelheim

Major Administration Leadership Positions

1989-	Founder and Chairman	PERFUSE Core Laboratories and Data Coordinating Center
-------	----------------------	--

1991-1994	Director, Quantitative Angiographic Core Lab	Beth Israel Hospital, Invasive Cardiology Section
1993-1994	Director, Coronary Care Unit	Beth Israel Hospital
1993-1994	Course Director, Acute Cardiac Care Elective (course #ME502M.1b)	Harvard Medical School
1994-1998	Director, Interventional Cardiology	West Roxbury Veteran's Administration Hospital, Boston MA
1996-1998	Director, Clinical Trials Unit	West Roxbury Veteran's Administration Hospital, Boston MA
1996-1998	Chief, Cardiovascular Division	West Roxbury Veteran's Administration Hospital, Boston MA
1997- 2009	Director, TIMI Master Database and Coordinating Center	Brigham and Women's Hospital
1998-1999	Director, Invasive Cardiology	Allegheny General Hospital
1998-1999	Director, Interventional Cardiology Fellowship Program	Allegheny General Hospital
1998-1999	Vice Chairman of Medicine, Clinical Research	Allegheny General Hospital
1999-2000	Associate Chief of Cardiology	University of California San Francisco
1999-2000	Chief, Interventional Cardiology	University of California, San Francisco
2001-2002	Director, Core Cardiovascular Services	Harvard Clinical Research Institute
2001-2002	Chief Academic Officer	Harvard Clinical Research Institute
2002-2006	Associate Chief of Cardiology and Director of Academic Affairs	Beth Israel Deaconess Medical Center, Cardiovascular Division
2006-	Chief of Clinical Research	Beth Israel Deaconess Medical Center, Cardiovascular Division

2010- 2014	Medical Director Communications	Duke Clinical Research Institute
2010 - 2014	Co-Director, Center, Educational Excellence	Duke Clinical Research Institute
2010- 2014	Senior Clinical Trialist	Duke Clinical Research Institute
2017 -	Chief Executive Officer	Baim Institute for Clinical Research

Committee Service

1992-1993	Intern Selection Committee 1992-1993	Brigham and Women's Hospital Member
1992-1993	Emergency Room Services Committee 1992-1993	Brigham and Women's Hospital Member
1993-1994	Critical Care Committee 1993-1994	Beth Israel Hospital Member
1993-1994	Quality Assurance Committee 1993-1994	Beth Israel Hospital Member
1993-1994	Patient Care Committee 1993-1994	Beth Israel Hospital Member
1993-1994	Intern Selection Committee 1993-1994	Beth Israel Hospital Member
1994-1995	TIMI 9B Morbidity and Mortality Classification Committee 1994-1995	Brigham & Women's Hospital Member
1996	TIMI 11A Morbidity and Mortality Classification Committee 1996	Brigham & Women's Hospital Member
1997	Conscious Sedation Committee 1997	West Roxbury Veteran's Administration Hospital, Boston MA Member
1997	Coronary Intermediate Care Unit and Outpatient Cardiac Catheterization Activation Committee 1997	West Roxbury Veteran's Administration Hospital, Boston MA Chairman

1998-1999	Cardiac Catheterization Laboratory Resource Utilization Committee 1998-1999	Allegheny General Hospital Chairman
1998-1999	Cardiac Catheterization Laboratory Executive Committee 1998-1999	Allegheny General Hospital Chairman
1999-2001	Cardiac Catheterization Laboratory Quality Assurance Committee 1999-2001	University of California San Francisco Member

Professional Societies

1986 -	American Medical Association 1986-	Member
1992-	American College of Angiology 1992-	Fellow
1996 -	American College of Cardiology 1996-	Fellow
2000-2001	California Academy of Medicine 2001-2002	Member
2002-	American Heart Association 2002-	Member: Council on Atherosclerosis, Thrombosis and Vascular Biology
	2011-	Fellow: Council on Atherosclerosis, Thrombosis and Vascular Biology
	2012-	Member: Commission of Professional Education Committee
2008	Transcatheter Cardiovascular Therapeutics (TCT) 2008-2010	Member: Scientific Committee

	2008-	Faculty
	2012-	Associate Director
2010-	Society for Cardiovascular Angiography and Interventions (SCAI)	
	2010-	Fellow
2011-	Royal College of Physicians and Surgeons	
	2011-	Fellow
2012-	Cardiovascular Research Technologies (CRT)	
	2012-	Faculty
	2012-	Course Director: ACS + AMI Management
2015 -	National Board of Physicians and Surgeons (NBPAS)	Member

Editorial Activities

Ad hoc Reviewer

American Journal of Cardiology

American Heart Journal

Cardiac Catheterization and Diagnosis

Circulation

Journal of the American College of Cardiology (JACC)

New England Journal of Medicine (NEJM)

Other Editorial Roles

2000-	Editorial Board	<i>Circulation</i>
2000-2005	Editorial Board	<i>Journal of the American College of Cardiology</i>
2000-	Editorial Board	<i>Journal of Thrombosis and Thrombolysis</i>
2000-	Editorial Board	www.theheart.org
2002-	Section Editor, Interventional Cardiology	<i>Journal of Critical Pathways</i>
2003-2007	Editor, online Clinical Trials Section	<i>American College of Cardiology</i>

2005-	Co-Editor, North American Editorial Office	<i>Journal of Geriatric Cardiology</i>
2006-	Section Editor, Interventional Cardiology	<i>Cardiovascular Revascularization Medicine Including Molecular Interventions</i>
2006-	Associate Editor, Clinical Trials	<i>Cardiosource Review Journal</i>
2007-	Editorial Board	<i>Journal of the American College of Cardiology (JACC): Cardiovascular Interventions</i>

Honors and Prizes

1978-1982	Dean's List	University of Chicago	
1982	Phi Beta Kappa	University of Chicago	
1984	National Young Investigator Award in Orthopedic Surgery		
1986	Alpha Omega Alpha	Pritzker School of Medicine, University of Chicago	
1986	Graduation with Honors	Pritzker School of Medicine, University of Chicago	
1993-1994	Julian and Eunice Cohen Scholar in Medicine	Brigham and Women's Hospital	
2003	Gold Medal	Institute of Geriatric Cardiology, Chinese Peoples Liberation Army General Hospital, Beijing China	Cardiovascular science
2005	Pro Bono Curantium Gold Medal for Merit	John Paul II Hospital, Krakow Poland	
2006	Medal of the Jagiellonian University	Jagiellonian University, Krakow	Outstanding achievement in education and research

		Poland	in cardiovascular science
2006	Creation of the C. Michael Gibson Angiographic and Clinical Research Center	John Paul II Hospital, Krakow Poland	
2009	Establishment of the C. Michael Gibson Research and Education Center	The Cardiovascular Division of Istanbul University, Turkey	
2009	Honored for establishing WikiDoc on September 27 th , World Heart Day	The Turkish Cardiac Society	
2009	Chosen by peers as one of Boston's Top Doctors	Boston Magazine	
2010	Chosen as one of America's Top Doctors	U.S. News & World Report	
2010	Chosen by peers as one of Boston's Top Doctors	Boston Magazine	
2011	Chosen as one of America's top doctors	U.S. News & World Report	
2012	Chosen by peers as one of Boston's Top Doctors	Boston Magazine	
2012	Chosen as one of America's top doctors	U.S. News & World Report	
2012	New Westminster College Distinguished Fellow	New Westminster College, British Columbia	
2013	Chosen as one of America's top doctors	U.S. News & World Report	
2014	Chosen as one of America's top doctors	U.S. News & World Report	
2014	Named one of the World's Most Influential Scientific Minds	Thomas Reuters	

Report of Funded and Unfunded Projects
Funding Information

Past

- 1988-1993 Harvard Atherosclerosis Reversibility Project, Lipid Lowering Trial
National Institutes of Health (Grant # Unknown)
PI – Quantitative Angiographic Core Laboratory
The major goal of HARP was to test whether lowering cholesterol from average to low levels with combination drug therapy slows the progression or causes regression of coronary artery stenosis, as determined by angiography.
- 1988-1993 Harvard Atherosclerosis Reversibility Project, Fish Oil Trial
National Institutes of Health (Grant # Unknown)
PI – Quantitative Angiographic Core Laboratory
The main goal was to test whether fish oil supplements could improve coronary atherosclerosis in humans.
- 1991-1993 Thrombolysis in Myocardial Infarction Phase 4 (TIMI 4)
Smith Kline Beecham
PI – Quantitative Angiographic Core Laboratory
TIMI 4 compared the efficacy of anisoylated plasminogen streptokinase activator (APSAC) to front loaded tPA to the combination of reduced dose tPA and APSAC for the treatment of patients with ST elevation myocardial infarction onset.
- 1993-1994 Thrombolysis in Myocardial Infarction Phase 9A (TIMI 9A)
Ciba Geigy
PI – Quantitative Angiographic Core Laboratory
The TIMI 9A trial studied patients with acute myocardial infarction to compare the safety and efficacy of thrombolysis and aspirin to intravenous hirudin with heparin as adjunctive therapy.
- 1993-1994 A prospective randomized trial comparing the efficacy of hirulog versus heparin in preventing post PTCA reocclusion
Biogen Inc
Site PI – Beth Israel Deaconess Medical Center
The major goal of the study was to compare the efficacy of hirulog versus heparin in preventing post PTCA reocclusion.
- 1993-1994 A randomized trial comparing the efficacy of Vesnirane to Dobutamine
Otsuka Pharmaceuticals
Site PI – Beth Israel Deaconess Medical Center This trial compared the efficacy of Vesnirane to Dobutamine
- 1993-1994 Coumadin Aspirin Reinfarction Study (CARS)
Merck Dupont
Site PI – Beth Israel Deaconess Medical Center
The major goal of this study was to compare the efficacy and safety of aspirin alone to fixed-dose combination Coumadin plus aspirin in people who have survived acute myocardial infarction.

- 1993-1994 Hirulog in the Treatment of Heparin Associated Thrombocytopenia
Biogen Inc
Site PI – West Roxbury Veteran’s Administration Hospital
This study evaluated the effect of hirulog on heparin-associated thrombocytopenia.
- 1994-1995 A Comparative Analysis of Disease Extent Prior to Coronary Artery Bypass Grafting
Health Care Finance Administration (HCFA)
PI – Quantitative Angiographic Core Laboratory
The main goal of this analysis was to examine disease extent prior to coronary artery bypass grafting (CABG).
- 1995-1996 Thrombolysis In Myocardial Infarction Phase 11 trial (TIMI 11A) of Enoxaparin
Rhône-Poulenc Rorer
PI – Quantitative Angiographic Core Laboratory
This study was designed to compare the tolerability and safety of two dosage regimens of enoxaparin in patients with non-Q wave myocardial infarction or unstable angina.
- 1995-1997 Thrombolysis in Myocardial Infarction Phase 12 trial (TIMI 12) a phase 2 trial of Ro 48-3657 (a new oral IIb/IIIa platelet receptor antagonist)
Genentech, Inc
Site PI – West Roxbury Veteran’s Administration Hospital
The major goal of this study was to evaluate the pharmacodynamics, pharmacokinetics, tolerability, and safety of sibrافiban in patients after acute coronary syndromes.
- 1995-1997 MK-383 in Patients Undergoing Conventional PTCA or Atherectomy (RESTORE)
Merck & Co., Inc
Site PI – West Roxbury Veteran’s Administration Hospital
This trial evaluated tirofiban in patients undergoing atherectomy or balloon angioplasty with either unstable angina pectoris or acute myocardial infarction.
- 1995-1997 MK-383 in Patients Undergoing Conventional PTCA or Atherectomy (RESTORE)
Merck & Co., Inc
PI – Quantitative Angiographic Core Laboratory
This trial evaluated tirofiban in patients undergoing atherectomy or balloon angioplasty with either unstable angina pectoris or acute myocardial infarction.
- 1995-1997 Triggers of acute MI study
National Institutes of Health (Grant # Unknown)
The goal of this study was to evaluate triggers of acute myocardial infarctions.

Site PI – West Roxbury Veteran’s Administration Hospital

- 1995-1997 Comparative evaluation of the FreeFlow catheter
Schneider Inc
PI - Angiographic and Electrocardiographic Core Laboratories
The main goal of this study was to evaluate the FreeFlow catheter.
- 1995-1998 Thrombolysis In Myocardial Infarction Phase 10 pilot trial (TIMI 10A)
Genentech, Inc
PI – Quantitative Angiographic Core Laboratory
This trial was designed to evaluate the safety, efficacy, and pharmacokinetics of
TNK-tPA in patients with acute myocardial infarction.
- 1996-1998 Medium sized vessel atherectomy trial
Guidant Corporation
PI – Quantitative Angiographic Core Laboratory
The main goal of this trial was to assess medium sized vessel atherectomy.
- 1996-1998 Thrombolysis In Myocardial Infarction Phase 10 B trial of TNK (TIMI 10B)
Genentech, Inc
PI – Quantitative Angiographic Core Laboratory
TIMI 10B compared the angiographic safety and efficacy of TNK doses with
front loaded rtPA in the treatment of ST elevation myocardial infarction.
- 1996-1998 AVERT trial (Atorvastatin Versus Revascularization Treatments)
Parke Davis
Site PI – West Roxbury Veteran’s Administration Hospital
This study examined the effect of an aggressive lipid-lowering therapy on
ischemic events in patients with single or double vessel coronary artery disease.
- 1996-1998 WALLSTENT Femoral Endoprosthesis and the Unistep Plus Delivery System
Schneider Inc
PI – Quantitative Angiographic Core Laboratory
The main goal was to examine the angiographic analysis of the WALLSTENT
Femoral Endoprosthesis and the Unistep Plus Delivery System.
- 1996-1998 WALLGRAFT Endoprosthesis with PET Covering and the Unistep LS Delivery
System
Schneider Inc
PI – Quantitative Angiographic Core Laboratory
The main goal was to examine the angiographic analysis of the WALLSTENT
Endoprosthesis with PET Covering and the Unistep LS Delivery System.
- 1996-2003 WALLSTENT in peripheral vessels
Schneider Inc
PI – Quantitative Angiographic Core Laboratory

The main goal was to examine the angiographic analysis of the Schneider WALLSTENT in peripheral vessels.

- 1996-2003 WALLSTENT in central vessels
Schneider Inc
PI – Quantitative Angiographic Core Laboratory
The main goal was to examine the angiographic analysis of the Schneider WALLSTENT in central vessels.
- 1997-1998 Thrombolysis in Myocardial Infarction Phase 11B Trial of Enoxaparin (TIMI 11B)
Rhône-Poulenc Rorer / Aventis Pharmaceuticals
Site PI – West Roxbury Veteran's Administration Hospital
TIMI 11B compared the safety and efficacy of subcutaneous enoxaparin to unfractionated heparin in treating patients with non-Q-wave myocardial infarction or unstable angina.
- 1997-1998 Phase 1B trial of rh-VEGF
Genentech, Inc.
PI – Quantitative Angiographic Core Laboratory
The main goal of this trial was to evaluate the safety and dosage of rh-VEGF, or recombinant human vascular endothelial growth factor
- 1998 BARD study of geometry of bifurcation lesions
Bard
PI – Quantitative Angiographic Core Laboratory
This study examined the geometry of bifurcation lesions.
- 1998-1999 VITAL Trial
Vascular Therapeutics Inc. (Phase II)
PI – Quantitative Angiographic Core Laboratory
This study studied the effect of Vasoflux, an antithrombin, in acute myocardial infarction.
- 1998-1999 The VIVA Trial (The Vascular Endothelial Growth Factor (VEGF) in Ischemia for Vascular Angiogenesis)
Genentech Inc. (Phase II)
PI – Quantitative Angiographic Core Laboratory
The main goal of this trial was to evaluate the efficacy and safety of intracoronary infusions of rhVEGF.

- 1998-1999 The ECHOGEN Trial
Sonus Pharmaceuticals (Phase III)
PI – Quantitative Angiographic Core Laboratory
The goal of this study was to assess a new echocardiographic contrast agent. It was a multicenter, single blind study comparing non-enhanced stress echocardiography in the visualization of wall motion and the diagnosis of coronary artery disease.
- 1998-2000 Thrombolysis In Myocardial Infarction Phase 14 trial of ReoPro in acute MI (TIMI 14)
Centocor and Eli Lilly
PI – Quantitative Angiographic Core Laboratory
TIMI 14 compared an abciximab bolus plus a 12-hour infusion alone versus an abciximab bolus plus a 12-hour infusion in conjunction with reduced dose thrombolytic therapy among patients with ST elevation myocardial infarction.
- 1998-2000 Rendering the final readings for the pooled data from the SPEED and TIMI 14 trials of ReoPro plus RPA in acute MI
Centocor and Eli Lilly
PI
The major goal was to render the final readings for the pooled data from the SPEED and TIMI 14 trials of ReoPro plus RPA in acute MI.
- 1998-2000 TACTICS - TIMI 18 trial (Treat Angina with aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy – Thrombolysis In Myocardial Infarction 18)
Merck & Co., Inc.
PI – Quantitative Angiographic Core Laboratory
TIMI 18 compared invasive to conservative strategies among patients with non-Q-wave myocardial infarction and unstable angina following treatment with tirofiban, a glycoprotein IIb/IIIa inhibitor.
- 1998-2000 LIMIT trial of rhuMAb CD18 as an adjunct to thrombolysis (an antibody directed against neutrophils)
Genentech Inc.
PI – Quantitative Angiographic Core Laboratory
The main goal of this study was to compare lytic monotherapy to lytic plus rhuMAb CD18.

- 1999-2000 The Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP AMI) Angiographic Trial.
AstraZeneca
PI – Quantitative Angiographic Core Laboratory
The main goal of this trial was to assess the safety, tolerability and the effect on coronary artery patency of intravenous AR-C69931MX as both monotherapy and adjunct to Activase in patients with ST-elevation myocardial infarction.
- 1999-2001 FASTER trial (Fibrinolytic and Aggrastat ST-elevation Resolution)
Merck & Co., Inc.
PI – Quantitative Angiographic Core Laboratory
The major goal of this study was to determine whether the addition of clopidogrel to aspirin had an additional benefit in reducing the number of strokes after TIA (transient ischemic attack) or minor stroke within 3 months of TIA or minor stroke when compared to aspirin alone.
- 1999-2001 The ENTIRE–TIMI 23 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction 23)
Aventis
PI – Quantitative Angiographic Core Laboratory
The goal of this study was to assess the efficacy and safety of enoxaparin as an adjunct to thrombolysis with or without GPIIb/IIIa therapy as reperfusion strategies in patients presenting with ST elevation myocardial infarction.
- 1999-2001 Integrilin and TNK in Acute Myocardial infarction
COR Therapeutics
PI – Quantitative Angiographic Core Laboratory
The main goal of this study was to evaluate the safety and efficacy of the combination of TNK and eptifibatide in patients with ST elevation myocardial infarction.
- 2000-2001 The ESPRIT Trial. (Enhanced suppression of the platelet GPIIb/IIIa receptor with Integrilin™ Therapy)
COR Therapeutics
PI – Quantitative Angiographic Core Laboratory
The main goal of ESPRIT was to assess intracoronary stenting with and without Integrilin.
- 2000-2001 PEARL study of estrogens in restenosis
National Institutes of Health (Grant # Unknown)
PI – Quantitative Angiographic Core Laboratory
PEARL investigated the ability of estrogen replacement therapy to inhibit or prevent restenosis in post-menopausal women that underwent balloon angioplasty with insertion of intra-coronary stent.

2002	The ELETRIPTAN Trial Pfizer Pharmaceuticals PI – Quantitative Angiographic Core Laboratory This trial assessed the presence and magnitude of coronary vasoconstriction associated with Eletriptan, a novel migraine compound.
2002-2003	ADVANCE MI (Addressing the Value of facilitated Angioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction) Millenium Pharmaceutical PI – Quantitative Angiographic Core Laboratory The main goal of this trial was to assess the efficacy of eptifibatide administered in the emergency room versus eptifibatide in combination with half dose TNK among patients undergoing percutaneous coronary intervention in the management of acute myocardial infarction.
2002-2003	Trial investigating the efficacy of a novel myocardial contrast agent Point Biomedical PI – Quantitative Angiographic Core Laboratory The main goal of this trial was to investigate the efficacy of a novel myocardial contrast agent.
2003-2004	The PLUS study (Perfusion by ThromboLytic and UltraSound) TIMI 3 Systems PI – Quantitative Angiographic Core Laboratory PLUS was an international multicenter trial evaluating the efficacy of transcutaneous ultrasound to facilitate thrombolysis.
2003-2005	An international multicenter dose escalation trial of the new thrombolytic agent BB10153 (activated only by clot bound thrombin) British Biotech Trial PI (TIMI) The major goal of this study was to assess the agent BB10153, a new thrombolytic agent.
2003-2005	TITAN – TIMI 34 (Time to Integrilin Therapy in Acute Myocardial Infarction - Thrombolysis In Myocardial Infarction 34) Millenium Pharmaceuticals (Phase IV) Trial PI (TIMI) TIMI 34 evaluated ranolazine, an anti-ischemic agent, in patients with acute coronary syndromes.

- 2003-2005 TITAN – TIMI 34 (Time to Integrilin Therapy in Acute Myocardial Infarction - Thrombolysis In Myocardial Infarction 34)
Millenium Pharmaceuticals (Phase IV)
PI – Quantitative Angiographic Core Laboratory
TIMI 34 evaluated ranolazine, an anti-ischemic agent, in patients with acute coronary syndromes.
- 2003-2005 CLARITY – TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy – Thrombolysis In Myocardial Infarction 28)
Bristol Meyers Squibb
PI – Quantitative Angiographic Core Laboratory
CLARITY was designed to assess the efficacy of clopidogrel in improving patency following thrombolytic administration.
- 2003-2005 PREVENT 4 (Project of Ex-vivo Vein Graft Engineering via Transfection)
Corgentec (Phase 3)
PI – Quantitative Angiographic Core Laboratory
PREVENT 4 was a 2,200 patient trial evaluating a novel agent to reduce saphenous vein graft occlusion.
- 2003-2005 The St. Judes Trial of a novel proximal anastomotic connector
St. Jude Medical
PI – Quantitative Angiographic Core Laboratory
The goal of this study was to evaluate a novel proximal anastomotic connector device for saphenous vein grafts.
- 2003-2005 The St. Judes Trial of a novel proximal anastomotic connector
St. Jude Medical
PI – CT Angiographic Core Laboratory
The goal of this study was to evaluate a novel proximal anastomotic connector device for saphenous vein grafts.
- 2003-2006 St. Jude Medical SVG 2nd Generation Aortic Connector System Trial Multicenter
St. Jude Medical
PI – Quantitative Angiographic Core Laboratory
The goal of this study was to assess the St. Jude SVG 2nd generation aortic connector system.
- 2003-2006 St. Jude Medical SVG 2nd Generation Aortic Connector System Trial Multicenter
St. Jude Medical
PI – CT Angiographic Core Laboratory
The goal of this study was to assess the St. Jude SVG 2nd generation aortic connector system.

- 2003-2006 St. Jude Medical CMR Imaging SVG 2nd Generation Aortic Connector System Trial.
St. Jude Medical
Co-PI – CMR Core Lab
The goal of this study was to assess the St. Jude SVG 2nd generation aortic connector system.
- 2004-2006 DELTA MI (Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction)
Kai Pharmaceuticals (Phase I/II study)
PI – Quantitative Angiographic Core Laboratory
The major goal of this study was to study KAI-9803 as an adjunct to percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
- 2004-2006 EXTRACT TIMI 25 Registry. (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment)
Sanofi-Aventi Pharmaceuticals (Phase III)
PI – Data Entry, Management, and Coordination
This trial evaluated the safety and efficacy of enoxaparin throughout the index hospitalization or unfractionated heparin for 48 or more hours among patients with ST-elevation myocardial infarction that were scheduled to undergo fibrinolysis.
- 2004-2009 EARLY ACS - TIMI 39 (Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome - Thrombolysis In Myocardial Infarction 39)
Millenium Pharmaceuticals & Schering-Plough (Phase III)
PI – Quantitative Angiographic Core Laboratory
This study assessed the effects of early front-loaded eptifibatide vs. placebo in the treatment of patients with non-ST segment elevation acute coronary syndrome (UA/NSTEMI).
- 2005-2006 ANTHEM – TIMI 32 (Anticoagulation With rNAPc2 to Help Eliminate MACE - Thrombolysis In Myocardial Infarction 32)
Nuvelo (Phase II)
PI – Quantitative Angiographic Core Laboratory
This study assessed the safety and efficacy of anticoagulation with rNAPc2 (a fVIIa/TF inhibitor) vs. placebo in patients with non-ST segment elevation acute coronary syndrome that were managed with an early invasive strategy.

- 2005-2007 TRITON – TIMI 38 (Trial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel - Thrombolysis In Myocardial Infarction 38)
Eli Lilly (Phase III)
PI – Quantitative Angiographic Core Laboratory
This trial compared prasugrel vs. clopidogrel in the treatment of patients with acute coronary syndromes who underwent percutaneous coronary intervention (PCI).
- 2005-2007 PROTECT – TIMI 30 (A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents - Thrombolysis In Myocardial Infarction 30)
Schering-Plough
Trial PI (TIMI)
This study compared eptifibatide with either unfractionated heparin or enoxaparin to bivalirudin alone in ACS patients that were undergoing percutaneous coronary intervention (PCI).
- 2005-2008 ALLAY (ALiskiren Left ventricular Assessment of hypertrophy)
Novartis
Co-PI – CMR Core Lab
ALLAY compared the efficacy and safety of Protocol SPP100A2316 in combination with Losartan compared to Losartan on the regression of left ventricular hypertrophy in overweight patients with essential hypertension.
- 2005-2009 The TRACS Study (The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis)
FoldRx Pharmaceuticals
Co-PI – CMR Core Lab
The goal of this study was to investigate the natural history of disease and burden of illness for patients with Familial Amyloid Cardiomyopathy (FAC) and Senile Systemic Amyloidosis (SSA).
- 2005-2011 ICE T – TIMI 49 (A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks - Thrombolysis In Myocardial Infarction 49)
Genentech, Inc. (N3370s - Phase II)
PI – Quantitative Angiographic Core Laboratory
The primary objective of this study is to gather preliminary data regarding the angiographic efficacy of the administration of low-dose adjunctive intracoronary (IC) tenecteplase during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

- 2006-2008 ACT-34 CMI (Autologous Cellular Therapy Utilizing CD34+ Cells)
Baxter Healthcare (Phase II)
Co-PI – CMR Core Lab
The main goal of this study was to evaluate the safety and efficacy of intramyocardial injections of adult stem cells in patients with refractory chronic myocardial ischemia.
- 2006-2008 ATLAS ACS - TIMI 46 Trial (Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes - Thrombolysis In Myocardial Infarction 46)
Johnson & Johnson, Bayer (Phase II – Grant # 39039039ACS2001)
Trial PI
The main goal of this study was to compare rivaroxaban, an oral direct Factor Xa inhibitor, to placebo in patients with acute coronary syndromes.
- 2006-2009 INOT-44 (Nitric Oxide in Myocardial Infarction Size (NOMI))
INO Therapeutics (Phase II)
PI – Quantitative Angiographic Core Laboratory
The main goal of this study was to evaluate the effects of nitric oxide for inhalation on myocardial infarction size-NOMI.
- 2006-2010 PLATO TIMI 41 (A Study of PLATelet inhibition and Patient Outcomes - Thrombolysis In Myocardial Infarction 41)
Astra-Zeneca (D5130C05262 - Phase III)
PI – Quantitative Angiographic Core Laboratory
The primary outcome measure will be the reduction in the relative risk of vascular death, nonfatal myocardial infarction, or nonfatal stroke (composite primary endpoint), comparing AZD6140 (a new, reversible, anti-platelet medication) to clopidogrel in patients with non-ST or ST elevation acute coronary syndrome (ACS).
- 2007-2008 ERASE-MI (Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI)
Portola (Phase II)
PI – Quantitative Angiographic Core Laboratory
ERASE-MI evaluated the safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
- 2007-2009 OCCULT MI (Optimal Cardiovascular Diagnostic Evaluation Enabling Faster Treatment of Myocardial Infarction)
Heartscape Technologies
Director/Chairman – Quantitative Angiographic Core Laboratory
This study compared 80-lead mapping electrocardiograms (ECGs) to 12 lead ECGs.

- 2007-2009 SEPIA-ACS1 TIMI 42 (Study Program to Evaluate the Prevention of Ischemia with direct Anti-Xa inhibition in Acute Coronary Syndromes 1 - Thrombolysis in Myocardial Infarction 42)
Sanofi-Aventis
PI – Quantitative Angiographic Core Laboratory
The main goal of this study was to evaluate the dose ranging of Otamixaban, a novel, intravenous direct Xa inhibitor.
- 2007-2010 INTENSIVE
Sanofi-Aventis
PI – Quantitative Angiographic Core Laboratory
This study assessed intensive Apidra®/Lantus® therapy versus Sliding Scale Insulin on infarct size in hyperglycemic subjects with anterior STEMI undergoing percutaneous coronary intervention (PCI).
- 2007-2010 INTENSIVE
Sanofi-Aventis
Co-PI – CMR Core Lab
This study assessed intensive Apidra®/Lantus® therapy versus Sliding Scale Insulin on infarct size in hyperglycemic subjects with anterior ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
- 2007-2011 IMPENDIA Trial (PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients)
Baxter Healthcare Corp (Protocol # 31998)
Co-PI – CMR Core Lab
The main goal of this trial is to demonstrate whether the use of glucose sparing prescriptions (PPEN vs DDDD) in Type 1 and Type 2 diabetic CAPD (Continuous Ambulatory Peritoneal Dialysis) patients will lead to improved metabolic control.
- 2008 - 2010 PAS-Port (Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery (EPIC))
Cardica, Inc. (30834_Perfuse1 - Phase III)
PI – Quantitative Angiographic Core Laboratory
This study evaluated the safety and effectiveness of the PAS-Port Proximal Anastomosis System and conventional suturing techniques in the creation of connections between graft veins and the aorta in coronary artery disease that are undergoing coronary artery bypass graft surgery.
- 2008-2010 FX1B-201 Study (Safety and Efficacy Evaluation of Fx-1006A in Patients With V1221 or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy)
FoldRx (30834_Perfuse3)

Co-PI- CMR Core Lab

The main goal of this study is to examine the effects of Fx-1006° on transthyretin stabilization in patients with V1221 or wild-type TTR amyloid cardiomyopathy.

- 2009-2010 Lantheus Development of One-Day Rest/Stress Cardiac Positron Emission Tomography (PET) Perfusion Imaging Protocols of BMS747158
Lantheus Medical Imaging (30834_Perfuse4 – Phase I)
PI-Quantitative Angiographic Core Laboratory
The main purpose of this study is to gain more information on using BMS747158 (the study drug), which is a drug with small amounts of radioactivity to allow for heart imaging, during a positron emission tomography (PET) scan which can then be compared to other images such as Single Photon Emission Computed Tomography (SPECT). The safety and quality of images will be studied.
- 2009- 2011 ATLAS ACS 2 – TIMI 51
Johnson & Johnson, Bayer (Grant #: 39039039ACS3001)
Trial PI
The main goal of this trial is to evaluate the safety and efficacy of rivaroxaban in patients with a recent acute coronary syndrome (ACS), including unstable angina and ST elevation and non-ST elevation myocardial infarctions.
- 2009-2011 ASCERT Study (American College of Cardiology Foundation-The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization sTrategies)
National Institutes of Health (Grant #: 1RC2HL101489-01)
PI – Quantitative Angiographic Core Laboratory
The main goal of this study is to evaluate the impact of the SYNTAX score as a potential prognostic guide for treatment selection (percutaneous coronary intervention vs. coronary artery bypass graft surgery).
- 2009-2012 IC CLEARLY (Intracoronary Abciximab With Clearway Catheter)
Atrium Medical Systems (30834_Perfuse8 - Phase III)
PI – Quantitative Angiographic Core Laboratory
IC CLEARLY is designed to compare the effectiveness of an intracoronary bolus of abciximab delivered through the ClearWay RX catheter to an intravenous bolus of abciximab in patients with ST-elevation myocardial infarction and angiographically visible thrombus.
- 2010-2012 DRONE_L_04316 Trial
Sanofi-Aventis (DRONE_L_04316)/ HESTIA 04316 Study
PI – EGM Core Laboratory
PERFUSE's main task in this study is to assess the quality of electrocardiograms (EGMs) and evaluate whether the sensitivity requirements and pacemaker programming are met.

- 2011-2012 TRACER Trial
 Merck & Co., Inc. (via Duke University)
 PI – Quantitative Angiographic Core Laboratory
 The baseline angiogram and all subsequent angiograms from interventions preceding the purported stent thrombosis or urgent revascularization must be reviewed to understand if conventional balloon angioplasty was performed or if preceding complications such as catheter dissection occurred in other parts of the vessel and to determine exactly where the stent was placed because some stents may not be sufficiently radio-opaque on follow-up angiography.
- 2011-2012 Clinical Performance of Elecsys High Sensitive Troponin T in Subjects with Symptoms Suggestive of Acute Coronary Syndrome (ACS) – Independent Clinical Endpoint Committee - CIM RD001088
 Roche Diagnostics Operations, Inc.
 PI – Clinical Endpoint Committee
 This is a prospective observational study among subjects presenting to the emergency department with non-traumatic chest symptoms suggestive of acute coronary syndrome (ACS), whose blood will be drawn at 0h, 3h, 6-9h, and 12-24h for measurement of TnT hs, as a primary claim to prove aid in diagnosis. The Clinical Endpoint Committee (CEC) adjudications will be used as a comparison by which the sensitivity and specificity of the TnT hs assay will be determined.
- 2009-2012 INFUSE AMI (A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction)
 Atrium Medical Systems (30834_Perfuse7)
 Trial Co-PI
 The primary objective of the study is to demonstrate that among subjects undergoing primary percutaneous coronary intervention (PCI) for anterior ST-segment elevation myocardial infarction (STEMI) treated with a bivalirudin monotherapy anticoagulation strategy, the intracoronary infusion of an abciximab bolus with or without thrombus aspiration prior to stent implantation, compared to no infusion with or without thrombus aspiration (standard of care), results in 1) reduced infarct size measured by cardiac MRI at 30 days, 2) reduce microvascular obstruction (MVO) by cardiac MRI at 5 + 2 days 3) enhanced ST-segment resolution, 4) improved myocardial perfusion, 5) reduced thrombus burden and angiographic complications, and 6) no increase in major and minor bleeding.
- 2011-2012 Swedish Thrombectomy Trial
 Walk Vascular
 PI – Quantitative Angiographic Core Laboratory
 Epicardial flow and myocardial perfusion are being assessed before and after

thrombectomy in patients with ST elevation myocardial infarction.

- 2011 - 2012 Swedish Thrombectomy Trial
Walk Vascular
PI – EKG Core Laboratory
ST segment resolution are being assessed using Schroeder Criteria before, immediately following, and 2-3 hours after thrombectomy in patients with ST elevation myocardial infarction.
- 2010- 2014 A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
The Medicines Company
Member, Executive Committee
The main goal of this study is to compare the efficacy and safety profile of cangrelor to standard of care in patients requiring percutaneous coronary intervention (PCI).
- 2011-2015 SPIRI 201: EMBRACE STEMI Trial (A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Repfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST segment Elevation Myocardial Infarction)
Stealth Peptides Inc.
PI
Evaluating the impact of Bendavia on limiting the size of infarcted myocardium in patients with first time anterior wall ST-segment elevation myocardial infarction (STEMI) who have undergone successful reperfusion using primary percutaneous coronary intervention (PCI) and stenting.
- 2011-2015 IK-5001-VENREM-201 (A Phase 2, Multicenter, Randomized, Double Blind, Double Dummy, Placebo-controlled Trial to Evaluate the Safety and Effectiveness of IK-5001 for the Prevention of Ventricular Remodeling and Congestive Heart Failure After Acute Myocardial Infarction)
Ikaria Subsidiary One, LLC (via Duke University)
PI - Quantitative Angiographic Core Laboratory
The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for prevention of ventricular remodeling and congestive heart failure when administered to subjects after ST-segment elevation myocardial infarction (STEMI) and successful primary percutaneous coronary intervention (PCI) revascularization.
- 2013-2015 RIVAROXFL3002: A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation
Johnson&Johnson and Bayer (VENTURE AF)

PI

The main goal of this study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult subjects with NVAf who undergo catheter ablation as measured by post-procedure major bleeding events.

- 2013-2015 Intracoronary Administration of Bivalirudin During Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction (IC BIVAL)
The Medicines Company
PI
The main goal of this study is to describe a single center experience with intracoronary (IC) injection of bivalirudin (Angiomax, the Medicines Company) during percutaneous coronary intervention (PCI) for acute ST-elevation myocardial infarction (STEMI) patients in an effort to reduce coronary thrombus burden, and to demonstrate non-inferiority of IC bivalirudin administration during PCI for STEMI compared to PCI for STEMI without IC bivalirudin administration.
- 2012 - 2016 ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients (AnalyzeST)
St. Jude Medical
Global PI
The main goal of this study is to demonstrate the safety and effectiveness of implantable defibrillators to detect ischemia through analyzing the sensitivity of the ST Monitoring Feature to identify clinical events and demonstrating a low percentage of patients with false positive events.
- 2013- 2016 Percutaneous Revascularization at Piedmont for Chronic Total Occlusions Survey (PERSPECTIVE)
Medtronic Vascular, Inc
PI
The main goal of this analysis is to evaluate procedural and 1-year clinical outcomes of death, myocardial infarction and repeat target lesion revascularization among patients undergoing attempted percutaneous CTO revascularization.
- 2013-2017 Phase 2b randomized, multi-center, double-blind, placebo-controlled Study to investigate the safety and tolerability of two intravenous infusion regimens of CSL112 in adults with acute myocardial infarction (AEGIS-1)
CSL Behring
Study Chairman
The main goal of this study is to assess the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 (low dose [2 g] or high dose [6 g]) compared with placebo in subjects with AMI.
- 2014-2017 RIVAROXACS2002: A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or

Ticagrelor Therapy in Subjects with Acute Coronary Syndrome (GEMINI ACS 1)
Janssen Research & Development, LLC.

Co-Chairman \

The main goal of this study is to estimate the bleeding risk with rivaroxaban compared with ASA, in addition to a single antiplatelet agent (a platelet adenosine diphosphate P2Y₁₂ receptor antagonist [P2Y₁₂ inhibitor], clopidogrel or ticagrelor), in subjects with a recent ACS (including ST-segment elevation myocardial infarction [STEMI] and non-ST-segment elevation acute coronary syndrome [NSTEMI]).

2015 - 2017 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department (MERCURY PE) - Independent Clinical Endpoint Committee

Janssen Research & Development, LLC.

PI \

The main goal of this study is to demonstrate that low risk PE patients who are discharged from the ED to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to patients who are treated with initial hospitalization and standard-of-care.

2009-2017 ALERT AMI (AngelMed for Early Recognition and Treatment of STEMI)
Angel Medical Systems (30834_Perfuse5 - Phase III)

PI – Quantitative Angiographic Core Laboratory

The main goal of this study is to evaluate subjects with a high-risk of having a myocardial infarction (MI) due to acute coronary syndrome or bypass surgery.

2015-2018 Phase 2b randomized, multi-center, double-blind, placebo-controlled, parallel-group, Study to investigate the safety and tolerability of two intravenous infusion regimens of CSL112 in adults with moderate renal impairment and myocardial infarction (CSL112_2001)

CSL Behring

Study Chairman

The main goal of this study is to assess the renal safety of CSL112 in subjects with moderate RI and AMI after administration of up to 4 weekly infusions of CSL112.

2009-2019 ALERT AMI (AngelMed for Early Recognition and Treatment of STEMI)
Angel Medical Systems (30834_Perfuse6 - Phase III)

Trial PI

The main goal of this study is to evaluate subjects with a high-risk of having a myocardial infarction (MI) due to acute coronary syndrome or bypass surgery.

2012-2017 Multicenter, Randomized Active-Controlled Efficacy and Safety Study
Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin for the Prevention of Venous Thromboembolism in Acute Medically Ill Patients

(APEX)

Portola Pharmaceuticals, Inc.

Executive Committee

The main goal of this study is to assess the efficacy and safety of extended duration the factor Xa inhibitor betrixaban with standard of care enoxaparin for the prevention of both in-hospital and post-discharge pulmonary embolism and deep vein thrombosis in high-risk acute medically ill patients.

2015-2017 Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who have Acute Major Bleeding (Andexanet alfa (PRT064445))
Portola Pharmaceuticals, Inc.

PI

The main goal of this study is to evaluate the hemostatic efficacy of andexanet in patients receiving a fXa inhibitor who have acute major bleeding and reduced fXa activity.

The study will be considered to have met its primary efficacy endpoint if the proportion of patients with excellent or good hemostasis (as adjudicated by the independent Endpoint Adjudication Committee [EAC]) is statistically significantly higher than 50% ($p < 0.05$).

Current

2012- RIVAROXFL3003: An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies (Rivaroxaban or Dose-Adjusted Oral Vitamin K Antagonist Plus Dual Antiplatelet Therapy Followed by Rivaroxaban Plus Single Antiplatelet Therapy) After Percutaneous Coronary Intervention in Subjects with Atrial Fibrillation. (PIONEER AF)

Johnson & Johnson and Bayer

PI The main goal of this study is to assess the safety of two treatment strategies involving rivaroxaban for anticoagulant therapy plus dual antiplatelet therapy following primary percutaneous coronary intervention (PCI) in patients with paroxysmal, persistent, or permanent non-valvular AF, based on the composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention events.

2013- Exenatide for Myocardial Protection during RepErfusion Study
A double-blind, placebo-controlled trial (EMPRES)

University Health Network/BMS

PI

The main goal of this study is to determine if exenatide will reduce the ratio of the cMRdetermined final infarct size at 3 months over the area at risk at 72 hours post Randomization.

- 2015 - ATLAS ACS 2
Johnson & Johnson
PI The main goal of this trial is to evaluate the safety and efficacy of rivaroxaban in patients with a recent acute coronary syndrome (ACS), including unstable angina and ST elevation and non-ST elevation myocardial infarctions.
- 2016 - A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Myocardial Infarction (AEGIS II)
Study Chairman
CSL Behring
The main goal of this study is to assess reduction of early atherothrombotic events in acute myocardial infarction (AMI) patients (either ST-segment elevation myocardial infarction [STEMI] or non-ST-segment elevation myocardial infarction [NSTEMI]) who are at high risk of recurrent events and are managed either with percutaneous intervention (PCI) or medically as clinically indicated
- 2018 - The International Spontaneous Coronary Artery Dissection Registry (iSCAD)
Core Lab
SCAD Alliance
The aim of the International SCAD (iSCAD) registry is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of patient recruitment and thereby increase statistical power of studies related to SCAD. The ultimate goal of iSCAD is to facilitate the development of best practices and clinical guidelines for the ultimate goal of preventing SCAD or its recurrence.

Report of Local Teaching and Training

Teaching of Students in Course

1989	Lecture – Chief Medical Resident	West Roxbury Veteran's Administration Hospital, Harvard Medical School
	Medical Students	2 hours/week for 26 weeks/year (Biweekly)
1992-1993	Lecture – Chief Medical Resident	Brigham and Women's Hospital, Harvard Medical School
	Medical Students	2 hours/week for 26 weeks/year (Biweekly)
1993-1994	Acute Cardiac Care Elective (ME502M.1b)	Harvard Medical School
	Medical Students	One 2-hour Lecture
1995	Human Systems Course –Cardiac Imaging	Harvard Medical School
	Medical Students	One 2-hour Lecture

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

1998-1999	SCORE (Scholars Concentrating on Research Excellence)	Medical College of Pennsylvania/Hahnemann University School of Medicine
	Residents & Fellows	2 hours/lecture for 16 Lectures

Clinical Supervisory and Training Responsibilities***Prior to Current HMS Appointment***

1993-1998	Supervising Cardiac Fellows in the Cath Lab / Beth Israel Hospital, Brigham and Women's Hospital, West Roxbury Veteran's Association Hospital	2 days/week, 8 hours/day, 40% effort
1993-1998	Supervising Medical Students, Interns, Residents in Coronary Care Unit / Beth Israel Hospital, Brigham and Women's Hospital, West Roxbury Veteran's Association Hospital	2 weeks/year, 8 hours/day
1998-1999	Supervising Cardiac Fellows in the Cath Lab / Allegheny General Hospital	2 days/week, 8 hours/day, 40% effort
1998-1999	Supervising Medical Students, Interns, Residents in Coronary Care Unit / Allegheny General Hospital	2 weeks/year, 8 hours/day
1999-2001	Supervising Cardiac Fellows in the Cath Lab / University of California San Francisco	2 days/week, 8 hours/day, 40% effort
1999-2001	Supervising Medical Students, Interns, Residents in Coronary Care Unit / University of California San Francisco	2 weeks/year, 8 hours/day

Current HMS Appointment

2001-present	Supervising Cardiac Fellows in the Cath Lab / Beth Israel Deaconess Medical Center	2 days/week, 8 hours/day, 40% effort
2001-	Supervising Medical Students, Interns, Residents in Coronary Care Unit / Beth Israel Deaconess Medical Center	2 weeks/year, 8 hours/day

2001-	Supervising Medical Students, Interns, Residents on the Paul M Zoll Cardiology Firm / Beth Israel Deaconess Medical Center	4 weeks/year, 8 hours/day
2016 -	Supervising Medical Students, Interns, Residents on the Cardia Direct Access Unit (CDAC) Firm / Beth Israel Deaconess Medical Center	1 week/year, 8 hours/day

Laboratory and Other Research Supervisory and Training Responsibilities

1989-present	Supervision and training of research assistants, quantitative angiographers, and physician over-readers / PERFUSE Core Laboratory	3 days/week, 8 hours/day
--------------	--	--------------------------

Formally Supervised Trainees and Faculty

2000	Graham Wong, MD / Director, Coronary Care Unit, Vancouver General Hospital Dr. Wong published a manuscript on the TACTICS-TIMI 18 study and worked clinically under my supervision.
2000	Ajay Kirtane, MD SM / Cardiovascular Research Foundation, Columbia University Dr. Kirtane published manuscripts together, primarily based upon the TIMI trials database, and worked clinically, under my supervision.
2001	Duane Pinto, MD / Beth Israel Deaconess Medical Center Dr. Pinto did research and worked clinically under my supervision.
2002	Dimitri Karpaliotis, MD / Cardiology of Georgia, PC Dr. Karpaliotis published manuscripts and served as assistant director of my Angiographic Core Laboratory under my supervision.
2002-2006	Allen Jeremias, MD / Assistant Professor of Medicine, SUNY-StonyBrook Dr. Jeremias published a manuscript and established an intravascular ultrasound core laboratory at TIMI under my supervision.
2002	Brain Bigelow, MD / University of Indiana Dr. Bigelow published manuscripts for which I was a research mentor and worked clinically under my supervision.
2002	Pedro Martinezclark, MD / University of Miami Dr. Martinezclark did research and worked under my supervision.
2003-2006	Daniela Budiu, MD Dr. Budiu was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2005- Evan Appelbaum, MD / Co Director of the PERFUSE CMR Core Laboratory, Beth Israel Deaconess Medical Center
Dr. Appelbaum helped establish the PERFUSE CMR Core Lab under my supervision.

2006-2008 Jersey Chen, MD / Yale University
Dr. Chen did research and worked clinically under my supervision.

2007-2008 Michael Nguyen, MBBS
Dr. Nguyen was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2007-2008 Vijayalakshmi Kunadian MBBS MD MRCP
Dr. Kunadian published manuscripts and was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2007-2009 Cafer Zorkun, MD PhD
Dr. Zorkun was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2007-2012 Yuri Pride, MD / Cardiology Fellow Beth Israel Deaconess Medical Center
Dr. Pride was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.

2009-2010 Jinhui Wu, MD
Dr. Wu was a visiting scholar who conducted research and worked under my supervision.

2010-2012 Varun Kumar, MD / Resident at Mount Sinai Hospital Medical Center
Dr. Kumar was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision

2010-2012 Lakshmi Gopalakrishnan, MD
Dr. Gopalakrishnan was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.

2010-2011 Weici Wang, MD
Dr. Wang was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2010-2011 Atif Mohammad, M.B.B.S.
Dr. Mohammad was trained as an overreader of my Angiographic Core Laboratory under my supervision.

2011-2014 Anjan K. Chakrabarti, MD / Cardiology Fellow Beth Israel Deaconess Medical Center
Dr. Chakrabarti did research and has published manuscripts under my supervision

2011-2013 Priya Singh, MD / Resident at Saint Vincent Hospital at Worcester Medical Center
Dr. Singh did research and worked under my supervision.

2011- Kashish Goel, MD / Resident at Wayne State University School of Medicine
Dr. Goel completed multiple external research blocks during residency and has published manuscripts under my supervision.

2013 - Cheng-Liang Chi, MD
Dr. Chi did research and worked under my supervision he was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.

- 2013 - Rim Halaby, MD / Resident at Beth Isreal Deaconess Medical Center
Dr. Halaby did research and worked under my supervision she was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.
- 2014 - Serge Korjian, MD / Resident at Beth Isreal Deaconess Medical Center
Dr. Korjian did research and worked under my supervision he was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.
- 2014 - Yazan Daaboul, MD / Resident at Tufts Medical Center
Dr. Daaboul did research and worked under my supervision he was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.
- 2016 - Dr. Tarek Nafee, MD
Dr. Nafee did research and worked under my supervision he was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.
- 2017 Dr. Arzu Kalaycia, MD
Dr. Kalaycia did research and worked under my supervision he was trained as an overreader of my Angiographic Core Laboratory and has published manuscripts under my supervision.

Formal Teaching of Peers (e.g. CME and other continuing education courses)

No presentations below were sponsored by outside entities

1995	Advances in the Management of Acute Myocardial Infarction Update in Internal Medicine (Beth Israel Hospital, Harvard Medical School)	Single Presentation Boston, MA
1996	Advances in the Management of Acute Myocardial Infarction and Ischemic Heart Disease Update in Internal Medicine (Beth Israel Hospital, Harvard Medical School)	Single Presentation Boston, MA
1997	Advances in the Management of Acute Myocardial Infarction Update in Internal Medicine (Beth Israel Hospital, Harvard Medical School)	Single Presentation Boston, MA

Local Invited Presentations

No presentations below were sponsored by outside entities

1994	Management of Acute Myocardial Infarction / Grand Rounds Beth Israel Hospital Summer Grand Rounds Lecture Series
------	---

- 1994 Update on the Management of Acute Myocardial Infarction / Cardiology Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1995 Update in Interventional Cardiology / Cardiology Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1996 Controversies in the Management of Acute MI / Cardiology Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1996 Management of Acute MI / Medical Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1996 Revascularization Strategies in Acute Myocardial Infarction / Medical Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1996 Reperfusion Strategies in Acute MI / Symposium Presentation
Symposium on Emergency Medicine into the 21st Century, Brigham and Women's Hospital, Massachusetts General Hospital
- 1997 New Insights into Coronary Blood Flow Following Acute Myocardial Infarction / Cardiology Grand Rounds
Massachusetts General Hospital
- 1998 Reperfusion Strategies in Acute MI / Surgical Grand Rounds
West Roxbury Veteran's Administration Hospital
- 1998 Management of Acute MI / Emergency Room Symposium
Allegheny General Hospital
- 1998 Revascularization Strategies for Acute MI / Medical Grand Rounds
Allegheny General Hospital
- 2004 Revascularization Strategies for Acute MI / Grand Rounds
Mt Auburn Hospital, Cambridge MA
- 2006 State of The Art in Revascularization Therapy in ACS / Grand Rounds
Massachusetts General Hospital
- 2007 Medical Therapy for Acute MI / Medical Grand Rounds
Beth Israel Deaconess Medical Center
- 2007 Medical Therapy for Acute MI / Cardiology Grand Rounds
Brigham and Women's Hospital
- 2009 State of The Art in Revascularization Therapy in ACS / Cardiology Grand Rounds
West Roxbury Veteran's Administration Hospital
- 2013 State of the Art in Acute Coronary Syndromes/ Medical Grand Rounds
Beth Israel Deaconess Medical Center
- 2014 State of the Art in Acute Coronary Syndromes / Cardiology Grand Rounds
Brigham and Women's Hospital
- 2016 State of the Art in Acute Coronary Syndromes/ Cardiology Grand Rounds
Beth Israel Deaconess Medical Center
- 2016 The HDL vs. LDL Hypothesis: Dead or Alive/ Cardiology Grand Rounds
Beth Israel Deaconess Medical Center
- 2016 Public Ownership of Information/Cardiology Grand Rounds
Beth Israel Deaconess Medical Center

Report of Regional, National and International Invited Teaching and Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor is identified.

Regional

- 1993 Hyperlipidemia and Atherosclerosis Regression / Cardiology Grand Rounds
Goddard Hospital
- 1993 Treatment of Acute Myocardial Infarction / Medical Grand Rounds
Southern Maine Medical Center
- 1993 Current Management of Acute Myocardial Infarction / Medical Grand Rounds
Frisbie Memorial Medical Center, Rochester NH
- 1994 Overview of Myocardial Infarction / Medical Grand Rounds
Marlborough Hospital, Marlborough MA
- 1995 Interventional Cardiology: An Update / Cardiology Grand Rounds
Manchester Veteran's Administration Hospital, Manchester NH
- 1995 Update on the Management of Acute MI / Medical Grand Rounds
Beverly Hospital, Beverly MA
- 1996 Current Management of the MI Patient: Direct PTCA versus Thrombolysis /
Medical Grand Rounds
St. Anne's Hospital, Fall River MA & Catholic Medical Center, Manchester NH
- 1996 Management of Acute MI in the Elderly Patient / Medical Grand Rounds
Beverly Hospital, Beverly MA
- 1996 Reperfusion options 1996: Therapy of Acute Myocardial Infarction / Twelfth
Annual Primary Care Conference
St Claire's Hospital, New Seabury MA
- 1996 Clinical Application of Coronary Flow Measurements in Acute Ischemic
Syndromes / Cardiovascular Grand Rounds
Boston University Medical Center
- 1996 Coronary Flow in Acute Ischemic Syndromes: The TIMI Flow Grades, The TIMI
Frame Count and Beyond / Presentation
Greater Boston Interventional Cardiology Forum
- 1996 New Thrombolytic Agents and New Approaches to Revascularization in Acute
Myocardial Infarction / Medical Grand Rounds
Cape Cod Hospital, MA
- 1996 The Open Artery Hypothesis: Past, Present and Future / Cardiology Grand
Rounds
Hartford Hospital, Hartford CT
- 1996 Thrombolytics for the future / Lecture
Holy Family Hospital and Medical Center, Andover MA
- 1997 Modern management of Acute MI / Medical Grand Rounds
Stamford Hospital, Stamford CT
- 1997 Update on Thrombolysis / Grand Rounds
Milton Hospital Grand Rounds, Milton MA
- 1998 Reperfusion Strategies in Acute MI: An Update / Symposium Presentation
Bradley Memorial Hospital, Hartford CT
- 1998 Current and Future Use of Thrombolysis / Grand Rounds
St Joseph's Hospital, Nashua NH
- 1998 Acute Coronary Syndromes: A Revolution in Practice / Symposium Presentation

Institute for Continuing Healthcare Education, Boston MA
 1998 Thrombolysis / Symposium Presentation
 6th Annual Cardiac Symposium Cardiology Update 1998, Eastern Maine
 Medical Center
 1998 Management of Acute MI / Invited Lecture
 8th Annual Primary Care Conference Allegheny General Hospital
 1998 Management of Acute MI / Medical Grand Rounds
 McKeesport Hospital, Pittsburgh PA
 1998 Management of Acute Coronary Syndromes / Cardiology Grand Rounds
 University of Pittsburgh Medical Center
 1998 Modern Management of Acute Coronary Syndromes / Cardiology Grand Rounds
 Allegheny General Hospital
 1998 Management of Acute Coronary Syndromes / Medical Grand Rounds
 Western Pennsylvania Hospital
 1999 Results of the AVERT Trial / Invited Lecture
 Cardiology Teaching Day, Upstate New York Veteran's Administration,
 Syracuse NY
 1999 Update on Acute MI / Cardiology Grand Rounds
 Monongahela Valley Hospital, PA
 1999 Conservative vs Invasive Management of Atherosclerosis / Cardiovascular
 Conference
 Hamlet Medical Center, Erie PA
 1999 Glycoprotein IIb/IIIa Inhibitors in the setting of Acute Coronary Syndromes /
 Cardiology Grand Rounds
 Beaver Medical Center, Beaver PA
 1999 Revascularization strategies in acute MI / Cardiology Grand Rounds
 Lake Hospital Medical Center, Willoughby OH
 1999 Era of Enhanced Thrombolysis in AMI with Glycoprotein IIb/IIIa Inhibitors /
 Invited Lecture
 Lakewood Hospital, Lakewood OH
 1999 Modern Management of Acute MI / Cardiovascular Conference
 Fairview Hospital, Cleveland OH
 1999 Modern Management of Acute MI / Symposium Presentation
 Acute Coronary Syndromes Symposium University of Pittsburgh, Nemacolin PA
 1999 The Expanding Role of Medical Imaging as a Surrogate Endpoint in Clinical
 Trials / Invited Lecture
 The Drug Information Agency, Philadelphia PA
 1999 Changing Paradigms in the Management of Coronary Artery Disease
 Lee Hospital, Johnstown PA
 1999 Future Strategies in the Management of Acute Coronary Syndromes / Grand
 Rounds
 Weirton Medical Center, Weirton PA
 1999 Thrombolytic Therapy Update / Cardiovascular Conference

Auburn Memorial Hospital, Auburn NY
 1999 Current Management of Acute MI / Critical Care Conference
 Cayuga Medical Center, Ithaca NY
 2000 State of the Art in the Management of Acute MI / Symposium Presentation
 Catholic Health West
 2000 State of the Art in Reperfusion Therapy / Grand Rounds
 Salinas Memorial Hospital, Salinas CA
 2000 State of the Art in Reperfusion Therapy / Grand Rounds
 Scripps Memorial Hospital, La Jolla CA
 2000 Management of Acute MI / Internal Medicine Course
 University of California
 2000 Update on the Management of Acute MI / Grand Rounds
 Monterey County Community Hospital
 2001 State of the Art in Reperfusion Therapy / Grand Rounds
 Watsonville Hospital, Watsonville CA
 2001 Management of Acute MI / Invited Lecture
 San Diego Naval Medical Center, San Diego, CA
 2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 University of Massachusetts, Worcester MA
 2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 Maine Medical Center, Portland ME
 2002 State of the Art in Reperfusion Therapy / Cardiovascular Research Seminar
 St. Elizabeth's Medical Center, Boston MA
 2002 State of the Art in Reperfusion Therapy
 Lahey Clinic, Burlington MA
 2002 Medical Therapy for Acute MI / Symposium Presentation
 Eastern Maine Medical Center, Bangor ME
 2003 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 Good Samaritan Hospital, Brockton MA
 2003 State of the Art in Reperfusion Therapy / Grand Rounds
 Eastern Maine Medical Center, Bangor ME
 2003 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 Sturdy Memorial Hospital, Attleboro MA
 2004 State of the Art in Reperfusion Therapy / Grand Rounds
 Wentworth Douglass Hospital, Dover NH
 2004 State of The Art in Revascularization Therapy in ACS / Grand Rounds
 Lahey Clinic, Burlington MA
 2004 State of The Art in Revascularization Therapy in ACS / Grand Rounds
 Worcester Medical Center, Worcester MA
 2004 Medical Therapy for Acute MI / Interventional Cardiology Grand Rounds

Lahey Clinic, Burlington MA

2004 Medical Therapy for Acute MI / Grand Rounds
York Hospital, York ME

2004 Medical Therapy for Acute MI / Cardiology Grand Rounds
Boston Medical Center, Boston MA

2004 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Dartmouth-Mary Hitchcock Hospital, Lebanon NH

2004 State of the Art in Reperfusion Therapy / Medicine Grand Rounds
Dartmouth-Mary Hitchcock Hospital, Lebanon NH

2005 State of the Art in Reperfusion Therapy / Grand Rounds
All Saints Memorial Hospital, Lowell MA

2005 State of the Art in Reperfusion Therapy / Grand Rounds
University of Massachusetts Medical Center, Worcester MA

2006 State of the Art in Reperfusion Therapy / Cath Conference
Bridgeport Hospital, Bridgeport CT (Schering-Plough)

2006 Acute Coronary Syndromes / Symposium Presentation
42nd Annual Robert Jeresaty Cardiovascular Symposium Hartford Medical
Society Hartford CT

2006 The Open Muscle Hypothesis / Cardiology Grand Rounds
New England Medical Center, Boston MA

2006 State of the Art in Reperfusion Therapy / Clinical Conference
St. Joseph's Hospital, Nashua NH

2007 The Open Muscle Hypothesis / Cath Conference
Rhode Island Hospital, Providence RI (Schering-Plough)

2007 The Open Muscle Hypothesis / Cardiology Grand Rounds
St. Vincent's Hospital, Worcester MA (Schering-Plough)

2008 State of the Art in Reperfusion Therapy / Invited Lecture
Memorial Lecture, Bethel ME

2008 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Saint's Memorial Hospital, Lowell MA (Schering-Plough)

2008 10th Annual Gary Garber Memorial Lecture / Keynote Speaker
Good Samaritan Hospital, Brockton MA

2009 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Brockton Hospital, Brockton MA (The Medicines Company)

2009 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
St Vincent's Hospital, Worcester MA

2009 Current Updates in ACS Therapy / Cardiology Grand Rounds
Maine Medical Center, Portland ME

2009 State of the Art in ACS Therapy / Cardiology Conference
Maine Medical Center, Portland ME

2010 State of the Art in Revascularization Therapy in Acute Coronary Syndromes /
Medical Grand Rounds – Annual Julius Litter, M.D. Lecture
Metro West Medical Center, Framingham, MA

2014 State of the Art in Acute Coronary Syndromes/ Medical Grand Rounds
MetroWest Medical Center

National

1993 State of the Art Review of Thrombolysis / Medical Grand Rounds
Kensington General Hospital, Kensington NY

1995 Update on the Management of Acute MI, 10th Annual Joseph E. Malia Memorial
Lecture Series / Invited Lecture
South Side Hospital and Center for Continuing Education in the Health Sciences,
University of Pittsburgh Medical Center

1995 Current Management of Acute MI / Cardiology Grand Rounds
Sharp Memorial Hospital, San Diego CA

1995 New Horizons in the Treatment of Acute MI / Invited Lecture
Scripps Memorial Hospital, La Jolla CA

1995 Management of Early MI in the Community Hospital / Internal Medicine Update
Cambria-Somerset Council for Education of Health Professionals

1995 Update on Thrombolysis / Cardiology Grand Rounds
Albert Einstein Medical Center, Philadelphia PA

1995 Management of Acute MI / Medical Grand Rounds
New York Methodist Hospital

1996 Current management of the MI patient: Direct PTCA versus Thrombolysis /
Medical Grand Rounds
Indiana Hospital, Indiana PA

1996 An Update in Thrombolytic Therapy / Cardiology Grand Rounds
Chester County Hospital, West Chester PA

1996 Advances in Thrombolytic Therapy and Interventional Cardiology / Medical
Grand Rounds
Crozet Chester Medical Center, Philadelphia PA

1997 Update on Thrombolysis and Primary Angioplasty for Acute MI / Cardiology
Grand Rounds
Cedars-Sinai Medical Center, Los Angeles CA

1997 Update on Thrombolysis and Primary Angioplasty for Acute MI / Cardiology
Grand Rounds
Sunset Hospital Kaiser Foundation, Los Angeles CA

1997 Update on Thrombolysis and Primary Angioplasty for Acute MI / Cardiology
Grand Rounds
St Joseph Medical Center, Burbank CA

1997 The Open Artery Hypothesis: Past, Present and Future / Grand Rounds
American Heart Association of Indiana

1997 The Open Artery Hypothesis: Past, Present and Future / Grand Rounds
Methodist Hospital of Indiana

1997 The Open Artery Hypothesis: Past, Present and Future / Grand Rounds
Southwood Community Hospital

1997 The Open Artery Hypothesis: Past, Present and Future / Grand Rounds
University of California San Francisco

1997 The Open Artery Hypothesis: Past, Present and Future / Invited Lecture
8th Annual Van Fleit Lectureship t Joseph's Medical Center, South Bend IN

1997 Newer Methods of Assessing Coronary Blood Flow / Invited Lecture
Ellis Hospital, Schenectady NY

1997 Meta-analysis of Trials of Primary PTCA. Interventions in Acute Coronary
Syndromes Course / Course Lecture
Allegheny General Hospital

1997 Newer Thrombolytics. Interventions in Acute Coronary Syndromes Course /
Course Lecture
Allegheny General Hospital

1997 The TIMI Frame Count in Acute Coronary Syndromes and its Relationship to
Adverse Outcomes / Course Lecture
Allegheny General Hospital

1997 Newer Thrombolytics and Primary Angioplasty / Cardiology Grand Rounds
Daniel Freeman Memorial Hospital, Los Angeles CA

1997 The Open Artery Hypothesis: Past, Present and Future / Invited Lecture
St. Mary's Hospital, Long Beach CA

1997 Newer Thrombolytics and Primary Angioplasty / Cardiology Grand Rounds
St. Mary's Hospital, Long Beach CA

1997 Acute MI in 1997 / Medical Grand Rounds
Mercy Medical Center, Lakeland MI

1997 Revascularization Strategies in Acute MI / Cardiology Grand Rounds
Allegheny General Hospital

1998 TNK-tPA: From TIMI 10° to GUSTO IV: What can we expect? / Invited
Lecture
Frontiers in Interventional Cardiology: Head to Toe Percutaneous Intervention,
University of Texas Medical School

1998 Management of Acute MI / Medical Grand Rounds
St. Elizabeth's Hospital, Youngstown OH

1998 Current Revascularization Strategies in Acute MI / Grand Rounds
St. Joseph's Medical Center, Tacoma WA

1998 Management of Acute MI / Medical Grand Rounds
Port Townsend Medical Center, Port Townsend WA

1998 New Approaches to Thrombolytic Therapy for Acute MI / Grand Rounds
St. Joseph Medical Center, Fort Wayne IN

1998 New Revascularization Strategies in Acute MI / Invited Lecture
World Series of Cardiology annual lecture series, Akron General Hospital,
Akron, Ohio

1998 Modern Management of Acute Coronary Syndromes / Medical Grand Rounds
Fairview Hospital, Cleveland Clinic Hospital System

1998 Update on Management of Acute Coronary Syndromes / Symposium
Presentation
George Washington University Interventional Symposium, Bethesda MD

1999 Angiogenesis / Symposium Presentation

1999 Hospital Hilton Vascular Interventional Symposium, Hilton Head NC
 Point/Counterpoint: Controversies in Coronary Intervention. Primary PTCA
 versus Combination therapy in the era of GP 2b3a inhibition. C. Michael Gibson
 versus Cindy Grines / Conference
 1999 Transcatheter Therapeutics Conference (TCT), Washington DC
 Morphologic Lesion Assessment (IVUS and QCA): Clinical Applications and
 Trial Results / Conference
 2000 Transcatheter Therapeutics Conference (TCT), Washington DC
 Update on the Management of Acute MI / Symposium Presentation
 Southern Colorado Heart Institute's 18th Annual Symposium, Colorado Springs
 CO
 2000 Update on the Management of Acute MI / Invited Lecture
 Colorado Chapter of the American College of Cardiology
 2000 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 Krannert Heart Institute University of Indiana
 2000 The Open Vasculature Hypothesis / Invited Lecture
 The Indiana Chapter of the American Heart Association
 2000 Update on New Thrombolytic Agents / Grand Rounds
 Memorial Hospital, South Bend IN
 2000 The Open Artery Hypothesis / Invited Lecture
 Nebraska Heart Institute
 2000 State of the art in acute MI management / Grand Rounds
 Tripler Army Hospital, HI
 2000 State of the art in the management of acute MI / Medical Grand Rounds
 Queens Medical Center, HI
 2000 State of the art in the management of acute MI / Cardiology Grand Rounds
 Castle Medical Center, HI
 2000 New thrombolytic agents / Invited Lecture
 Annual National Meeting of the National Registry of Myocardial Infarction
 2000 Protecting the microvasculature in acute MI / Symposium Presentation
 Transcatheter Cardiovascular Therapeutics (TCT) 2000, Washington DC: AMI
 Intervention 2000 Symposium
 2000 Results of the ESPRIT angiographic substudy. New considerations on
 Optimizing Outcomes and Cost-Effectiveness in Percutaneous Coronary
 Intervention / Presentation
 Transcatheter Cardiovascular Therapeutics (TCT) 2000, Washington DC
 2000 The impact of glycoprotein IIb/IIIa inhibitors on the microcirculation /
 Presentation
 Transcatheter Cardiovascular Therapeutics (TCT) 2000, Washington DC
 2000 Weight adjusted dosing of the thrombolytic agents, the good and the bad /
 Symposium Presentation
 George Washington University Symposium, AHA 2000
 2000 State of the art in the Management of Acute MI / Cardiology Grand Rounds
 Montefiore Hospital, New York, NY
 2000 Acute MI Update / Cardiology Grand Rounds
 Saint Joseph's Mercy Hospital, Detroit MI

2000 State of the art in reperfusion therapy / Cardiology Grand Rounds
Henry Ford Hospital, Detroit MI

2000 Management of Acute MI / Cardiology Grand Rounds
Oakwood Health System, Detroit MI

2000 State of the art in reperfusion therapy / Emergency Medicine Grand Rounds
Detroit Receiving Hospital, Detroit MI

2001 Management of Acute MI / Grand Rounds
St. Michael's Hospital, Stevens Point WI

2001 State of the Art in Acute MI / Cardiology Grand Rounds
Mayo Clinic Hospital, Rochester MN

2001 Update on the Management of Acute MI / Grand Rounds
St. Luke's Hospital, Milwaukee WI

2001 State of the Art in Reperfusion Therapy / Presentation
American College of Cardiology Satellite Symposium, Lake Louise Canada

2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Baylor Medical Center, Houston TX

2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Herman Hospital, Houston TX

2001 State of the Art in Reperfusion Therapy / Invited Lecture
St. Luke's Hospital University of Texas, Houston TX

2001 Beyond TIMI Grade 3 Flow / Presentation
Duke Clinical Research / Cardiovascular Research Foundation Symposium,
American College of Cardiology Meetings, Atlanta GA

2001 The Benefits of An Aggressive Upstream Approach to Glycoprotein 2b3a
Inhibition / Presentation
American College of Cardiology Meetings, Atlanta GA

2001 The Safety of Weight Adjusting TNK / Presentation
American College of Cardiology Meetings, Atlanta GA

2001 Outlook for the Care of the ACS Patient / Presentation
Symposium, Miami FL

2001 State of the Art in Reperfusion Therapy / Presentation
Minneapolis Heart Institute Symposium, Minneapolis MN

2001 The Microvasculature / Grand Rounds
Hurley Medical Center, Flint MI

2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Fairview Medical Center, Cleveland Clinic Hospital, Cleveland OH

2001 State of the Art in Reperfusion Therapy / Invited Lecture
Toledo OH

2001 State of the Art in Reperfusion Therapy / Symposium Presentation
1st Annual Symposium on Cardiovascular Disease at Evanston Hospital,
Northwestern University, Chicago IL

2001 Management of Acute MI / Grand Rounds
Emory University, Atlanta GA

2001 State of the Art in Reperfusion Therapy / Invited Lecture
Hendrick Medical Center, Fort Wayne TX

2001 Update on the Management of Acute MI / Grand Rounds

Regions Hospital, Minneapolis MN

2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Prairie Heart Institute, Springfield IL

2001 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
University of West Virginia, Morgantown WV

2001 Management of Acute MI / Medical Grand Rounds
University of West Virginia, Morgantown WV

2001 Reperfusion / Invited Lecture
Johns Hopkins School of Medicine, Cardiovascular Division

2001 State of the Art in Reperfusion Therapy / Invited Lecture
Washington Hospital Center

2001 Historical Perspectives on Reperfusion Therapy / Grand Rounds
Mount Carmel Hospital, Columbus OH

2001 State of the Art in Reperfusion Therapy / Visiting Lectureship
St. Joseph's Hospital, Baptist Health Care System, Tampa FL

2002 State of the Art in Reperfusion Therapy / Invited Lecture
Fellows Conference, Baylor University, Houston TX

2002 Assessment of Epicardial and Tissue Level Perfusion / Cardiology Grand Rounds
University of Texas – Southwestern, Dallas TX

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
University of Alabama at Birmingham Medical Center

2002 State of the Art in Reperfusion Therapy / Medical Grand Rounds
Mercer University, Memorial Medical Center, Savannah GA

2002 State of the Art in Reperfusion Therapy / Cardiovascular Conference Lecture
Bergan Mercy Medical Center, Omaha NE

2002 State of the Art in Reperfusion Therapy / Cardiovascular Conference Lecture
Nebraska Heart Institute, Lincoln NE

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Orlando Regional Health Care System, Orlando FL

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Halifax Medical Center, Daytona FL

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
University of Virginia Medical Center, Charlottesville VA

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Lynchburg General Hospital, Charlottesville VA

2002 State of the Art in Reperfusion Therapy / Medical Staff Lecture
Good Samaritan Hospital, San Jose CA

2002 Thrombolytics: Combination Therapy and Beyond / Symposium Presentation
The San Fernando Valley Heart Institute's 8th Annual Cardiology Symposium,
Woodland Hills CA

2002 Unstable Angina: Moving Upstream to Treat Downstream Circulation /
Symposium Presentation
The San Fernando Valley Heart Institute's 8th Annual Cardiology Symposium,
Woodland Hills CA

2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
St. John's Hospital, Warren MI

- 2002 Thrombolytics: Strategies in ST Elevation MI / Symposium Presentation
3rd Annual Antithrombotic Therapy Symposium, Detroit MI
- 2002 Considerations When Evaluating Adjunctive Antiplatelet and Antithrombin
Therapy in Patients with non-ST Elevation ACS and Those Undergoing PCI /
Symposium Presentation
American College of Cardiology Scientific Sessions Satellite Symposium: New
insights on the Need For GP IIb/IIIa Inhibitor Therapy, Atlanta GA
- 2002 Current and Future Trends in Facilitated PCI / Symposium Presentation
American College of Cardiology Scientific Sessions Satellite Symposium: The
Future of Acute MI Care: Optimizing Pharmacologic and Interventional
Reperfusion, Atlanta GA
- 2002 State of the Art in Reperfusion Therapy / Medical Grand Rounds
University of Pittsburgh Medical Center
- 2002 State of the Art in Reperfusion Therapy / Cardiovascular Conference
Holy Cross Hospital, Ft. Lauderdale FL
- 2002 State of the Art in Reperfusion Therapy / Cardiovascular Conference
Memorial Regional Hospital, Hollywood FL
- 2002 State of the Art in Reperfusion Therapy / Cardiology Conference
East Jefferson Hospital, New Orleans LA
- 2002 Upstream Use of GP IIb/IIIa Therapies Along With Adjunctive Pharmacology, A
Changing Landscape of Acute Coronary Syndromes / Symposium Presentation
Admission to Discharge Symposium, New York NY
- 2002 State of the Art in Reperfusion Therapy / Medical Resident Lecture
South Shore Hospital, New Rochelle NY
- 2002 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
St. Luke's Hospital, Cedar Rapids IA
- 2002 Update: Evolution in the management of Acute Myocardial Infarction: Optimal
Pharmacologic and Interventional Reperfusion Strategies / Symposium
Presentation
12th Annual Cardiology at the BIX Symposium, Davenport, IA
- 2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
Hailfax Medical Center, Orlando FL
- 2002 Confrontation of Clot Busters: Treating Ischemic Coronary Artery Disease /
Symposium Presentation
Hailfax Medical Center Symposium, Orlando FL
- 2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
University of Chicago, Maywood IL
- 2002 Cardiac Catheterization Case Presentations / Catheterization conference
Memorial Hospital, Chicago IL
- 2002 New Insights into CPK elevations after PCI – MRI and Blush Studies /
Symposium Presentation
Transcatheter Cardiovascular Therapeutics (TCT) Meeting Session: New Insights
into CPK elevations after PCI – MRI and Blush Studies, Washington D.C.
- 2002 Surrogate Methodologies to Assess Reperfusion Success: Blush II – TIMI
Methodology and Data / Symposium Presentation
Transcatheter Cardiovascular Therapeutics (TCT) Meeting Session: Duke/CRF

- Special Concurrent Session: Optimal Reperfusion in AMI: Defining It, Achieving It, Washington D.C
- 2002 Rescue Intervention after Failed Lysis – the TIMI 10B and TIMI 14 Experiences / Symposium Presentation
Transcatheter Cardiovascular Therapeutics (TCT) Meeting Session: Harmonizing Pharmacologic and Mechanical Approaches in ACS and AMI – Part I: AMI – Rescue and Facilitated PCI, Washington D.C
- 2002 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
St. Joseph’s Hospital, Lexington KY
- 2002 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
Central Baptist Hospital, Lexington KY
- 2002 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
University of Tennessee Medical Center, Knoxville TN
- 2002 State of the Art in Reperfusion Therapy / Conference Lecture
Erlanger Medical Center, Chattanooga TN
- 2002 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
Memorial Hospital, Chattanooga TN
- 2002 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
York Hospital, York PA
- 2002 State of the Art in Reperfusion Therapy / Cardiology Fellows Meeting
Hershey Medical Center, Hershey PA
- 2002 ACS & Diabetes Mellitus: Is Microvascular Reperfusion the Missing Link? / Conference Presentation
The 2nd Annual Diabetes Summit: Linking Science to Medicine, Chicago IL
- 2002 Preservation of the Microvasculature During PCI: Rationale for GP IIb-IIIa Inhibitors / Symposium Presentation
American Heart Association Scientific Sessions Satellite Symposium: New Advances in GP IIb-IIIa Inhibition: From Pharmacodynamics to Inflammation to Pharmacogenesis, Chicago IL
- 2002 State of the Art in Revascularization Therapy in ACS / Cardiology Grand Rounds
Beth Israel Medical Center, Manhattan NY
- 2002 State of the Art in Revascularization Therapy in ACS / Invited Lecture
Long Island Jewish Hospital, Long Island NY
- 2002 State of the Art in Revascularization Therapy in ACS / Cardiology Cath Conference
Morristown Hospital, Morristown NJ
- 2002 State of the Art in Revascularization Therapy in ACS / Invited Lecture
Robert Wood Johnson Hospital, New Brunswick NJ
- 2003 State of the Art in Revascularization Therapy in ACS / Grand Round
Akron General Hospital, Akron OH
- 2003 State of the Art in Reperfusion Therapy / Clinical Conference Lecture
Elyria Memorial Hospital, Cleveland OH
- 2003 State of the Art in Reperfusion Therapy / Clinical Conference
St. Vincent’s Hospital, Toledo OH
- 2003 State of the Art in Reperfusion Therapy / Medical Grand Rounds
Wheeling Hospital, Wheeling WV

2003 State of the Art in Reperfusion Therapy / Symposium Presentation
Swedish American Hospital Symposium, Swedish American Hospital, Rockford IL

2003 State of the Art in Reperfusion Therapy / Medical Grand Rounds
Hindsdale Hospital, Hindsdale IL

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
Illinois Masonic Hospital, Chicago IL

2003 State of the Art in Revascularization Therapy in ACS / Cardiology Meeting
Central DuPage Hospital, Winfield IL

2003 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization Conference
Elmhurst Hospital, Elmhurst IL

2003 State of the Art in Reperfusion Therapy / Cardiology Section Meeting
Wakashau Memorial Hospital, Wakashau WI

2003 State of the Art in Reperfusion Therapy / Grand Rounds
Sinai Hospital, Milwaukee WI

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
Reading Medical Center, Reading PA

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
St. Joseph's Hospital, Reading PA

2003 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
Winchester Hospital, Winchester VA

2003 State of the Art in Reperfusion Therapy / Clinical Conference
Methodist Hospital, Dallas TX

2003 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization Conference
Buffalo General Hospital, Buffalo NY

2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
Christ Hospital, Chicago IL

2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
University of Chicago, Chicago IL

2003 Role of the Direct Thrombin Inhibitors in PCI: Considerations on the need for GP IIb-IIIa Inhibitor Therapy / Symposium Presentation
American Heart Association Scientific Sessions Satellite Symposium:
Controversies Surrounding the need for GP IIb-IIIa Inhibitor Therapy: Examining the Evidence, Chicago IL

2003 New Perspectives and Points of Contention in ACS / Panel Discussion
American Heart Association Scientific Sessions Satellite Symposium: New Perspectives and Points of Contention in ACS, Chicago IL

2003 State of the Art in Reperfusion Therapy / Clinical Conference
Riverside Medical Center, Kankakee IL

2003 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
St. Luke's Hospital, Cedar Rapids IL

2003 State of the Art in Reperfusion Therapy / Grand Rounds
Mercy Medical Center, Des Moines IA

2003 State of the Art in Reperfusion Therapy / Grand Rounds

University of Iowa, Des Moines IA
 2003 State of the Art in Reperfusion Therapy / Clinical Conference
 St. Luke's Hospital, St. Louis, MO
 2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 St. Mary's Hospital, St. Louis, MO
 2003 State of the Art in Revascularization Therapy in ACS / Cardiology Grand Rounds
 Einstein Medical Center, Philadelphia PA
 2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Lecture
 Cooper Hospital, Camden NJ
 2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 St. Mary's Hospital, Philadelphia PA
 2003 State of the Art in Revascularization Therapy / Grand Rounds
 Our Lady of Lourdes Hospital, Lafayette LA
 2003 State of the Art in Revascularization Therapy / Grand Rounds
 Christus Schumpert St. Mary Place, Shreveport LA
 2003 State of the Art in Revascularization Therapy / Grand Rounds
 Willis Knighton Medical Center, Shreveport LA
 2003 State of the Art in Revascularization Therapy in ACS / Symposium Presentation
 Condell Medical Center, Chicago IL
 2003 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 Columbia University Medical Center, New York NY
 2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Lecture
 St. Michael's Medical Center, Newark NJ
 2003 State of the Art in Reperfusion Therapy / Grand Rounds
 Kennedy Memorial Hospital, Cherry Hill NJ
 2003 State of the Art in Reperfusion Therapy / Clinical Conference
 Rex Hospital, Raleigh NC
 2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 East Carolina University, Greenville NC
 2003 State of the Art in Reperfusion Therapy / Grand Rounds
 University of North Carolina, Chapel Hill NC
 2003 State of the Art in Reperfusion Therapy / Clinical Conference
 Craven Regional Medical Center, New Bern NC
 2003 Aspirin, Warfarin, Plavix, Lovenox, and Aggrenox – Who, What, When and Why
 / Symposium Presentation
 Prairie Cardiovascular Consultants Symposium, St. Louis MO
 2003 State of the Art in Reperfusion Therapy / Clinical Conference
 Mercy Franciscan Hospital – Mt. Airy Campus, Cincinnati OH
 2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 Kettering Medical Center, Cincinnati OH
 2003 State of the Art in Reperfusion Therapy / Clinical Conference
 Dayton Heart Hospital, Dayton OH
 2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 St. Joseph Hospital, Lexington KY

2003 State of the Art in Reperfusion Therapy / Cardiology Conference
University of Tennessee Medical Center, Knoxville TN

2003 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
Johnson Medical Center, Johnson City TN

2003 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization
Conference
Holston Valley Medical Center, Kingsport TN

2003 State of the Art in Reperfusion Therapy / Clinical Conference
Parkwest Hospital, Knoxville TN

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
Erlanger Medical Center, Chattanooga TN

2003 State of the Art in Revascularization Therapy in ACS / Symposium Presentation
15th Annual Invitational Symposium Akron General Medical Center, Akron OH

2003 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Fairview General Hospital, Cleveland OH

2003 Relationship of Microvascular Flow and Outcomes in ACS Prior to and After
PCI / Symposium Presentation
Transcatheter Cardiovascular Therapeutics (TCT) Meeting Session: Cutting Edge
Strategies in ACS and MI, Washington D.C

2003 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization
Conference
Seton Medical Center, San Carlos CA

2003 Reperfusion / Medical Grand Rounds
San Jose Medical Center, San Jose CA

2003 Reperfusion / Cardiology and Cardiac Surgery Conference
Salinas Valley Memorial Healthcare System, Salina CA

2003 Reperfusion / Grand Rounds
Dominican Hospital, Santa Cruz CA

2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
University of Michigan, Ann Arbor MI

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference
Borgess Hospital, Kalamazoo MI

2003 Relationship of Microvascular Flow and Outcomes in ACS / Symposium
Presentation
American Heart Association Scientific Sessions Satellite Symposium: Standards
in ACS for 2004 – From Diagnosis to Discharge – The Complementary Roles of
Drug Therapies and Devices, Orlando FL

2003 Care of ST-segment Elevation Patients: Insights from NRM I / Symposium
Presentation
American Heart Association Scientific Sessions Satellite Symposium:
International QI Summit on ACS, Orlando FL

2003 State of the Art in Revascularization Therapy in ACS / Cardiology Grand Rounds
St. Luke's Roosevelt Medical Center, New York NY

2003 State of the Art in Revascularization Therapy in ACS / Grand Rounds
University of Pennsylvania, Philadelphia PA

2003 State of the Art in Revascularization Therapy in ACS / Clinical Conference

2003 Cooper Medical Center, Philadelphia PA
 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 Deborah Heart and Lung Center, Brown Mills NJ
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Maury Regional Medical Center, Columbia TN
 2004 Reperfusion / Clinical Conference
 Gateway Medical Center, Clarksville TN
 2004 Reperfusion / Grand Rounds
 Cedars Medical Center, Miami FL
 2004 Reperfusion / Clinical Conference
 South Miami Hospital, Miami FL
 2004 Reperfusion / Clinical Conference
 Memorial Regional Hospital, Hollywood FL
 2004 Reperfusion / Clinical Conference
 Broward General Hospital, Ft. Lauderdale FL
 2004 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 University of North Texas, Ft. Worth TX
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Heart Place Medical Center, Arlington TX
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Presbyterian Medical Center, Dallas TX
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Baylor Garland Medical Center, Garland TX
 2004 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 Grossmont Hospital, San Diego CA
 2004 State of the Art in Reperfusion Therapy / Clinical Conference
 Santa Monica Cardiology, Santa Monica CA
 2004 State of the Art in Reperfusion Therapy / Grand Rounds
 St. Joseph Medical Center, Burbank CA
 2004 State of the Art in Reperfusion Therapy / Cardiac Catheterization Conference
 Holy Cross Medical Center- Oliveview/UCLA, Mission Hills CA
 2004 State of the Art in Reperfusion Therapy / Grand Rounds
 Sharp Memorial Hospital, San Diego CA
 2004 State of the Art in Reperfusion Therapy / Cardiology Grand Rounds
 UCLA Medical Center, Westwood CA
 2004 The Open Artery Hypothesis / Clinical Conference
 Community Medical Center, Scranton PA
 2004 The Open Artery Hypothesis / Clinical Conference
 Mercy Hospital, Scranton PA
 2004 The Open Artery Hypothesis / Clinical Conference
 Geisenger Medical Center, Danville PA
 2004 The Open Artery Hypothesis / Clinical Conference
 Washington Adventist Hospital, Tacoma Park, MD
 2004 The Open Artery Hypothesis / Clinical Conference
 Louisiana Heart Hospital, La Combe LA
 2004 State of the Art in Reperfusion Therapy / Grand Rounds

2004 Our Lady of the Lake Regional Medical Center, Baton Rouge LA
 Clinical Implications of Concomitant Non-Opioid Analgesia in Patients with or at
 Risk of Cardiovascular Disease / Symposium Presentation
 American Heart Association Satellite Symposium, New Orleans LA
 2004 Non-Inferiority Trials: Future Role in Clinical Studies / Symposium Presentation
 American Heart Association Satellite Symposium: Future Directions in the
 Management of ACS, New Orleans LA
 2004 State of the Art in Reperfusion Therapy / Clinical Conference
 Cleveland Clinical Hospital, Weston FL
 2004 State of the Art in Reperfusion Therapy / Clinical Conference
 Jackson Memorial Hospital/University of Miami, Miami FL
 2004 State of the Art in Reperfusion Therapy / Grand Rounds
 Gastonia Memorial Hospital, Gastonia NC
 2004 State of the Art in Reperfusion Therapy / Clinical Conference
 Chandler Regional Medical Center, Phoenix AZ
 2004 State of the Art in Revascularization Therapy in ACS / Grand Rounds
 St. Joseph's Hospital, Phoenix AZ
 2004 State of the Art in Revascularization Therapy in ACS / Keynote Speaker
 American College of Osteopathic Emergency Physicians Annual Meeting,
 Phoenix AZ
 2004 State of the Art in Revascularization Therapy in ACS / Residents Conference
 Maricopa Medical Center, Phoenix AZ
 2004 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization
 Conference
 Krannert Institute of Cardiology, Indianapolis IN
 2004 Treatment of Acute MI: Pharmaco-Invasive Approach –
 Pharmacology/Thrombosis / Symposium Presentation
 Updates in Thrombosis Conference Symposium, Indianapolis IN
 2004 Optimal Management of Unstable Angina/non-ST Elevation MI / Symposium
 Presentation
 Emory University Symposium – EPIC 2004, Atlanta GA
 2004 Facilitated vs. Rescue Angioplasty / Conference Presentation
 Cardiovascular Research Institute 2004 Scientific Meeting Session: Complex
 Coronary & Peripheral Interventions, Washington D.C
 2004 Inflammatory Cessation with Integrilin / Conference Presentation
 Cardiovascular Research Institute 2004 Scientific Meeting Session: Complex
 Coronary & Peripheral Interventions, Washington D.C.
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Lower Bucks Hospital, Bristol PA
 2004 State of the Art in Revascularization Therapy in ACS / Cardiac Cath Conference
 York Hospital, York PA
 2004 State of the Art in Revascularization Therapy in ACS / Clinical Conference
 Shadyside Hospital, Pittsburgh PA
 2004 State of the Art in Revascularization Therapy in ACS / Cardiac Catheterization
 Conference
 Wilson Hospital, Johnson City NY

2004 State of the Art in Revascularization Therapy in ACS / Grand Rounds
Mother Francis Hospital, Tyler TX

2004 State of the Art in Reperfusion Therapy / Clinical Conference
Louisiana Willis Knighton Medical Center, Shreveport LA

2004 State of the Art in Reperfusion Therapy / Clinical Conference
LSU Medical Center, Shreveport LA

2004 State of The Art in Revascularization Therapy in ACS / Grand Rounds
United Regional Medical Center, Wichita Falls TX

2004 State of The Art in Revascularization Therapy in ACS / Basic Science
Conference
St. Luke's Medical Center, Houston TX

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Clear Lake Regional Medical Center, Webster TX

2004 State of The Art in Revascularization Therapy in ACS / Grand Rounds
St. Luke's Medical Center, Houston TX

2004 State of The Art in Revascularization Therapy in ACS / Cardiac Catheterization
Conference
Baylor/Methodist Medical Center, Houston TX

2004 State of the Art in Reperfusion Therapy / Grand Rounds
Kennestone Hospital, Marietta GA

2004 State of The Art in Revascularization Therapy in ACS / Grand Rounds
St. Joseph Hospital, Pontiac MI

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
McLaren Hospital, Flint MI

2004 State of the Art in Reperfusion Therapy / Clinical Conference
Veterans Administration Medical Center, Washington D.C

2004 State of the Art in Reperfusion Therapy / Grand Rounds
Mercy Franciscan Hospital, Cincinnati OH

2004 State of the Art in Reperfusion Therapy / Clinical Conference
Ohio State University Medical Center, Columbus OH

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Parkridge Medical Center, Chattanooga TN

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Chattanooga Heart Institute, Chattanooga TN

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Erlanger Medical Center, Chattanooga TN

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Baptist Hospital, Memphis TN

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Shands Hospital – University of Florida, Jacksonville FL

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Flagler Hospital, Jacksonville FL

2004 State of the Art in Reperfusion Therapy / Grand Rounds
University of Nebraska Hospital, Lincoln NE

2004 State of the Art in Reperfusion Therapy / Grand Rounds
St. Luke's Medical Center (Mid American Heart), Kansas City MO

2004 Recognition of Myocardial Ischemia and Myocardial Infarction – Risk Stratification to Decrease Mortality / Symposium Presentation
Cardiovascular Institute of the South Symposium

2004 Update on Clinical Treatment for ACS / Symposium Presentation
American Heart Association Northeast Affiliate Symposium, Fishkill NY

2004 State of the Art in Reperfusion Therapy / Clinical Conference
Good Samaritan Hospital, Suffern NY

2004 State of the Art in Reperfusion Therapy / Guest Lecture
Texas Heart Institute Symposium: Advancing the Standard of Care

2004 Late Breaking Clinical Trials: PROTECT Results / Symposium Presentation
American Heart Association Satellite Symposium, New Orleans LA

2004 The Need for GP IIb/IIIa Inhibitors in PCI: Result from PROTECT / Symposium Presentation
American Heart Association Satellite Symposium: (HSC/DCRI) Late Breaking Findings on GP IIb/IIIa Inhibition, New Orleans LA

2004 Pathophysiology of the Microvasculature / Research Conference
Washington Hospital Center, Washington D.C.

2004 Management of STEMI and non-STEMI patients: The importance of the Microvasculature / Cardiac Cath Conference
Washington Hospital Center, Washington D.C

2004 State of the Art in Reperfusion Therapy / Grand Rounds
Good Samaritan Hospital, Baltimore MD

2004 State of The Art in Revascularization Therapy in ACS / CCU Conference
University of North Carolina at Chapel Hill, Chapel Hill NC

2004 State of The Art in Revascularization Therapy in ACS / Cardiac Cath Conference
Pitt Memorial Hospital, Greenville NC

2004 State of The Art in Revascularization Therapy in ACS / Clinical Conference
REX Healthcare, Raleigh NC

2004 State of the Art in Reperfusion Therapy / Cardiac Cath Conference
Heart Hospital of New Mexico, Albuquerque NM

2004 State of the Art in Reperfusion Therapy / Grand Rounds
St. Vincent Hospital, Santa Fe NM

2005 Guidelines Based Therapy and Treatment of the Microvasculature / Grand Rounds
Hahnemann University Hospital, Philadelphia PA

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Our Lady of Lourdes Hospital, Camden NJ

2005 State of the Art in Reperfusion Therapy / Grand Rounds
University of Pittsburgh Medical Center, Pittsburgh PA (Schering-Plough)

2005 State of the Art in Reperfusion Therapy / Grand Rounds
West Pennsylvania Hospital, Pittsburgh PA (Millennium Pharmaceuticals, Inc.)

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Stanford University Medical Center, Stanford CA (Millennium Pharmaceuticals, Inc.)

2005 State of The Art in Revascularization Therapy in ACS / Cardiology Fellows Journal Club

California Pacific Medical Center, San Francisco CA (Millennium Pharmaceuticals, Inc.)

2005 State of The Art in Revascularization Therapy in ACS / Symposium Presentation
Sutter Health Institute 5th Annual Current Therapy in Cardiovascular Disease Symposium, Sacramento, CA

2005 The PROTECT Trial / Symposium Presentation
American College of Cardiology Scientific Session Satellite Symposium:
Optimal Treatment of Patients with ACS Throughout the Spectrum of Risk,
Orlando FL

2005 Treatment of the Microvasculature / Medical Grand Rounds
St. Joseph Regional Medical Center, Milwaukee WI

2005 Treatment of the Microvasculature / Grand Rounds
St. Luke's Hospital, Milwaukee WI

2005 Facilitated vs. Rescue Angioplasty / Presentation
CRT Session: Complex Coronary Interventions, Washington D.C.

2005 Inflammatory Cessation with Integrilin / Presentation
CRT Session: Complex Coronary Interventions, Washington D.C.

2005 Treatment of the Microvasculature / Grand Rounds
St. Agnes Hospital, Baltimore MD

2005 Treatment of the Microvasculature / Grand Rounds
University of Maryland, Baltimore MD

2005 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Wilford Hall Medical Center, San Antonio TX (Millennium Pharmaceuticals, Inc.)

2005 State of The Art in Revascularization Therapy in ACS / Grand Rounds
Methodist Hospital, San Antonio TX (Millennium Pharmaceuticals, Inc.)

2005 State of The Art in Revascularization Therapy in ACS / Clinical Conference
Audie Murphy Memorial Veterans Hospital, San Antonio TX (Millennium Pharmaceuticals, Inc.)

2005 Treatment of the Microvasculature / Symposium Presentation
Piedmont Hospital 16th Annual Cardiovascular Symposium, Atlanta GA

2005 Pharmacologic and Percutaneous Management of ST Elevation MI: the
Importance of Time and Myocardial Perfusion / Cardiovascular Educational
Presentation
Health East – St. Joseph's Hospital, St. Paul MN (Genentech)

2005 Pharmacologic and Percutaneous Management of ST Elevation MI: the
Importance of Time and Myocardial Perfusion / Clinical Conference
Fairview Southdale Hospital, St. Paul MN (Genentech)

2005 Pharmacologic and Percutaneous Management of ST Elevation MI: the
Importance of Time and Myocardial Perfusion / Clinical Conference
University of Minnesota Hospital, St Paul MN (Schering-Plough)

2005 Pharmacologic and Percutaneous Management of ST Elevation MI: the
Importance of Time and Myocardial Perfusion / Grand Rounds
United Hospital Foundation St Paul's Heart Clinic, St Paul MN (Genentech)

2005 Protecting the Myocardium During PCI – Key Strategies / Presentation
Hilton Head, NC

2005 State of the Art in Reperfusion Therapy / Catheterization Conference (CME program)
Hoag Hospital, Newport Beach CA (Millennium Pharmaceuticals, Inc.)

2005 State of the Art in Reperfusion Therapy / Catheterization Conference
Downey Regional Medical Center, Downey CA

2005 State of the Art in Reperfusion Therapy / Cardiology Fellows Conference
Loma Linda Medical Center, Loma Linda CA (Millennium Pharmaceuticals, Inc.)

2005 State of the Art in Reperfusion Therapy / Grand Rounds (CME program)
Fountain Valley Regional Hospital, Fountain Valley CA (Millennium Pharmaceuticals, Inc.)

2005 State of the Art in Reperfusion Therapy / Catheterization Conference
Ventura Community Memorial Hospital, Ventura CA (Millennium Pharmaceuticals, Inc.)

2005 State of the Art in Reperfusion Therapy / Cardiology Meeting
Santa Barbara Cottage Hospital, Santa Barbara CA

2005 Predicting Outcomes in myocardial and ischemic syndromes: Clinical History, Bio Markers, Coronary Flow Rates: can we change outcome? / Catheterization Conference (CME program)
Medical College of Virginia, Richmond VA (Millennium Pharmaceuticals, Inc.)

2005 Predicting Outcomes in myocardial and ischemic syndromes: Clinical History, Bio Markers, Coronary Flow Rates: can we change outcome? / Clinical Conference (CME program)
Naval Medical Center, Portsmouth VA (Millennium Pharmaceuticals, Inc.)

2005 Updates in ACS: Risk Assessment & Treatment Strategies / Clinical Conference
Lewis-Gale Medical Center, Salem VA (Schering-Plough)

2005 Treatment Strategies in PCI / Clinical Conference
Roanoke Memorial Hospital, Roanoke VA (Schering-Plough)

2005 Evolution of Acute MI Care / Cardiology Fellow's Program
University of California San Francisco

2005 Evolution of Acute MI Care / Clinical Conference
O'Connor Hospital, San Jose CA (Schering-Plough)

2005 Timing Issues in Primary PCI / Symposium Presentation
Transcatheter Cardiovascular Therapeutics (TCT) Symposium: Evolving Strategies in the Management of AMI, Washington DC

2005 Management of ACS: A Clinical Trial Update / Clinical Conference
Robert Wood Johnson Hospital, New Brunswick NJ

2005 State of the Art in Reperfusion Therapy / Clinical Conference
St. Anthony's Medical Center, St Louis MO (Schering-Plough)

2005 Late Breaking Clinical Trial TITAN/TIMI 34: Upstream IIb/IIIa in MI Patients Undergoing MI Patients Undergoing PCI / Symposium Presentation
American Heart Association THI Symposium, Dallas TX

2005 An Evaluation of the use of IIb/IIIa Inhibitors in ACS: Emergency Department versus the cath lab / Symposium Presentation
Symposium: Improving Outcomes in the Management of Patients with non-ST-segment Elevation ACS: New Findings, Clinical Initiatives, Dallas TX

2005 Pre-PCI TNK is Associated with Improved Myocardial Perfusion Following PCI: Data from the GRACIA II Trial / Conference Presentation
American Heart Association Session: Featured Research: STEMI-Facilitated PCI, Dallas TX

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Pinnacle Health Care at Harrisburg Hospital, Harrisburg, PA

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Lehigh Valley Hospital, Allentown, PA

2005 State of the Art in Reperfusion Therapy / Clinical Conference
St. Mary's Hospital, Langhorne, PA

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Wake Forest Baptist Medical Center, Winston Salem NC

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Forsyth Medical Center, Winston Salem NC

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Cardiovascular Associates, Kingsport TN

2005 State of the Art in Reperfusion Therapy / Clinical Conference
St. Luke's Medical Center, Milwaukee WI

2005 State of the Art in Reperfusion Therapy / Dinner Program
Phoenix AZ

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Sharp Memorial Hospital, San Diego CA

2005 State of the Art in Reperfusion Therapy / Clinical Conference
Sharp Grossmont Hospital, La Mesa CA

2006 State of the Art in Revascularization Therapy / Clinical Conference
Florida Hospital, Orlando FL (Schering-Plough)

2006 State of the Art in Revascularization Therapy / Clinical Conference
Orlando Heart Center, Orlando FL (Schering-Plough)

2006 State of the Art in Revascularization Therapy / Clinical Conference
Memorial Regional Hospital, Hollywood FL

2006 Treatment of the Microvasculature / Symposium Presentation
St. Luke's Episcopal Hospital Houston TX

2006 Thrombolysis in Myocardial Perfusion Grade and Outcome / Symposium Presentation
American College of Cardiology Symposium: Role of Microcirculation in AMI: Myocardial Salvage after the 4-Hour Window, Atlanta GA

2006 What will be the Clinical Impact of New Data from ACC 2006? / Forum Presentation
American College of Cardiology International ACS Forum, Atlanta GA

2006 State of the Art in Revascularization Therapy / Grand Rounds
Southshore Hospital, Trenton MI (Schering-Plough)

2006 Acute Coronary Syndromes / Symposium Presentation
Henry Ford Antithrombotic Symposium, Detroit MI

2006 Management of Acute MI / Cardiology Conference
St John Hospital, Detroit MI (Schering-Plough)

2006 State of the Art in Revascularization Therapy / Grand Rounds

2006 St John Macomb Hospital, Warren MI (Schering-Plough)
 Management of Acute MI / Conference
 Henry Ford Hospital, Detroit MI (Schering-Plough)
 2006 State of the art in revascularization therapy in ACS / Cath Lab Conference
 Morristown Memorial Hospital, Morristown NJ
 2006 ACS: An update from the ACC 06 Scientific Sessions / Clinical Conference
 Robert Wood Johnson University Hospital, New Brunswick NJ
 2006 Current Guidelines and Report Card / Symposium Presentation
 CRT: ACS & AMI Management, Washington DC
 2006 Glycoprotein IIb/IIIa Inhibitors in PCI and ACS: How Early Should we Give
 Them? / Symposium Presentation
 CRT: ACS & AMI Management, Washington DC
 2006 Thrombolysis for Acute AMI: Lessons from ASSENT 4 / Symposium
 Presentation
 CRT: ACS & AMI Management, Washington DC
 2006 Debate I: Superior Strategies for AMI Management - No Need for Facilitated
 Pharmacology / Symposium Presentation
 CRT: ACS & AMI Management, Washington DC
 2006 State of the Art in Revascularization Therapy / Clinical Conference
 Cedars-Sinai Hospital, Los Angeles CA (Schering-Plough)
 2006 Adjunctive Pharmacologic Therapy for PCI and ACS and Role on Clinical
 Outcomes / Symposium Presentation
 2006 The Open Muscle Hypothesis / Cath Lab Conference
 Inova Fairfax Hospital, Falls Church VA
 2006 Management of Acute MI / Conference
 Washington University (Barnes) Medical Center St Louis, MO (Schering-Plough)
 2006 Management of Acute MI / Grand Rounds
 St. Louis University Hospital, St Louis MO
 2006 State of the art in ACS / Medical Grand Rounds
 Charleston Area Medical Center, Charleston WV (Schering-Plough)
 2006 State of the art in ACS / Clinical Conference
 Lake Cumberland Regional Hospital, Somerset KY (Schering-Plough)
 2006 State of the art in ACS / Clinical Conference
 Marymount Hospital, London KY (Schering-Plough)
 2006 The Open Muscle Hypothesis / Cath Lab Conference
 University of North Carolina, Chapel Hill NC
 2006 State of the Art in Revascularization Therapy / Cardiology Grand Rounds
 Temple University, Philadelphia PA
 2006 The Open Muscle Hypothesis / Cath Lab Conference
 St. Luke's Hospital, Allentown PA
 2006 The Open Muscle Hypothesis / Cath Lab Conference
 Memorial Regional Hospital, Hollywood FL (Schering-Plough)
 2006 Management of Acute MI / Clinical Conference
 Broward General Medical Center, Ft. Lauderdale FL (Schering-Plough)
 2006 Pharmacoinvasive Management of ACS: Applying the Expanding Evidence Base
 to Real World Issue / Symposium Presentation

- 2006 Transcatheter Cardiovascular Therapeutics (TCT) Symposium, Washington DC
Current Therapies and Issues Guiding Research in the Chronic Care of ACS
Patients / Symposium Presentation
Symposium: Future of Oral Anticoagulation: Exploring Novel Agents to Manage
Thrombosis in Acute Coronary Syndromes and Atrial Fibrillation, Chicago IL
(Scios)
- 2006 Updates to the Management of Acute Coronary Syndromes: ExTRACT TIMI 25
Subgroup Analysis / Ask the Experts Discussion
American Heart Association, Chicago IL
- 2006 Xa vs. LMWH: Which to Choose? / Ask the Experts Discussion
American Heart Association, Chicago IL
- 2006 Optimizing outcomes in ACS and PCI: Evaluating Findings from Recent Clinical
Trials in Antithrombin Therapy / Ask the Experts Discussion
American Heart Association, Chicago IL
- 2006 Adjunctive antithrombotic therapy in ST-segment elevation myocardial infarction
(STEMI) / Expert Panel Discussion CME Program
The Heart.org, Chicago IL
- 2006 The Pharmacoinvasive strategy in STEMI / Symposium Presentation
The XII Annual Duke ACS Symposium: Measuring a Decade of Progress in
Antithrombotic Therapy, Chicago IL
- 2006 Association of Treatment with Non-Steroidal Anti-inflammatory agents
(NSAIDS) on Study Entry with 30 Day Adverse Outcomes Among ST Elevation
MI (STEMI) Patients Treated with a Fibrinolytic Agent: An EXTRACT – TIMI
25 Analysis / Oral Presentation
American Heart Association Session: Contemporary Issues for Antiplatelet
Therapy in ACS, Chicago IL
- 2006 Association of Ventricular Fibrillation and Ventricular Tachycardia (VT/VF)
with Impaired TIMI Myocardial Perfusion Grades (TMPG) Even in the Presence
of Normal TIMI Grade 3 Flow / Oral Presentation
American Heart Association Session: Insights into Mechanisms of Ventricular
Arrhythmias, Chicago IL
- 2006 State of the Art in Revascularization Therapy / Clinical Conference
UPMC Presbyterian Hospital, Pittsburgh PA (Schering-Plough)
- 2006 State of the Art in Revascularization Therapy / Clinical Conference
UPMC Shadyside, Pittsburgh PA (Schering-Plough)
- 2006 State of the Art in Revascularization Therapy / Cardiology Grand Rounds
West Moreland General Hospital, Greensburg PA (Schering-Plough)
- 2007 The Open Muscle Hypothesis / Cath Lab Conference
St. Joseph's Hospital, Lexington KY (Schering-Plough)
- 2007 Management of Acute MI / Clinical Conference
The Baptist Heart and Vascular Institute, Lexington KY (Schering-Plough)
- 2007 State of the art in ACS / Clinical Conference
Community Medical Center, Scranton PA (Schering-Plough)
- 2007 State of the art in ACS / Grand Rounds
Mercy Hospital, Scranton PA (Schering-Plough)
- 2007 State of the Art in Revascularization Therapy / Cardiology Grand Rounds

Pocono Medical Center, East Stroudsburg PA (Schering-Plough)

2007 State of the art in ACS / Fellow's Conference

St. Luke's Medical Center, Kansas City MO (Schering-Plough)

2007 State of the art in ACS / Fellow's Conference

Kansas University Medical Center, Kansas City KA (Schering-Plough)

2007 State of the art in ACS / Conference (CME program)

Research Medical Center, Kansas City MO (Schering-Plough)

2007 Glycoprotein IIb/IIIa Inhibitors in PCI and ACS: How Early Should We Give Them? / Symposium Presentation

CRT Session: ACS & AMI Management, Washington DC

2007 Insights to the Latest TIMI Trials / Symposium Presentation

CRT Session: ACS & AMI Management, Washington DC

2007 What Should be the Upstream Therapy in ACS: Bivalirudin, Low Molecular Heparin, Fondaparinux, IIB/IIIA? / Panel Discussion

CRT Session: ACS & AMI Management, Washington DC

2007 Who Should Get Lytic Therapy Prior to PCI? / Symposium Presentation

CRT Session: ACS & AMI Management, Washington DC

2007 Complex PCI: What is the Right Drug cocktail? / Conference Presentation

American College of Cardiology i2 Summit Lunch and Learn Session, New Orleans LA

2007 Platelet Glycoprotein IIb/IIIa Inhibitors: When do we need them? / Conference Presentation

American College of Cardiology Mini Course: Antithrombotic therapy in ACS and AMI: State of the art 2007, New Orleans LA

2007 Targeted Inhibition of alpha-protein Kinase C to Ameliorate Reperfusion Injury During Primary PCI for Acute MI: Results from DELTA MI Study / Conference Presentation

American College of Cardiology i2 Special Session Late Breaking Clinical Trials II, New Orleans LA

2007 State of the art in ACS / Fellow's Conference

Vanderbilt Med Center, Nashville TN

2007 ACC 2007 Update / Grand Rounds

Norfolk General Hospital, Norfolk VA (Schering-Plough)

2007 Acute Coronary Syndromes / Fellow's Conference

Washington Hospital Center, Washington DC (Schering-Plough)

2007 State of the art in ACS / Clinical Conference

Pitt County Memorial Hospital, Greenville NC (Schering-Plough)

2007 State of the art in ACS / Clinical Conference

Wake Medical Center, Raleigh NC (Schering-Plough)

2007 The Open Muscle Hypothesis / Clinical Conference

Parrish Medical Center, Titusville FL

2007 The Open Muscle Hypothesis / Clinical Conference

Baptist Hospital, Jacksonville FL

2007 The Open Muscle Hypothesis / Clinical Conference

Memorial Hospital, Jacksonville FL

2007 State of the art in ACS / Grand Rounds

2007 Riverside Medical Center Kankakee, IL (Schering-Plough)
 Management of Acute MI / Grand Rounds
 Rush University Medical Center, Chicago IL
 2007 Management of Acute MI / Clinical Conference
 Condell Hospital, Libertyville IL (Schering-Plough)
 2007 State of the art in ACS / Clinical Conference
 White Memorial Medical Center, Los Angeles, CA
 2007 The Open Muscle Hypothesis / Cath Lab Conference
 Encino-Tarzana Regional Medical Center, Los Angeles CA
 2007 State of the art in ACS / Clinical Conference
 St. John's Hospital, CA
 2007 Management of Acute MI / Clinical Conference
 Riverside Hospital, Columbus OH
 2007 Management of Acute MI / Grand Rounds
 Heart Hospital of New Mexico, Albuquerque NM (Schering-Plough)
 2007 Management of Acute MI / Emergency and Cardiology Conference
 St. Vincent's Vascular and Heart Center, Toledo OH (Schering-Plough)
 2007 The Open Muscle Hypothesis / Cath Lab Conference
 Sparrow Professional Building, Lansing, MI
 2007 State of the art in ACS / Clinical Conference
 Borgess Medical Center, Kalamazoo MI
 2007 State of the art in ACS / Clinical Conference
 Cape Fear Valley Regional Medical Center, Fayetteville NC (Schering-Plough)
 2007 State of the art in ACS / Clinical Conference
 UNC Hospital, Chapel Hill NC (Schering-Plough)
 2007 Welcome and Overview & Interactive Discussion of Case Studies / Symposium
 Presentation
 Symposium: Making your case: Up to date answers for developing trends in PCI,
 Washington DC (Sanofi-aventis, Rockpointe)
 2007 Antiplatelet therapy: anti-ischemic benefits versus bleeding risk / Symposium
 Presentation
 Symposium: Antiplatelet treatment for ACS: Weighing Long-term outcomes vs.
 short-term risk, Washington DC (Schering-Plough)
 2007 The Evolution of Antithrombotic Care in ACS / Symposium Presentation
 Symposium, Washington DC (Scios)
 2007 Getting in the Stream of Antithrombotic Therapy for ACS – What do the trials
 tell us? /
 Symposium: Critical Challenges in Cardiovascular Medicine, Washington DC
 (MedCo)
 2007 State of the art in ACS / Grand Rounds
 Geisinger Hospital, Danville PA (Schering-Plough)
 2007 State of the art in ACS / Grand Rounds
 Wilson Hospital, Johnson City NY (Schering-Plough)
 2008 The Open Muscle Hypothesis / Cath Lab Conference
 Baystate Medical Center, Springfield MA (Schering-Plough)
 2008 State of the Art in Revascularization Therapy / Clinical Conference

2008 Good Samaritan Hospital, Los Angeles CA
 State of the art in ACS / Grand Rounds
 Doylestown Hospital, Doylestown PA (Schering-Plough)
 2008 The Open Muscle Hypothesis / Cath Lab Conference
 Abington Memorial Hospital, Abington PA (Schering-Plough)
 2008 State of the art in ACS / Clinical Conference
 Bryn Mawr Hospital, Bryn Mawr PA (Schering-Plough)
 2008 State of the art in ACS / Clinical Conference
 Indiana Heart Hospital, Indianapolis IN (Schering-Plough)
 2008 State of the art in ACS / Grand Rounds
 Methodist Hospital, Indianapolis IN (Schering-Plough)
 2008 State of the art in ACS / Clinical Conference
 St. Vincent Heart Center of Indiana, Indianapolis IN (Schering-Plough)
 2008 State of the Art in Revascularization Therapy / Clinical Conference
 Lutheran Hospital, Ft Wayne IN (Schering-Plough)
 2008 New Antiplatelet and Antithrombotic Drugs for PCI / Symposium Presentation
 American College of Cardiology Sessions: Pharmacology for PCI & ACS,
 Chicago IL
 2008 State of the Art in Revascularization Therapy / Clinical Conference
 UNC Hospital, Chapel Hill NC (Schering-Plough)
 2008 Anticoagulant and Antiplatelet Strategies for Management of ACS / Clinical
 Conference
 Robert Packer Hospital, Guthrie PA
 2008 State of the Art in Revascularization Therapy / Fellow's Conference
 Ohio State University, Columbus OH
 2008 Long Term Prasugrel for Most: Preserve the Myocardium, and Keep Stents from
 Thrombosing! / Conference Presentation
 Transcatheter Cardiovascular Therapeutics (TCT) ACS Session IV: Antiplatelet
 and Antithrombin Decisions in NSTEMI-ACS: Data-driven Debates -
 Thienopyridine Decisions: Clopidogrel vs. Prasugrel in NSTEMI-ACS? Washington
 DC
 2008 Prasugrel – A Potent Newcomer: Optimizing Use to Reduce Stent Thrombosis
 without Increasing Bleeding! / Conference Presentation
 Transcatheter Cardiovascular Therapeutics (TCT) DES Summit: Dual Anti-
 Platelet Use Considerations – Other Important Antiplatelet Agents, Washington
 DC
 2008 Upstream Drug Initiation in ACS - Impact on Clinical and Angiographic
 Outcomes / Conference Presentation
 Transcatheter Cardiovascular Therapeutics (TCT): Controversies in Adjunct
 Pharmacology: Agenda, Washington DC
 2008 Upstream and Downstream Use of Glycoprotein IIb/IIIa Inhibitors: Integrating
 the Latest Clinical Trial Results / Conference Presentation
 Transcatheter Cardiovascular Therapeutics (TCT): Coronary Theater - II: Focus
 on Interventional Pharmacology, Washington DC
 2008 Antiplatelet Therapy in AMI: Data from TIMI 38 / Symposium Presentation
 24th Annual International Symposium on Interventional and Pharm. Reperfusion

- of STEMI, New Orleans LA
- 2008 Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial / Conference Presentation
American Heart Association Late-Breaking Clinical Trials II Presentation, New Orleans LA
- 2009 State of the art in ACS / Cardiology Conference
Henry Ford Hospital, Detroit MI
- 2009 State of the art in ACS / Grand Rounds
Mt. Clemens Hospital, Mt Clemens MI
- 2009 Open Muscle Hypothesis / Cath Conference
Genesys Hospital, Grand Blanc MI
- 2009 State of the art in ACS / Symposium Presentation
New York Cardiovascular Symposium, NY
- 2009 Long-term anticoagulation post ACS?: Dissecting the evidence / Symposium Presentation
Unresolved Issues in antithrombotic therapy: The known, unknown and the unknowable Symposium, Orlando FL (Johnson & Johnson, Bayer)
- 2009 Optimal Adjunctive Pharmacology During PCI: Focus on Antiplatelet Therapy / Conference Presentation
Oral Presentation i2 Summit, Session: Acute Myocardial Infarction, American College of Cardiology Scientific Sessions, Orlando FL
- 2009 Anticoagulant Therapy for Elderly Patients (and a case study – NSTEMI early invasive / Symposium Presentation
Maximizing Benefit and Minimizing Risk in ACS: Anticoagulant Therapy in Vulnerable Patient Populations Symposium, Orlando FL (Vox, Sanofi-aventis)
- 2009 Current Updates in ACS Therapy / Cath Conference
Olathe Medical Center, Olathe KS (Schering-Plough)
- 2009 Current Updates in ACS Therapy / Cath Conference
Boone Hospital Center, Columbia MO (Schering-Plough)
- 2009 Current Updates in ACS Therapy / Cath Lab Conference
St. John's Hospital, St Louis MO (Schering-Plough)
- 2009 Emerging Therapy: Antiplatelet Drugs / Session Co Chair
SCAI 32nd Annual Scientific Sessions, Las Vegas NV
- 2009 Do we need new Antiplatelet Drugs? / Oral Presentation
SCAI 32nd Annual Scientific Sessions, Las Vegas NV
- 2009 The Future of Ambulatory Monitoring: Moving Beyond Rate and Rhythm to Monitor ST Shifts/ Symposium Chair
Heart Rhythm Society Annual Meeting, Boston MA
- 2009 Current Updates in ACS Therapy / Clinical Conference
St. Agnes Hospital, Baltimore MD (Schering Plough)
- 2009 Emerging Oral Anticoagulants for Recurrent Prevention in the Treatment of ACS / Symposium: Thromboprophylaxis in Atrial Fibrillation and ACS: How can we do better?
American Heart Association Satellite Symposium 2009, Orlando, FL
- 2010 DES vs. BMS in NSTEMI and STEMI: How to Choose / Duke ACS Forum:

“Acute Coronary Syndromes Management: The Current State of Clinical Practice”

2010 The Gaylord National Hotel and Convention Center, Washington, DC
Intro/overview and Results of DETECT Study/Invited Lecture
Heart Rhythm Society Meeting, Denver CO

2010 ALERT-AMI – Ongoing Trials of Implantable Holter Monitors to Detect Ischemia/ Invited Lecture
Heart Rhythm Society Meeting, Denver CO

2011 STEMI: Bottom Line Recommendations for State-of-the-Art-Care / Symposium Presentation
ACC/i2 Scientific Sessions, New Orleans LA

2011 Targeted Intracoronary Therapies (presentation #2603-6)/ Oral Presentation
ACC/i2 Scientific Sessions, New Orleans LA

2011 ATLAS ACS 2 – TIMI 51 Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome / Oral Presentation
American Heart Association Scientific Sessions 2011, Orlando, FL

2012 Magnitude And Duration Of Intracardiac St-Segment Changes For Confirmed Clinical Events: First In-man Experience (presentation #1171-353)/ Oral Presentation
ACC/i2 Scientific Sessions, Chicago IL

2012 Platelet Inhibition in 2012: What You Need To Know (presentation #2617-1)/ Symposium Presentation
ACC/i2 Scientific Sessions, Chicago IL

2012 State of the Art STEMI: All You Need to Know – Strategies for thrombus removal (presentation # 2638-5)/ Symposium Presentation
ACC/i2 Scientific Sessions, Chicago IL

2012 Strategies for the ACS Patient with Chronic Atrial Fibrillation/ Invited Lecturer
Transcatheter Therapeutics, Miami Beach, FL

2012 Rivaroxaban Update: ATLAS-ACS-2 TIMI-51: Recent Analyses and FDA Redux/ Invited Lecturer
Transcatheter Therapeutics, Miami Beach, FL

2012 Optimizing Use of Today’s Antithrombotic and Antiplatelet Drugs in ACS and PCI/Invited Discussant
Transcatheter Therapeutics, Miami Beach, FL

2012 Primary PCI for STEMI: Drugs, Devices, and Technique Controversies/Invited Lecturer & Discussant
Transcatheter Therapeutics, Miami Beach, FL

2012 How to Treat Theater: Coronary Artery Disease II/Invited Lecturer
Transcatheter Therapeutics, Miami Beach, FL

2012 ACC Special Fellows Session II. Oral Anticoagulation 2012 for VTE, Atrial Fibrillation, and Valvular Heart Disease/ Invited Moderator
Transcatheter Therapeutics, Miami Beach, FL

2012 Pelnary Session 19. Pharmacology Spotlight/ Invited Discussant
Transcatheter Therapeutics, Miami Beach, FL

2012 A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and

- Bleeding Events in ATLAS ACS 2 – TIMI 51 (presentation #13152)/ Poster Presentation
American Heart Association Scientific Sessions 2012, Los Angeles, CA
- 2012 Are Factor Xa Inhibitors Ready for Primetime Secondary Prevention?/ Oral Presentation
American Heart Association Scientific Sessions 2012, Los Angeles, CA
- 2012 Ask the Experts: Acute Perspectives (In-Hospitals)/ Oral Presentation
American Heart Association Scientific Sessions 2012, Los Angeles, CA
- 2013 DAPT + Chronic Oral Anticoagulation: Indications and Risk Amelioration / ACC-CRF CME Symposium
ACC/i2 Scientific Sessions, San Francisco, CA
- 2013 Adjunct Pharmacology II: PCI in Acute Coronary Syndromes / Session Co-Chair
ACC/i2 Scientific Sessions, San Francisco, CA
- 2013 Year in Review Speaker: Acute Coronary Syndrome / Invited Lecturer
ACC/i2 Scientific Sessions, San Francisco, CA
- 2013 Antiplatelet Therapy and Anticoagulation Following PCI / Session Co-Chair
ACC/i2 Scientific Sessions, San Francisco, CA
- 2013 Myocardial Perfusion in Acute Coronary Syndrome / Cardiology Grand Rounds
University of California San Francisco, San Francisco, CA
- 2014 WikiDoc and the Open Access Movement/ Medical Grand Rounds
Stanford University, Palo Alto, CA
- 2014 State of the Art in Acute Coronary Syndromes/ Cardiology Grand Rounds
Yale University, New Haven, CT
- 2016 Diadactic Session: Clinical Trial Design, Statistics, and Interpretation/Moderator
Transcatheter Cardiovascular Therapeutics, Session I. Hot Topics in Clinical Trial Design, Washington, DC.
- 2016 If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor
Transcatheter Cardiovascular Therapeutics Session III: DAPT Duration, Washington, DC.
- 2016 Is Oral Agent Preloading Before PCI Safe or Effective? Theory and Evidence
Transcatheter Cardiovascular Therapeutics, A New Era of P2Y12 Inhibitors: Transitioning From Intravenous to Oral Platelet Inhibition After PCI(Sponsored by CRF,Supported by CHIESI USA,Inc.), Washington, DC.
- 2016 Is There a Current Role for Intracoronary Lytics or GP IIb/IIIa Inhibitors During Primary PCI?
Transcatheter Cardiovascular Therapeutics, Session III. All the Rest: Thrombus Aspiration, Radial Intervention, Intracoronary Therapeutics, and Novel Stent Designs, Washington, DC.
- 2016 FDA Town Hall Meeting at TCT 2016, Part 1: Overarching Concepts/Moderator
Transcatheter Cardiovascular Therapeutics, Washington, DC.
- 2016 Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding
Transcatheter Cardiovascular Therapeutics, Session I. Management of the Patient With Atrial Fibrillation and Coronary Artery Disease (ACS and PCI),

- Washington, DC.
- 2016 The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status
Transcatheter Cardiovascular Therapeutics, Session II: Ongoing Dual vs Triple Antithrombotic Trials in Atrial Fibrillation, Washington, DC.
- 2016 Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies
Transcatheter Cardiovascular Therapeutics, Fellows Sessions: ACS and Pharmacotherapy Year-in-Review (Sponsored by the American College of Cardiology), Washington, DC.
- 2016 Case Discussion/Panel Discussant
Transcatheter Cardiovascular Therapeutics, Best Management for Complex Patients With Complex Disease: The Next Frontier Beyond Revascularization, Washington, DC.
- 2016 Beyond Revascularization: Role of PCSK9 Inhibition in Patients Post PCI
Transcatheter Cardiovascular Therapeutics, Best Management for Complex Patients With Complex Disease: The Next Frontier Beyond Revascularization
- 2016 #Medicine: How to Use Social Media to Improve Care
American Heart Association Health Tech: Technology in Practice, New Orleans, LA
- 2016 An OPEN-label, Randomized, Controlled, Multicenter Study ExplorIng Two TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI (Abstract/Presentation #)
American Heart Association Scientific Sessions 2016, New Orleans, LA
- 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial
American Heart Association Scientific Sessions 2016, New Orleans, LA
- 2016 When AF and ACS Collide: Many Regimens, Few Solutions!
American Heart Association, CH.CVS.149 – Bleeding and Clotting and Stents – Oh My! Looking behind Antithrombotic Curtain, New Orleans, LA
- 2016 IMPROVEDD Score: Addition of D-Dimer to the IMPROVE Score Improves Venous Thromboembolism Risk Stratification. An APEX Trial Substudy
American Heart Association, TH.APS.P111 - Hemostasis, Thrombosis and Fibrinolysis, New Orleans, LA.
- 2016 Extended Duration Betrixaban Reduces the Risk of Stroke vs Standard Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Substudy
American Heart Association, TH.AOS.103.N - Sol Sherry Distinguished Lecture in Thrombosis, New Orleans, LA.
- 2017 Interrupting DAPT for Surgery, Afib, or Bleeding/ Invited Lecturer, Panelist
American College of Cardiology, Scientific Session, Washington, D.C.
- 2017 Social Media for the Cardiologist/Invited Panelist
Society for Cardiovascular Angiography and Interventions, Scientific Sessions, New Orleans, LA
- 2017 Pharmacologic Choices for STEMI: Still a Challenge/Invited Lecturer

Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
 New Orleans, LA
 2017 Optimal Anti-platelet Coverage in STEMI: From IV to Oral Agents/Invited
 Lecturer
 Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
 New Orleans, LA
 2017 TCT360: Ongoing Major Randomized Trials - Anticipating the Future/Session
 Chair
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Antiplatelet Therapy for Contemporary PCI/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 CardioVascular Professionals (CVP) Course: 26th Annual Cardiovascular Nurse
 and Technologist Symposium Part II - Main Sessions/Invited Lecturer,
 Discussant
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Didactic Session: Left Atrial Appendage Closure, Part 1 - Indications, Outcomes,
 and Imaging/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet
 Inhibition (Sponsored by CRF, Supported Through By CHIESI USA,
 Inc.)/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Evening Satellite Symposium: The Approach to the High Bleeding Risk
 Patient/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 The Controversy of Data Transparency In Clinical Research: Point-
 Counterpoint/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Social Media in Cardiology: Applications for Clinicians and Researchers/Session
 Moderator, Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Atrial Fibrillation Management in Patients With ACS and PCI - Decisions and
 Dilemmas/Session Moderator, Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Journal Club With the Trialists and Critics - Top Late-Breaking Trials of the Last
 Year/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 DAPT and Triple Therapy: A Case-Based Guide to Optimal Antiplatelet
 Therapies/Invited Lecturer
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 Late-Breaking Clinical Trials and First Report Investigations Press
 Conference/Invited Discussant
 Transcatheter Cardiovascular Therapeutics, Scientific Session, Denver, Colorado
 2017 The YELPification of Medicine: What do Rankings, Ratings, and Reviews Mean
 for My Practice?/Invited Lecturer
 American Heart Association, Scientific Sessions, Anaheim, California

2017 Therapeutic Potential of HDL: New Directions/Session Moderator
American Heart Association, Scientific Sessions, Anaheim, California

2018 The Impact of the Cantos study on Treatment of Patients Post MI/Invited
Lecturer, Panelist
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.

2018 Third Generation Antiplatelet Therapy: The Case of Cangrelor/ Invited Lecturer,
Panelist
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.

2018 Optimization of Anticoagulation for STEMI Therapy/Invited Moderator
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.

2018 DOACs Beyond AF: Management Strategies for VTE/ Session Chair, Invited
Lecturer, Panelist
American College of Cardiology, Scientific Sessions, Orlando, FL

2018 Antiplatelet Therapy: Practical Management Pearls/Invited Lecturer
American College of Cardiology, Scientific Sessions, Orlando, FL

2018 Social Media in Cardiology/Invited Lecturer
American College of Cardiology, Scientific Sessions, Orlando, FL

2018 Walking the Fine Line: High Bleeding Risk Patient and Bleeding Avoidance
Strategies/Invited Lecturer, Panelist
American College of Cardiology, Scientific Sessions, Orlando, FL

2018 Boston Scientific - The Place for Social Media in Medicine/Session Chair
Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
San Diego, CA

2018 Changing Direction with Anticoagulation and Antiplatelet Therapy in Secondary
Prevention of CAD/Invited Lecturer
Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
San Diego, CA

2018 Preventing Cardioembolism: Left Atrial Appendage (LAA) Exclusion/Invited
Lecturer, Panelist
Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
San Diego, CA

2018 Intravenous Platelet Inhibition In and Beyond the Cath Lab/Invited Lecturer
Society for Cardiovascular Angiography and Interventions, Scientific Sessions,
San Diego, CA

2018 The Shared Future of Digital Health and Medical Devices: A Think Tank
Meeting at TCT/Invited Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA

2018 Drug-eluting stents, bioresorbable scaffolds and the coronary drug – coated
balloons/Invited Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA

2018 FDA Town Hall Meeting Part 1: Evaluation and Regulation of Devices Using
Machine Learning and Artificial Intelligence/Session Moderator
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA

2018 Everyday antiplatelet decisions: Making the right choices (sponsored by CRF,
supported by Chiesi): Everyday antiplatelet decisions/Invited Faculty, Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA

- 2018 PCI Pharmacotherapy – procedural antithrombins and acute/chronic
DAPT/Invited Moderator
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 PCI Pharmacotherapy – procedural antithrombins and acute/chronic
DAPT/Invited Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 The approach to the high bleeding risk patients (sponsored by CRF, supported by
Abbot, Boston Scientific Biosensor, Celonova Biosciens, Medtronic)/Invited
Faculty, Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 Late-Breaking Clinical Trials Press Conference III/Invited Discussant
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 Late Breaking Trials 4/Session Moderator
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 Fascinating Lectures III: Social Media, Digital Health and Communication
Skills/Session Moderator
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 DAPT and triple therapy: A case-based guide to optimal antiplatelet therapies
(sponsored by CRF, supported by Abbott, Astrazeneca, Boston scientific corp,
celonova biosciences, Chiesi and Medtronic)/Invited Faculty, Lecturer
Transcatheter Cardiovascular Therapeutics, Scientific Session, San Diego, CA
- 2018 State of the Art in Anti-Thrombin, ACS & AFib / Cardiology Grand Rounds
Bertram Pitt Visiting Professor , University of Michigan
- 2018 State of the art in anti-coagulation, ACS, AFib & CAD/ Cardiology Grand
Rounds, California Pacific Medical Center
- 2018 State of the art in anti-coagulation, ACS, AFib & CAD/ Cardiology Grand
Rounds, Stanford University
- 2018 State of the art in anti-coagulation, ACS, AFib & CAD/ Cardiology Grand
Rounds, University of California, Davis
- 2019 How PIONEER, REDUAL and ATLAS Have Changed my Practice / Invited
Lecturer, Panelist
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.
- 2019 Results of a Randomized Trial to Assess Implantation of a Device to Alarm
Patients to ST Deviation / Invited Lecturer, Panelist
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.
- 2019 Rivaroxaban 2.5 mg BID Combined with Dual Antiplatelet Therapy for the
Prevention of Death/MI/Stroke: A Patient Level Data Meta - Analysis of the
ATLAS-ACS-2 TIMI-51 and the COMMANDER HF Trials / Invited Lecturer
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.
- 2019 AngeLmed for Early Recognition and Treatment of STEMI (ALERTS) Trial: A
Randomized, Prospective Clinical Investigation / Invited Lecturer
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.
- 2019 Optimization of Anticoagulation for STEMI Therapy / Session Moderator
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.
- 2019 Poly Pharmacy Anticoagulation OAC & DAPT / Invited Lecturer, Panelist
Cardiovascular Research Technologies, Scientific Sessions, Washington, D.C.

- 2019 Future Hub: The HEARTLINE™ Study: Helping to Change the Trajectory of Cardiovascular Healthcare / Invited Lecturer
American College of Cardiology, Scientific Sessions, New Orleans, LA
- 2019 Storytellers: Art, Passion, Faith, and Family – Art / Invited Lecturer
American College of Cardiology, Scientific Sessions, New Orleans, LA
- 2019 Social Media for Today's Cardiologist: A Necessary Professional Pathway or a Potentially Dangerous Fad for CV Science / Invited Panelist
American College of Cardiology, Scientific Sessions, New Orleans, LA
- 2019 Late-Breaking Clinical Trials V: Interventional / Invited Panelist
American College of Cardiology, Scientific Sessions, New Orleans, LA
- 2019 Accruing Evidence for Low-Dose DOACs: From ACS to CAD to AF / Invited Lecturer
American College of Cardiology, Scientific Sessions, New Orleans, LA

International

- 1997 Patency, the TIMI Frame Count, and the Status of the Open-Artery Theory / Symposium Presentation
The Second International Thrombolytic Collegium, Boston MA
- 1997 Understanding the TIMI Frame Count / Symposium Presentation
Canadian Cardiovascular Society Satellite Symposium. Winnipeg, Manitoba
- 2001 Impact of fibrinolytic dose on clinical outcomes / Conference Presentation
European Society of Cardiology, Stockholm, Sweden
- 2002 State of the Art in Reperfusion Therapy / Guest Lecture
The Heart Institute of Hochiminh City, Hochiminh Vietnam
- 2002 State of the Art in Reperfusion Therapy / Guest Lecture
12th Great Wall International Symposium on Cardiology, Beijing China
- 2005 Creating a Center of Excellence, and Evaluation of Study Results / Symposium Presentation
Krakow, Poland
- 2005 Management of Cardiovascular Diseases / Symposium Presentation
Krakow, Poland
- 2005 State of the Art in Reperfusion Therapy / Grand Rounds
Krakow, Poland
- 2005 Time is Muscle: Rapid Inhibition of Platelet Aggregation Improves Myocardial Perfusion / Symposium Presentation
GSK Symposium: New Insights for the Improvement of ACS Management, Stockholm Sweden (GlaxoSmithKline)
- 2005 The Microperfusion in STEMI: Implications for Pharmacotherapy and Mechanical Intervention / Symposium Presentation
Satellite Symposium, Montreal QC Canada
- 2006 PCI-ExTRACT-TIMI 25: PCI outcomes among patients treated with Enoxaparin versus unfractionated heparin (UFH) following fibrinolytic administration for ST-segment elevation MI in the ExTRACT-TIMI 25 Investigators / Symposium Presentation
European Society of Cardiology Hotline Press Conference, Barcelona Spain
- 2009 Facilitated PCI's: Is the Concept Still valid? / Oral Presentation

- XV SOLACI (Latin American Society of Interventional Cardiology) – XXXI SBHCI (Brazilian Society of Hemodynamics and Interventional Cardiology)
2009 Interventional Cardiovascular Congress, Rio de Janeiro Brazil
- 2009 Prasugrel: A Clinically Significant Breakthrough / Oral Presentation
XV SOLACI – XXXI SBHCI 2009 Interventional Cardiovascular Congress, Rio de Janeiro Brazil
- 2009 Prasugrel: A Clinically Significant Breakthrough Advance for Our Patients?
XV SOLACI – XXXI SBHCI 2009 Interventional Cardiovascular Congress, Rio de Janeiro Brazil
- 2009 Thrombosis/ Symposium Presentation
Kyoto Thrombosis Seminar, Kyoto Japan (Bayer Japan)
- 2009 Meeting the unmet needs in anticoagulant therapy / Symposium Presentation
International Society on Thrombosis and Haemostasis –Annual Meeting, Boston MA
- 2010 State of the Art in STEMI Management Including Antiplatelet Therapy and Antithrombin Therapy / Opening Session Oral Presentation
Sociedade de Cardiologia do Estado de São Paulo (SOCESP), São Paulo, Brazil
- 2010 Myocardial Perfusion and Clinical Outcomes / Round Table Oral Presentation
Sociedade de Cardiologia do Estado de São Paulo (SOCESP), São Paulo, Brazil
- 2010 How to Evaluate a Clinical Trial: Bias in inclusion, exclusion criteria, statistical bias type A, B, C / Invited Presentation
Dong A Medical Center, Regional Clinical Trial Center, Busan, Korea
- 2010 The importance of achieving myocardial perfusion / Oral Presentation
Beijing Great Wall Meeting, Beijing, China
- 2010 Reassessing the role of thrombus aspiration in primary PCI AMI / Oral Presentation
Beijing Great Wall Meeting, Beijing China
- 2010 How to Evaluate a Clinical Trial: Bias in inclusion, exclusion criteria, statistical bias type A, B, C / Invited Presentation
The Heart Center, First Nanjing Hospital, Nanjing Medical University, Nanjing, China
- 2012 Anticoagulation in patients with atrial fibrillation or acute coronary syndrome: interpreting the latest findings/Satellite Symposium
European Society of Cardiology, Munich, Germany
- 2013 EMBRACE-STEMI: Bendavia for cardioprotection/Satellite Symposium
European Society of Cardiology, Amsterdam, Netherlands
- 2014 Increasing the breadth of oral anticoagulant use in cardiology: the rivaroxaban profile/Satellite Symposium
European Society of Cardiology, Barcelona, Spain
- 2015 Novel oral anticoagulant use for secondary prevention of acute coronary syndromes: where are we now?/Satellite Symposium
European Society of Cardiology, London, United Kingdom
- 2016 Advancing approaches to dyslipidemia management: optimizing risk reduction in primary and secondary prevention populations/Satellite Symposium
European Society of Cardiology, Rome, Italy
- 2017 DOACs to prevent VTE and to reduce the risk of stroke during hospitalization

	and during the first several months after hospital discharge/Satellite Symposium European Society of Cardiology, Barcelona, Spain
2018	State of the art in anti-coagulation, ACS, AFib & CAD/ Cardiology Grand Rounds, Population Health Research Institute, McMaster University
2018	Redefining Cardiovascular Protection (Overall Brand Story), Xarelto – The NOAC of Choice/Invited Lecturer European Society of Cardiology, Scientific Session, Munich, Germany
2018	Cardiology 10 Years from now – My Predictions and how to get yourself ready/Session Chair European Society of Cardiology, Scientific Session, Munich, Germany
2018	Preventing PE & DVT in Heart Failure and Other Medically Ill Patients: An Innovative Plan/Invited Lecturer European Society of Cardiology, Scientific Session, Munich, Germany
2018	DOACs to Prevent VTE and Stroke During Hospitalization: Focus on Heart Failure Patients/Invited Lecturer European Society of Cardiology, Scientific Session, Munich, Germany

Report of Clinical Activities and Innovations

Current Licensure and Certification

1987	National Board of Medical Examiner's Certification
1988	Massachusetts License Registration
1989	American Board of Internal Medicine Certification
1992	American Board of Internal Medicine, Certification in Cardiovascular Disease
1999	California License Registration
2002	American Board of Internal Medicine, Re-Certification in Cardiovascular Disease

Practice Activities

2002-	Interventional Cardiology	Beth Israel Deaconess Medical Center, Boston MA	2 days/week
2002-	Coronary Care Unit (CCU) Attending	Beth Israel Deaconess Medical Center, Boston MA	2 weeks/year
2002-	CMI Attending	Beth Israel Deaconess Medical Center, Boston MA	4 weeks/year
2010-	Consult Service Attending	Beth Israel Deaconess Medical Center, Boston MA	2 weeks/year

Clinical Innovations

TIMI Frame Count (TFC)	I developed the TFC, in which the number of cineframes for dye to reach standardized distal landmarks is counted as an index of coronary blood flow. This measure is now the primary endpoint of some acute myocardial infarction (MI) trials and is also used as a diagnostic tool in clinical practice (as TFC is a
---------------------------	--

	multivariate predictor of mortality in acute MI patients).
TIMI Myocardial Perfusion Grade (TMPG)	I developed the TMPG to measure microvasculature perfusion. In this method, the rate of dye entry and exit is assessed visually. TMPG is now the primary endpoint of some acute MI trials and is also used as a diagnosis tool in clinical practice (as TMPG is a multivariate predictor of mortality in acute MI patients).
Guidewire Velocity	I developed a method to determine absolute velocity and flow in patients undergoing percutaneous coronary angiography (see Am J Cardiol. 1997 Dec 14; 80(12): 1536-9). This method can be used as a diagnostic tool in clinical practice.

Report of Education of Patients and Service to the Community

Educational Material for Patients and the Lay Community

No educational materials below were sponsored by outside entities.

Books, Monographs, Articles and Presentations in Other Media

1999-	Clinical Trial Results	Founder & Editor in Chief	Online: www.clinicaltrialresults.org
2006-	WikiDoc	Founder & Editor in Chief	Online: www.wikidoc.org
2007-	MD TV	Founder & Editor in Chief	Online: www.themdtv.org
2018-	Cardiology Now News	Founder & Editor in Chief	Online: www.cardiologynownews.org

Patient Educational Material

2006-	WikiPatient	Founder	Online: www.wikipatient.org
-------	-------------	---------	--

Recognition

2004-2005	America's Top Physicians	Consumer Research Council of America
2009	Boston's Top Doctors	Boston Magazine
2010	America's Top Doctors	Castle Connolly Medical Ltd.
2010	America's Top Physicians In Interventional Cardiology	Consumer Research Council of America
2010	America's Top Cardiologists	Consumer Research Council of America
2011	Boston Super Doctor's	www.superdoctors.com
2011	America's Top Cardiologists	Consumer Research Council of America
2011	America's Top Doctors	Castle Connolly Medical Ltd.

		(health.usnews.com)
2011	Boston's Top Doctors	Boston Magazine
2012	Boston's Top Doctors	Boston Magazine
2012	American's Top Doctors	Castle Connolly Medical Ltd.
2013	America's Top Doctors	Castle Connolly Medical Ltd.
2013	Regional Top Doctors	Castle Connolly Medical Ltd.
2014	America's Top Doctors	Castle Connolly Medical Ltd.
2014	Regional Top Doctors	Castle Connolly Medical Ltd.
2015	America's Top Doctors	Castle Connolly Medical Ltd.
2016	America's Top Doctors	Castle Connolly Medical Ltd.

Report of Scholarship

Publications

Peer reviewed publications in print or other media

Research investigations

1. **Gibson CM**, Gurney CW, Simmons EL, Gaston EO. Cyclic erythropoiesis in the Sl/Sl^d mouse. *Experimental Hematology*. 1984 Jun;12:343-8.
2. **Gibson CM**, Gurney CW, Simmons EL, Gaston EO. Further studies of cyclic erythropoiesis in mice. *Experimental Hematology*. 1985 Oct 01;13:855-60.
3. **Gibson CM**, Reider B, Mikosz R, Andriacchi T. Analysis of the Mueller anterolateral femorotibial ligament (ALFTL) reconstruction using a computerized knee model. *American Journal of Sports Medicine*. 1986 Sep;14:371-5. [Winner Young Investigator Award]
4. **Gibson CM**, Sandor T, Stone PH, Pasternak RC, Rosner B, Sacks FM. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. *American Journal of Cardiology*. 1992 May 15; 69:1286-90.
5. Carrozza JP, Kuntz RE, Levine MJ, Pomerantz RM, Fishman RF, Mansour M, **Gibson CM**, Senerchia CC, Diver DD, Safian RD, Baim DS. Angiographic and clinical outcome of intracoronary stenting: Acute and long-term results from a large single-center experience. *Journal American College of Cardiology* 1992 Aug;20:328-37.
6. Kuntz RE, **Gibson CM**, Nobuyoshi S, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. *Journal American College of Cardiology*. 1993 Jan;21:15-25.
7. **Gibson CM**, Diaz L, Kandarpa K, Sacks FM, Pasternak RC, Sandor T, Feldman C, Stone PH. Relation of vessel wall shear stress to atherosclerosis progression in human coronary arteries. *Arteriosclerosis and Thrombosis*. 1993 Feb;13:310-15.
8. **Gibson CM**, Kuntz RE, Nobuyoshi M, Rosner B, Baim DS. Lesion-to-lesion independence of restenosis following treatment by conventional angioplasty, stenting, or directional atherectomy: Validation for lesion-based restenosis analysis. *Circulation*. 1993 Apr;87:1123-9.
9. Gordon PC, **Gibson CM**, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents: A quantitative angiographic assessment. *Journal American College of Cardiology*. 1993 Apr; 21:1166-74.
10. Stone PH, **Gibson CM**, Pasternak RC, McManus K, Diaz L, Boucher T, Spears R, Sandor T, Rosner B, Sacks FM. Natural history of coronary atherosclerosis using quantitative angiography in men, and

- implications for clinical trials of coronary regression. The Harvard Atherosclerosis Reversibility Project Study Group. *American Journal of Cardiology*. 1993 Apr;71:766-72.
11. Gordon PC, Friederich SP, Piana RN, Kugelmass AD, Leidig GA, **Gibson CM**, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Is 40-70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? *American Journal of Cardiology*. 1994;74:26-32.
 12. Piana RN, Paik GY, Moscucci M, Cohen DJ, **Gibson CM**, Kugelmass AD, Carrozza JP, Kuntz RE, Baim DS. The incidence and treatment of "no-reflow" following percutaneous coronary intervention. *Circulation*. 1994;89:2514-8.
 13. Sacks FM, Pasternak RC, **Gibson CM**, Rosner B, Stone PH. The effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. *Lancet*. 1994;344:1182-1186.
 14. Ahmed WH, Shubrooks SJ, **Gibson CM**, Baim DS, Bittl JA. Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patients. *American Heart Journal*. 1994 Aug;128:252-5.
 15. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, Palmeri S, Davis V, **Gibson CM**, Poole WK, Braunwald E & THE TIMI 4 INVESTIGATORS. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. *Journal American College Cardiology* 1994 Dec;24:1602-10.
 16. **Gibson CM**, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CM, Flaker GC, Baim DS, Braunwald E. Angiographic predictors of early reocclusion after thrombolysis: Results from the TIMI 4 trial. *Journal American College Cardiology*. 1995;25:582-9.
 17. Kloner RA, Shook TS, Przyklenk K, Davis V, Junio L, Mathews RV, Burstein S, **Gibson CM**, Poole K, Cannon CP, McCabe C, Braunwald E for the TIMI 4 Investigators. Previous angina alters in hospital outcome in TIMI 4: A clinical correlate to preconditioning? *Circulation*. 1995;91:37-47.
 18. Sacks FM, **Gibson CM**, Rosner B, Pasternak RC, Stone PH for the Harvard Atherosclerosis Reversibility Project (HARP) Research Group. The influence of pre-treatment LDL-cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials. *American Journal of Cardiology*. 1995;76:78C-85C.
 19. Sacks FM, Pasternak RC, **Gibson CM**, Rosner B, Stone PH. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. *Journal American College Cardiology*. 1995;25:1492-8.
 20. Dotani I, Dodge TJ, Goel M, Al-Mousa EN, McLean C, Rizzo MJ, Ryan K, Vatner R, Marble SJ, Daley WL, **Gibson CM**. New Techniques in the angiographic analysis of coronary flow. *Journal of Interventional Cardiology*. 1996;9:429-44.
 21. Pasternak RC, Brown LE, Stone PH, Silverman DI, **Gibson CM**, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. *Annals of Internal Medicine*. 1996;125:529-40.
 22. **Gibson CM**, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. The TIMI Frame Count: A Quantitative Method of Assessing Coronary Artery Flow. *Circulation*. 1996;93:879-88.
 23. Cannon CP, McCabe CH, **Gibson CM**, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E and the TIMI 10A Investigators. TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A Dose-ranging Trial. *Circulation*. 1997;95:351-6.
-

24. **Gibson CM**, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, Diver DJ, Baim DS, Braunwald E for the TIMI 4 study group. Rescue angioplasty in the TIMI 4 Trial. *American Journal of Cardiology*. 1997;80:21-6.
25. **Gibson CM**, Marble SJ, Rizzo MJ, Moynihan J, McLean C, Ryan K, Sparano A, Piana RN, McCabe CH, Cannon CP for the TIMI 4 study group. Relationship between injections prior to 90 minute angiography and coronary patency. Results of the TIMI 4 trial. *American Heart Journal*. 1997;134(3):351-4.
26. **Gibson CM**, Dodge JT, Goel M, Al-Mousa EN, Rizzo M, McLean C, Ryan K, Sparano A, Marble SJ, Daley WL, Cannon CP, Antman EM. The PTCA guidewire velocity. A new simple method to measure absolute coronary velocity and blood flow. *American Journal of Cardiology*. 1997;80:1536-9.
27. Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, **Gibson CM**, Winkelman JW, Antman EM, Braunwald E for the TIMI 10A Investigators. Myoglobin, CK-MB and Cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction. Results from TIMI 10A. *American Heart Journal*. 1997;134:622-30.
28. Al-Mousa E, Dodge JT, Rizzo M, McLean C, Ryan K, Moynihan J, Kelley M, Marble SJ, Goel M, Daley WL, **Gibson CM**: The TIMI frame count in saphenous vein grafts. *American Heart Journal*. 1998;135:323-8.
29. Cannon CP, **Gibson CM**, McCabe CH, Adgey AAJ, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Fox NL, Weaver WD, Van de Werf F, Braunwald E for the TIMI 10B Investigators. TNK-Tissue Plasminogen Activator compared with Front-loaded Alteplase in Acute Myocardial Infarction: Results of the TIMI 10B Trial. *Circulation*. 1998;98:2805-14.
30. Dauerman HL, Baim DS, Cutlip DE, Sparano AM, **Gibson CM**, Kuntz RE, Carrozza JP, Garber GR, Cohen DJ. Mechanical debulking versus balloon angioplasty for the treatment of diffuse in-stent restenosis. *Am J Cardiol*. 1998;82:277-84.
31. Dauerman HL, Higgins PJ, Baim DS, Carrozza JP, Kuntz RE, Garber GR, Shubrooks SJ, Sparano AM, **Gibson CM**, Cohen DJ. Mechanical debulking versus balloon angioplasty for the treatment of true bifurcation lesions. *J Am Coll Cardiol*. 1998;18:45-52.
32. Dodge JT, Nykiel M, Altman J, Hobkirk K, Brennan M, **Gibson CM**. Coronary artery injection technique: A quantitative in vivo investigation using modern catheters. *Cardiac Catheterization and Diagnosis*. 1998;44:34-9.
33. Dodge JT, Rizzo M, Nykiel M, Altman J, Hobkirk K, Brennan M, **Gibson CM**. Impact of injection rate on the TIMI Frame Count. *American Journal of Cardiology*. 1998;81:1268-70.
34. **Gibson CM**, Goel M, Cohen DE, Piana RN, Deckelbaum LI, Harris KE, King SB for the RESTORE Investigators. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *J Am Coll Cardiol*. 1998;32:28-34.
35. Antman EM, Giugliano RP, **Gibson CM**, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AAJ, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Abciximab facilitates the rate and the extent of thrombolysis: Results of TIMI 14 trial. *Circulation*. 1999;99:2720-32.
36. **Gibson CM**, Cannon CP, Murphy SA, Adgey J, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Weaver D, Van de Werf F, Braunwald E. Weight adjusted dosing of TNK-tissue plasminogen activator and its relationship to angiographic outcomes in the TIMI 10B trial. *Am J Cardiol*. 1999;84:976-80.
37. **Gibson CM**, Murphy SA, Menown I, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M; Frey M, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, and Braunwald E for the TIMI Study Group. Determinants of Coronary Blood Flow Following Thrombolytic Administration. *J Am Coll Cardiol*. 1999;34:1403-12.
38. **Gibson CM**, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F,

- Braunwald E. The relationship between the TIMI Frame Count and clinical outcomes after thrombolytic administration. *Circulation*. 1999;99:1945-50.
39. **Gibson CM**, Ryan KA, Murphy SA, Mesley R, Marble SJ, Guigliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in non-culprit arteries in the setting of acute myocardial infarction. *J Am Coll Cardiol*. 1999;34:974-82.
 40. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, **Gibson CM**, Winkelman JW, Braunwald E for the TIMI 10B investigators. Myoglobin, CK-MB and Cardiac troponin – I- 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction. Results from TIMI 10B. *J Am Coll Cardiol*. 1999;34:739-47.
 41. **Gibson CM**, Ryan K, Sparano A, Moynihan JL; Rizzo MJ; Kelley M; Marble SJ; Laham R; Simons M; McClusky TR; Dodge JT. Angiographic Methods to Assess and Classify Human Coronary Angiogenesis. *American Heart Journal*. 1999;137:169-79.
 42. **Gibson CM**, Ryan K, Sparano A, Rizzo M, Moynihan J, Kelley M, Marble SJ, Dodge JT, Antman EM for the TIMI Study Group. Methodologic Drift in the Assessment of TIMI Grade 3 Flow and its Implications with Respect to the Reporting of Angiographic Trial Results. *Am Heart Journal*. 1999;137:1179-84.
 43. Cannon CP, **Gibson CM**, Lambrew CT, Tiefenbrunn AJ, French WJ, Gore JM, Hilbe J, Sanathanan L, Weaver WD, Rogers WJ for the NRMI-2 Investigators. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA*. 2000;283:2941-7.
 44. Cannon L, Senior D, Fiet F, Attubato M, Rosenberg J, O'Donnell M, Hirst J, **Gibson CM**. Results from the intermediate vessel atherectomy trial (IVAT). *Catheterization and Cardiovascular Interventions*. 2000;49:396-400.
 45. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AAJ, **Gibson CM**, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14. *Circulation*. 2000;101:2690-5.
 46. Dauerman HL, Pinto DS, Ho KKL, **Gibson CM**, Kuntz RE, Cohen DJ, Baim DS, Carrozza JP. Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials. *Cathet Cardiovasc Intervent*. 2000;49:237-243.
 47. de Lemos JA, Antman EM, **Gibson CM**, McCabe CH, Giugliano RP, Murphy SA, Frey MJ, Van der Wieken R, Van de Werf F, and Braunwald E the TIMI 14 Investigators. Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST Elevation Myocardial Infarction: A TIMI 14 Analysis. *Circulation*. 2000;101:239-243.
 48. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F, **Gibson CM**, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Resolution of ST-Segment Elevation Correlates with Infarct Related Artery Patency and Flow After Thrombolytic Therapy. *Am J Cardiol*. 2000;85:299-304.
 49. de Lemos JA, Antman EM, Morrow DA, Llevadot J, Giugliano RP, Coulter SA, Schuhwerk K, Arslanian S, McCabe CH, **Gibson CM**, Rifai N. Heart-type Fatty Acid Binding Protein as a marker of reperfusion after thrombolytic therapy. *Clin Chimica Acta*. 2000;298:85-97.
 50. **Gibson CM**, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van de Werf F and Braunwald E for the TIMI Study Group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. *Circulation*. 2000;101:125-30.
 51. Llevadot J, Giugliano RP, McCabe C, Cannon CP, Antman EM, Murphy S, **Gibson CM** for the TIMI Investigators. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration
-

- (Thrombolysis In Myocardial Infarction [TIMI] trials). *Am J Cardiol.* 2000;85:1409-13.
52. Roe MT, Giugliano RP, Harrington RA, **Gibson CM**, Strony J, Kitt MM, Califf RM, Braunwald E. Combination reperfusion therapy for acute myocardial infarction with eptifibatide and tenecteplase. Design and methodology of the (INTEGRILIN and tenecteplase in acute myocardial infarction) INTEGRITI trial. *Heart Drug.* 2000 Aug;1:5-13.
 53. Fang JC, Kinlay S, Wexberg P, Amirzadeh A, **Gibson CM**, Ganz P. Use of the TIMI Frame Count for the quantitative assessment of transplant associated arteriosclerosis. *Am J Cardiol.* 2000 Aug 15;86(8):890-2.
 54. Barron HV, Cannon CP, Murphy SA, Braunwald E, **Gibson CM**. The association between white blood cell count, epicardial blood flow, myocardial perfusion and clinical outcomes in the setting of acute MI. A TIMI 10B substudy. *Circulation.* 2000 Nov 7;102(19):2329-34.
 55. Dotani MI, Elnicki DM, Jain AC, **Gibson CM**. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. *Am J Cardiol.* 2000 Nov 15;86(10):1128-30.
 56. Antman EM, **Gibson CM**, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E for the TIMI Investigators. Combination reperfusion therapy with abciximab and reduced dose Reteplase: Results from TIMI 14. *Eur Heart J.* 2000 Dec 1;21(23):1944-1953.
 57. **Gibson CM**, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MHC, Antman EM, Cannon CP, Braunwald E for the TIMI study group. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. *Am J Cardiol.* 2000 Dec 15;86(12):1378-9.
 58. **Gibson CM**, Goel M, Rizzo M, Ryan K, Marble SJ, Deckelbaum L, King S for the RESTORE Investigators. Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *Am J Cardiol.* 2000 Dec 15;86(12):1375-7.
 59. **Gibson CM**, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E for the TIMI Study Group. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? *Am J Cardiol.* 2000 Dec 15;86(12):1375-7.
 60. Angeja BG, Alexander JH, Chin R, Li X, Barron HV, Granger CB, Van de Werf F, **Gibson CM**. Safety of the Weight-Adjusted Dosing Regimen of Tenecteplase in the ASSENT-2 Trial. *Am J Cardiol.* 2001;88:1240-5.
 61. de Lemos JA, **Gibson CM**, Antman EM, Murphy SA, Schuhwerk KM, Schweiger M, Coussement P, Van de Werf F, Braunwald E for the TIMI 14 Investigators. Abciximab and early adjunctive percutaneous coronary intervention enhance microvascular perfusion after thrombolysis: Observations from the TIMI 14 Trial. *Am Heart Journal.* 2001;141:592-8.
 62. Peters RJG, Spickler W, Theroux P, White H, **Gibson CM**, Molhoek PG, Anderson HV, Hirsh J, Weaver D. Randomized comparison of vasoflux, a novel anticoagulant, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction. Results of the VITAL study: Vasoflux International Trial for AMI Lysis. *Am Heart J.* 2001;142:237-43.
 63. Schweiger MJ, Cannon CP, Murphy SA, **Gibson CM**, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald E for the TIMI 10B and TIMI 14 Investigators. Early Coronary Intervention Following Pharmacologic Therapy for Acute Myocardial Infarction- The Combined TIMI 10B- TIMI 14 Experience. *Am J Cardiol.* 2001;88(8):831-6.
 64. Wang-Clow F, Fox NL, Cannon CP, **Gibson CM**, Beroli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DC. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. *Am Heart J.* 2001 Jan;141(1):33-40.
 65. **Gibson CM**, Kirtane AJ, Murphy SA, Marble SJ, de Lemos JA, Antman EM, Braunwald E for the TIMI

- Study Group. Impact of Contrast Agent Type (Ionic versus Non-ionic) Used for Coronary Angiography on Angiographic, Electrocardiographic and Clinical Outcomes Following Thrombolytic Administration in Acute MI. *Catheter Cardiovasc Interv*. 2001 May;53(1):6-11.
66. **Gibson CM**, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E for the TIMI Study Group. Combination Therapy with Abciximab Reduces Angiographically Evident Thrombus in Acute MI: A TIMI 14 Substudy. *Circulation*. 2001 May 29;103(21):2550-4.
 67. **Gibson CM**, Cohen D, Cohen E, Liu H, Murphy S, Marble SJ, Kitt M, Lorenz T, Tchong JE for the ESPRIT study Group. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. *Am J Cardiol*. 2001 Jun 1;87(11):1293-5.
 68. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, **Gibson CM**, Robertson DH, DeLucca PT, McCabe CH, Braunwald E for the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-TIMI 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001 Jun 21;344(25):1879-87.
 69. Srinivas VS, Cannon CP, **Gibson CM**, Antman EM, Tanasijevic MJ, Murphy S, Sokol S, Braunwald E, Mueller HS. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. *Am Heart J*. 2001 Jul;142(1):29-36.
 70. de Lemos JA, Morrow DA, **Gibson CM**, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E for the TIMI 14 Investigators. Early Noninvasive Detection of Failed Epicardial Reperfusion After Fibrinolytic Therapy. *Am J Cardiol*. 2001 Aug 15;88(4):353-8.
 71. Solomon DH, Stone PH, Glynn RJ, Ganz DA, **Gibson CM**, Tracy R, Avorn J. Use of Risk Stratification To Identify Patients With Unstable Angina Likeliest to Benefit From an Invasive Versus Conservative Management Strategy. *J Am Coll Cardiol*. 2001 Oct;38(4):969-76.
 72. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, **Gibson CM**, Barron HV for the LIMIT AMI Investigators. A double-blind, randomized trial of an anti-CD18 antibody in conjunction with rtPA for acute myocardial infarction: the LIMIT AMI Study. *Circulation*. 2001 Dec 4;104(23):2778-83.
 73. Antman EM, Cooper H, **Gibson CM**, de Lemos JA, McCabe CH, Giugliano RP, Coussement P, Murphy SA, Scherer J, Anderson K, Van de Werf F, Braunwald E for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Determinants of Improvement in Epicardial Flow and Myocardial Perfusion for ST Elevation Myocardial Infarction: Insights from TIMI 14 and InTIME-II. *European Heart Journal*. 2002;23:928-33.
 74. Bahit MC, Murphy SA, **Gibson CM**, Cannon CP. Critical pathway for acute ST-segment elevation myocardial infarction estimating its potential impact in the TIMI 9 trial registry. *Critical Pathways in Cardiology*. 2002;1:107-12.
 75. Cannon CP, Bahit MC, Haugland JM, Henry TD, Schweiger MJ, McKendall GR, Shah PK, Murphy SA, **Gibson CM**, McCabe CH, Antman EM, Braunwald E for the TIMI 9 Registry Investigators. Underutilization of evidence-based medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. *Critical Pathways in Cardiology*. 2002;1:44-52.
 76. **Gibson CM**, de Lemos JA, Murphy SA, Marble SJ, Antman EM, Cannon CP. Methodologic and Clinical Validation of the TIMI Myocardial Perfusion Grade in Acute MI. *J Thromb Thrombolysis*. 2002;14(3):233-7.
 77. de Lemos JA, Morrow DA, **Gibson CM**, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST segment elevation acute coronary syndromes: results from the TIMI 11B and TACTICS-TIMI 18 studies. *J Am Coll*
-

Cardiol. 2002;40:238–44.

78. **Gibson CM**, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E for the TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. *Circulation.* 2002;105:1909-13.
 79. Scirica BM, Cannon CP, **Gibson CM**, Murphy SA, Moliterno DJ, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald E. The effect of clinical guidelines on the management of unstable angina and non-ST-elevation myocardial infarction in the TIMI III (1990-93) and the GUARANTEE (1995-96) Registries. *Critical Pathways in Cardiology.* 2002;150–158.
 80. Solomon DH, Ganz DA, Avorn J, Glynn RJ, Knight EL, **Gibson CM**, Stone PH. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. *Journal of Clinical Epidemiology.* 2002;55:121–8.
 81. Weber J, Murphy SA, Braunwald E, **Gibson CM**. Epicardial and myocardial perfusion abnormalities in the setting of cocaine induced myocardial infarction. *J Thromb Thrombolysis.* 2002;14(3):239-45.
 82. **Gibson CM**, Murphy SA, Hynes C, Marble SJ, Cohen DJ, Cohen E, Lui HK, Kitt MM, Lorenz TJ, and Tchong JE for the ESPRIT study group. Relationship of CK-MB Release to TIMI Myocardial Perfusion Grade Following Intracoronary Stent Placement: An ESPRIT Substudy. *Am Heart J.* 2002 Jan;143(1):106-110.
 83. Angeja BG, Gunda M, Murphy SA, Sobel BE, Rundle AC, Syed M, Asfour A, Borzak S, Gourlay SG, Barron HV, Gibbons RJ, **Gibson CM** for the LIMIT AMI Study Group. TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association with Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging. *Circulation.* 2002 Jan 22;105(3):282-5.
 84. Colyer WR Jr, Burket MW, Ansel GM, Ramee SR, Minor RL, **Gibson CM**, Cooper CJ. Intra-aortic balloon pump placement following aorto-iliac angioplasty and stent placement. *Catheter Cardiovasc Interv.* 2002 Feb;55(2):163-8.
 85. **Gibson CM**, Chen M, Goel M, Angeja BG, Murphy SA, Marble SJ, Cannon CP, for the TIMI Study Group. Precordial ST-Segment Depression in Inferior Myocardial Infarction is Associated with Slow Flow in the Non-Culprit Left Anterior Descending Artery. *J Thromb Thrombolysis.* 2002 Feb;13(1):9-12.
 86. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand JP, Bigonzi F, Pisapia G, **Gibson CM**, Heidebuchel H, Braunwald E, and Frans Van de Werf F for the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Investigators. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-TIMI 23 Trial. *Circulation.* 2002 Apr 9;105(14):1642-9.
 87. **Gibson CM**, Frisch D, Murphy SA, Gourlay SG, Gibbons R, Barron HV for the LIMIT AMI Study Group. The Relationship of Intracoronary Stent Placement Following Thrombolytic Therapy to Tissue Level Perfusion. *Journal of Thrombolysis and Thrombosis.* 2002 Apr;13(2):63-8.
 88. Sabatine MS, Morrow DA, de Lemos JA, **Gibson CM**, Murphy SA, McCabe CH, Antman EM, Cannon CP, Braunwald E. A multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, c-reactive protein and B-type natriuretic peptide. *Circulation.* 2002 Apr 16;105(15):1760-3.
 89. Becker RC, Spencer FA, **Gibson CM**, Rush J, Sanderink G, Murphy S, Ball SP, Antman E for the TIMI 11A investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. *Am Heart J.* 2002 May;143(5):753-9.
 90. Angeja BG, **Gibson CM**, Chin R, Frederick PD, Every NR, Ross AM, Stone GW, and Barron HV for the Participants in the National Registry of Myocardial Infarction 2-3. Predictors of door-to-balloon delay in
-

primary angioplasty. *Am J Cardiol.* 2002 May 15;89(10):1156-61.

91. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, **Gibson CM** for the TIMI Study Group. The Smoker's Paradox: Insights from the Angiographic Substudies of the TIMI Trials. *J Thromb Thrombolysis.* 2002 Jun;13(3):133-9.
92. Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, **Gibson CM**. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. *J Invasive Cardiol.* 2002 Jun;14(6):299-302.
93. **Gibson CM**, Dotani MI, Murphy SA, Marble SJ, Dauterman KW, Michaels AD, Dodge JT for The RESTORE Investigators. Correlates of Coronary Blood Flow Before and After Percutaneous Coronary Intervention and Their Relationship to Angiographic and Clinical Outcomes in the RESTORE Trial. *Am Heart J.* 2002 Jul;144(1):130-5.
94. Murphy SA, **Gibson CM**, Van de Werf F, McCabe CH, Cannon CP. Comparison of errors in estimating weight and dosing of single-bolus TNK with tissue plasminogen activator (TIMI 10B and ASSENT I). *Am J Cardiol.* 2002 Jul 1;90(1):51-4.
95. Wong GC, Krammer N, Pai R, James D, Murphy SA, Cannon CP, **Gibson CM** for the TACTICS-TIMI 18 Study Group. Elevations in Troponin T and I are Associated with Abnormal Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy. *Circulation.* 2002 Jul 9;106:202-7.
96. Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow D, Sabatine MS, McCabe CH, **Gibson CM**, Braunwald E. Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for unstable angina and non-ST-elevation myocardial infarction in the TIMI III Registry. *Am J Cardiol.* 2002 Aug 1;90(3):303-5.
97. Brener SJ, Murphy SA, **Gibson CM**, DiBattiste P, Demopolous L, and Cannon CP for the TACTICS Investigators. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. *Am J Cardiol.* 2002 Sep 15;90(6):631-3.
98. Angeja B, de Lemos JA, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, **Gibson CM**. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. *Am Heart J.* 2002 Oct;144(4):649-56.
99. Popma JJ, Cox N, Hauptmann KE, Reifart N, Virmani R, Emira K, Murphy S, **Gibson CM**, Grube E. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. *Catheter Cardiovasc Interv.* 2002 Oct;57(2):125-34.
100. Popma JJ, Hauptmann KE, Reifart N, Virmani R, Cox N, Esfir K, McColl M, Tully G, Murphy SA, **Gibson CM**, Grube E. Initial Clinical Experience with Distal Coronary Protection using the FilterWire Ex™ in Patients Undergoing Coronary Artery and Saphenous Vein Graft Percutaneous Intervention. *Catheter Cardiovasc Interv.* 2002 Oct;57(2):125-34.
101. Murphy SA, Chen C, Cannon CP, Braunwald E, **Gibson CM**. The impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute MI. *Am J Cardiol.* 2002 Oct 1;90(7):766-770.
102. Sharis PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, **Gibson CM**, Stone PH, Braunwald E. Predictors of mortality, coronary angiography and revascularization in unstable angina and acute non-q wave myocardial infarction (The TIMI III Registry). *Am J Cardiol.* 2002 Nov 15;90(10):1154-6.
103. Cooper HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, **Gibson CM**, Antman EM, Braunwald E. Minimal ST-Segment Deviation: A Simple, Noninvasive Method to Identify Patients with a Patent Infarct-Related Artery following Fibrinolysis. *Am Heart J.* 2002 Nov;144(5):790-5.
104. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, **Gibson CM**. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in

Myocardial Infarction 18 trial) substudy. *J Am Coll Cardiol*. 2002 Nov 20;40(10):1761-8.

105. **Gibson CM**, Gibson WJ, Murphy SA, Marble SJ, McCabe CH, Turakhia MP, Kirtane AJ, Karha J, Aroesty JM, Giugliano RP, Antman EM. The association of the Fibonacci cascade with the distribution of coronary artery lesions responsible for ST segment elevation myocardial infarction. Submitted to *Am J Cardiol*. 2003;92(5):595-7.
106. **Gibson CM**, Karha J, Murphy SA, James DJ, Antman EM, Cannon CP, Braunwald E for the TIMI Study Group. Early and Long Term Clinical Outcomes Associated with Reinfarction Following Fibrinolytic Administration. *J Am Coll Cardiol*. 2003;42:7-16.
107. **Gibson CM**, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance From the Coronary Ostium to the Culprit Lesion in Acute ST-Elevation Myocardial Infarction and its Implications Regarding The Potential Prevention of Proximal Plaque Rupture. *J Thromb Thrombolysis*. 2003; 15(3): 189-96.
108. **Gibson CM**, Pinto DS, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. *J Am Coll Cardiol*. 2003;42(9):1535-43.
109. Giugliano RP, Roe MT, Harrington RA, **Gibson CM**, Zeymer U, Van de Werf F, Baran K, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM, MD on behalf of the INTEGRITI Investigators. Combination Reperfusion Therapy With Eptifibatide and Reduced Dose Tenecteplase For ST-Elevation Myocardial Infarction: Results of the Integrilin® and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) Phase II Angiographic Trial. *J Am Coll Cardiol*. 2003;41:1251- 60ii.
110. Karha J, Murphy SA, Kirtane AJ, de Lemos JA, Aroesty JM, Cannon CP, Antman EM, Braunwald E, **Gibson CM** for the TIMI Study Group. Association of Proximal Culprit Artery Lesion Location with Clinical Outcomes In Acute Myocardial Infarction. *Am J Cardiol*. 2003;92(8):913-8.
111. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, **Gibson CM**, Cannon CP, Braunwald E, Schönbeck U. Soluble CD40L: Risk Prediction After Acute Coronary Syndromes. *Circulation*. 2003;108:r43-r46.
112. Bahit MC, Cannon CP, Antman EM, Murphy SA, **Gibson CM**, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. *Am Heart J*. 2003 Jan;145(1):109-17.
113. Murphy SA, Chen C, Gourlay S, Barron HV, **Gibson CM**. Impairment of myocardial perfusion in both culprit and nonculprit arteries in acute myocardial infarction: a LIMIT AMI substudy. *Am J Cardiol*. 2003 Feb 1;91(3):325-8.
114. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, **Gibson CM**, Antman EM, McCabe CH, Cannon CP, and Braunwald E for the TIMI Study Group. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. *Circulation*. 2003 Feb 11;107(5):690-5.
115. Henry TD, Annex BH, McKendall GR, Azrin, MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, **Gibson CM**, Bajamonde A, Rundle AC, Fine J, McCluskey ER for the VIVA Investigators. The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis. *Circulation*. 2003 Mar 18;107(10):1359-65.
116. Pinto DS, Murphy SA, Marble SJ, Cannon CP, Braunwald E, **Gibson CM**. Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). *Am J Cardiol*. 2003 Apr 15;91(8):976-8, A4.
117. Weber JE, **Gibson CM**, Murphy SA, Larkin GL, Hollander JE. Cocaine induced myocardial infarction is

associated with reduced microvascular perfusion. *Acad Emerg Med*. 2003 May;10(5):428-9.

118. Dotani MI, Morise AP, Haque R, Jain AC, **Gibson CM**. Association between short-term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. *Am J Cardiol*. 2003 May 1;91(9):1107-9.
119. Giugliano GR, Giugliano RP, **Gibson CM**, Kuntz RE. Meta-analysis of Corticosteroid treatment for acute myocardial infarction. *Am J Cardiol*. 2003 May 1;91(9):1055-9.
120. Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Krammer N, Katsiyannis PT, Marble SJ, DiBattiste PT, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, **Gibson CM**, for the LIMIT AMI and TACTICS-TIMI 18 Study Groups. Time for Contrast Material to Traverse the Epicardial Artery and the Myocardium in Acute ST Segment Elevation Myocardial Infarction Versus Unstable Angina/Non ST Elevation MI. *Am J Cardiol*. 2003 May 15;91(10):1163-7.
121. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopolous LA, DiBattiste PM, McCabe CH, **Gibson CM**, Cannon CP, and Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. *J Am Coll Cardiol*. 2003 Apr 16;41(8):1264-72. Erratum in: *J Am Coll Cardiol*. 2003 May 21;41(10):1852.
122. Murphy SA, Dauterman K, de Lemos JA, Kermgard S, Marble SJ, Antman EM, Braunwald E, and **Gibson CM** for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Non-Q-Wave MI in the Modern Thrombolytic Era: Angiographic and Clinical Characteristics Associated with the Development of Non-Q-Wave MI in the TIMI 14 trial. *Am Heart J*. 2003 Jul;146(1):42-7.
123. Chen EW, Canto JG, Parson LS, Peterson ED, Littrell K, Every NR, **Gibson CM**, Hochman JS, Ohman EM, Cheeks M, Barron HV for the Investigators in the National Registry of Myocardial Infarction. Relation Between Hospital Intra-aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock. *Circulation*. 2003 Aug 26;108(8):951-7. Epub 2003 Aug 11.
124. Hobbach HP, **Gibson CM**, Giugliano RP, Hundertmark J, Schaeffer C, Tscherleniak W, Schuster P. The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction. *J Thromb Thrombolysis*. 2003 Dec;16(3):167-74.
125. Choi JW, **Gibson CM**, Murphy SA, Davidson CJ, Kim RJ, Ricciardi M. Myonecrosis following stent placement: Association between impaired TIMI myocardial perfusion grade (TMPG) and MRI visualization of microinfarction. *Catheter Cardiovasc Interv*. 2004;61(4):472-6.
126. **Gibson CM**, Bigelow B, James D, Tepper MR, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E for the TIMI Study Group. Association of American College of Cardiology/American Heart Association Task Force Association of Lesion Complexity Following Fibrinolytic Administration with Mortality in ST Elevation Myocardial Infarction. *Am J Cardiol*. 2004;94(1):108-11.
127. **Gibson CM**, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E for the TIMI Study Group. Association of a Pulsatile Blood Flow Pattern on Coronary Arteriography and Short-Term Clinical Outcomes in Acute Myocardial Infarction. *J Am Coll Cardiol*. 2004;43(7):1170-6.
128. **Gibson CM** and Schomig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. *Circulation*. 2004;109(25):3096-105.
129. Giugliano RP, Sabatine MS, **Gibson CM**, Roe MT, Harrington RA, Murphy SA, DA Morrow, EM Antman, and E Braunwald. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. *Am J Cardiol*. 2004;93(11):1362.
130. Herrmann HC, Murphy SA, DiBattiste PM, DeLucca, PT, Demopoulos LA, **Gibson CM** and Cannon CP. Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared with Non-United States Patients: A TACTICS-TIMI 18 Substudy. *Critical*

Pathways in Cardiology. 2004;3(2):95-100.

131. Kirtane A, Barron HV, Murphy SA, **Gibson CM**. Association of absolute neutrophil count with patency in AMI. *Am J Cardiol*. 2004;93(5):532-6.
 132. Kirtane AJ, Bui A, Murphy SA, Karpaliotis D, Rahman A, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, and **Gibson CM** for the TIMI Study Group. Association of Epicardial and Tissue-level Reperfusion with Left Ventricular End-Diastolic Pressures in ST-Elevation Myocardial Infarction. *Journal of Thrombosis and Thrombolysis*. 2004;17(3):177-84.
 133. McCullough PA, **Gibson CM**, DiBattiste PM, Demopoulos LA, Murphy SA, Weintraub WS, Neumann FJ, Khanal S, and Cannon CP for the TACTICS TIMI-18 Investigators. Timing of angiography and revascularization in acute coronary syndromes: an analysis from the TACTICS-TIMI 18 trial. *J Interv Cardiol*. 2004;17(2):81-86.
 134. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, **Gibson CM**, McCabe CH, Barron HV, Van De Werf F, and Braunwald E. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. *Eur Heart J*. 2004;25(13):1139.
 135. Roe MT, Green CL, Giugliano RP, **Gibson CM**, Baran K, Greenberg M, Palmeri ST, Crater S, Trollinger K, Hannan K, Harrington RA, Krucoff MW; INTEGRITI Investigators. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute st-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2004;43(4):549-56.
 136. Sadanandan S, Cannon CP, Cheuri K, Murphy SA, DiBattiste PM, Morrow DA, de Lemos JA, Braunwald E, and **Gibson CM**. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non ST elevation myocardial infarction. *J Am Coll Cardiol*. 2004;44:564-8.
 137. Sadanandan S, Cannon CP, **Gibson CM**, Desai R, Murphy SA, DiBattiste PM, and Braunwald E. A risk score for predicting coronary artery bypass surgery in patients with non-ST elevation acute coronary syndromes. *J Am Coll Cardiol*. 2004;44:799-803.
 138. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, **Gibson CM**, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. *Circulation*. 2004;109(5):580-6.
 139. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, **Gibson CM**, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the Thrombolysis In Myocardial Infarction Risk Index in the National Registry of Myocardial Infarction-3 and -4. A Simple Index That Predicts Mortality in ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol*. 2004;44:783-9.
 140. Kirtane AJ, Bui A, Murphy SA, Barron HV, **Gibson CM**. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. *Curr Treat Options Cardiovasc Med*. 2004 Feb;6(1):69-77.
 141. **Gibson CM**, Karha J, Giugliano RP, Roe MT, Murphy SA, Harrington RA, Green CL, Schweiger MJ, Miklin JS, Baran KW, Palmeri S, Braunwald E, and Krucoff MW for the INTEGRITI Study Group. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. *Am Heart J*. 2004 May;147(5):847-52.
 142. Goldstein JA, Massey KD, Kirby S, **Gibson CM**, Hettiarachchi J, Rankin AJ & Jackson NC. Effect of high-dose intravenous eletriptan on coronary artery diameter. Effect of high-dose intravenous eletriptan on coronary artery diameter. *Cephalalgia*. 2004 Jul;24(7):515-21.
 143. Gardner GS, Frisch DR, Murphy SA, Aroesty JM, Giugliano RP, Antman EM, Braunwald E and **Gibson CM** for the TIMI Study Group. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. *Am J Cardiol*. 2004
-

Jul 15;94(2):178-81.

144. Mega JL, Morrow DA, deLemos JA, Sabatine MS, Murphy SA, Rifai N, **Gibson CM**, Antman EM, Braunwald E. BNP at Presentation and Prognosis in Patients with ST-Elevation Myocardial Infarction: An ENTIRE-TIMI 23 Substudy. *J Am Coll Cardiol*. 2004 Jul 21;44(2):335-9.
 145. **Gibson CM**, Murphy SA, Morrow DA, Aroesty JM, Gibbons RJ, Gourlay SG, Barron HV, Giugliano RP, Antman EM, Braunwald E. Angiographic Perfusion Score: An Angiographic Variable That Integrates Both Epicardial and Tissue Level Perfusion Before and After Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. *Am Heart J*. 2004 Aug;148(2):336-40.
 146. **Gibson CM**, Jennings LK, Lorenz D, Giugliano RP, Harrington RA, Roe MT, Murphy SA, Cholera S, Baran KW, Hobbach H, Braunwald E. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. *Circulation*. 2004 Aug 10;110(6):679-84.
 147. **Gibson CM**, Singh KP, Murphy SA, DiBattiste P, Demopoulos L, Cannon CP and Braunwald E for the TIMI Study Group. Association Between Duration of Tirofiban Therapy Before Percutaneous Intervention and Tissue Level Perfusion: A TACTICS-TIMI 18 Substudy. *Am J Cardiol*. 2004 Aug 15;94(4):492-4.
 148. **Gibson CM**, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, and Braunwald E for the TIMI Study Group. Association of Duration of Symptoms at Presentation with Angiographic and Clinical Outcomes Following Fibrinolytic Therapy. *J Am Coll Cardiol*. 2004 Sep 1;44(5):980-7.
 149. Kashani A, Giugliano RP, Antman EM, Morrow DA, **Gibson CM**, Murphy SA, and Braunwald E. Severity of Heart Failure, Treatments, and Outcomes After Fibrinolysis in Patients With ST-Elevation Myocardial Infarction. *Eur Heart J*. 2004 Oct 1;25(19):1702.
 150. **Gibson CM**, Dumaine R, Murphy SA, Cannon CP, Antman EM, Braunwald E. Association of Glomerular Filtration Rate on Presentation in Unstable Angina and Non ST Elevation Myocardial Infarction with Subsequent Mortality. *Eur Heart J*. 2004 Nov 1;25(22):1998-2005.
 151. **Gibson CM**. NRMI and current treatment patterns for ST-elevation myocardial infarction. *Am Heart J*. 2004 Nov 1;148(5 Suppl):S29.
 152. Karmaliotis D, Turakhia MP, Morrow DA, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, and **Gibson CM**. Sequential Risk Stratification using the TIMI Risk Score and TIMI Flow Grade among Patients Treated with Fibrinolytic Therapy for acute ST Segment Elevation Myocardial Infarction. *Am J Cardiol*. 2004 Nov 1;94(9):1113.
 153. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, **Gibson CM**, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM; CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *JAMA*. 2004 Nov 3;292(17):2096-104.
 154. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, **Gibson CM**; Thrombolysis in Myocardial Infarction Study Group. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. *Am J Cardiol*. 2004 Dec 1;94(11):1406-10.
 155. Turakhia M, Pinto T, Murphy SA, Antman EM, Cannon CP, Braunwald E, **Gibson CM**. Higher platelet counts are associated with greater thrombus burden in patent arteries following thrombolytic administration: A TIMI angiographic substudy. *Am J Cardiol*. 2004 Dec 1;94(11):1406.
 156. Karha J, **Gibson CM**, Murphy SA, Dibattiste PM, Cannon CP; TIMI Study Group. Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. *Am J Cardiol*. 2004 Dec 15;94(12):1537-9.
-

157. Alexander KP, Chen AY, Roe MT, Newby LK, **Gibson CM**, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED for the CRUSADE Investigators. Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes. *JAMA*. 2005; 294(24): p. 3108-3116.
 158. Kashani A, **Gibson CM**, Murphy SA, Sabatine MS, Morrow DA, Antman EM, Giugliano RP. Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. *Am J Cardiol*. 2005 Jan 15;95(2):228-33.
 159. Kirtane AJ, Weisbord A, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Harrington RA, Ohman EM, Roe MT, Braunwald E, and **Gibson CM**, for the TIMI Study Group. Relation of Impaired TIMI Myocardial Perfusion Grades to Residual Thrombus Following the Restoration of Epicardial Patency in ST-Elevation Myocardial Infarction. *Am J Cardiol*. 2005 Jan 15;95(2):224-7.
 160. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, and **Gibson CM**. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2005 Jan 18;45(2):321-3.
 161. Ray KK, Morrow DA, **Gibson CM**, Murphy SA, Antman EM, and Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. *Eur Heart J*. 2005 Jan 26;26(5):440-446.
 162. Sabatine MS, McCabe CH, **Gibson CM**, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. *Am Heart J*. 2005 Feb;149(2):227-33.
 163. **Gibson CM**, Kirtane AJ, Boundy K, Ly H, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, and TIMI Study Group. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. *J Am Coll Cardiol*. 2005 Feb 1;45(3):357-362.
 164. Kirtane AJ, Kosmidou I, Karpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, **Gibson CM**, and TIMI Study Group. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. *Am J Cardiol*. 2005 Feb 1;95(3):337-42.
 165. Ly HQ, Kirtane AJ, Buros J, Giugliano RP, Popma JJ, Antman EM, Harrington RA, Ohman EM, **Gibson CM**, and for the TIMI Study Group. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. *Am J Cardiol*. 2005 Feb 1;95(3):383-6.
 166. Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, **Gibson CM**, Cannon CP. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. *Circulation*. 2005 Mar 15;111(10):1217-24.
 167. Sabatine MS, Cannon CP, **Gibson CM**, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*. 2005 Mar 24;352(12):1179-89.
 168. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, **Gibson CM**, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. *Circulation*. 2005 Apr 26;111(16):2042-9.
 169. Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, **Gibson CM**, Antman EM,
-

- Braunwald E, Theroux P. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. *Am Heart J*. 2005 May;149(5):846-50.
170. Jeremias A, **Gibson CM**. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. *Ann Intern Med*. 2005 May 3;142(9):786-91.
 171. Giugliano RP, Newby LK, Harrington RA, **Gibson CM**, Van de Werf F, Armstrong P, Montalescot G, Gilbert J, Strony JT, Califf RM, Braunwald E; EARLY ACS Steering Committee. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. *Am Heart J*. 2005 Jun;149(6):994-1002.
 172. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karpalitis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, **Gibson CM**; TIMI Study Group. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol*. 2005 Jun 7;45(11):1781-6.
 173. Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, **Gibson CM**, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E; FASTER (TIMI 24) Investigators. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. *Am Heart J*. 2005 Jul;150(1):79-88.
 174. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, **Gibson CM**; TIMI Study Group. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2005 Jul 5;46(1):178-80.
 175. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, **Gibson CM**, Braunwald E, Cannon CP; TIMI Study Group. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). *Am J Cardiol*. 2005 Sep 1;96(5):635-8.
 176. Sabatine MS, Cannon CP, **Gibson CM**, Lopez-Sendon JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. *JAMA*. 2005 Sep 14;294(10):1224-32.
 177. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, **Gibson CM**, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol*. 2005 Oct 18;46(8):1417-24.
 178. Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, **Gibson CM**, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators. The PROject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. *Am Heart J*. 2005 Oct;150(4):643-9.
 179. Ly HQ, Denault A, Dupuis J, Vadeboncoeur A, Harel F, Arsenault A, **Gibson CM**, Bonan R. A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). *Am Heart J*. 2005 Nov;150(5):933.9-933.
 180. Shavelle DM, Rasouli ML, Frederick P, **Gibson CM**, French WJ; National Registry of Myocardial Infarction Investigators. Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). *Am J Cardiol*. 2005 Nov 1;96(9):1227-32.
 181. Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, **Gibson CM**, Cannon CP, Antman EM, Braunwald E. Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial

- Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial. *Circulation*. 2005 Nov 15;112:3846-3854.
182. Pinto DS, Kirtane AJ, Ruocco NA, Deibele AJ, Shui A, Buros J, Murphy SA, **Gibson CM**. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. *Am J Cardiol*. 2005 Dec 1;96(11):1494-7. Epub 2005 Oct 17.
 183. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, **Gibson CM**. Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy. *Circulation*. 2006; 114:2019-2025
 184. Sabatine MS, Morrow DA, McCabe CH, Antman EM, **Gibson CM**, Cannon CP. Combination of Quantitative ST Deviation and Troponin Elevation Provide Independent Prognostic and Therapeutic Information in Unstable Angina and Non-ST-Elevation Myocardial Infarction. *Am Heart J*. 2006 Jan 1;151(1): p. 25-31.
 185. Svensson L, Aasa M, Dellborg M, **Gibson CM**, Kirtane A, Herlitz J, Ohlsson A, Karlsson T, Grip L. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. *Am Heart J*. 2006 Apr;151(4):798.e1-7.
 186. Dumaine R, **Gibson CM**, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. *J Clin Hypertens* (Greenwich). 2006 May;8(5):315-22.
 187. **Gibson CM**, Karpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T, Jennings LK, Cohen DJ, Morrow DA; TIMI Study Group. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. *Am J Cardiol*. 2006 May 15;97(10):1473-7.
 188. Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, **Gibson CM**, Cannon CP, Braunwald E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. *Am J Cardiol*. 2006 Jun 1;97(11):1573-7.
 189. **Gibson CM**, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. *J Am Coll Cardiol*. 2006 Jun 20;47(12):2364-73.
 190. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, **Gibson CM**; TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. *J Am Coll Cardiol*. 2006 Jun 20;47(12):2374-9.
 191. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, **Gibson CM**; TIMI Study Group. Association of Platelet Counts on Presentation and Clinical Outcomes in ST-Elevation Myocardial Infarction (from the TIMI Trials). *Am J Cardiol*. 2006 Jul 1;98(1):1-5.
 192. Scirica BM, Sabatine MS, Morrow DA, **Gibson CM**, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, and Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. *J Am Coll Cardiol*. 2006 Jul 4;48(1): p. 37.
 193. Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, **Gibson CM**. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI:

- a CLARITY-TIMI 28 substudy. *Eur Heart J*. 2006 Jul 17;27(17):2040-2045.
194. Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, **Gibson CM**. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. *J Thromb Thrombolysis*. 2006 Aug;22(1):47-50.
 195. **Gibson CM**, Zorkun C, Molhoek P, Zmudka K, Greenberg M, Mueller H, Wesdorp J, Louwerenburg H, Niederman A, Westenburg J, Bikkina M, Batty J, de Winter J, Murphy SA, McCabe CH. Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial. *J Thromb Thrombolysis*. 2006 Aug;22(1):13-21.
 196. **Gibson CM**, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP. Usefulness of Clopidogrel in Abolishing the Increased Risk of Reinfarction Associated with Higher Platelet Counts in Patients with ST-Elevation Myocardial Infarction: Results from CLARITY-TIMI 28. *Am J Cardiol*. 2006 Sep 15;98(6):761-3.
 197. **Gibson CM**, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings LK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E. Association Between TIMI Myocardial Perfusion Grade, Biomarkers, and Clinical Outcomes Among Patients with Moderate to High-Risk Acute Coronary Syndromes: Observations from the PROTECT- TIMI 30 Trial. *Am Heart J*. 2006 Oct;152(4):756-61.
 198. **Gibson CM**, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazzuha S, Rokos I, Shammass NW, Palabrica TM, Fish P, McCabe CH, Braunwald E. Early Initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34. *Am Heart J*. 2006 Oct;152(4):668-675.
 199. Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, **Gibson CM**, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. *Am Heart J*. 2006 Oct;152(4):641-7.
 200. Wiviott SD, Antman EM, **Gibson CM**, Montalescot G, Reismeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 28 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet Inhibition with prasugrel Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI-38). *Am Heart J*. 2006 Oct;152(4):627-635.
 201. Gibson WJ, **Gibson CM**. The association of impaired myocardial perfusion and monocyte activation with late recovery of left ventricular function following primary percutaneous coronary intervention. *Eur Heart J*. 2006 Nov;27(21):2487-8.
 202. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP Jr, Antman EM, Cannon CP, **Gibson CM**. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. *Circulation*. 2006 Nov 7;114(19):2019-25.
 203. Kirtane AJ, **Gibson CM**. Distal embolization of thrombus in acute myocardial infarction. *Am J Med*. 2006 Dec;119(12):e1-2.
 204. Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, **Gibson CM**, Tolleson TR, O'shea JC, Tcheng JE. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial. *Catheter Cardiovasc Interv*. 2007 Jan 3;70(1):44-51.
 205. Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, **Gibson CM**, Califf RM, Ferguson TB Jr., Peterson ED; PREVENT IV Investigators. Outcomes associated with the use of secondary prevention medications after coronary artery

- bypass graft surgery. *Ann Thorac Surg.* 2007 Mar;83(3):993-1001.
206. Fernandez-Aviles F, Alonso JJ, Pena G, Blanco J, Alonso-Briales J, Lopez-Mesa J, Fernandez-Vazquez F, Moreu J, Hernandez RA, Castro-Beiras A, Gabriel R, **Gibson CM**, Sanchez PL; GRACIA-2 (Grupo de Analisis de Cardiopatía Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. *Eur Heart J.* 2007 Apr;28(8):949-60. Epub 2007 Jan 23.
 207. Karmaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmour D, Kosmidou I, Jarolim P, de Lemos JA, Sabatine MS, **Gibson CM**, Morrow D. Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. *Chest.* 2007 Apr;131(4):964-71.
 208. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, **Gibson CM**, Braunwald E. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. *Eur Heart J.* 2007 Apr;28(7):806-13. Epub 2007 Apr 2.
 209. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, **Gibson CM**, Hoekstra JW, Pollack CV Jr., Ohmann EM, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). *Am J Cardiol.* 2007 May 15;99(10):1389-93. Epub 2007 Mar 26.
 210. **Gibson CM**, Ten Y, Murphy SA, Ciaglo LN, Southard MC, Lincoff AM, Waksman R. Association of prerandomization anticoagulant switching with bleeding in the setting of Percutaneous Coronary Intervention (A REPLACE-2 Analysis). *Am J Cardiol.* 2007 Jun 15;99(12):1687-90. Epub 2007 Apr 26.
 211. **Gibson CM**, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E; EXTRACT-TIMI 25 Investigators. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the EXTRACT-TIMI 25 trial. *J Am Coll Cardiol.* 2007 Jun 12;49(23):2238-46. Epub 2007 May 25.
 212. Steinberg BA, Moghbeli N, Buros J, Ruda M, Parkhomenko A, Raju BS, García-Castillo A, Janion M, Nicolau JC, Fox KA, Morrow DA, **Gibson CM**, Antman EM. Global outcomes of ST-elevation myocardial infarction: comparisons of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) registry and trial. *Am Heart J.* 2007 Jul;154(1):54-61.
 213. **Gibson CM**, Buros J, Ciaglo LN, Southard MC, Takao S, Harrigan C, Filopei J, Lew M, Marble SJ, Murphy SA, Cohen MG, and TITAN-TIMI 34 Investigators. Impact of Iodinated Contrast Injections on Percent Diameter Coronary Arterial Stenosis and Implications for Trials of Intracoronary Pharmacotherapies in Patients With ST-Elevation Myocardial Infarction. *Am J Cardiol.* 2007 Jul 1;100(1): p. 13.
 214. Shah SR, Hochberg CP, Pinto DS, and **Gibson CM**. Reperfusion Strategies for ST-Elevation Myocardial Infarction. *Curr Cardiol Rep.* 2007 Jul 1;9(4): p. 281.
 215. Yeon SB, Sabir A, Clouse M, Martinezclark PO, Peters DC, Hauser TH, **Gibson CM**, Nezafat R, Maintz D, Manning WJ, Botnar RM. Delayed-enhancement cardiovascular magnetic resonance coronary artery wall imaging: comparison with multislice computed tomography and quantitative coronary angiography. *J Am Coll Cardiol.* 2007 Jul 31;50(5):441-7.
 216. Pride YB, **Gibson CM**. Efficacy and safety of single-bolus tenecteplase compared with front-loaded alteplase in Chinese patients with acute myocardial infarction. *Journal of Geriatric Cardiology.* 2007 Sep; 4(3): 142-143.
 217. Murphy SA, **Gibson CM**, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, and Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-

- analysis. *Eur Heart J*. 2007 Sep;28(17):2077-86. Epub 2007 Jun 28.
218. Greenbaum AB, Ohman EM, **Gibson CM**, Borzak S, Stebbins AL, Lu M, Le May MR, Stankowski JE, Emanuelsson H, Weaver WD. Preliminary experience with intravenous P2Y₁₂ platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. *Am Heart J*. 2007 Oct;154(4):702-9.
 219. Aasa M, Kirtane AJ, Dellborg M, **Gibson CM**, Pahl-Abrahamsson U, Svensson L, Grip L. Temporal changes in TIMI myocardial perfusion grade in relation to epicardial flow, ST-resolution and left ventricular function after primary percutaneous coronary intervention. *Coronary Artery Disease*. 2007 Nov;18(7):513-518.
 220. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, **Gibson CM**, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007 Nov 15;357(20):2001-15.
 221. Yeh RW, Wiviott SD, Giugliano RP, Morrow DA, Shui A, Qin J, Scirica B, Bradner JE, Jang IK, **Gibson CM**, Antman E. Effect of Thrombocytopenia on Outcomes Following Treatment With Either *Enoxaparin* or Unfractionated *Heparin* in Patients Presenting with Acute Coronary Syndromes. *Am J Cardiol*. 2007 Dec 15;100(12):1734-8.
 222. Maron M, Appelbaum E, Harrigan C, Buros J, **Gibson CM**, Hanna C, Lesser R, Udelson J, Manning WJ, Maron B. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. *Circulation: Heart Failure*. 2008;1:184-191. Epub 2008 June 23.
 223. **Gibson CM**, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E; TIMI Study Group. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. *Am Heart J*. 2008 Jan;155(1):133-9.
 224. Voisine P, Rosinberg A, Wykrzykowska JJ, Shamis Y, Wu GF, Appelbaum E, Li J, Sellke FW, Pinto D, **Gibson CM**, Mitrani E, Laham RJ. Skin-derived microorgan autotransplantation as a novel approach for therapeutic angiogenesis. *Am J Physiol Heart Circ Physiol*. 2008 Jan;294(1):H213-9.
 225. Magee MJ, Alexander JH, Hafley G, Ferguson TB Jr, **Gibson CM**, Harrington RA, Peterson ED, Califf RM, Kouchoukos NT, Herbert MA, Mack MJ; PREVENT IV Investigators. Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. *Ann Thorac Surg*. 2008 Feb;85(2):494-9; discussion 499-500.
 226. Olenchock SA Jr, Karpaliotis D, Gibson WJ, Murphy SA, Southard MC, Ciaglo L, Buros J, Mack MJ, Alexander JH, Harrington RA, Califf RM, Kouchoukos NT, Ferguson TB Jr, **Gibson CM**. Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. *Ann Thorac Surg*. 2008 Feb;85(2):520-4.
 227. Wu GF, Wykrzykowska JJ, Rana JS, Pinto DS, **Gibson CM**, Li J, Sellke FW, Laham RJ. Effects of B-type natriuretic peptide (nesiritide) on coronary epicardial arteries, systemic vasculature and microvessels. *J Invasive Cardiol*. 2008 Feb;20(2):76-80.
 228. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, **Gibson CM**; CLARITY-TIMI 28 Investigators. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). *Am J Cardiol*. 2008 Feb 1;101(3):303-7.
 229. **Gibson CM**, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME; TIMI Study Group. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2008 Feb

5;51(5):546-51.

230. Direct Inhibition of δ -Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, Bates E, Bode C, Costa M, **Gibson CM**, Granger C, Green C, Grimes K, Harrington R, Huber K, Kleiman N, Mochly-Rosen D, Roe M, Sadowski Z, Solomon S, Widimsky P. Intracoronary KAI-9803 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. *Circulation*. 2008 Feb 19;117(7):886-96. Epub 2008 Feb 4.
231. Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, **Gibson CM**, Lesser JR, Udelson JE, Manning WJ, Maron MS. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Am J Cardiol*. 2008 Mar 1;101(5):668-73.
232. Rinaldi MJ, Kirtane AJ, Piana RN, Caputo RP, Gordon PC, Lopez JJ, Dauerman HL, Ryan TJ Jr, Kiernan FJ, Cutlip DE, Ho KK, **Gibson CM**, Murphy SA, Cohen DJ. Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events. *Am Heart J*. 2008 Apr;155(4):654-60. Epub 2008 Feb 21.
233. O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, **Gibson CM**, Sabatine MS. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. *Eur. Heart J*. 2008 Apr;29(8):984-91. Epub 2008 Mar 16.
234. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, **Gibson CM**, Lesser JR, Hanna CA, Udelson JE, Manning WJ, Maron MS. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2008 Apr 8;51(14):1369-74.
235. **Gibson CM**, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald E. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. *Am J Cardiol*. 2008 May 1;101(9):1232-8.
236. Kosmidou I, Karpaliotis D, Kirtane AJ, Barron HV, **Gibson CM**. Vascular endothelial growth factors in pulmonary edema: an update. *J Thromb Thrombolysis*. 2008 Jun; 25(3):259-264.
237. Kosmidou I, Karpaliotis D, Kirtane AJ, Barron HV, **Gibson CM**. Vascular endothelial growth factors in pulmonary edema: an update. *J Thromb Thrombolysis*. 2008 Jun;25(3):259-64. Epub 2007 Jun 7.
238. Yau JM, Alexander JH, Hafley G, Mahaffey KW, Mack MJ, Kouchoukos N, Goyal A, Peterson ED, **Gibson CM**, Califf RM, Harrington RA, Ferguson TB; PREVENT IV Investigators. Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from Project of Ex-vivo Vein graft Engineering via Transfection [PREVENT] IV). *Am J Cardiol*. 2008 Sep 1;102(5):546-51. Epub 2008 Jul 2.
239. Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, **Gibson CM**; for the TIMI Study Group. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. *J Thromb Thrombolysis*. 2008 Oct;26(2):106-12. Epub 2007 Jul 12.
240. Mehta RH, Hafley GE, **Gibson CM**, Harrington RA, Peterson ED, Mack MJ, Kouchoukos NT, Califf RM, Ferguson Jr. TB, Alexander JH, and Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) – IV Investigators. Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg*. 2008 Nov 1;136(5):1149-1155.
241. De Luca G, **Gibson CM**, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, Van't Hof AW. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an
-

- individual patient data meta-analysis. *Heart*. 2008 Dec;94(12):1548-58. Epub 2008 May 12.
242. Kunadian V, Zorkun C, Williams SP, Biller LH, Palmer AM, Ogando KJ, Lew ME, Nethala N, Gibson WJ, Marble SJ, Buros JL, **Gibson CM**. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. *J Thromb Thrombolysis*. 2008 Dec;26(3):234-42. Epub 2008 Sep 26.
 243. **Gibson CM**, Pride YB, Frederick PD, Pollack Jr. CV, Canto JG, Tiefenbrunn AJ, Weaver WD, Lambrew CT, French WJ, Peterson ED, Rogers WJ and for the NRMJ Investigators. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J*. 2008 Dec 1;156(6): 1035-1044
 244. Peterson ED, Shah BR, Parsons L, Pollack Jr. CV, French WJ, Canto JG, **Gibson CM**, Rogers WJ, and for the NRMJ Investigators. Trends in quality of care for patient with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J*. 2008 Dec 1;156(6):1045-1055
 245. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, **Gibson CM**, Pollack Jr CV, Gore JM, Chandra-Strobos N, Peterson ED, French WJ, and for the National Registry of Myocardial Infarction Investigators. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J*. 2008 Dec 1; 156(6): 1026-1034
 246. Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, Braunwald E, **Gibson CM**. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. *Int J Cardiol*. 2008 Dec 17;131(1):105-12. Epub 2008 Jan 9.
 247. **Gibson CM**, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. *J Thromb Thrombolysis*. 2009 Jan;27(1):11-7. Epub 2008 Aug 10.
 248. Kunadian V, Zorkun C, Gibson WJ, Nethala N, Harrigan C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, **Gibson CM**. Transfusion associated microchimerism: a heretofore little recognized complication following transfusion. *J Thromb Thrombolysis*. 2009 Jan;27(1):57-67. Epub 2008 Sep 3.
 249. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, **Gibson CM**, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. *Lancet*. 2009 Feb 28;373(9665):723-31.
 250. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, **Gibson CM**, Moliterno DJ, Van de Werf F, White HD, Harrington RA, Roe MT. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. *Am Heart J*. 2009 Apr;157(4):716-23.
 251. Abraham JM, **Gibson CM**, Pena G, Sanz R, Almahameed A, Murphy SA, Blanco J, Alonso-Briales J, Lopez-Mesa J, Gimeno F, Sánchez PL, Fernández-Avilés F; for the GRACIA-2 (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Investigators. Association of angiographic perfusion score following percutaneous coronary intervention for ST-elevation myocardial infarction with left ventricular remodeling at 6 weeks in GRACIA-2. *J Thromb Thrombolysis*. 2009 Apr;27(3):253-8. Epub 2008 Mar 11.
 252. Kunadian V, Harrigan C, Zorkun C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, Gibson WJ, **Gibson CM**. Use of the TIMI frame count in the assessment of coronary artery blood flow and microvascular function over the past 15 years. *J Thromb Thrombolysis*. 2009 Apr;27(3):316-28. Epub 2008 Apr 20.
 253. Appelbaum E, Kirtane AJ, Clark A, Pride YB, Gelfand EV, Harrigan CJ, Kissinger KV, Manning WJ, **Gibson CM**. Association of TIMI Myocardial Perfusion Grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-

- segment elevation myocardial infarction. *J Thromb Thrombolysis*. 2009 Apr;27(2):123-9. Epub 2008 Feb 2.
254. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, **Gibson CM**. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). *Am J Cardiol*. 2009 Apr 15;103(8):1056-60.
 255. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, **Gibson CM**, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT; CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. *Eur Heart J*. 2009 May;30(10):1195-202. Epub 2009 Apr 1.
 256. Frisch DR, Giedrimas E, Mohanavelu S, Shui A, Ho KK, **Gibson CM**, Josephson ME, Zimetbaum PJ. Predicting irreversible left ventricular dysfunction after acute myocardial infarction. *Am J Cardiol*. 2009 May 1;103(9):1206-9.
 257. Haraldsdottir S, Gudnason T, Sigurdsson AF, Gudjonsdottir J, Lehman SJ, Eyjolfsson K, Scheving SS, **Gibson CM**, Hoffmann U, Jonsdottir B, Andersen K. Diagnostic accuracy of 64-slice multidetector CT for detection of in-stent restenosis in an unselected, consecutive patient population. *Eur J Radiol*. 2009 Jun 29. [Epub ahead of print]
 258. Appelbaum E, Abraham JM, Pride YB, Harrigan CJ, Peters DC, Biller LH, Manning WJ, **Gibson CM**. Association of Thrombolysis in Myocardial Infarction Myocardial Perfusion Grade with cardiovascular magnetic resonance measures of infarct architecture after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *Am Heart J*. 2009 Jul;158(1):84-91.
 259. **Gibson CM**, Pride YB, Buros JL, Ciaglo LN, Morrow DA, Scirica BM, Stone PH; TIMI Study Group. Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis). *Am J Cardiol*. 2009 Jul 1;104(1):36-40. Epub 2009 May 4.
 260. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, **Gibson CM**; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet*. 2009 Jul 4;374(9683):29-38. Epub 2009 Jun 17.
 261. Maron MS, Maron BJ, Harrigan C, Buros J, **Gibson CM**, Olivetto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2009 Jul 14;54(3):220-8.
 262. Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, **Gibson CM**, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. *N Engl J Med*. 2009 Jul 16;361(3):235-44.
 263. Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, **Gibson CM**; TIMI Study Group. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. *Am J Cardiol*. 2009 Aug 15;104(4):475-9.
 264. Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, Braunwald E, **Gibson CM**; TIMI Study Group. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. *Am Heart J*. 2009 Sep;158(3):e21-6.
 265. De Luca G, **Gibson CM**, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof AW; EGYPT Cooperation. Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb/IIIa

- inhibitors. *Am Heart J*. 2009 Sep;158(3):416-21.
266. Pride YB, Canto JG, Frederick PD, **Gibson CM**; NRMI Investigators. Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. *JACC Cardiovasc Interv*. 2009 Oct;2(10):944-52.
 267. De Luca G, **Gibson CM**, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz H-R, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, Van't Hof AWJ. Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. *J Thromb Thrombolysis*. 2009 Oct;28(3):288-98. Epub 2008 Nov 22.
 268. Pride YB, Canto JG, Frederick PD, **Gibson CM**; NRMI Investigators. Outcomes among patients with ST-segment-elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. *Circ Cardiovasc Qual Outcomes*. 2009 Nov;2(6):574-82. Epub 2009 Nov 3.
 269. De Luca G, **Gibson CM**, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. *Atherosclerosis*. 2009 Nov;207(1):181-5. Epub 2009 Apr 5.
 270. De Luca G, **Gibson CM**, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. *Atherosclerosis*. 2009 Nov;207(1):181-5. Epub 2009 Apr 5.
 271. Hoekstra JW, O'Neill BJ, Pride YB, Lefebvre C, Diercks DB, Peacock WF, Fermann GJ, **Gibson CM**, Pinto D, Giglio J, Chandra A, Cairns CB, Konstam MA, Massaro J, Krucoff M. Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. *Ann Emerg Med*. 2009 Dec;54(6):779-788.e1. Epub 2009 Sep 19.
 272. Berger JS, Roe MT, **Gibson CM**, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y₁₂ ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. *Am Heart J*. 2009 Dec;158(6):998-1004.e1.
 273. **Gibson CM**, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. *J Am Coll Cardiol*. 2009 Dec 8;54(24):2290-5.
 274. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, **Gibson CM**, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med*. 2009 Dec 10;361(24):2318-29.
 275. Bhatt DL, Lincoff AM, **Gibson CM**, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. *N Engl J Med*. 2009 Dec 10;361(24):2330-41.
 276. Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, **Gibson CM**. Intracoronary Eptifibatide Bolus

- administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary Eptifibatide (ICE) trial. *Circulation*. 2010 Feb 16;121(6):784-91. Epub 2010 Feb 1.
277. Hudson M, Greenbaum A, Brenton L, **Gibson CM**, Siegel R, Reeves LR, Sala MF, McKendall G, Blughermann J, Echt D, Ohman EM, Weaver WD. Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. *JACC Cardiovasc Interv*. 2010 Mar;3(3):352-9.
 278. De Luca G, **Gibson CM**, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, Van't Hof AW. Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. *J Thromb Thrombolysis*. 2010 Mar 8. [Epub ahead of print]
 279. Giugliano RP, Giraldez RR, Morrow DA, Antman EM, **Gibson CM**, Mohanavelu S, Murphy SA, McCabe CH, Braunwald E. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. *Eur Heart J*. 2010 Apr 22. [Epub ahead of print]
 280. Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, **Gibson CM**, Cannon CP, Braunwald E, Sabatine MS. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLOpidogrel as Adjunctive Reperfusion Therapy (CLARITY) - Thrombolysis in Myocardial Infarction (TIMI) 28. *Am Heart J*. 2010 Jun;159(6):964-971.e1.
 281. Leonardi S, Rao SV, Harrington RA, Bhatt DL, **Gibson CM**, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). *Am Heart J*. 2010 Jul;160(1):65-72.
 282. De Luca G, **Gibson CM**, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW. Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. *J Thromb Thrombolysis*. 2010 Jul;30(1):23-8.
 283. Ray KK, Nazer B, Cairns R, **Gibson CM**, Cannon CP. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. *J Thromb Thrombolysis*. 2010 Jul;30(1):10-3.
 284. Leonardi S, Rao SV, Harrington RA, Bhatt DL, **Gibson CM**, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). *Am Heart J*. 2010 Jul;160(1):65-72.
 285. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, **Gibson CM**, Udelson JE, O'Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. *Am J Cardiol*. 2010 Jul 15;106(2):261-7.
 286. Pride YB, Tung P, Mohanavelu S, Zorkun C, Wiviott SD, Antman EM, Giugliano R, Braunwald E, **Gibson CM**; TIMI Study Group. Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) Substudy. *JACC Cardiovasc Interv*. 2010 Aug;3(8):806-811.
 287. Pride YB, Giuseffi JL, Mohanavelu S, Harrigan CJ, Manning WJ, **Gibson CM**, Appelbaum E. Relation

- Between Infarct Size in ST-Segment Elevation Myocardial Infarction Treated Successfully by Percutaneous Coronary Intervention and Left Ventricular Ejection Fraction Three Months After the Infarct. *Am J Cardiol*. 2010 Sep 1;106(5):635-640.
288. Henry TD, **Gibson CM**, Pinto DS. Moving toward improved care for the patient with ST-elevation myocardial infarction: a mandate for systems of care. *Circ Cardiovasc Qual Outcomes*. 2010 Sep;3(5):441-3.
 289. Fischell TA, Fischell DR, Avezum A, John MS, Holmes D, Foster M 3rd, Kovach R, Medeiros P, Piegas L, Guimaraes H, **Gibson CM**. Initial clinical results using intracardiac electrogram monitoring to detect and alert patients during coronary plaque rupture and ischemia. *J Am Coll Cardiol*. 2010 Sep 28;56(14):1089-98.
 290. Becker RC, **Gibson CM**, Jennings LK, Morrow DA. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. *Am J Cardiol*. 2010 Oct 15;106(8):S2-3.
 291. Kunadian V, **Gibson CM**. Thrombolytics and Myocardial Infarction. *Cardiovasc Ther*. 2010 Nov 11
 292. **Gibson CM**, Pinto D. Fractional flow reserve: a new set of lenses for the oculostenotic reflex? *JACC Cardiovasc Interv*. 2010 Dec;3(12):1282-3.
 293. Harrigan CJ, Peters DC, **Gibson CM**, Maron BJ, Manning WJ, Maron MS, Appelbaum E. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. *Radiology*. 2011 Jan;258(1):128-33. PubMed PMID: 21045187.
 294. **Gibson CM**, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. *Am Heart J*. 2011 Mar;161(3):478-486.e7. PubMed PMID: 21392601.
 295. Erkol A, Pala S, Kırmacı C, Oduncu V, Dündar C, Izgi A, Tigen K, **Gibson CM**. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. *Am J Cardiol*. 2011 Mar 15;107(6):857-62. PubMed PMID: 21247537.
 296. Uyarel H, Ergelen M, Cicek G, Kaya MG, Ayhan E, Turkkan C, Yildirim E, Kirbas V, Onturk ET, Erer HB, Yesilcimen K, **Gibson CM**. Red cell distribution width as a novel prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. *Coron Artery Dis*. 2011 May;22(3):138-44. PubMed PMID: 21233710.
 297. Cicek G, Uyarel H, Ergelen M, Ayhan E, Abanonu GB, Eren M, **Gibson CM**. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. *Coron Artery Dis*. 2011 May;22(3):131-7. PubMed PMID: 21394027.
 298. **Gibson CM**, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. *Am Heart J*. 2011 May;161(5):815-821.e6. PubMed PMID: 21570509.
 299. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. *Circulation*. 2011 Jun 14;123(23):2736-47. PubMed PMID: 21670242.
 300. Wu J, Pride YB, Frederick PD, **Gibson CM**. Association of initial thrombolysis in myocardial infarction flow grade with mortality among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a National Registry of Myocardial Infarction-5 (NRM-5) analysis. *Am Heart J*. 2011 Jul; 162(1):178-83. PubMed PMID: 21742106.
-

301. Maron MS, Olivotto I, Harrigan C, Appelbaum E, **Gibson CM**, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. *Circulation*. 2011 Jul 5;124(1):40-7. Epub 2011 Jun 13. PubMed PMID:21670234.
 302. Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, **Gibson CM**, Harrington RA, Califf RM, Peterson ED, Alexander JH; Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. *Circulation*. 2011 Jul 19;124(3):280-8. Epub 2011 Jun 27. PubMed PMID: 21709060.
 303. Steg PG, Mehta SR, Jukema JW, Lip GY, **Gibson CM**, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB; RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *Eur Heart J*. 2011 Oct;32(20):2541-54. Epub 2011 Aug 30. PubMed PMID: 21878434.
 304. Akpek M, Kaya MG, Uyarel H, Yarlioglues M, Kalay N, Gunebakmaz O, Dogdu O, Ardic I, Elcik D, Sahin O, Oguzhan A, Ergin A, **Gibson CM**. The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. *Atherosclerosis*. 2011 Nov;219(1):334-41. Epub 2011 Jul 22. PubMed PMID: 21831375.
 305. Kunadian V, Pride YB, Buros JL, Ciaglo LN, Morrow DA, **Gibson CM**. Coronary flow reserve varies depending upon the location within the artery it is assessed and the TIMI myocardial perfusion grade: a PROTECT TIMI-30 analysis. *J Thromb Thrombolysis*. 2011 Nov;32(4):448-52. PubMed PMID: 21713377.
 306. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, **Gibson CM**, Pollack CV Jr, Ornato JP, Zalenski RJ, Penney J, Tiefenbrunn AJ, Greenland P; NRMI Investigators. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. *JAMA*. 2011 Nov 16;306(19):2120-7. PubMed PMID: 22089719.
 307. Pinto DS, Frederick PD, Chakrabarti AK, Kirtane AJ, Ullman E, Dejam A, Miller DP, Henry TD, Gibson CM; National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. *Circulation*. 2011 Dec 6;124(23):2512-21. Epub 2011 Nov 7. PubMed PMID: 22064592.
 308. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, **Gibson CM**; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012 Jan 5;366(1):9-19. Epub 2011 Nov 13. PubMed PMID: 22077192.
 309. White HD, Chew DP, Dauerman HL, Mahaffey KW, **Gibson CM**, Stone GW, Gruberg L, Harrington RA, Bhatt DL. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. *Am Heart J*. 2012 Feb;163(2):182-90.e4. PubMed PMID: 22305835.
 310. Lopes RD, Mehta RH, Hafley GE, Williams JB, Mack MJ, Peterson ED, Allen KB, Harrington RA, **Gibson CM**, Califf RM, Kouchoukos NT, Ferguson TB Jr, Alexander JH; Project of Ex Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) Investigators. Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. *Circulation*. 2012 Feb 14;125(6):749-56. Epub 2012 Jan 11. PubMed PMID: 22238227.
 311. Leonardi S, Mahaffey KW, White HD, **Gibson CM**, Stone GW, Steg GW, Hamm CW, Price MJ, Todd M, Dietrich M, Gallup D, Liu T, Skerjanec S, Harrington RA, Bhatt DL. Rationale and design of the Cangrelor
-

- versus standard therapy to achieve optimal Management of Platelet InhibitiON PHOENIX trial. *Am Heart J*. 2012 May;163(5):768-776.e2. PubMed PMID: 22607853.
312. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, **Gibson CM**; for the INFUSE-AMI Investigators. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. *JAMA*. 2012 May 2;307(7):1817-26. Epub 2012 Mar 25. PubMed PMID: 22447888.
 313. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y₁₂ inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. *Circ Cardiovasc Interv*. 2012 Jun;5(3):336-46. Epub 2012 May 29. PubMed PMID: 22647518.
 314. Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G; EGYPT Cooperation. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. *J Invasive Cardiol*. 2012 Jul;24(7):324-7. PubMed PMID: 22781470.
 315. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, **Gibson CM**, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. *Circ Cardiovasc Imaging*. 2012 Jul 1;5(4):441-7. Epub 2012 May 4. PubMed PMID: 22563033.
 316. Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, Pollack CV Jr, Montalescot G, Van de Werf F, **Gibson CM**, Giugliano RP, Califf RM, Harrington RA, Newby LK. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. *Circulation*. 2012 Jul 3;126(1):41-9. Epub 2012 May 29. PubMed PMID: 22645292.
 317. Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX Jr, Gibson CM, Califf RM, Newby LK. Age, treatment, and outcomes in high-risk non ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial. *Int J Cardiol*. 2012 Jul 12. PubMed PMID: 22795720.
 318. De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyongyosi M, Bellandi F, Noc M, Arntz HR, Maioli M, Secco GG, Zorman S, Gabriel HM, Emre A, Rakowski T, Van't Hof AW. Time-related impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. *EuroIntervention*. 2012 Aug 25;8(4):470-6. PubMed PMID: 22917731.
 319. Pride YB, Mohanavelu S, Zorkun C, Kunadian V, Giugliano RP, Newby LK, Braunwald E, Califf RM, Harrington RA, Gibson CM; EARLY ACS Investigators. Association Between Angiographic Complications and Clinical Outcomes Among Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) Angiographic Substudy. *JACC Cardiovasc Interv*. 2012 Sep;5(9):927-35. PubMed PMID: 22995880.
 320. Maron MS, Rowin EJ, Lin D, Appelbaum E, Gibson CM, Chan RH, Lesser JR, Lindberg J, Haas TS, Udelson JE, Manning WJ, Maron BJ. Response to letter regarding article, "prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy". *Circ Cardiovasc Imaging*. 2012 Sep 1;5(5):e67-37. PubMed PMID: 22991291.
 321. Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, Ergin A, **Gibson CM**. Relation of Neutrophil/Lymphocyte Ratio to Coronary Flow to In-Hospital Major Adverse Cardiac Events in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Coronary Intervention. *Am J Cardiol*. 2012
-

- Sep 1;110(5):621-7. Epub 2012 May 18. PubMed PMID: 22608360.
322. Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PROject of Ex-vivo Vein graft Engineering via Transfection IV(PREVENT IV) 5-year results. *Am Heart J*. 2012 Sep;164(3):379-386.e1. PubMed PMID: 22980305.
 323. Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes hypertrophic cardiomyopathy. *Am J Cardiol*. 2012 Oct 1;110(7):1027-32. Epub 2012 Jul 16. PubMed PMID: 22809754.
 324. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, Gibson CM, Pollack CV Jr, Ornato JP, Zalski RJ, Penney J, Tiefenbrunn AJ, Greenland P; NRM Investigators. Atherosclerotic Risk Factors and Their Association With Hospital Mortality Among Patients With First Myocardial Infarction (from the National Registry of Myocardial Infarction). *Am J Cardiol*. 2012 Nov 1;110(9):1256-61. Epub 2012 Jul 26. PubMed PMID: 22840346.
 325. Nazer B, Ray KK, Murphy SA, **Gibson CM**, Cannon CP. Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. *J Thromb Thrombolysis*. Epub 2012 Dec 5. PubMed PMID: 23212806.
 326. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, **Gibson CM**, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II Safety and Clinical Comparison With Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease: Fluripidaz F 18 Positron Emission Tomography. *J Am Coll Cardio*. 2013 Jan 29; Epub 2012 Dec 13. PubMed PMID: 23265345.
 327. Leonardi S, Truffa AA, Neely ML, Tricoci P, White HD, **Gibson CM**, Wilson M, Stone GW, Harrington RA, Bhatt DL, Mahaffey KW. A novel approach to systematically implement the universal definition of myocardial infarction insights from the CHAMPION PLATFORM trial. *Heart*. 2013 Feb 23. PubMed PMID: 23434768.
 328. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Todd M, Bhatt DL, Stone GW, Lincoff AM, Dauerman HL, **Gibson CM**, White HD, Parikh KH, Gruberg L, Hermann HC, McLaurin BT, Goodman SG, Mahaffey KW. Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. *Corn Artery Dis*. 2013 Feb 25. PubMed PMID: 23442944.
 329. Mega JL, Braunwald E, Murphy SA, Plotnikov A, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, **Gibson CM**. Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. *J Am Coll Cardio*. 2013 Mar 7. PubMed PMID: 23500262.
 330. Bhatt DL, Stone GW, Mahaffey KW, **Gibson CM**, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, G  n  reux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; the CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. *N Eng J Med*. 2013 Mar 10. PubMed PMID: 23473369.
 331. De Luca G, Van't Hof AW, Huber K, **Gibson CM**, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Secco GG, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D. Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors. *Heart Vessels*. 2013 Jan;29(1):15-20. PubMed PMID: 23494604.

332. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, **Gibson CM**. Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. *Am Heart J*. 2013 Apr 1; 165(4):509-514. PubMed PMID: 23537966.
333. Klutstein MW, Westerhout CM, Armstrong PW, Giugliano RP, Lewis BS, **Gibson CM**, Lutchmedial S, Widimsky P, Steg PG, Dalby A, Zeymer U, Van de Werf F, Harrington RA, Newby LK, Rao SV. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. *Am Heart J*. 2013 April 165(4):583-590. PubMed PMID: 2357976.
334. Kaul P, Tanguay JF, Newby LK, Hochman JS, Westerhout CM, Califf RM, Tricoci P, **Gibson CM**, Giugliano RP, Harrington RA, Van de Werf F, Armstrong PW. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. *Am Heart J*. 2013 Oct;166(4):723-728. PubMed PMID: 24093853.
335. Généreux P, Stone GW, Harrington RA, **Gibson CM**, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL. Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial. *J Am Coll Cardiol*. 2013 Oct 24. pii: S0735-1097(13)05865-8. PubMed PMID: 24184169.
336. Williams JB, Lopes RD, Hafley GE, Ferguson TB Jr, Mack MJ, **Gibson CM**, Harrington RA, Peterson ED, Smith PK, Mehta RH, Alexander JH. Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. *J Thromb Thrombolysis*. 2013 Nov;36(4):384-393. PubMed PMID: 23543398.
337. Celik T, Kaya MG, Akpek M, Gunebakmaz O, Balta S, Sarli B, Duran M, Demirkol S, Uysal OK, Oguzhan A, **Gibson CM**. Predictive Value of Admission Platelet Volume Indices for In-hospital Major Adverse Cardiovascular Events in Acute ST-Segment Elevation Myocardial Infarction. *Angiology*. 2013 Dec 3. PubMed PMID: 24301422.
338. Harskamp RE, Alexander JH, Schulte PJ, Jones WS, Williams JB, Mack MJ, Peterson ED, **Gibson CM**, Califf RM, Kouchoukos NT, Ferguson TB, de Winter RJ, Lopes RD. Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes After Coronary Artery Bypass Surgery. *Ann Thorac Surg*. 2013 Dec 19. pii:S0003-4975(13)02270-4. PubMed PMID: 24360877.
339. van Diepen S, Brennan JM, Hafley GE, Reyes EM, Allen KB, Ferguson TB, Peterson ED, Williams JB, **Gibson CM**, Mack MJ, Kouchoukos NT, Alexander JH, Lopes RD. Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *Ann Surg*. 2013 Dec 23. PubMed PMID: 24368640.
340. Waks JW, Sabatine MS, Cannon CP, Morrow DA, **Gibson CM**, Wiviott SD, Giugliano RP, Sloan S, Scirica BM. Clinical Implications and Correlates of Q Waves in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolysis: Observations from the CLARITY-TIMI 28 Trial. *Clin Cardiol*. 2014 Jan 22. PubMed PMID: 24452727.
341. Rhee JW, Wiviott SD, Scirica BM, **Gibson CM**, Murphy SA, Bonaca MP, Morrow DA, Mega JL. Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular Outcomes Among Patients With Chronic Kidney Disease Following Non-ST-Elevation Acute Coronary Syndrome. *Clin Cardiol*. 2014 Jan 30. PubMed PMID: 24481910.

342. Chakrabarti AK, Grau-Sepulveda MV, O'Brien S, Abueg C, Ponirakis A, Delong E, Peterson E, Klein LW, Garratt KN, Weintraub WS, **Gibson CM**. Angiographic validation of the american college of cardiology foundation-the society of thoracic surgeons collaboration on the comparative effectiveness of revascularization strategies study. *Circ Cardiovasc Interv*. 2014 Feb 1;7(1):11-18. PubMed PMID: 24496239.
343. G  n  reux P, Stone GW, Harrington RA, **Gibson CM**, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, Lasalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). *J Am Coll Cardiol*. 2014 Feb 25;63(7):619-29. PubMed PMID: 24184169.
344. De Ferrari GM, Fox KA, White JA, Giugliano RP, Tricoci P, Reynolds HR, Hochman JS, **Gibson CM**, Th  roux P, Harrington RA, Van de Werf F, White HD, Califf RM, Newby LK. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. *Eur Heart J Acute Cardiovasc Care*. 2014 Mar;3(1):37-45. PubMed PMID: 24562802.
345. Dizon JM, Brener SJ, Maehara A, Witzenbichler B, Biviano A, Godlewski J, Parise H, Dambrink JH, Mehran R, **Gibson CM**, Stone GW. Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. *Eur Heart J Acute Cardiovasc Care*. 2014 Mar;3(1):78-83. PubMed PMID: 24562806.
346. Waks JW, Sabatine MS, Cannon CP, Morrow DA, **Gibson CM**, Wiviott SD, Giugliano RP, Sloan S, Scirica BM. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. *Clin Cardiol*. 2014 Mar;37(3):160-6. PubMed PMID: 24452727.
347. Harskamp RE, Alexander JH, Schulte PJ, Jones WS, Williams JB, Mack MJ, Peterson ED, **Gibson CM**, Califf RM, Kouchoukos NT, Ferguson TB, de Winter RJ, Lopes RD. Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. *Ann Thorac Surg*. 2014 Mar;97(3):824-30. PubMed PMID: 24360877.
348. Cohen AT, Harrington R, Goldhaber SZ, Hull R, **Gibson CM**, Hernandez AF, Kitt MM, Lorenz TJ. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. *Am Heart J*. 2014 Mar;167(3):335-41. PubMed PMID: 24576517.

Geller BJ, Mega JL, Morrow DA, Guo J, Hoffman EB, **Gibson CM**, Ruff CT. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. *J Thromb Thrombolysis*. 2014 Apr;37(3):310-6. PubMed PMID: 23860881.
349. Sanidas EA, Brener SJ, Maehara A, G  n  reux P, Witzenbichler B, El-Omar M, Fahy M, Mehran R, **Gibson CM**, Stone GW. Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: results from the INFUSE-AMI study. *Catheter Cardiovasc Interv*. 2014 Apr 1;83(5):704-10. PubMed PMID: 24030863.
350. Kunadian V, Giugliano RP, Newby LK, Zorkun C, Guo J, Bagai A, Montalescot G, Braunwald E, Califf RM, Van de Werf F, Armstrong PW, Harrington R, **Gibson CM**. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). *Am J Cardiol*. 2014 Apr 15;113(8):1297-305. PubMed PMID: 24607027.
351. Brener SJ, Oldroyd KG, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, **Gibson CM**, Stone GW. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). *Am J Cardiol*. 2014 May 1;113(9):1457-60. PubMed PMID:

24630789.

352. Rhee JW, Wiviott SD, Scirica BM, **Gibson CM**, Murphy SA, Bonaca MP, Morrow DA, Mega JL. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. *Clin Cardiol*. 2014 Jun;37(6):350-6. PubMed PMID: 24481910.
353. Guerchicoff A, Brener SJ, Maehara A, Witzenbichler B, Fahy M, Xu K, Gersh BJ, Mehran R, **Gibson CM**, Stone GW. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). *JACC Cardiovasc Interv*. 2014 Jul;7(7):733-40. PubMed PMID: 25060015.
354. Halaby R, Popma CJ, Cohen A, Chi G, Zacarkim MR, Romero G, Goldhaber SZ, Hull R, Hernandez A, Mentz R, Harrington R, Lip G, Peacock F, Welker J, Martin-Loeches I, Daaboul Y, Korjian S, **Gibson CM**. D-Dimer elevation and adverse outcomes. *J Thromb Thrombolysis*. 2014 Jul 9. PubMed PMID: 25006010.
355. Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, **Gibson CM**, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, Lopes RD. Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. *JAMA Surg*. 2014 Aug;149(8):798-805. PubMed PMID: 25073921.
356. Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL Jr, Jolly SS, Jacobs A, Newby LK, **Gibson CM**, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. *JACC Cardiovasc Interv*. 2014 Aug;7(8):857-67. PubMed PMID: 25147030.
357. van Diepen S, Brennan JM, Hafley GE, Reyes EM, Allen KB, Ferguson TB, Peterson ED, Williams JB, **Gibson CM**, Mack MJ, Kouchoukos NT, Alexander JH, Lopes RD. Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgery. *Ann Surg*. 2014 Aug;260(2):402-8. PubMed PMID: 24368640.
358. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, **Gibson CM**, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation*. 2014 Aug 5;130(6):484-95. PubMed PMID: 25092278.
359. **Gibson CM**, Krucoff M, Kirtane AJ, Rao SV, Mackall JA, Matthews R, Saba S, Waksman R, Holmes D. Design and rationale of the ANALYZE ST study: a prospective, nonrandomized, multicenter ST monitoring study to detect acute coronary syndrome events in implantable cardioverter-defibrillator patients. *Am Heart J*. 2014 Oct;168(4):424-429.e1. PubMed PMID: 25262250.
360. Gruner C, Chan RH, Crean A, Rakowski H, Rowin EJ, Care M, Deva D, Williams L, Appelbaum E, **Gibson CM**, Lesser JR, Haas TS, Udelson JE, Manning WJ, Siminovitsh K, Ralph-Edwards AC, Rastegar H, Maron BJ, Maron MS. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. *Eur Heart J*. 2014 Oct 14;35(39):2706-13. PubMed PMID: 24810389.
361. Cavender MA, **Gibson CM**, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchástegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. *Eur Heart J Acute Cardiovasc Care*. 2014 Oct 15. pii:

2048872614554109. PubMed PMID: 25318481.

362. Hess CN, Lopes RD, **Gibson CM**, Hager R, Wojdyla DM, Englum BR, Mack MJ, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. *Circulation*. 2014 Oct 21;130(17):1445-51. PubMed PMID: 25261549.
363. Tomey MI, Mehran R, Brener SJ, Maehara A, Witzencbichler B, Dizon JM, El-Omar M, Xu K, **Gibson CM**, Stone GW. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: An analysis of Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI). *Am Heart J*. 2015 Jan;169(1):86-93. PubMed PMID: 25497252.
364. Koshizaka M, Lopes RD, Reyes EM, **Gibson CM**, Schulte PJ, Hafley GE, Hernandez AF, Green JB, Kouchoukos NT, Califf RM, Ferguson TB, Peterson ED, Alexander JH. Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PROject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. *Am Heart J*. 2015 Jan;169(1):175-84. PubMed PMID: 25497264.
365. Celik T, Kaya MG, Akpek M, Gunebakmaz O, Balta S, Sarli B, Duran M, Demirkol S, Uysal OK, Oguzhan A, **Gibson CM**. Predictive Value of Admission Platelet Volume Indices for In-hospital Major Adverse Cardiovascular Events in Acute ST-Segment Elevation Myocardial Infarction. *Angiology*. 2015 Feb;66(2):155-62. PubMed PMID: 24301422.
366. Dohi T, Maehara A, Brener SJ, G  n  reux P, Gershlick AH, Mehran R, **Gibson CM**, Mintz GS, Stone GW. Utility of Peak Creatine Kinase-MB Measurements in Predicting Myocardial Infarct Size, Left Ventricular Dysfunction, and Outcome After First Anterior Wall Acute Myocardial Infarction (from the INFUSE-AMI Trial). *Am J Cardiol*. 2015 Mar 1;115(5):563-70. PubMed PMID: 25586335.
367. De Luca G, Van't Hof AW, **Gibson CM**, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Emre A, Rakowski T, Gyongyosi M, Huber K, Bellandi F, Dudek D; EGYPT cooperation. Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb/IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation). *Am J Cardiol*. 2015 Mar 15;115(6):711-5. PubMed PMID: 25655867.
368. White HD, Bhatt DL, **Gibson CM**, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). *JACC Cardiovasc Interv*. 2015 Mar;8(3):424-33. PubMed PMID: 25703887.
369. Abizaid A, Costa JR Jr, **Gibson CM**. Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes? *J Am Coll Cardiol*. 2015 Mar 3;65(8):802-4. PubMed PMID: 25720623.
370. Kobayashi N, Maehara A, Mintz GS, Wolff SD, G  n  reux P, Xu K, Mehran R, **Gibson CM**, Brener SJ, Stone GW. Usefulness of the Left Anterior Descending Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (an INFUSE-AMI Substudy). *Am J Cardiol*. 2015 Feb 19. pii: S0002-9149(15)00730-4. PubMed PMID: 25770973.
371. **Gibson CM**, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). *Am Heart J*. 2015 Apr;169(4):472-8.e5. PubMed PMID: 25819853.
-

372. Ghobrial J, **Gibson CM**, Pinto DS. Delayed clopidogrel transit during myocardial infarction evident on angiography. *J Invasive Cardiol*. 2015 May;27(5):E68-9. PubMed PMID: 25929306.
373. Sarich TC, Seltzer JH, Berkowitz SD, Costin J, Curnutte JT, **Gibson CM**, Hoffman M, Kaminskas E, Krucoff MW, Levy JH, Mintz PD, Reilly PA, Sager PT, Singer DE, Stockbridge N, Weitz JI, Kowey PR. Novel oral anticoagulants and reversal agents: Considerations for clinical development. *Am Heart J*. 2015 Jun;169(6):751-7. PubMed PMID: 26027611.
374. Hess CN, Lopes RD, **Gibson CM**, Hager R, Wojdyla DM, Englum BR, Mack MJ, Kouchoukos NT, Peterson ED, Alexander JH. Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". *Circulation*. 2015 Jul 28;132(4):e29. PubMed PMID: 26216091.
375. Badgett RG, Vindhyal M, Stirnaman JT, **Gibson CM**, Halaby R. A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants. *JAMA Pediatr*. 2015 Aug 1;169(8):788-9. doi: 10.1001/jamapediatrics.2015.0681. PubMed PMID: 26099054.
376. Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, Liu J, **Gibson CM**, Harrison RW, Joseph DS, Heyrman R, Krucoff MW. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial *Am Heart J*. 2015 Nov;170(5):929-37. doi: 10.1016/j.ahj.2015.08.017. Epub 2015 Aug 24. PubMed PMID: 26542501
377. Korjian S, Daaboul Y, Halaby R, Goldhaber SZ, Cohen AT, Singh K, Susheela AT, Harrington RA, Hull RD, Hernandez AF, **Gibson CM**. Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. *J Cardiovasc Pharmacol Ther*. 2015 Sep 3. pii: 1074248415601894. PubMed PMID: 26341120.
378. Gutierrez JA, Harrington RA, Blankenship JC, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Généreux P, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. *Eur Heart J*. 2015 Sep 23. pii: ehv498. PubMed PMID: 26400827.
379. Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, **Gibson CM**, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. *J Thromb Thrombolysis*. 2015 Oct;40(3):317-22. PubMed PMID: 26024789.
380. Cavender MA, **Gibson CM**, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchástegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. *Eur Heart J Acute Cardiovasc Care*. 2015 Oct;4(5):468-74. PubMed PMID: 25318481.
381. **Gibson CM**, Giugliano RP, Kloner RA, Bode C, Tendera M, Jánosi A, Merkely B, Godlewski J, Halaby R, Korjian S, Daaboul Y, Chakrabarti AK, Spielman K, Neal BJ, Weaver WD. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. *Eur Heart J*. 2016 Apr 21;37(16):1296-303. doi: 10.1093/eurheartj/ehv597. Epub 2015 Nov 19. PubMed PMID: 26586786.
382. Yu J, Mehran R, Clayton T, **Gibson CM**, Brodie BR, Witzenbichler B, Lincoff AM, Deliargyris EN, Gersh BJ, Pocock SJ, Stone GW, Dangas GD. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. *Catheter*

- Cardiovasc Interv. 2016 Feb 15;87(3):391-400. doi: 10.1002/ccd.26146. Epub 2015 Dec 1. PubMed PMID: 26624854.
383. Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, **Gibson CM**, Peterson ED, Harrington RA, Smith PK, Lopes RD. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. *Circulation*. 2016 Jan 12;133(2):131-8. doi: 10.1161/CIRCULATIONAHA.115.015549. Epub 2015 Dec 8. PubMed PMID 26647082.
 384. Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, **Gibson CM**, Grainger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody GJ, Nissen SE. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. *Am Heart J*. 2015 Dec;170(6):1061-9. doi: 10.1016/j.ahj.2015.09.007. Epub 2015 Sep 16. PubMed PMID 26678626.
 385. Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf F, James SK, Cannon CP, Armstrong PW, White HD, Califf RM, **Gibson CM**, Giugliano RP, Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini JP. High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. *Am Heart J*. 2016 Jan;171(1):25-32. doi: 10.1016/j.ahj.2015.09.004. Epub 2015 Sep 12. PubMed PMID 26699597.
 386. O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. *Circulation*. 2016 Jan 19;133(3):248-55. doi: 10.1161/CIRCULATIONAHA.115.017300. PubMed PMID 26762525.
 387. Jatene T, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. *J Am Coll Cardiol*. 2016 Feb 9;67(5):596-8. doi: 10.1016/j.jacc.2015.11.027. PubMed PMID 26846956.
 388. Little RJ, Wang J, Sun X, Tian H, Suh EY, Lee M, Sarich T, Oppenheimer L, Plotnikov A, Wittes J, Cook-Bruns N, Burton P, **Gibson CM**, Mohanty S. The treatment of missing data in a large cardiovascular clinical outcomes study. *Clin Trials*. 2016 Feb 17. pii: 1740774515626411. PubMed PMID 26908543.
 389. Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, **Gibson CM**. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. *Am Heart J*. 2016 Apr;174:120-8. doi: 10.1016/j.ahj.2016.01.004. Epub 2016 Jan 18. PubMed PMID 26995378.
 390. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, **Gibson CM**, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. *J Am Coll Cardiol*. 2016 May 17;67(19):2224-34. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11. PubMed PMID 27079334.
 391. Popma CJ, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, Moliterno DJ, White HD, Van de Werf F, Harrington RA, Wallentin L, Held C, Armstrong PW, Aylward PE, Strony J, Mahaffey KW, **Gibson CM**. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. *Circ Cardiovasc Interv*. 2016 May;9(5). pii: e003114. doi: 10.1161/CIRCINTERVENTIONS.115.003114.
-

PubMed PMID 27162212.

392. Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, **Gibson CM**, Peterson ED, Harrington RA, Smith PK, Lopes RD. Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". *Circulation*. 2016 May 24;133(21):e665. doi: 10.1161/CIRCULATIONAHA.116.022510. PubMed PMID 27217439
393. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, **Gibson CM**; APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. *N Engl J Med*. 2016 May 27. PubMed PMID 27232649
394. Vaduganathan M, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. *Circ Cardiovasc Interv*. 2016 Jun;9(6). pii: e003612. doi: 10.1161/CIRCINTERVENTIONS.116.003612. PubMed PMID 27313282
395. Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, **Gibson CM**, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. *JACC Cardiovasc Interv*. 2016 Jul 11;9(13):1349-57. doi: 10.1016/j.jcin.2016.04.009. PubMed PMID 27388822
396. Daaboul Y, Korjian S, Weaver WD, Kloner RA, Giugliano RP, Carr J, Neal BJ, Chi G, Cochet M, Goodell L, Michalak N, Rusowicz-Orazem L, Alkathery T, Allaham H, Routray S, Szlosek D, Jain P, **Gibson CM**. Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial). *Am J Cardiol*. 2016 Jun 15. pii: S0002-9149(16)31047-5. doi: 10.1016/j.amjcard.2016.06.025. PubMed PMID 27392509
397. Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, **Gibson CM**, Chieffo A, Moliterno DJ, Colombo A, Pocock S, Mehran R. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. *JACC Cardiovasc Interv*. 2016 Jul 25;9(14):1461-9. doi: 10.1016/j.jcin.2016.04.004. PubMed PMID 27478113
398. Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA; CHAMPION PHOENIX Investigators. Consistent Reduction in Peri-Procedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX. *Circulation*. 2016 Aug 1. pii: CIRCULATIONAHA.115.020829. PubMed PMID: 27482008
399. Leonardi S, Lopes RD, Steg PG, Abnoui F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, **Gibson CM**, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. *Eur Heart J Acute Cardiovasc Care*. 2016 Aug 2. pii: 2048872616661692. PubMed PMID: 27485140
400. Rao SV, Zeymer U, Douglas PS, Al-Khalidi H, White JA, Liu J, Levy H, Guetta V, **Gibson CM**, Tanguay JF, Vermeersch P, Roncalli J, Kasprzak JD, Henry TD, Frey N, Kracoff O, Traverse JH, Chew DP, Lopez-Sendon J, Heyrman R, Krucoff MW. Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. *J Am Coll Cardiol*. 2016 Aug 16;68(7):715-23. doi: 10.1016/j.jacc.2016.05.053. PubMed PMID: 27515331
-

401. Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, Roe MT, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, **Gibson M**. Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV). *N Engl J Med*. 2016 Aug 4;375(5):407-9. doi: 10.1056/NEJMp1605260. PubMed PMID: 27518659
402. Gennaro G, Brener SJ, Redfors B, Kirtane AJ, G  n  reux P, Maehara A, Neunteufl T, Metzger DC, Mehran R, **Gibson CM**, Stone GW. Effect of Smoking on Infarct Size and Major Adverse Cardiac Events in Patients With Large Anterior ST-Elevation Myocardial Infarction (from the INFUSE-AMI Trial). *Am J Cardiol*. 2016 Oct 15;118(8):1097-1104. doi: 10.1016/j.amjcard.2016.07.019. PubMed PMID: 27553094
403. Connolly SJ, Milling TJ, Eikelboom JW, **Gibson CM**, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. PubMed PMID: 27573206
404. Selvaraj S, Bhatt DL, Stone GW, **Gibson CM**, Steg PG, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX. *J Am Coll Cardiol*. 2016 Aug 25. pii: S0735-1097(16)35036-7. doi: 10.1016/j.jacc.2016.08.023. PubMed PMID: 27591042
405. Abtan J, Steg PG, Stone GW, Mahaffey KW, **Gibson CM**, Hamm CW, Price MJ, Abnoui F, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL; CHAMPION PHOENIX Investigators. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. *JACC Cardiovasc Interv*. 2016 Sep 26;9(18):1905-13. doi: 10.1016/j.jcin.2016.06.046. PubMed PMID: 27659566
406. **Gibson CM**, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. *Am Heart J*. 2016 Oct;180:22-8. doi: 10.1016/j.ahj.2016.06.017. Epub 2016 Jul 5. PubMed PMID: 27659879
407. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, **Gibson CM**, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. *Circ Cardiovasc Interv*. 2016 Nov;9(11). PubMed PMID: 27803042
408. Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, **Gibson CM**, Ohman EM. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. *Am Heart J*. 2016 Nov;181:92-100. doi: 10.1016/j.ahj.2016.08.008. Review. PubMed ID 27823698.
409. **Gibson CM**, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GY, Cohen M, Peterson ED, Fox KA. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. *Circulation*. 2017 Jan 24;135(4):323-333. doi: 10.1161/CIRCULATIONAHA.116.025783. Erratum in: *Circulation*. 2017 Mar 21;135(12):e789. PubMed

410. **Gibson CM**, Chi G, Halaby R, Korjian S, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Gold A, Bandman O, Harrington RA, Cohen AT; APEX Investigators. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). *Circulation*. 2017 Feb 14;135(7):648-655. doi: 10.1161/CIRCULATIONAHA.116.025427. PubMed ID 27881569
411. Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. *JAMA Cardiol*. 2017 Feb 1;2(2):127-135. doi: 10.1001/jamacardio.2016.4556. PubMed ID 27902833.
412. Baber U, Dangas G, Cohen DJ, **Gibson CM**, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, Kastrati A, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. *Am Heart J*. 2016 Dec;182:125-134. doi: 10.1016/j.ahj.2016.09.006. PubMed ID 27914492.
413. Gargiulo G, Windecker S, Vranckx P, **Gibson CM**, Mehran R, Valgimigli M. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? *Circulation*. 2016 Dec 6;134(23):1881-1906. PubMed ID 279200743
414. **Gibson CM**, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N Engl J Med*. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. PubMed ID 27959713.
415. **Gibson CM**. The Democratization of Medical Research and Education Through Social Media: The Potential and the Peril. *JAMA Cardiol*. 2017 Jan 1;2(1):9-11. doi: 10.1001/jamacardio.2016.4933. PubMed ID 27973665
416. Cohen AT, Harrington RA, **Gibson CM**. Betrixaban in Acutely Ill Medical Patients. *N Engl J Med*. 2016 Dec 15;375(24):e50. doi: 10.1056/NEJMc1613217. PubMed ID: 27974029
417. Connolly SJ, **Gibson CM**, Crowther M. Andexanet Alfa for Factor Xa Inhibitor Reversal. *N Engl J Med*. 2016 Dec 22;375(25):2499-500. doi: 10.1056/NEJMc1613270. PubMed ID 28002711
418. Sawlani NN, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. *Circ Cardiovasc Interv*. 2017 Jan;10(1). pii: e004380. doi: 10.1161/CIRCINTERVENTIONS.116.004380. PubMed ID 28039321.
419. **Gibson CM**. Going Polymer Free and Dual Antiplatelet Free Earlier: The Coevolution of Stent and Pharmacotherapy. *J Am Coll Cardiol*. 2017 Jan 17;69(2):172-175. doi: 10.1016/j.jacc.2016.10.056. PubMed ID 28081826
420. Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2017 Jan 17;69(2):176-185. doi: 10.1016/j.jacc.2016.10.055. PubMed ID: 28081827

421. Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, **Gibson CM**, Ohman EM. Corrigendum to "A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease" [Am Heart J 181 (2016) 92-100]. Am Heart J. 2017 Feb;184:156. doi: 10.1016/j.ahj.2017.01.004. PubMed ID: 28224931
422. Tamez H, Pinto DS, Kirtane AJ, Litherland C, Yeh RW, Dangas GD, Mehran R, Deliargyris EN, Ortiz G, **Gibson CM**, Stone GW. Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. JAMA Cardiol. 2017 Mar 1. doi: 10.1001/jamacardio.2016.5669. PubMed ID: 28249084.
423. **Gibson CM**, Halaby R, Korjian S, Daaboul Y, Arbetter DF, Yee MK, Goldhaber SZ, Hull R, Hernandez AF, Lu SP, Bandman O, Leeds JM, Gold A, Harrington RA, Cohen AT; APEX Investigators.. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar;185:93-100. doi: 10.1016/j.ahj.2016.12.004. PubMed ID: 28267480
424. **Gibson CM**, Wildgoose P, Fox KA. Prevention of Bleeding in Atrial Fibrillation. N Engl J Med. 2017 Mar 9;376(10):994. doi: 10.1056/NEJMc1700532. PubMed ID: 28273012
425. Nafee T, Aslam A, Chi G, Pahlavani S, Nimri D, Kuchkuntla AR, Talib U, Michalak N, Daaboul Y, Korjian S, Gallo A, **Gibson CM**. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Rev Cardiovasc Ther. 2017 Mar 22:1-9. doi: 10.1080/14779072.2017.1305889. PubMed ID: 28282497
426. Fanaroff AC, Hasselblad V, Roe MT, Bhatt DL, James SK, Steg PG, **Gibson CM**, Ohman EM. Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. Int J Cardiol. 2017 Mar 14. pii: S0167-5273(16)34724-6. doi: 10.1016/j.ijcard.2017.03.046. PubMed ID: 28320608
427. Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park DW, Bode C, Welsh RC, **Gibson CM**. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017 Mar 17. pii: S0140-6736(17)30751-1. doi: 10.1016/S0140-6736(17)30751-1. PubMed ID: 28325638
428. Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, **Gibson CM**, White HD, Storey RF; CHAMPION PHOENIX Investigators. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thromb Haemost. 2017 Jun 2;117(6):1093-1100. doi: 10.1160/TH16-12-0958. Epub 2017 Apr 6. PubMed ID: 28382371
429. **Gibson CM**, Korjian S. Collateral Circulation in Chronic Total Occlusions: A Marker of Hope or Hype? JACC Cardiovasc Interv. 2017 May 8;10(9):915-917. doi: 10.1016/j.jcin.2017.03.009. PubMed ID: 28473113
430. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, **Gibson CM**, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McElean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. PubMed ID: 28514624
431. Hortmann M, Robinson S, Mohr M, Mauler M, Stallmann D, Reinöhl J, Duerschmied D, Peter K, Carr J, **Gibson CM**, Bode C, Ahrens I. The mitochondria-targeting peptide elamipretide diminishes circulating

- HtrA2 in ST-segment elevation myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. 2017 May 1;2048872617710789. doi: 10.1177/2048872617710789. PubMed ID 28534645
432. Chandrasekhar J, Baber U, Sartori S, Aquino M, Tomey M, Kruckoff M, Moliterno D, Henry TD, Weisz G, **Gibson CM**, Iakovou I, Kini A, Faggioni M, Vogel B, Farhan S, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Pocock S, Dangas G, Mehran R. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. *Int J Cardiol*. 2017 Sep 15;243:132-139. doi: 10.1016/j.ijcard.2017.05.049. Epub 2017 May 12. PubMed ID 28554669
 433. Abnoui F, Sundaram V, Yong CM, Prats J, Deliargyris EN, Stone GW, Hamm CW, Steg PG, **Gibson CM**, White HD, Price MJ, G  n  reux P, Desai M, Yang L, Ding VY, Harrington RA, Bhatt DL, Mahaffey KW. Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. *Am Heart J*. 2017 Jun;188:147-155. doi: 10.1016/j.ahj.2017.02.031. Epub 2017 Mar 6. PubMed ID 28577670
 434. **Gibson CM**, Goldhaber SZ, Cohen AT, Nafee T, Hernandez AF, Hull R, Korjian S, Daaboul Y, Chi G, Yee M, Harrington RA. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. *Am Heart J*. 2017 Jul;189:1-8. doi: 10.1016/j.ahj.2017.03.018. Epub 2017 Mar 31. No abstract available. PubMed ID 28625365
 435. Campo G, Pavasini R, Morciano G, Lincoff AM, **Gibson CM**, Kitakaze M, Lonborg J, Ahluwalia A, Ishii H, Frenneaux M, Ovize M, Galvani M, Atar D, Ibanez B, Cerisano G, Biscaglia S, Neil BJ, Asakura M, Engstrom T, Jones DA, Dawson D, Ferrari R, Pinton P, Ottani F. Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. *Int J Cardiol*. 2017 Oct 1;244:59-66. doi: 10.1016/j.ijcard.2017.06.040. Epub 2017 Jun 13. PubMed ID: 28634037
 436. **Gibson CM**, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, Lopes RD, Gold A, Cohen AT, Harrington RA; APEX Investigators. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. *J Am Heart Assoc*. 2017 Jul 11;6(7). pii: e006015. doi: 10.1161/JAHA.117.006015. PubMed ID: 28698258
 437. Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, **Gibson CM**. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. *J Thromb Haemost*. 2017 Aug 1. doi: 10.1111/jth.13783. PubMed ID: 28762617
 438. Schoos M, Chandrasekhar J, Baber U, Bhasin A, Sartori S, Aquino M, Vogel B, Farhan S, Sorrentino S, Kini A, Kruckoff M, Moliterno D, Henry TD, Weisz G, **Gibson CM**, Iakovou I, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Dangas G, Pocock S, Mehran R. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). *Am J Cardiol*. 2017 Sep 15;120(6):904-910. doi: 10.1016/j.amjcard.2017.06.016. Epub 2017 Jun 28. PubMed ID: 28778417
 439. Cavender MA, Bhatt DL, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Elkin S, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators*. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. *Circ Cardiovasc Interv*. 2017 Aug;10(8). pii: e005257. doi: 10.1161/CIRCINTERVENTIONS.117.005257. PubMed ID: 28801539

440. Vaduganathan M, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). *Am J Cardiol*. 2017 Oct 1;120(7):1043-1048. doi: 10.1016/j.amjcard.2017.06.042. Epub 2017 Jul 18. PubMed ID: 28802512
441. Giustino G, Redfors B, Brener SJ, Kirtane AJ, G  n  reux P, Maehara A, Dudek D, Neunteufl T, Metzger DC, Crowley A, Mehran R, **Gibson CM**, Stone GW. Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial. *Eur Heart J Acute Cardiovasc Care*. 2017 Aug 1;2048872617719649. doi: 10.1177/2048872617719649. PubMed ID: 28828881
442. Arbetter DF, Jain P, Yee MK, Michalak N, Hernandez AF, Hull RD, Goldhaber SZ, Harrington RA, Gold A, Cohen AT, **Gibson CM**. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. *Pharm Stat*. 2017 Aug 24. doi: 10.1002/pst.1823. PubMed ID: 28840662
443. Chi G, Januzzi JL, Korjian S, Daaboul Y, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Cohen AT, Harrington RA, **Gibson CM**. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. *J Thromb Thrombolysis*. 2017 Sep 13. doi: 10.1007/s11239-017-1552-7. PubMed ID: 28905172
444. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, **Gibson CM**, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). *Circ Cardiovasc Interv*. 2017 Sep;10(9). pii: e004981. doi: 10.1161/CIRCINTERVENTIONS.117.004981. PubMed ID: 28916600
445. Vaduganathan M, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Lopes RD, Leonardi S, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. *EuroIntervention*. 2017 Oct 8. pii: EIJ-D-17-00723. doi: 10.4244/EIJ-D-17-00723. PubMed ID: 28988157
446. Eisen A, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. *Int J Cardiol*. 2018 Jan 1;250:49-55. doi: 10.1016/j.ijcard.2017.10.006. Epub 2017 Oct 5. PubMed ID: 29030140
447. Eisen A, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL; CHAMPION Investigators. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. *Int J Cardiol*. 2018 Jan 1;250:49-55. doi: 10.1016/j.ijcard.2017.10.006. Epub 2017 Oct 5. PubMed ID: 29030140
448. Koshy LM, Aberle LH, Krucoff MW, Hess CN, Mazzaferri E Jr, Jolly SS, Jacobs A, **Gibson CM**, Mehran R, Gilchrist IC, Rao SV. Comparison of Radial Access, Guided Femoral Access, and Non-Guided Femoral Access Among Women Undergoing Percutaneous Coronary Intervention. *J Invasive Cardiol*. 2018 Jan;30(1):18-22. Epub 2017 Oct 15. PubMed ID: 29035844
449. Yee MK, Nafee T, Daaboul Y, Korjian S, AlKhalfan F, Kerneis M, Wiest C, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, **Gibson CM**. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. *J Thromb Thrombolysis*. 2017 Nov 29. doi: 10.1007/s11239-017-1583-0. PubMed ID: 29188425

450. Chi G, Goldhaber SZ, Hull RD, Hernandez AF, Kerneis M, Al Khalfan F, Cohen AT, Harrington RA, **Gibson CM**. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. *Thromb Haemost*. 2017 Dec;117(12):2389-2395. doi: 10.1160/TH17-08-0538. Epub 2017 Dec 6. PubMed ID: 29212126
451. Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, Jain P, Plotnikov A, Burton P, **Gibson CM**. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. *Eur Heart J Acute Cardiovasc Care*. 2017 Dec 1;2048872617745003. doi: 10.1177/2048872617745003. PubMed ID: 29249166
452. Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, **Gibson CM**. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). *Circulation*. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187. PubMed ID: 29279341
453. **Gibson CM**, Nafee T, Kerneis M. Silent Myocardial Infarction: Listen to the Evidence. *J Am Coll Cardiol*. 2018 Jan 2;71(1):9-11. doi: 10.1016/j.jacc.2017.10.069. PubMed ID: 29301632
454. Effron MB, **Gibson CM**. Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy - "Real World" Experience. *Prog Cardiovasc Dis*. 2018 Jan - Feb;60(4-5):531-536. doi: 10.1016/j.pcad.2018.01.010. Epub 2018 Jan 31. PubMed ID: 29360524
455. Effron MB, **Gibson CM**. The Waxing and Waning of Antithrombotic Therapy in Cardiovascular Disease - Where Is the Moon Now? *Prog Cardiovasc Dis*. 2018 Jan - Feb;60(4-5):457-459. doi: 10.1016/j.pcad.2018.01.011. Epub 2018 Jan 31. PubMed ID: 29366879
456. Kerneis M, Talib U, Nafee T, Daaboul Y, Pahlavani S, Pitliya A, Furqan MM, Datta S, Kazmi HA, Younes A, **Gibson CM**. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. *Prog Cardiovasc Dis*. 2018 Jan - Feb;60(4-5):524-530. doi: 10.1016/j.pcad.2018.01.008. Epub 2018 Feb 3. PubMed ID: 29397950
457. Sherwood MW, Lopes RD, Sun JL, Liaw D, Harrington RA, Wallentin L, Laskowitz DT, James SK, Goodman SG, Darius H, Lewis BS, **Gibson CM**, Pieper KS, Alexander JH. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. *Am Heart J*. 2018 Mar;197:1-8. doi: 10.1016/j.ahj.2017.09.020. Epub 2017 Oct 24. PubMed ID: 29447769
458. Kumar V, Gopalakrishnan L, Singh M, Singh S, Kovacs DF, Benatar D, **Gibson CM**, Khosla S. Effect of Cocaine on Coronary Microvasculature. *J Am Coll Cardiol*. 2018 Feb 27;71(8):954-955. doi: 10.1016/j.jacc.2017.12.030. PubMed ID: 29471946
459. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, **Gibson CM**, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. PubMed ID: 29483172
460. Daaboul Y, Korjian S, Plotnikov AN, Burton P, Braunwald E, Wiviott SD, **Gibson CM**. Rivaroxaban and Post-Stroke Neurological Outcomes in Patients With Acute Coronary Syndrome. *J Am Coll Cardiol*. 2018 Mar 6;71(9):1048-1049. doi: 10.1016/j.jacc.2017.12.045. PubMed ID: 29495985

461. Kerneis M, **Gibson CM**, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. *JACC Cardiovasc Interv.* 2018 Apr 9;11(7):626-634. doi: 10.1016/j.jcin.2017.11.009. Epub 2018 Mar 14. PubMed ID: 29550085
462. **Gibson CM**, Hankey GJ, Nafee T, Welsh RC. Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. *Thromb Haemost.* 2018 May;118(S 01):S34-S44. doi: 10.1055/s-0038-1635086. Epub 2018 Mar 22. PubMed ID: 29566416
463. Groves EM, Bhatt DL, Steg PG, Deliangryis EN, Stone GW, **Gibson CM**, Hamm CW, Mahaffey KW, White HD, Angiolillo D, Prats J, Harrington RA, Price MJ. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circ Cardiovasc Interv.* 2018 Apr;11(4):e005635. doi: 10.1161/CIRCINTERVENTIONS.117.005635. PubMed ID: 29632238
464. **Gibson CM**, Nafee T, Yee MK, Chi G, Korjian S, Daaboul Y, AlKhalfan F, Kerneis M, Goldhaber SZ, Hull R, Hernandez AF, Cohen AT, Harrington RA. Symptomatic event reduction with extended-duration brixaban in acute medically ill hospitalized patients. *Am Heart J.* 2018 Apr;198:84-90. doi: 10.1016/j.ahj.2017.12.015. Epub 2017 Dec 27. PubMed ID: 29653652
465. Chi G, **Gibson CM**, Hernandez AF, Hull RD, Kazmi SHA, Younes A, Walia SS, Pitliya A, Singh A, Kahe F, Kalayci A, Nafee T, Kerneis M, AlKhalfan F, Cohen AT, Harrington RA, Goldhaber SZ. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. *Am J Med.* 2018 Apr 13. pii: S0002-9343(18)30312-7. doi: 10.1016/j.amjmed.2018.03.031. PubMed ID: 29660351
466. Tamez H, G  n  reux P, Yeh RW, Amin AP, Fan W, White HD, Kirtane AJ, Stone GW, **Gibson CM**, Harrington RA, Bhatt DL, Pinto DS; CHAMPION PHOENIX ECONOMICS Investigators. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. *Catheter Cardiovasc Interv.* 2018 May 4. doi: 10.1002/ccd.27638. 29726596
467. Tricoci P, Newby LK, Clare RM, Leonardi S, **Gibson CM**, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2018 May 14;11(9):856-864. doi: 10.1016/j.jcin.2018.02.006. PubMed ID: 29747915
468. Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). *Circ Cardiovasc Interv.* 2018 Mar;11(3):e006144. doi: 10.1161/CIRCINTERVENTIONS.117.006144. PubMed ID: 29870385
469. Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, White HD, Desai M, Lynch DR Jr, Harrington RA, Mahaffey KW; CHAMPION PLATFORM and CHAMPION PCI Investigators. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. *Int J Cardiol.* 2018 Jun 8. pii: S0167-5273(17)38082-8. doi: 10.1016/j.ijcard.2018.06.034. PubMed ID: 29937301

470. Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, **Gibson CM**. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. *J Thromb Thrombolysis*. 2018 Jun 26. doi: 10.1007/s11239-018-1703-5. PubMed ID: 29943350
471. **Gibson CM**. Moving From Hope to Hard Work in Data Sharing. *JAMA Cardiol*. 2018 Jul 3. doi: 10.1001/jamacardio.2018.0130. PubMed ID: 29971341
472. Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, Dangas G, Rollini F, Kimura T, Collet JP, **Gibson CM**, Steg PG, Lopes RD, Gwon HC, Storey RF, Franchi F, Bhatt DL, Serruys PW, Angiolillo DJ. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. *Nat Rev Cardiol*. 2018 Aug;15(8):480-496. doi: 10.1038/s41569-018-0049-1. Review. PubMed ID: 29973709
473. **Gibson CM**, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. *J Am Coll Cardiol*. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055 PubMed ID: 29976285
474. Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, **Gibson CM**. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. *Am Heart J*. 2018 Jun 13;203:17-24. doi: 10.1016/j.ahj.2018.06.003. PubMed ID: 30015064
475. Kerneis M, Yee MK, **Gibson CM**. ECURE PCI: how important can a subgroup analysis be? *J Thorac Dis*. 2018 Jun;10(Suppl 17):S2032-S2034. doi: 10.21037/jtd.2018.05.155. PubMed ID: 30023111
476. Kerneis M, **Gibson CM**, Cohen M. Reply: In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, One Size Cannot Fit All. *JACC Cardiovasc Interv*. 2018 Aug 13;11(15):1539-1540. doi: 10.1016/j.jcin.2018.04.028. PubMed ID: 0093062
477. Stone GW, G  n  reux P, Harrington RA, White HD, **Gibson CM**, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. *Eur Heart J*. 2018 Sep 9. doi: 10.1093/eurheartj/ehy562. PubMed ID: 30203006
478. AlKhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, Braunwald E, **Gibson CM**. D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy). *Am J Cardiol*. 2018 Nov 1;122(9):1459-1464. doi: 10.1016/j.amjcard.2018.07.032. Epub 2018 Aug 4. PubMed ID: 30217378
479. Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, **Gibson CM**, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RP. Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. *Eur Heart J*. 2018 Nov 7;39(42):3810-3820. doi: 10.1093/eurheartj/ehy556. PubMed ID: 30239711
480. Chi G, **Gibson CM**, Liu Y, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. *Am J Hematol*. 2018 Sep 25. doi: 10.1002/ajh.25296. PubMed ID: 30252149

481. **Gibson CM**, Nafee T, Kerneis M. Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. *J Am Coll Cardiol*. 2018 Oct 9;72(15):1801-1803. doi: 10.1016/j.jacc.2018.07.053. PubMed ID: 30286923
482. Nafee T, **Gibson CM**, Yee MK, Alkhalafan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpassand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouza M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. *Expert Rev Cardiovasc Ther*. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. PubMed ID: 30296387
483. Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FWA, Cohen M, Bode C, Burton P, Plotnikov AN, **Gibson CM**. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). *Am J Cardiol*. 2018 Dec 1;122(11):1896-1901. doi: 10.1016/j.amjcard.2018.08.034. Epub 2018 Sep 7. PubMed ID: 30340765
484. Capodanno D, Mehran R, **Gibson CM**, Angiolillo DJ. CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. *Expert Opin Investig Drugs*. 2018 Dec;27(12):997-1005. doi: 10.1080/13543784.2018.1543399. Epub 2018 Nov 3. PubMed ID: 30376729
485. Kalayci A, **Gibson CM**, Chi G, Yee MK, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Qamar I, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. *Thromb Haemost*. 2018 Nov 12. doi: 10.1055/s-0038-1675606. PubMed ID: 30419597
486. Korjian S, Daaboul Y, Laliberté F, Zhao Q, Mehran R, Bode C, Halperin J, Verheugt FWA, Lip GYH, Cohen M, Peterson ED, Fox KAA, **Gibson CM**, Pinto DS; PIONEER AF-PCI Investigators. Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). *Am J Cardiol*. 2019 Feb 1;123(3):355-360. doi: 10.1016/j.amjcard.2018.10.033. Epub 2018 Nov 6. PubMed ID: 30502047
487. Ranney DN, Williams JB, Mulder H, Wojdyla D, Cox ML, **Gibson CM**, Mack MJ, Daneshmand MA, Alexander JH, Lopes RD. Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). *Am J Cardiol*. 2019 Feb 15;123(4):571-575. doi: 10.1016/j.amjcard.2018.11.029. Epub 2018 Nov 24. PubMed ID: 30538035
488. Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, **Gibson CM**, Hamm C, Price MJ, Prats J, Elkin S, Deliargyris EN, White HD, Menozzi A, Harrington RA, Bhatt DL; MPH on Behalf of the CHAMPION PHOENIX Investigators. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. *Int J Cardiol*. 2019 Mar 1;278:217-222. doi: 10.1016/j.ijcard.2018.11.114. Epub 2018 Nov 23. PubMed ID: 30563770
489. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, **Gibson CM**, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. *Circulation*. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722. PubMed ID: 30571525
490. **Gibson CM**, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, Tricoci P, Alexander JH, Kastelein JJP, Mehran R, Bode C, Lewis BS, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo DJ, Duerschmied D, Ophuis TO, Merkely B. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among

- subjects with moderate renal impairment after acute myocardial infarction. *Am Heart J*. 2019 Feb;208:81-90. doi: 10.1016/j.ahj.2018.11.008. Epub 2018 Nov 22. PubMed ID: 30580130
491. Baber U, Leisman DE, Cohen DJ, **Gibson CM**, Henry TD, Dangas G, Moliterno D, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. *Circ Cardiovasc Qual Outcomes*. 2019 Jan;12(1):e004945. doi: 10.1161/CIRCOUTCOMES.118.004945. PubMed ID: 30606052
 492. Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, **Gibson CM**. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. *Circ Cardiovasc Interv*. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124. PubMed ID: 30704287
 493. Connolly SJ, Crowther M, Eikelboom JW, **Gibson CM**, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. *N Engl J Med*. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7. PubMed ID: 30730782
 494. Chi G, **Gibson CM**, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. *Intensive Care Med*. 2019 Apr;45(4):477-487. doi: 10.1007/s00134-019-05565-6. Epub 2019 Feb 18. PubMed ID: 30778649
 495. Nafee T, **Gibson CM**, Yee MK, Kerneis M, Daaboul Y, Korjian S, Chi G, Kalayci A, Afzal MK, Kazmi H, Datta S, AlKhalfan F, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Goldhaber SZ. Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. *Circulation*. 2019 Feb 26;139(9):1234-1236. doi: 10.1161/CIRCULATIONAHA.118.038654. No abstract available. PubMed ID: 30802169
 496. **Gibson CM**, Holmes D, Mikdadi G, Presser D, Wohns D, Yee MK, Kaplan A, Ciuffo A, Eberly AL 3rd, Iteld B, Krucoff MW. Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol*. 2019 Feb 25. pii: S0735-1097(19)30237-2. doi: 10.1016/j.jacc.2019.01.014. PubMed ID: 30842028
 497. Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, Zeitouni M, Afzal MK, Jafarizade M, Walia SS, Qamar I, Pitliya A, Kalayci A, Al Khalfan F, **Gibson CM**. Most Promising Therapies in Interventional Cardiology. *Curr Cardiol Rep*. 2019 Mar 13;21(4):26. doi: 10.1007/s11886-019-1108-x. Review. PubMed ID: 30868280
 498. Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y₁₂ Inhibitor Pretreatment. *Circ Cardiovasc Interv*. 2019 Mar;12(3):e007445. doi: 10.1161/CIRCINTERVENTIONS.118.007445. PubMed ID: 30871355
 499. Sharma S, Kaadan MI, Duran JM, Ponzini F, Mishra S, Tsiaras SV, Scott NS, Weinberg I, Ghoshhajra B, Lindsay M, **Gibson CM**, Chi G, Michalak N, Wood MJ. Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection. *Am J Cardiol*. 2019 Mar 8. pii: S0002-9149(19)30284-X. doi: 10.1016/j.amjcard.2019.02.040. PubMed ID: 30929769

Other peer-reviewed publications

500. **Gibson CM**, Safian RD. Measurement of arterial dimensions: Review of visual and quantitative angiographic techniques. *J Invasive Cardiol*. 1991 Mar-Apr; 3(2):66-74.
501. **Gibson CM**, Safian RD. Limitations of cineangiography: Impact of new technologies for image processing and quantitation. *Trends Cardiovascular Medicine*. 1992 Jul-Aug;2(4):156-160
502. **Gibson CM**, Stone PH. How do intracoronary hemodynamics affect the natural history of coronary atherosclerosis? *Choices in Cardiology*. 1993;7:333-335.
503. Goel M, Rizzo MJ, McLean C, Ryan K, Dotani I, Marble SJ, Daley WL, Dodge T, **Gibson CM**. The Open artery Hypothesis: Past, Present and Future. *J Thromb Thrombolysis*. 1998;5:101-112.
504. **Gibson CM**. Newer thrombolytic agents and combination therapy in acute myocardial infarction. *Rev Soc Cardiol Estado de Sao Paulo*. 1999;1:831.
505. **Gibson CM**, Moynihan JL, Al-Mousa E, Campsey M, Gandhi R, Murphy S, Mattson S, Ryan KA, Mesley R, Swanson J, Arshad MN, Marble SJ. Glycoprotein IIb/ IIIa Receptor Inhibition in Interventional Cardiology. *J Thromb Thrombolysis*. 1999;7:287-302.
506. Appleby MA, Michaels AD, Chen M, **Gibson CM**. The Importance of the TIMI Frame Count: Implications for future trials. *Curr Control Trials Cardiovasc Med*. 2000;1(1):31-34.
507. Michaels A, **Gibson CM**, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. *Am J Cardiol*. 2000; 85: 50B-60B.
508. Goel M, Marble SJ, **Gibson CM**. Key references on a wide variety of topics pertaining to coronary artery blood flow and patency. *J Thromb Thrombolysis*. 2000 Jan;9(1):85-93.
509. Angeja BG, **Gibson CM**, Chin R, Canto JG, Barron HV. Use of reperfusion therapies in elderly patients with acute myocardial infarction. *Drugs and Aging*. 2001;18(8): 587-96.
510. **Gibson CM**, Marble SJ. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). *Clin Cardiol*. 2001 Sep;24(9):577-84.
511. Dumaine R, Bigelow B, Aroesty J, **Gibson CM**. Myocardial reperfusion: its assessment and its relation to clinical outcomes. *Am Heart Hosp J*. 2003 Spring;1(2):120-7. Review.
512. Guerra DR, Karha J, **Gibson CM**. Safety and Efficacy of Tenecteplase (TNK-tPA) in acute myocardial infarction. *Expert Opin Pharmacother*. 2003 May;4(5):791-8.
513. Pinto DS, Aroesty JM, Reynolds MR, **Gibson CM**. State of the Art in Facilitated Percutaneous Coronary Intervention in the Setting of Acute Myocardial Infarction. *Cardiovascular Review and Reports*. 2003 May; 24(5): 267-275.
514. Guerra DR, **Gibson CM**. Door-to-Balloon Delays with PCI in Acute Myocardial Infarction. *Curr Treat Options Cardiovasc Med*. 2004 Feb;6(1):69-77. 2003.
515. Chang A, **Gibson CM**. Current Assessments of the Adequacy of Myocardial Perfusion During Acute MI. *Curr Treat Options Cardiovasc Med*. 2005 May;7(1):25-34.
516. Gaziano JM, **Gibson CM**. Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. *Am J Cardiol*. 2006 May 8;97(9A):23-9. Epub 2006 Mar 30. Review
517. Perez de Prado A, Fernandez-Vazquez F, Cuellas-Ramon JC, **Gibson CM**. Coronary Angiography: Beyond Coronary Anatomy. *Rev Esp Cardiol*. 2006 Jun;59(6):596-608.
518. Pinto DS, Southard M, Ciaglo L, **Gibson CM**. Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. *Am Heart J*. 2006 Jun;151(6 Suppl):S24-9. Review.
519. **Gibson CM**, Ciaglo LN, Southard MC, Takao S, Harrigan C, Lewis J, Filopei J, Lew M, Murphy SA,

- Buros J. Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. *J Thromb Thrombolysis*. 2007 Apr;23(2):135-45. Review.
520. Lee S, **Gibson CM**. Enoxaparin in acute coronary syndromes. *Expert Rev Cardiovasc Ther*. 2007 May;5(3):387-99.
 521. Hollander JE, **Gibson CM**, Pollack CV Jr. Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes. *Am J Emerg Med*. 2009 Jun;27(5):595-606. Review.
 522. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, **Gibson CM**, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. *Am Heart J*. 2009 Dec;158(6):881-886.e1.
 523. **Gibson CM**. Long-term anticoagulation in cardiovascular indications. *European Journal of Haematology*. 2010 Jul; 85(Suppl. 72): 20-28.
 524. Navarese EP, De Servi S, **Gibson CM**, Buffon A, Castriota F, Kubica J, Petronio AS, Andreotti F, De Luca G. Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. *QJM*. 2011 Mar;104(3):193-200. PubMed PMID: 21262739.
 525. Kunadian V, **Gibson CM**. Recombinant tissue-type plasminogen activators: "time matters". *Drugs Today (Barc)*. 2011 Jul;47(7):559-70.
 526. Navarese EP, De Luca G, Castriota F, Kozinski M, Gurbel PA, **Gibson CM**, Andreotti F, Buffon A, Siller-Matula JM, Sukiennik A, De Servi S, Kubica J. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. *J Thromb Haemost*. 2011 Oct;9(10):1902-15. PubMed PMID: 21777368.
 527. Pride YB, **Gibson CM**. Percutaneous coronary interventions in facilities without cardiac surgery on site. *Curr Cardiol Rep*. 2011 Oct;13(5):432-8. Review. PubMed PMID: 21750909.
 528. Chakrabarti AK, **Gibson CM**. The SYNTAX score: usefulness, limitations, and future directions. *J Invasive Cardiol*. 2011 Dec;23(12):511-2. PubMed PMID: 22147398.
 529. Navarese EP, Kubica J, Castriota F, **Gibson CM**, De Luca G, Buffon A, Bolognese L, Margheri M, Andreotti F, Di Mario C, De Servi S. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. *EuroIntervention*. 2011 Dec;7(8):985-94. PubMed PMID: 22116195.
 530. **Gibson CM**, Kao RH, Blevins KK, Travers PD. Integrative taxonomy for continental-scale terrestrial insect observations. *PLoS One*. 2012;7(5):e37528. Epub 2012 May 29. PubMed PMID: 22666362.
 531. Vissel D, Gil RJ, Koo BK, **Gibson CM**, Nguyen T, Hoang T, Gotcheva N. The determinants of side branch compromise after main vessel stenting in coronary bifurcation lesions. *Kardiol Pol*. 2012; 70(10):989-97. PubMed PMID: 23080087.
 532. Isik T, Uyarel H, Tanboga IH, Kurt M, Ekinci M, Kaya A, Ayhan E, Ergelen M, Bayram E, **Gibson CM**. Relation of red cell distribution width with the presence, severity, and complexity of coronary artery disease. *Coron Artery Dis*. 2012 Jan;23(1):51-6. PubMed PMID: 22133925.
 533. Wu Y, Wu H, Mueller C, **Gibson CM**, Murphy S, Shi Y, Xu G, Yang J. Baseline platelet count and clinical outcome in acute coronary syndrome. *Circ J*. 2012;76(3):704-11. Epub 2012 Jan 26. PubMed PMID: 22277319.
 534. Appelbaum E, Maron BJ, Adabag S, Hauser TH, Lesser JR, Haas TS, Riley AB, Harrigan CJ, Delling FN, Udelson JE, **Gibson CM**, Manning WJ, Maron MS. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. *Circ*
-

- Cardiovasc Imaging*. 2012 Jan;5(1):78-85. Epub 2011 Dec 1. PubMed PMID: 22135401.
535. Kırmacı C, Erkol A, Pala S, Oduncu V, Dündar C, İzgi A, Tigen K, **Gibson CM**. Intracoronary bolus-only compared with intravenous bolus plus infusion of tirofiban application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2012 Jan 1;79(1):59-67. Epub 2011 Nov 30. PubMed PMID: 21523892.
 536. Chakrabarti AK, Singh P, Gopalakrishnan L, Kumar V, Elizabeth Doherty M, Abueg C, Wang W, **Gibson CM**. Admission hyperglycemia and acute myocardial infarction: outcomes and potential therapies for diabetics and nondiabetics. *Cardiol Res Pract*. 2012;2012:704314. Epub 2012 Jul 9. PubMed PMID: 22830071.
 537. Kaya MG, Uyarel H, Akpek M, Kalay N, Ergelen M, Ayhan E, Isik T, Cicek G, Elcik D, Sahin O, Cosgun SM, Oguzhan A, Eren M, **Gibson CM**. Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. *Am J Cardiol*. 2012 Feb 15;109(4):486-91. Epub 2011 Nov 17. PubMed PMID: 22100027.
 538. Chakrabarti AK, **Gibson CM**. Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI. *Evid Based Med*. 2012 Apr;17(2):61-2. Epub 2011 Sep 21. PubMed PMID: 21937502.
 539. Kunadian V, **Gibson CM**. Thrombolytics and myocardial infarction. *Cardiovasc Ther*. 2012 Apr;30(2):e81-8. Epub 2010 Nov 11. PubMed PMID: 21070617.
 540. Gopalakrishnan L, Kumar V, Kohli P, Singh P, Rastogi U, **Gibson CM**. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. *Expert Opin Drug Metab Toxicol*. 2012 Jul;8(7):889-900. Epub 2012 May 11. PubMed PMID: 22577900.
 541. Chakrabarti AK, **Gibson CM**, Pinto DS. Optimal selection of STEMI treatment strategies in the current era: benefit of transferring STEMI patients for PCI compared with administration of onsite fibrinolytic therapy. *Curr Opin Cardiology*. 2012 Nov;27(6):651-4. PubMed PMID: 23032713.
 542. Pride YB, Piccirillo BJ, **Gibson CM**. Prevalence, Consequences, and Implications for Clinical Trials of Unrecognized Myocardial Infarction. *Am J Cardiol*. Epub 2012 Dec 28. PubMed PMID: 23276472.
 543. Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, **Gibson CM**, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O'Connor CM. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. *Int J Cardiol*. Epub 2013 Jan 5. PubMed PMID: 23298559.
 544. Celik T, Kaya MG, Akpek M, Yarlioglu M, Sarli B, Topsakal R, **Gibson CM**. Does Serum Bilirubin Level on Admission Predict TIMI Flow Grade and In-Hospital MACE in Patients With STEMI Undergoing Primary PCI. *Angiology*. 2014 Mar;64(3):198-204. PubMed PMID: 23378197.
 545. Pride YB, Piccirillo BJ, **Gibson CM**. Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction. *Am J Cardiol*. 2013 Mar 15; 111(6):914-8. PubMed PMID: 2357961.
 546. Goel K, Pinto DS, **Gibson CM**. Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: A systematic review. *Am Heart J*. 2013 Apr; 165(4):451-67. PubMed PMID: 23537961.
 547. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, **Gibson CM**. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. *Am Heart J*. 2013 Apr;165(4):509-514. PubMed PMID: 23537966.

548. Klutstein MW, Westerhout CM, Armstrong PW, Giugliano RP, Lewis BS, **Gibson CM**, Lutchmedial S, Widimsky P, Steg PG, Dalby A, Zeymer U, Van de Werf F, Harrington RA, Newby LK, Rao SV. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. *Am Heart J*. 2013 Apr;165(4):583-590. PubMed PMID: 23537976.
549. Buyukkaya E, Poyraz F, Karakas MF, Kurt M, Akcay AB, Akpinar I, Motor S, Turak O, Ozturk OH, Sen N, Akpek M, Kaya MG, **Gibson CM**. Usefulness of monocyte chemoattractant protein-1 to predict no-reflow and three-year mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol*. 2013 Jul 15;112(2):187-93. PubMed PMID: 23601576.
550. **Gibson CM**, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. *J Am Coll Cardiol*. 2013 Jul 23;62(4):286-90. PubMed PMID: 23602776.
551. Olivotto I, Maron BJ, Tomberli B, Appelbaum E, Salton C, Haas TS, **Gibson CM**, Nistri S, Servetini E, Chan RH, Udelson JE, Lesser JR, Cecchi F, Manning WJ, Maron MS. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. *J Am Coll Cardiol*. 2013 Jul 30;62(5):449-57. PubMed PMID: 23643593.
552. Tricoci P, Leonardi S, White J, White HD, Armstrong PW, Montalescot G, Giugliano RP, **Gibson CM**, Van de Werf F, Califf RM, Harrington RA, Braunwald E, Mahaffey KW, Newby LK. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. *J Am Coll Cardiol*. 2013 Jul 16;62(3):242-51. PubMed PMID:23684676.
553. Mega JL, Braunwald E, Wiviott SD, Murphy SA, Plotnikov A, Gotcheva N, Ruda M, **Gibson CM**. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51). *Am J Cardiol*. 2013 Aug 15;112(4):472-8. PubMed PMID: 23711804.
554. Brener SJ, Dambrink JH, Maehara A, Chowdhary S, Gershlick AH, Genereux P, Koolen J, Mehran R, Fahy M, **Gibson CM**, Stone GW. Benefits of optimising coronary flow before stenting in primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from INFUSE-AMI. *EuroIntervention*. 2013 Jun 14. doi:pii: 20130401-06. PubMed PMID:23764966.
555. Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, **Gibson CM**, Stone GW. nfarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. *Am Heart J*. 2013 Jul;166(1):64-70. PubMed PMID: 23816023.
556. Piccini JP, White JA, Mehta RH, Lokhnygina Y, Al-Khatib SM, Tricoci P, Califf RM, Harrington RA, Newby LK, Pollack CV Jr, Montalescot G, Van de Werf F, **Gibson CM**, Giugliano RP. Response to letter regarding article, "sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment elevation acute coronary syndromes". *Circulation*. 2013 May 21;127(20):e634. PubMed PMID: 23833786.
557. Geller BJ, Mega JL, Morrow DA, Guo J, Hoffman EB, **Gibson CM**, Ruff CT. Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial. *J Thromb Thrombolysis*. 2013 Jul 17. PubMed PMID: 23860881.
558. Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, **Gibson CM**. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). *JACC Cardiovasc Interv*. 2013 Jul;6(7):671-83. PubMed PMID:

23866179.

559. Brener SJ, Maehara A, Dizon JM, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, **Gibson CM**, Stone GW. Relationship between myocardial reperfusion, infarct size, and mortality: the INFUSE-AMI (Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. *JACC Cardiovasc Interv.* 2013 Jul;6(7):718-24. PubMed PMID:23866184.
560. De Luca G, Van't Hof AW, Huber K, **Gibson CM**, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D; EGYPT cooperation. Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and Mortality in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. *Am J Cardiol.* 2013 Oct 15;112(8):1083-1086. PubMed PMID: 23910428.
561. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, **Gibson CM**, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet.* 2013 Nov 23;382(9906):1712-1722. PubMed PMID: 24004642.
562. Steg PG, Bhatt DL, Hamm CW, Stone GW, **Gibson CM**, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; for the CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. *Lancet.* 2013 Dec14;382(9909):1981-1992. PubMed PMID: 24011551.
563. Hess CN, Rao SV, Kong DF, Aberle LH, Anstrom KJ, **Gibson CM**, Gilchrist IC, Jacobs AK, Jolly SS, Mehran R, Messenger JC, Newby LK, Waksman R, Krucoff MW. Embedding a randomized clinical trial into an ongoing registry infrastructure: Unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). *Am Heart J.* 2013 Sep;166(3):421-428. PubMed PMID: 24016489
564. Bagai A, White JA, Lokhnygina Y, Giugliano RP, Van de Werf F, Montalescot G, Armstrong PW, Tricoci P, **Gibson CM**, Califf RM, Harrington RA, Newby LK. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. *Am Heart J.* 2013 Sep;166(3):466-473.e1. PubMed PMID: 24016495.
565. Patrick WL, Patel C, Guddeti R, Narayan A, Maddaleni M, Kumar S, Dolma K, Serla VV, Sangha M, Govindavarjulla A, Saddala P, Singh P, Halaby R, **Gibson CM**. Is There a Need for "Triple Therapy"? Role of Anticoagulation with Dual Antiplatelet Therapy in Acute Coronary Syndromes (ATLAS Study & TRAP Study). *Curr Cardiol Rep.* 2013 Oct;15(10):411. PubMed PMID: 24022544.
566. Sanidas EA, Brener SJ, Maehara A, Génèreux P, Witzenbichler B, El-Omar M, Fahy M, Mehran R, **Gibson CM**, Stone GW. Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE-AMI study. *Catheter Cardiovasc Interv.* 2013 Sep 13. PubMed PMID:24030863.
567. Main ML, Grayburn PA, Lang RM, Goldman JH, **Gibson CM**, Sherwin P, Demaria AN. Effect of Optison on Pulmonary Artery Systolic Pressure and Pulmonary Vascular Resistance. *Am J Cardiol.* 2013 Nov 15;112(10):1657-1661. PubMed PMID: 24041914.
568. Palmerini T, Brener SJ, Genereux P, Maehara A, Della Riva D, Mariani A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Fahy M, Xu K, **Gibson CM**, Stone GW. Relation Between White Blood
-

Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial). *Am J Cardiol*. 2013 Dec 15;112(12):1860-1866. PubMed PMID: 24063843.

569. Stone GW, Witzenbichler B, Godlewski J, Dambrink JH, Ochala A, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Dizon JM, Wolff SD, Brener SJ, Mehran R, Maehara A, **Gibson CM**. Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction: One-Year Results From the INFUSE-AMI Trial. *Circ Cardiovasc Interv*. 2013 Oct 1. PubMed PMID: 24084626.
570. Hess CN, Roe MT, **Gibson CM**, Temple RJ, Pencina MJ, Zarin DA, Anstrom KJ, Alexander JH, Sherman RE, Fiedorek FT, Mahaffey KW, Lee KL, Chow SC, Armstrong PW, Califf RM. Independent data monitoring committees: preparing a path for the future. *Am Heart J*. 2014 Aug;168(2):135-41.e1. PubMed PMID: 25066551.
571. **Gibson CM**, Fox K. Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy". *Circulation*. 2017 Jul 4;136(1):117. doi: 10.1161/CIRCULATIONAHA.117.028416. PubMed ID: 28674098.
572. **Gibson CM**, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? *Am J Med*. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. . PubMed ID: 28390791

Research publications without named authorship

573. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the TIMI 9A trial. *Circulation*. 1994 Oct;90:1624-30. [**Gibson CM** listed in appendix as a participant of the study group]
574. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable angina or postinfarction angina. *N Eng J Med*. 1995;333:764-9. [**Gibson CM** listed in appendix as a participant of the study group]
575. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. *Circulation*. 1996;94:911-921. [**Gibson CM** listed in appendix as a participant of the study group]
576. McCormick LS, Black DM, Waters D, Brown WV, Pitt B for the AVERT Investigators. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin versus revascularization treatments (AVERT). *American Journal of Cardiology*. 1997;80:1130-3. [**Gibson CM** listed in appendix as a participant of the study group]
577. The RESTORE Investigators. The effects of platelet glycoprotein IIb/IIIa blockade with Tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. *Circulation*. 1997; 96:1445-1453. [**Gibson CM** listed in appendix as a participant of the study group]
578. The TIMI 11A Investigators. Dose- ranging trial of Enoxaparin for unstable angina: Results of TIMI 11A. *Journal American College of Cardiology*. 1997;29:1474-82. [**Gibson CM** listed in appendix as a participant of the study group]
579. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E for the TIMI 12 Investigators. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, Sibrafiban, in patients post an acute coronary syndrome: Results of the TIMI 12 trial. *Circulation*. 1998;97:340-9. [**Gibson CM** listed in appendix as a participant of

the study group]

580. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink JLM, Salein D, de Luna AB, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E for the TIMI 11B Investigators. *Circulation*. 1999;100:1593-1601. [**Gibson CM** listed in appendix as a participant of the study group]
581. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin Versus Revascularization Treatment (AVERT) Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. *N Engl J Med*. 1999;341-6. [**Gibson CM** listed in appendix as a participant of the study group]
582. Direct Thrombin Inhibitor Trialists' Collaboration. Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data. [**Gibson CM** is a member of the Direct Thrombin Inhibitor Trialists' Collaboration and is listed with all authors in the appendix]. *Am Heart J*. 2001 Jan;141(1):E2.

Non-peer reviewed scientific or medical publications/materials in print or other media

Proceedings of meetings or other non-peer reviewed research publications

1. Cannon CP, **Gibson CM**. TIMI Flow Grade and TIMI Frame Count, in The First International Thrombolytic Collegium, Prognostic Markers for the Management of Acute Myocardial Infarction, published by Medical Forum, Parsippany NJ, 1997.
2. Braunwald E, **Gibson CM**. New strategies in the management of acute MI: Protecting the microcirculation. *Medical Education Reports, Interviews and Testimony*. 2000; 2: 20-21.

Reviews, chapters, monographs and editorials

1. **Gibson CM**. "Profiles in Coronary Artery Disease." In: William Grossman, Donald S. Baim, editors. *Cardiac Catheterization, Angiography and Intervention*, 5th ed. Baltimore: Williams & Wilkins; 1996. p.757-62.
2. **Gibson CM**, Stone PH, Pasternak RC, Sacks FM, for the Harvard Atherosclerosis Reversibility Project Group. "Impact Upon Angiographic Disease Progression Following Step Drug Therapy in Normolipidemic Patients: Results of the Harvard Atherosclerosis Reversibility Project (HARP)." In: A.V.G., Bruschke, editors. *Lipid lowering therapy and progression of coronary atherosclerosis*. Dordrecht; Boston: Kluwer Academic Publishers; 1996. p. 179-91.
3. **Gibson CM**. "Primary and Rescue Angioplasty in the Setting of Acute Myocardial Infarction." In: Charles H. Hennekens, editor. *Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease*, 1st ed. Philadelphia: W.B. Saunders, 1999.
4. **Gibson CM**, Marble SJ, Rizzo MJ, Ryan K, Goel M. "Insights into the Pathophysiology of Acute Coronary Syndromes Using the TIMI Flow Grade and TIMI Frame Counting Methods." In: Christopher P. Cannon, editor. *Management of Acute Coronary Syndromes*, 1st ed. Totowa, NJ: Humana Press; 1999. p. 87-107.
5. Goel M, Sparano A, Moynihan J, Kelley M, **Gibson CM**. "New Device Strategies in the Management of Acute Coronary Syndromes". In: Christopher P. Cannon, editor. *Management of Acute Coronary Syndromes*, 1st ed. Totowa, NJ: Humana Press; 1999. p. 477-96.
6. **Gibson CM**. Primary angioplasty compared with thrombolysis: new issues in the era of glycoprotein IIb/IIIa inhibition and intracoronary stenting. *Annals of Internal Medicine* 1999; 130: 841-847.
7. **Gibson CM**. The sundial and the stopwatch. *American Heart Journal*, 1999; 138:614-617.
8. **Gibson CM**. "Profiles in Coronary Artery Disease." In: William Grossman and Donald S. Baim, editors. *Cardiac Catheterization, Angiography and Intervention*, 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2000.
9. **Gibson CM**. A union in reperfusion: The concept of facilitated Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2000 Nov 1;36(5):1497-9.

10. Angeja B, **Gibson CM**. Preserved Coronary Flow Reserve in Viable Myocardium: Further Evidence for the Microvascular Hypothesis. *Am Heart J*. 2001 Mar;141(3):329-30.
11. Appleby MA, Angeja BG, Dauterman K, **Gibson CM**. Angiographic assessment of myocardial perfusion: TIMI myocardial perfusion (TMP) grading system. *Heart*. 2001 Nov;86(5):485-6.
12. **Gibson CM**. Time is myocardium and time is outcomes. *Circulation*. 2001 Nov 27;104(22):2632-4.
13. Chatterjee K, **Gibson CM**. "Recognition and Management of Patients with Stable Angina Pectoris." In: Eugene Braunwald and Lee Goldman, editors. *Primary Cardiology*, 2nd ed. Philadelphia: Saunders; 2003. p. 379-408.
14. **Gibson CM**, Murphy SA, Popma JJ. "Insights into the Pathophysiology of Acute Ischemia Syndromes Using the TIMI Flow Grade, TIMI Frame Count, and TIMI Myocardial Perfusion Grade." In: Christopher P. Cannon, editor. *Management of Acute Coronary Syndromes*, 2nd ed. Totowa, NJ: Humana Press; 2003. p. 95-118.
15. Singh K, **Gibson CM**. "Current Device Strategies in the Management of Acute Coronary Syndromes." In: Christopher P. Cannon, editor. *Management of Acute Coronary Syndromes*, 2nd ed. Totowa, NJ: Humana Press; 2003. p. 535-65.
16. Popma JJ, **Gibson CM**. "Quantitative Coronary Arteriography." In: Topol EJ, editor. *Textbook of Interventional Cardiology*, 4th edition. Philadelphia: Saunders; 2003.
17. **Gibson CM**. Has My Patient Achieved Adequate Myocardial Reperfusion? *Circulation*. 2003 Aug 5;108(5):504-7.
18. **Gibson CM**. Confusion in reperfusion. *J Am Coll Cardiol*. 2003 Oct 1;42(7):1186-7.
19. Karha J, **Gibson CM**. "Angioplasty: Primary, Rescue, and Adjunctive Mechanical Interventions." In: Manson J, Buring J, Ridker P, Gaziano JM, editors. *Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease*, 2nd ed. Philadelphia: Elsevier Saunders; 2004. p. 129-40.
20. **Gibson CM**, DeLemos JA, Antman EM. Time is muscle in primary PCI: the strength of the evidence grows. *Eur Heart J*. 2004 Jun;25(12):1001-2.
21. Dodge JT, **Gibson CM**. "Thrombolysis in the elderly." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
22. **Gibson CM**. "Elevated serum cardiac troponin concentration in the absence of an acute coronary syndrome." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
23. **Gibson CM**. "Pre Hospital Thrombolysis." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
24. **Gibson CM**. "Prehospital thrombolysis for suspected acute ST elevation (Q wave) myocardial infarction." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
25. **Gibson CM**. "Primary angioplasty versus thrombolysis in acute myocardial infarction: Strengths and limitations." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
26. **Gibson CM**, Al-Mousa EN. "Newer thrombolytic agents." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
27. **Gibson CM**, Anderson JL. "Management of failed thrombolysis or threatened reocclusion in acute ST elevation (Q wave) myocardial infarction-I." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
28. **Gibson CM**, Anderson JL. "Management of failed thrombolysis or threatened reocclusion in acute ST elevation (Q wave) myocardial infarction-II." In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.
29. **Gibson CM**, Carrozza J, Laham R. "Primary PCI in acute ST elevation (Q wave) myocardial infarction: Clinical use- I". In: *UpToDate*, Rose BD, editor. *UpToDate*, Waltham, MA, 2006.

30. **Gibson CM**, Carrozza J, Laham R. "Primary PCI in acute ST elevation (Q wave) myocardial infarction: Clinical use- II." In: *UpToDate*, Rose BD, editor. UpToDate, Waltham, MA, 2006.
31. **Gibson CM**, Carrozza J, Laham R. "Primary PCI in acute ST elevation (Q wave) myocardial infarction: Clinical use- III." In: *UpToDate*, Rose BD, editor. UpToDate, Waltham, MA, 2006.
32. **Gibson CM**, Carrozza J, Laham R. "Primary PCI versus thrombolysis in acute ST elevation (Q wave) myocardial infarction: Clinical trials- I." In: *UpToDate*, Rose BD, editor. UpToDate, Waltham, MA, 2006.
33. **Gibson CM**, Carrozza J, Laham R. "Primary PCI versus thrombolysis in acute ST elevation (Q wave) myocardial infarction: Clinical trials- II." In: *UpToDate*, Rose BD editor. UpToDate, Waltham, MA, 2006.
34. **Gibson CM**, Carrozza J, Laham R. "Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation (Q wave) myocardial infarction." In: *UpToDate*, Rose BD, editor. UpToDate, Waltham, MA, 2006.
35. **Gibson CM**, Cutlip D, Pinto D. "Selecting a reperfusion strategy for acute ST elevation (Q wave) myocardial infarction- I." In: *UpToDate*, Rose BD, editor. UpToDate, Waltham, MA, 2006.
36. **Gibson CM**, Cutlip D, Pinto D. "Selecting a reperfusion strategy for acute ST elevation (Q wave) myocardial infarction- II." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
37. **Gibson CM**, Gardner G, Pinto DS. „Ischemic reperfusion injury of the heart." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
38. **Gibson CM**, Levin T. "Thrombolytic agents in acute ST elevation (Q wave) myocardial infarction: Clinical use- I." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
39. **Gibson CM**, Levin T. "Thrombolytic agents in acute ST elevation (Q wave) myocardial infarction: Clinical use- II." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
40. **Gibson CM**, Levin T. "Thrombolytic agents in acute ST elevation (Q wave) myocardial infarction: Markers of efficacy- I." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
41. **Gibson CM**, Levin T. "Thrombolytic agents in acute ST elevation (Q wave) myocardial infarction: Markers of efficacy- II." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
42. **Gibson CM**, Levin T. "Use of thrombolytic agents in clinical practice-I." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
43. **Gibson CM**, Levin T. "Use of thrombolytic agents in clinical practice-II." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
44. **Gibson CM**, Lincoff AM. "Fondaparinux in acute coronary syndromes." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
45. **Gibson CM**, Mousa E, Levin T. "Characteristics of thrombolytic agents and efficacy in clinical trials-I." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
46. **Gibson CM**, Mousa E, Levin T. "Characteristics of thrombolytic agents and efficacy in clinical trials-II." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
47. **Gibson CM**, Moynihan J. "Reocclusion Following Thrombolysis." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
48. **Gibson CM**, Murphy SA. "Pathogenesis of and predictors for coronary artery reocclusion following thrombolysis." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
49. **Gibson CM**, Post T, Henrich W. "Chronic kidney disease and coronary heart disease- I." In: *UpToDate*. Rose BD, editor. UpToDate, Waltham, MA, 2006.
50. Pinto DS, **Gibson CM**. "Glycoprotein IIB/IIIA Receptor Antagonists During ST Elevation Myocardial Infarction." In: Purcell and Katz, editors. *Clinical Practice: Acute Coronary Syndromes*. 1st edition, Kidlington, Oxford, UK. Churchill Livingstone, 2006.
51. Gaziano, JM; **Gibson, CM**. Clinical implications of concomitant nonopioid analgesia in patients with or at

risk for cardiovascular disease – Introduction. *American Journal of Cardiology*. 2006 May;97(9A):1E-2E.

52. Nguyen T, Turakhia MP, **Gibson CM**. “Management of ST-Elevation Acute Myocardial Infarction in Practical Handbook of Interventional Cardiology.” In: Nguyen T, Grines C, Hu D, Kim M-H, editors. *Management of Complex Cardiovascular Problems*. 3rd ed. Blackwell Pub.;2007.
53. **Gibson CM**. “Coronary reperfusion for acute myocardial infarction in older adults.” In: *UpToDate*. Cannon CP, Schmader KE (Ed), UpToDate, Waltham, MA, 2008.
54. **Gibson CM**, Watkins B, Merlo K. Antiplatelet Treatment for ACS: Weighing Long-Term Outcomes Vs. Short-Term Risk Introduction. *Journal of Interventional Cardiology*. 2008;21: S1-S2.
55. **Gibson CM**, Zorkun C, Kunadian V. Intracoronary administration of abciximab in ST-elevation myocardial infarction. *Circulation*. 2008 Jul;118(1):6-8.
56. **Gibson CM**, Pride YB. Myocardial infarct size reduction with pexelizumab: the role of chance is patently clear. *JACC Cardiovasc Imaging*. 2010 Jan;3(1):61-3.
57. Chakrabarti AK, Patel SJ, Salazar RL, **Gibson CM**, et al. “Newer Pharmaceutical Agents for STEMI Interventions.” In: Sameer Mehta, Samin K. Sharma and Igor F. Palacios, editors. *Interventional Cardiology Clinics: STEMI Interventions*. 2012 Oct; 1(4): p. 429-440. Philadelphia: Saunders.

Letters to the Editor

1. Ridker P, **Gibson CM**. Atrial fibrillation induced by breath spray [letter]. *N Eng J Med*. 1989 Jan 12;320:124
2. Kloner RA, **Gibson CM**, Cannon CP, Braunwald E. Preinfarction angina (letter). *N Eng J Med*. 1996;335:59-60.
3. Diminution in Flow Following Primary Stenting in the INAMI Study. Murphy SA, **Gibson CM**. *Catheter Cardiovasc Interv*. 2003 Jul;59(3):417.

Professional Educational Materials or Reports, in Print or Other Media

1. **Gibson CM**. “How to do the TIMI Frame Count” [demonstration]. www.perfuse.org
2. **Gibson CM**. “How to do the TIMI Myocardial Perfusion Grade” [demonstration]. www.perfuse.org
3. **Gibson CM**. “TIMI frame count and TIMI myocardial perfusion grades. New methods to assess coronary reperfusion.” www.chestpainonline.org, Jan 2000.
4. **Gibson CM**, Sperling R. “Management of Anastomotic Lesions.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
5. **Gibson CM**, Pinto D. “Management of Angulated Lesions.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
6. **Gibson CM**, Pinto D. “Management of Anticoagulation in PCI.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
7. **Gibson CM**, Pinto D. “Management of Bifurcation Lesions.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
8. **Gibson CM**, Tu T. “Management of Calcified Lesions.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
9. **Gibson CM**, Lorenz D. “Management of Coronary Spasm.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
10. **Gibson CM**, Frisch D. “Management of the Diabetic Patient.” In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
11. **Gibson CM**, Tu T. “Management of Left Main Disease.” In: *Treatment Strategies in Interventional*

- Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
12. **Gibson CM**, Sperling R. "Management of Multivessel Disease." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 13. **Gibson CM**, Pinto D. "Management of No-Reflow." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 14. **Gibson CM**, Pinto D. "Management of Ostial Lesions." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 15. **Gibson CM**, Pinto D. "Management of Perforation." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 16. **Gibson CM**, Lorenz D. "Primary Percutaneous Intervention for Acute Myocardial Infarction." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 17. **Gibson CM**, Frisch D. "Management of the PCI Patient with Renal Failure." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 18. **Gibson CM**, Sperling R. "Management of Thrombotic Lesions". In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 19. **Gibson CM**, Pinto D. "Management of the Chronic Total Occlusion." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 20. **Gibson CM**, Lorenz D. "Management of the PCI Patient with Unstable Angina." In: *Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; 2002.
 21. **Gibson CM**, editor. 3CPO [summary]. www.cardiosource.com
 22. **Gibson CM**, editor. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia [summary]. www.cardiosource.com
 23. **Gibson CM**, editor. A Comparison of On-Pump and Off-Pump Coronary Bypass Surgery in Low-Risk Patients [summary]. www.cardiosource.com
 24. **Gibson CM**, editor. A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation [summary]. www.cardiosource.com
 25. **Gibson CM**, editor. A Long-Term Perspective on the Protective Effects of an Early Invasive Strategy in Unstable Coronary Artery Disease: Two-Year Follow-up of the FRISC-II Invasive Study. [summary]. www.cardiosource.com
 26. **Gibson CM**, editor. A Prospective, Randomized, Controlled Trial of Distal Protection With the Third Generation Mednova Emboshield Compared to the GuardWire or FilterWire [summary]. www.cardiosource.com
 27. **Gibson CM**, editor. A Prospective, Randomized, Controlled Trial of Thrombectomy With the AngioJet in Acute Myocardial Infarction [summary]. www.cardiosource.com
 28. **Gibson CM**, editor. A Prospective, Randomized Trial of Enoxaparin and Unfractionated Heparin in Patients With Acute Coronary Syndromes - Results in Patients Undergoing Percutaneous Coronary Intervention [summary]. www.cardiosource.com
 29. **Gibson CM**, editor. A Randomized Comparison of a Sirolimus Eluting Stent with A Standard Stent for Coronary Revascularization. [summary]. www.cardiosource.com
 30. **Gibson CM**, editor. A Randomized Comparison of the Value of Additional Stenting After Optimal Balloon

- Angioplasty for Long Coronary Lesions [summary]. www.cardiosource.com
31. **Gibson CM**, editor. A Randomized Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities [summary]. www.cardiosource.com
 32. **Gibson CM**, editor. A study of risk factors for first myocardial infarction in 52 countries and over 27,000 subjects [summary]. www.cardiosource.com
 33. **Gibson CM**, editor. Abciximab-Carbostent Evaluation [summary]. www.cardiosource.com
 34. **Gibson CM**, editor. Abciximab Versus Tirofiban and Recovery of Left Ventricular Function [summary]. www.cardiosource.com
 35. **Gibson CM**, editor. Acetylcysteine for Prevention of Renal Deterioration after Angiography [summary]. www.cardiosource.com
 36. **Gibson CM**, editor. Acolysis During Treatment of Lesions Affecting Saphenous Vein Bypass Grafts [summary]. www.cardiosource.com
 37. **Gibson CM**, editor. Actinomycin Eluting Stent Improves Outcomes by Reducing Neointimal Hyperplasia [summary]. www.cardiosource.com
 38. **Gibson CM**, editor. Action in Diabetes and Vascular Disease (ADVANCE) [summary]. www.cardiosource.com
 39. **Gibson CM**, editor. Acute and Chronic Therapeutic Impact of a Vasopressin 2 Antagonist (Tolvaptan) in Congestive Heart Failure [summary]. www.cardiosource.com
 40. **Gibson CM**, editor. Acute Catheterization and Urgent Intervention Triage Strategy Trial (ACUTITY) [summary]. www.cardiosource.com
 41. **Gibson CM**, editor. Acute Hemodynamic Effects of Conivaptan in Patients with Advanced Heart Failure [summary]. www.cardiosource.com
 42. **Gibson CM**, editor. Acute Myocardial Infarction Study of Adenosine II [summary]. www.cardiosource.com
 43. **Gibson CM**, editor. Acute Myocardial Infarction Study of Adenosine Trial [summary]. www.cardiosource.com
 44. **Gibson CM**, editor. Acute Myocardial Infarction With Hyperoxemic Therapy [summary]. www.cardiosource.com
 45. **Gibson CM**, editor. AdenosINE Sestamibi Post-InfARction Evaluation (INSPIRE) Trial [summary]. www.cardiosource.com
 46. **Gibson CM**, editor. Additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty [summary]. www.cardiosource.com
 47. **Gibson CM**, editor. Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) [summary]. www.cardiosource.com
 48. **Gibson CM**, editor. African American Antiplatelet Stroke Prevention Study [summary]. www.cardiosource.com
 49. **Gibson CM**, editor. African-American Heart Failure Trial [summary]. www.cardiosource.com
 50. **Gibson CM**, editor. African American Study of Kidney Disease and Hypertension [summary]. www.cardiosource.com
 51. **Gibson CM**, editor. Aggrastat to Zocor [summary]. www.cardiosource.com
 52. **Gibson CM**, editor. Aggressive Lipid-Lowering Initiation Abates New Cardiac Events [summary]. www.cardiosource.com
 53. **Gibson CM**, editor. The Air Primary Angioplasty in Myocardial Infarction Study. [summary].

www.cardiosource.com

54. **Gibson CM**, editor. Alcohol Consumption and Plasma Concentration of CRP [summary].
www.cardiosource.com
55. **Gibson CM**, editor. Aliskiren, an oral renin inhibitor, in hypertensive patients [summary].
www.cardiosource.com
56. **Gibson CM**, editor. Aliskiren and Valsartan for Antihypertensive Therapy [summary].
www.cardiosource.com
57. **Gibson CM**, editor. Alternans Before Cardioverter Defibrillator (ABCD) Trial [summary].
www.cardiosource.com
58. **Gibson CM**, editor. American College of Cardiology Acute Myocardial Infarction Guidelines Applied to Practice Study [summary]. www.cardiosource.com
59. **Gibson CM**, editor. Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation [summary]. www.cardiosource.com
60. **Gibson CM**, editor. Amiodarone, Losartan, and Perindopril in Atrial Fibrillation [summary].
www.cardiosource.com
61. **Gibson CM**, editor. Amiodarone Versus Implantable Defibrillator in Patients with Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia study [summary].
www.cardiosource.com
62. **Gibson CM**, editor. Aneurysm Detection and Management Veterans Affairs Cooperative Study [summary].
www.cardiosource.com
63. **Gibson CM**, editor. Angiogenic GENE Therapy Trial [summary]. www.cardiosource.com
64. **Gibson CM**, editor. Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial [summary]. www.cardiosource.com
65. **Gibson CM**, editor. Angiorad Radiation Therapy for In-Stent Restenosis Trial In Coronaries [summary].
www.cardiosource.com
66. **Gibson CM**, editor. Anglo-Scandinavian Cardiac Outcomes Trial [summary]. www.cardiosource.com
67. **Gibson CM**, editor. Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm [summary]. www.cardiosource.com
68. **Gibson CM**, editor. Anglo-Scandinavian Study of Early Thrombolysis [summary]. www.cardiosource.com
69. **Gibson CM**, editor. Antibiotic Therapy After An Acute Myocardial Infarction [summary].
www.cardiosource.com
70. **Gibson CM**, editor. Anticoagulants in Secondary Prevention of Events in Coronary Thrombosis [summary].
www.cardiosource.com
71. **Gibson CM**, editor. Anticoagulation for Cardioversion using Enoxaparin [summary].
www.cardiosource.com
72. **Gibson CM**, editor. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [summary]. www.cardiosource.com
73. **Gibson CM**, editor. Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study [summary]. www.cardiosource.com
74. **Gibson CM**, editor. Antiplatelet Trialist Group [summary]. www.cardiosource.com
75. **Gibson CM**, editor. Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis [summary]. www.cardiosource.com

76. **Gibson CM**, editor. Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2 [summary]. www.cardiosource.com
77. **Gibson CM**, editor. Anti-TNF Therapy Against Congestive Heart Failure Trial [summary]. www.cardiosource.com
78. **Gibson CM**, editor. Aortic Stentless versus Stented valve assessed by Echocardiography Randomized Trial (ASSERT) [summary]. www.cardiosource.com
79. **Gibson CM**, editor. ApoA-I Milano on Coronary Atherosclerosis in Acute Coronary Syndromes [summary]. www.cardiosource.com
80. **Gibson CM**, editor. Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte [summary]. www.cardiosource.com
81. **Gibson CM**, editor. ARCHeR [summary]. www.cardiosource.com
82. **Gibson CM**, editor. ARCHeR One Year Follow-up [summary]. www.cardiosource.com
83. **Gibson CM**, editor. Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation [summary]. www.cardiosource.com
84. **Gibson CM**, editor. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 [summary]. www.cardiosource.com
85. **Gibson CM**, editor. Arterial Disease Multiple Intervention Trial [summary]. www.cardiosource.com
86. **Gibson CM**, editor. Arterial Revascularization Therapies Study [summary]. www.cardiosource.com
87. **Gibson CM**, editor. Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents for the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions [summary]. www.cardiosource.com
88. **Gibson CM**, editor. Asian Paclitaxel-Eluting Stent Clinical Trial [summary]. www.cardiosource.com
89. **Gibson CM**, editor. Aspirin on the Risk of Embolic Events in Patients With Infective Endocarditis [summary]. www.cardiosource.com
90. **Gibson CM**, editor. Assessment of a Cardiac Support Device (CSD) in Patients With Heart Failure [summary]. www.cardiosource.com
91. **Gibson CM**, editor. Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial [summary]. www.cardiosource.com
92. **Gibson CM**, editor. Assessment of Lescol in Renal Transplantation [summary]. www.cardiosource.com
93. **Gibson CM**, editor. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) [summary]. www.cardiosource.com
94. **Gibson CM**, editor. Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation, and On-going Necrosis [summary]. www.cardiosource.com
95. **Gibson CM**, editor. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen [summary]. www.cardiosource.com
96. **Gibson CM**, editor. Assessment of Treatment with Lisinopril and Survival [summary]. www.cardiosource.com
97. **Gibson CM**, editor. ASTAMI [summary]. www.cardiosource.com
98. **Gibson CM**, editor. ASTEROID [summary]. www.cardiosource.com
99. **Gibson CM**, editor. Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) [summary]. www.cardiosource.com

100. **Gibson CM**, editor. Atherosclerosis Risk in Communities [summary]. www.cardiosource.com
101. **Gibson CM**, editor. ATLAS [summary]. www.cardiosource.com
102. **Gibson CM**, editor. Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery (ARMYDA-3) [summary]. www.cardiosource.com
103. **Gibson CM**, editor. Atorvastatin for Reduction of Myocardial Damage During Angioplasty [summary]. www.cardiosource.com
104. **Gibson CM**, editor. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation [summary]. www.cardiosource.com
105. **Gibson CM**, editor. Atrial Dynamic Overdrive Pacing Trial [summary]. www.cardiosource.com
106. **Gibson CM**, editor. Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) [summary]. www.cardiosource.com
107. **Gibson CM**, editor. Atrial Therapy Efficacy and Safety Trial [summary]. www.cardiosource.com
108. **Gibson CM**, editor. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). [summary]. www.cardiosource.com
109. **Gibson CM**, editor. Australian National Blood Pressure Study Group [summary]. www.cardiosource.com
110. **Gibson CM**, editor. Autologous Skeletal Myoblast Transplantation in Patients Undergoing Coronary Artery Bypass Graft Surgery [summary]. www.cardiosource.com
111. **Gibson CM**, editor. Azimilide—CardiOverion MaintenancE Trial-I (A-COMET-I) [summary]. www.cardiosource.com
112. **Gibson CM**, editor. Azimilide—CardiOverion MaintenancE Trial-II (A-COMET-II) [summary]. www.cardiosource.com
113. **Gibson CM**, editor. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators [summary]. www.cardiosource.com
114. **Gibson CM**, editor. Azithromycin and coronary events study in patients with stable coronary disease [summary]. www.cardiosource.com
115. **Gibson CM**, editor. Azithromycin in Acute Coronary Syndrome [summary]. www.cardiosource.com
116. **Gibson CM**, editor. Balloon Equivalent to Stent Trial [summary]. www.cardiosource.com
117. **Gibson CM**, editor. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. [summary]. www.cardiosource.com
118. **Gibson CM**, editor. Bavarian Reperfusion Alternatives Evaluation [summary]. www.cardiosource.com
119. **Gibson CM**, editor. Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups [summary]. www.cardiosource.com
120. **Gibson CM**, editor. Benefits of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension: a LIFE substudy [summary]. www.cardiosource.com
121. **Gibson CM**, editor. Beraprost for Treatment of Intermittent Claudication [summary]. www.cardiosource.com
122. **Gibson CM**, editor. Beraprost Therapy for Pulmonary Arterial Hypertension [summary]. www.cardiosource.com
123. **Gibson CM**, editor. Bergamo Nephrologic Diabetes Complications Trial [summary]. www.cardiosource.com

124. **Gibson CM**, editor. BeStent in Small Arteries Trial [summary]. www.cardiosource.com
125. **Gibson CM**, editor. Beta Blocker Evaluation of Survival Trial [summary]. www.cardiosource.com
126. **Gibson CM**, editor. Beta Radiation in Europe [summary]. www.cardiosource.com
127. **Gibson CM**, editor. Beta-Radiation Investigation With Direct Stenting and Galileo in Europe [summary]. www.cardiosource.com
128. **Gibson CM**, editor. Beta Radiation to reduce In-stent restEnosis [summary]. www.cardiosource.com
129. **Gibson CM**, editor. Beta Radiation to reduce In-stent restEnosis II [summary]. www.cardiosource.com
130. **Gibson CM**, editor. Beta Radiation to reduce In-stent restEnosis in Saphenous Vein Grafts [summary]. www.cardiosource.com
131. **Gibson CM**, editor. Beta radiation Trial To Eliminate Restenosis [summary]. www.cardiosource.com
132. **Gibson CM**, editor. BEzafibrate Coronary Atherosclerosis Intervention Trial [summary]. www.cardiosource.com
133. **Gibson CM**, editor. Beyond 12 Hours Reperfusion Alternative Evaluation Trial [summary]. www.cardiosource.com
134. **Gibson CM**, editor. Beyond Endorsed Lipid Lowering With EBT Scanning [summary]. www.cardiosource.com
135. **Gibson CM**, editor. Bisoprolol Reduces Perioperative Events in Vascular Patients: Data From the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group [summary]. www.cardiosource.com
136. **Gibson CM**, editor. Biventricular Pacing After Ablate Compared With Right Ventricular Therapy [summary]. www.cardiosource.com
137. **Gibson CM**, editor. Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion [summary]. www.cardiosource.com
138. **Gibson CM**, editor. Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration [summary]. www.cardiosource.com
139. **Gibson CM**, editor. Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Patients [summary]. www.cardiosource.com
140. **Gibson CM**, editor. Brain natriuretic peptide for Acute Shortness of breath Evaluation: a randomized comparison [summary]. www.cardiosource.com
141. **Gibson CM**, editor. Breathing Not Properly [summary]. www.cardiosource.com
142. **Gibson CM**, editor. British Doctors Trial [summary]. www.cardiosource.com
143. **Gibson CM**, editor. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events [summary]. www.cardiosource.com
144. **Gibson CM**, editor. Calderet in ST Elevation Myocardial Infarction [summary]. www.cardiosource.com
145. **Gibson CM**, editor. Campanian Postprandial Hyperglycemia Study [summary]. www.cardiosource.com
146. **Gibson CM**, editor. Canadian Antioxidant Restenosis Trial [summary]. www.cardiosource.com
147. **Gibson CM**, editor. Canadian Sirolimus-Eluting Stent in Coronary Lesions [summary]. www.cardiosource.com
148. **Gibson CM**, editor. Canadian Trial of Physiologic Pacing [summary]. www.cardiosource.com
149. **Gibson CM**, editor. Candesartan in Heart Failure Added Trial [summary]. www.cardiosource.com

150. **Gibson CM**, editor. Candesartan in Heart Failure Alternative Trial [summary]. www.cardiosource.com
151. **Gibson CM**, editor. Candesartan in Heart Failure assessment of reduction in mortality and morbidity [summary]. www.cardiosource.com
152. **Gibson CM**, editor. Candesartan in Heart Failure Preserved Trial [summary]. www.cardiosource.com
153. **Gibson CM**, editor. Captopril Prevention Project [summary]. www.cardiosource.com
154. **Gibson CM**, editor. Cardiac Arrest Study Hamburg [summary]. www.cardiosource.com
155. **Gibson CM**, editor. Cardiac Resynchronization Heart Failure Study [summary]. www.cardiosource.com
156. **Gibson CM**, editor. Cardiac resynchronization therapy for the treatment of heart failure in patients with ventricular tachyarrhythmias [summary]. www.cardiosource.com
157. **Gibson CM**, editor. Cardiovascular Health Study [summary]. www.cardiosource.com
158. **Gibson CM**, editor. Cardiovascular Morbidity and Mortality in Patients with Diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol. [summary]. www.cardiosource.com
159. **Gibson CM**, editor. Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone (CHICAGO) [summary]. www.cardiosource.com
160. **Gibson CM**, editor. The Carvedilol and ACE-inhibitor Remodeling Mild Heart Failure Evaluation Trial [summary]. www.cardiosource.com
161. **Gibson CM**, editor. Carvedilol Hibernating Reversible Ischaemia Trial [summary]. www.cardiosource.com
162. **Gibson CM**, editor. Carvedilol in Children With Heart Failure [summary]. www.cardiosource.com
163. **Gibson CM**, editor. Carvedilol Or Metoprolol European Trial [summary]. www.cardiosource.com
164. **Gibson CM**, editor. Catheter Ablation for the Cure of Atrial Fibrillation Study [summary]. www.cardiosource.com
165. **Gibson CM**, editor. Chinese Cardiac Study [summary]. www.cardiosource.com
166. **Gibson CM**, editor. Chicago Stroke Study [summary]. www.cardiosource.com
167. **Gibson CM**, editor. Cholesterol and Recurrent Events [summary]. www.cardiosource.com
168. **Gibson CM**, editor. Cholesterol Lowering and Arrhythmias Recurrences After Internal Defibrillator Implantation (CLARIDI) [summary]. www.cardiosource.com
169. **Gibson CM**, editor. Cholesterol-Lowering Effect of a Theaflavin-Enriched Green Tea Extract [summary]. www.cardiosource.com
170. **Gibson CM**, editor. Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure [summary]. www.cardiosource.com
171. **Gibson CM**, editor. Cilostazol for Restenosis [summary]. www.cardiosource.com
172. **Gibson CM**, editor. Clinical and Angiographic Outcomes After Use of Sr-90 Beta Radiation for the Treatment of de novo and restenotic coronary lesions [summary]. www.cardiosource.com
173. **Gibson CM**, editor. Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [summary]. www.cardiosource.com
174. **Gibson CM**, editor. Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis [summary]. www.cardiosource.com

175. **Gibson CM**, editor. Clopidogrel as Adjunctive Reperfusion Therapy [summary]. www.cardiosource.com
176. **Gibson CM**, editor. Clopidogrel for High Atherothrombotic Risk, Ischemic Stabilization, Management, and Avoidance (CHARISMA) [summary]. www.cardiosource.com
177. **Gibson CM**, editor. Clopidogrel for Reduction of Events During Observation [summary]. www.cardiosource.com
178. **Gibson CM**, editor. Clopidogrel in Unstable angina to prevent Recurrent Events [summary]. www.cardiosource.com
179. **Gibson CM**, editor. Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets Study [summary]. www.cardiosource.com
180. **Gibson CM**, editor. Collaborative Atorvastatin Diabetes Study [summary]. www.cardiosource.com
181. **Gibson CM**, editor. Combination Hemotherapy and Mortality Prevention (CHAMP) Study [summary]. www.cardiosource.com
182. **Gibson CM**, editor. Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS in AMI) [summary]. www.cardiosource.com
183. **Gibson CM**, editor. Combined Angioplasty and Pharmacological Intervention Versus Thrombolytics Alone in Acute Myocardial Infarction [summary]. www.cardiosource.com
184. **Gibson CM**, editor. Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis [summary]. www.cardiosource.com
185. **Gibson CM**, editor. Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events [summary]. www.cardiosource.com
186. **Gibson CM**, editor. Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter Defibrillators Trial (EMPIRIC) [summary]. www.cardiosource.com
187. **Gibson CM**, editor. Comparison of medical therapy, resynchronization, and defibrillation therapies in heart failure trial [summary]. www.cardiosource.com
188. **Gibson CM**, editor. Comparison of Stent Implantation and Off-Pump Bypass Surgery in Patients Referred for Coronary Angioplasty [summary]. www.cardiosource.com
189. **Gibson CM**, editor. Complement and Reduction of Infarct Size After Angioplasty or Lytics [summary]. www.cardiosource.com
190. **Gibson CM**, editor. Continuous Positive Airway Pressure for Heart Failure Patients With Central Sleep Apnea [summary]. www.cardiosource.com
191. **Gibson CM**, editor. Continuous Quality Improvement in Coronary Artery Bypass Graft [summary]. www.cardiosource.com
192. **Gibson CM**, editor. CONTRAST [summary]. www.cardiosource.com
193. **Gibson CM**, editor. Contrast-Induced Nephropathy Prevention With Sodium Bicarbonate [summary]. www.cardiosource.com
194. **Gibson CM**, editor. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications [summary]. www.cardiosource.com
195. **Gibson CM**, editor. Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints Trial [summary]. www.cardiosource.com
196. **Gibson CM**, editor. Controlled Safety and Pharmacology Study of ALT-711 in Older Patients with Stiffened Cardiovasculature [summary]. www.cardiosource.com
197. **Gibson CM**, editor. Conventional Stenting Versus Direct Stenting in (Un)stable Angina Pectoris

- [summary]. www.cardiosource.com
198. **Gibson CM**, editor. COOLing as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction [summary]. www.cardiosource.com
 199. **Gibson CM**, editor. Coronary artery bypass surgery vs stenting for the treatment of multivessel disease: a meta-analysis of ARTS, SoS, ERACI-2 and MASS-2 [summary]. www.cardiosource.com
 200. **Gibson CM**, editor. Coronary Artery Revascularization Prophylaxis [summary]. www.cardiosource.com
 201. **Gibson CM**, editor. Coronary Artery Surgery Study [summary]. www.cardiosource.com
 202. **Gibson CM**, editor. Coronary Bypass Surgery Performed off Pump versus on Pump [summary]. www.cardiosource.com
 203. **Gibson CM**, editor. Coronary artery bypass surgery vs. percutaneous coronary intervention with stent implantation in patients with multivessel coronary disease (the Stent or Surgery Trial) [summary]. www.cardiosource.com
 204. **Gibson CM**, editor. Coronary disease trial investigating outcome with nifedipine GITS [summary]. www.cardiosource.com
 205. **Gibson CM**, editor. Corticosteroids for the Prevention of Atrial Fibrillation After Cardiac Surgery [summary]. www.cardiosource.com
 206. **Gibson CM**, editor. Cost-Effectiveness of Sirolimus Drug-Eluting Stents for Treatment of Complex Coronary Stenoses [summary]. www.cardiosource.com
 207. **Gibson CM**, editor. Cost/Utility Ratio in Chronic Heart Failure: Comparison Between Heart Failure Management Program Delivered by Day-Hospital and Usual Care [summary]. www.cardiosource.com
 208. **Gibson CM**, editor. Coumadin Aspirin Reinfarction Study [summary]. www.cardiosource.com
 209. **Gibson CM**, editor. COX-2 Inhibitors After Cardiac Surgery [summary]. www.cardiosource.com
 210. **Gibson CM**, editor. Daclizumab to Prevent Rejection after Cardiac Transplantation [summary]. www.cardiosource.com
 211. **Gibson CM**, editor. Danish Study Group on Verapamil in MI [summary]. www.cardiosource.com
 212. **Gibson CM**, editor. Danish Trial in Acute Myocardial Infarction-2 [summary]. www.cardiosource.com
 213. **Gibson CM**, editor. DEDICATION [summary]. www.cardiosource.com
 214. **Gibson CM**, editor. Defibrillator in Acute Myocardial Infarction Trial [summary]. www.cardiosource.com
 215. **Gibson CM**, editor. Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation [summary]. www.cardiosource.com
 216. **Gibson CM**, editor. DELIVER [summary]. www.cardiosource.com
 217. **Gibson CM**, editor. DELIVER II Registry [summary]. www.cardiosource.com
 218. **Gibson CM**, editor. Detect Supraventricular Tachycardia Study [summary]. www.cardiosource.com
 219. **Gibson CM**, editor. Deutsche Diabetes Dialysis Study [summary]. www.cardiosource.com
 220. **Gibson CM**, editor. Diabetes Abciximab Stent Evaluation [summary]. www.cardiosource.com
 221. **Gibson CM**, editor. Diabetes Prevention Program Trial [summary]. www.cardiosource.com
 222. **Gibson CM**, editor. Diabetic Insulin-Glucose Infusion in Acute MI [summary]. www.cardiosource.com
 223. **Gibson CM**, editor. Diabetic Postoperative Mortality and Morbidity Trial [summary]. www.cardiosource.com

224. **Gibson CM**, editor. Diabetics exposed to telmisartan and enalapril [summary]. www.cardiosource.com
225. **Gibson CM**, editor. Dietary Approaches to Stop Hypertension [summary]. www.cardiosource.com
226. **Gibson CM**, editor. Dilation versus Ablation Revascularization Trial [summary]. www.cardiosource.com
227. **Gibson CM**, editor. Diltiazem Reinfarction Study [summary]. www.cardiosource.com
228. **Gibson CM**, editor. Direct Myocardial Revascularization in Regeneration of Endocardial Channels Trial [summary]. www.cardiosource.com
229. **Gibson CM**, editor. Direct Stenting Using the Sirolimus-Eluting Stent [summary]. www.cardiosource.com
230. **Gibson CM**, editor. Doppler Endpoints Balloon Angioplasty Trial Europe [summary]. www.cardiosource.com
231. **Gibson CM**, editor. Drug-Eluting Stent Late Thrombosis Meta-Analysis [summary]. www.cardiosource.com
232. **Gibson CM**, editor. Drug-Eluting Stent Mortality Meta-Analysis [summary]. www.cardiosource.com
233. **Gibson CM**, editor. Drug-eluting stents for in-stent restenosis [summary]. www.cardiosource.com
234. **Gibson CM**, editor. Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics [summary]. www.cardiosource.com
235. **Gibson CM**, editor. Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial [summary]. www.cardiosource.com
236. **Gibson CM**, editor. Dual Site Atrial Pacing to Prevent Atrial Fibrillation [summary]. www.cardiosource.com
237. **Gibson CM**, editor. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V (DECREASE-V) [summary]. www.cardiosource.com
238. **Gibson CM**, editor. Early Discharge After Transradial Stenting of Coronary Arteries [summary]. www.cardiosource.com
239. **Gibson CM**, editor. Eastbourne Syncope Assessment Study [summary]. www.cardiosource.com
240. **Gibson CM**, editor. Echocardiographic Predictors of Adverse Outcomes in Primary Pulmonary Hypertension. [summary]. www.cardiosource.com
241. **Gibson CM**, editor. Effect of an Indo-Mediterranean Diet on Progression of Coronary Artery Disease in High Risk Patients (Indo-Mediterranean Diet Heart Study): A Randomized Single-blind Trial. [summary]. www.cardiosource.com
242. **Gibson CM**, editor. Effect of Carvedilol on Survival in Severe Chronic Heart Failure [summary]. www.cardiosource.com
243. **Gibson CM**, editor. Effect of estrogen replacement on the progression of coronary artery atherosclerosis [summary]. www.cardiosource.com
244. **Gibson CM**, editor. Effect of Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome [summary]. www.cardiosource.com
245. **Gibson CM**, editor. Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q Wave Myocardial Infarction. A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy. [summary]. www.cardiosource.com
246. **Gibson CM**, editor. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction [summary]. www.cardiosource.com
247. **Gibson CM**, editor. Effects of PG-116800, a Matrix Metalloproteinase Inhibitor, to Prevent Left

- Ventricular Remodeling After Acute Myocardial Infarction [summary]. www.cardiosource.com
248. **Gibson CM**, editor. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study [summary]. www.cardiosource.com
 249. **Gibson CM**, editor. Effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels [summary]. www.cardiosource.com
 250. **Gibson CM**, editor. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia [summary]. www.cardiosource.com
 251. **Gibson CM**, editor. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia [summary]. www.cardiosource.com
 252. **Gibson CM**, editor. Efficacy and Safety of Eplerenone, Enalapril, and Eplerenone/Enalapril Combination Therapy in Patients With Left Ventricular Hypertrophy [summary]. www.cardiosource.com
 253. **Gibson CM**, editor. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients after acute myocardial infarction [summary]. www.cardiosource.com
 254. **Gibson CM**, editor. Efficacy of Ompatrilat in Patients with Hypertension and Atherosclerotic Disease [summary]. www.cardiosource.com
 255. **Gibson CM**, editor. Efficacy of Ranolazine in Chronic Angina (ERICA) [summary]. www.cardiosource.com
 256. **Gibson CM**, editor. Elective PCI in Outpatient Study (EPOS) [summary]. www.cardiosource.com
 257. **Gibson CM**, editor. ELISA 2 [summary]. www.cardiosource.com
 258. **Gibson CM**, editor. Emory Angioplasty vs Surgery Trial [summary]. www.cardiosource.com
 259. **Gibson CM**, editor. EndoCoronary-Rhenium-Irradiation-Study [summary]. www.cardiosource.com
 260. **Gibson CM**, editor. Endothelin Receptor Antagonist Trial in Heart Failure [summary]. www.cardiosource.com
 261. **Gibson CM**, editor. Endovascular Valve Edge-to-Edge Repair Study [summary]. www.cardiosource.com
 262. **Gibson CM**, editor. Enhanced Myocardial Efficacy and Removal by Aspiration of Liberated Debris [summary]. www.cardiosource.com
 263. **Gibson CM**, editor. Enhancing Recovery in Coronary Heart Disease [summary]. www.cardiosource.com
 264. **Gibson CM**, editor. Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction (EXTRACT-TIMI-25) [summary]. www.cardiosource.com
 265. **Gibson CM**, editor. Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction [summary]. www.cardiosource.com
 266. **Gibson CM**, editor. Enoxaparin Versus Tinzaparin in Non-ST-Segment Elevation Acute Coronary Syndromes [summary]. www.cardiosource.com
 267. **Gibson CM**, editor. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study [summary]. www.cardiosource.com
 268. **Gibson CM**, editor. Eptifibatide for Acute Coronary Syndromes—Rapid Versus Late Administration for Therapeutic Yield [summary]. www.cardiosource.com
 269. **Gibson CM**, editor. Estrogen in the Prevention of Atherosclerosis Trial [summary]. www.cardiosource.com
 270. **Gibson CM**, editor. Estudios Cardiológicos Latinoamérica Glucose-Insulin-Potassium Pilot Trial

- [summary]. www.cardiosource.com
271. **Gibson CM**, editor. EUROACTION Trial [summary]. www.cardiosource.com
 272. **Gibson CM**, editor. European Cobalt stent with antiproliferative for restenosis trial [summary]. www.cardiosource.com
 273. **Gibson CM**, editor. European evaLUation of pacliTaxel Eluting Stent [summary]. www.cardiosource.com
 274. **Gibson CM**, editor. European Sirolimus-Eluting Stent in Coronary Lesions [summary]. www.cardiosource.com
 275. **Gibson CM**, editor. European Sonotherapy Trial to Prevent Arterial Hyperplasia [summary]. www.cardiosource.com
 276. **Gibson CM**, editor. European Stroke Treatment With Ancrod Trial (ESTAT) [summary]. www.cardiosource.com
 277. **Gibson CM**, editor. European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis [summary]. www.cardiosource.com
 278. **Gibson CM**, editor. European trial on reduction of cardiac events with perindopril in stable coronary artery disease [summary]. www.cardiosource.com
 279. **Gibson CM**, editor. Evaluation of early versus delayed initiation of simvastatin in patients who receive guideline based treatment for acute coronary syndrome [summary]. www.cardiosource.com
 280. **Gibson CM**, editor. Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function [summary]. www.cardiosource.com
 281. **Gibson CM**, editor. Evaluation of Reopro and Stenting to Eliminate Restenosis [summary]. www.cardiosource.com
 282. **Gibson CM**, editor. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness [summary]. www.cardiosource.com
 283. **Gibson CM**, editor. Exercise in Left Ventricular Dysfunction and Chronic Heart Failure Trial [summary]. www.cardiosource.com
 284. **Gibson CM**, editor. ExPORT [summary]. www.cardiosource.com
 285. **Gibson CM**, editor. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators [summary]. www.cardiosource.com
 286. **Gibson CM**, editor. Ezetimibe Add-on to Statin Therapy for Effectiveness Trial [summary]. www.cardiosource.com
 287. **Gibson CM**, editor. Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia [summary]. www.cardiosource.com
 288. **Gibson CM**, editor. Ezetimibe Coadministered With Atorvastatin in Patients With Primary Hypercholesterolemia [summary]. www.cardiosource.com
 289. **Gibson CM**, editor. Ezetimibe Coadministered With Lovastatin in Patients With Primary Hypercholesterolemia [summary]. www.cardiosource.com
 290. **Gibson CM**, editor. Fatty Acid Antiarrhythmia Trial (FAAT). [summary]. www.cardiosource.com
 291. **Gibson CM**, editor. Feasibility and efficacy of balloon-based neuroprotection during carotid artery stenting in a single-center setting. [summary]. www.cardiosource.com
 292. **Gibson CM**, editor. Federal Study of Adherence to Medications (FAME) [summary]. www.cardiosource.com
 293. **Gibson CM**, editor. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) [summary].

www.cardiosource.com

294. **Gibson CM**, editor. Fibrinolytic Therapy Trialists' Collaborative Group [summary]. www.cardiosource.com
295. **Gibson CM**, editor. FilterWire-Ex as an Adjunct to Primary PCI [summary]. www.cardiosource.com
296. **Gibson CM**, editor. FilterWire EX Randomized Evaluation [summary]. www.cardiosource.com
297. **Gibson CM**, editor. Finnish Diabetes Prevention Study [summary]. www.cardiosource.com
298. **Gibson CM**, editor. First Use To Underscore Restenosis Reduction with Everolimus [summary]. www.cardiosource.com
299. **Gibson CM**, editor. Five year clinical follow-up of the arterial revascularisation therapy study [summary]. www.cardiosource.com
300. **Gibson CM**, editor. Fluvastatin on Risk Diminishing After Acute Myocardial Infarction [summary]. www.cardiosource.com
301. **Gibson CM**, editor. Folate After Coronary Intervention Trial [summary]. www.cardiosource.com
302. **Gibson CM**, editor. Folate Therapy and In-Stent Restenosis After Coronary Stenting [summary]. www.cardiosource.com
303. **Gibson CM**, editor. Folic Acid for Secondary Prevention: Effects on Clinical Outcomes [summary]. www.cardiosource.com
304. **Gibson CM**, editor. Follow-Up Serial Infusions of Nesiritide Trial [summary]. www.cardiosource.com
305. **Gibson CM**, editor. For the Syst-Eur Investigators. The Prevention of Dementia With Antihypertensive Treatment. New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study [summary]. www.cardiosource.com
306. **Gibson CM**, editor. FRagmin and Fast Revascularization during InStability in coronary artery disease [summary]. www.cardiosource.com
307. **Gibson CM**, editor. Fragmin in Unstable Coronary Artery Disease [summary]. www.cardiosource.com
308. **Gibson CM**, editor. Gamma II Localized Radiation Therapy to Inhibit Restenosis [summary]. www.cardiosource.com
309. **Gibson CM**, editor. Gamma V Localized Radiation Therapy to Inhibit Restenosis [summary]. www.cardiosource.com
310. **Gibson CM**, editor. German Cypher Registry [summary]. www.cardiosource.com
311. **Gibson CM**, editor. Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome [summary]. www.cardiosource.com
312. **Gibson CM**, editor. Glucose abnormalities in patients with myocardial infarction: prevalence, diagnosis, and prognostic implications [summary]. www.cardiosource.com
313. **Gibson CM**, editor. Glucose - Insulin - Potassium Study in Patients With ST Elevation Myocardial Infarction Without Signs of Heart Failure [summary]. www.cardiosource.com
314. **Gibson CM**, editor. Glycemic Effects in Diabetes Mellitus: Carvedilol - Metoprolol Comparison in Hypertensives Trial [summary]. www.cardiosource.com
315. **Gibson CM**, editor. Guggulipid for the Treatment of Hypercholesterolemia [summary]. www.cardiosource.com
316. **Gibson CM**, editor. Guidelines Applied in Practice in Medicare Patients With Acute Myocardial Infarction [summary]. www.cardiosource.com

317. **Gibson CM**, editor. HDL-Atherosclerosis Treatment Study [summary]. www.cardiosource.com
318. **Gibson CM**, editor. Heart Disease on the Mend [summary]. www.cardiosource.com
319. **Gibson CM**, editor. Heart Outcomes Prevention Evaluation (HOPE) Infections Substudy [summary]. www.cardiosource.com
320. **Gibson CM**, editor. The Heart Outcomes Prevention Evaluation Study [summary]. www.cardiosource.com
321. **Gibson CM**, editor. Helsinki Heart Study [summary]. www.cardiosource.com
322. **Gibson CM**, editor. Heparin-Coated Stents in Small Coronary Arteries [summary]. www.cardiosource.com
323. **Gibson CM**, editor. Hirulog and Early Reperfusion or Occlusion Trial [summary]. www.cardiosource.com
324. **Gibson CM**, editor. Hirulog Early Reperfusion/Occlusion Trial [summary]. www.cardiosource.com
325. **Gibson CM**, editor. Home or Hospital Heart Failure (HHH) [summary]. www.cardiosource.com
326. **Gibson CM**, editor. Impact of Glucose-Insulin-Potassium on Mortality and Morbidity in Over 20,000 Patients With Acute Myocardial Infarction: The CREATE-ECLA International Trial [summary]. www.cardiosource.com
327. **Gibson CM**, editor. IMPROVE-CHF [summary]. www.cardiosource.com
328. **Gibson CM**, editor. Increased Risk of Arrhythmic Events in Long-QT Syndrome with Mutations in the Pore Region of the Human Ether-a-go-go-Related Gene Potassium Channel [summary]. www.cardiosource.com
329. **Gibson CM**, editor. Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) [summary]. www.cardiosource.com
330. **Gibson CM**, editor. Infarct Size and Mortality After Glucose-Insulin-Potassium Infusion in Primary Angioplasty for Acute Myocardial Infarction [summary]. www.cardiosource.com
331. **Gibson CM**, editor. Initiation Management PredischARGE: Process for Assessment of Carvedilol Therapy in Heart Failure [summary]. www.cardiosource.com
332. **Gibson CM**, editor. International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment [summary]. www.cardiosource.com
333. **Gibson CM**, editor. Intracoronary Beta Irradiation to Reduce Restenosis After Balloon Angioplasty [summary]. www.cardiosource.com
334. **Gibson CM**, editor. Intracoronary Stenting and Angiographic Restenosis: Promote Endothelial Cells With Estradiol (ISAR-PEACE) [summary]. www.cardiosource.com
335. **Gibson CM**, editor. Invasive Strategy Among Women With Non-ST-Elevation Acute Coronary Syndrome [summary]. www.cardiosource.com
336. **Gibson CM**, editor. Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary Artery [summary]. www.cardiosource.com
337. **Gibson CM**, editor. Invasive versus conservative treatment in unstable coronary syndromes [summary]. www.cardiosource.com
338. **Gibson CM**, editor. Investigation of Lipid Level Management using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation (ILLUSTRATE) [summary]. www.cardiosource.com
339. **Gibson CM**, editor. Irbesartan Diabetic Nephropathy Trial [summary]. www.cardiosource.com

340. **Gibson CM**, editor. Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment [summary]. www.cardiosource.com
341. **Gibson CM**, editor. Integrilin and Tenecteplase in Acute Myocardial Infarction [summary]. www.cardiosource.com
342. **Gibson CM**, editor. Integrilin in Acute Myocardial Infarction [summary]. www.cardiosource.com
343. **Gibson CM**, editor. International Verapamil-Trandolapril Study [summary]. www.cardiosource.com
344. **Gibson CM**, editor. Intracoronary Autologous Bone-Marrow Cell Transfer After Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial [summary]. www.cardiosource.com
345. **Gibson CM**, editor. Intracoronary Beta-Blocker During PCI [summary]. www.cardiosource.com
346. **Gibson CM**, editor. Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) [summary]. www.cardiosource.com
347. **Gibson CM**, editor. Intracoronary Stenting and Angiographic results - Strut Thickness Effect on Restenosis Outcome Trial - 2 [summary]. www.cardiosource.com
348. **Gibson CM**, editor. Intracoronary Stenting with Antithrombotic Regimen Cooling-Off [summary]. www.cardiosource.com
349. **Gibson CM**, editor. Intravenous Streptokinase in Acute Myocardial Infarction [summary]. www.cardiosource.com
350. **Gibson CM**, editor. Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics [summary]. www.cardiosource.com
351. **Gibson CM**, editor. ISAR SMART-2 [summary]. www.cardiosource.com
352. **Gibson CM**, editor. Ivabradine in Stable Angina [summary]. www.cardiosource.com
353. **Gibson CM**, editor. JIKEI Heart Study [summary]. www.cardiosource.com
354. **Gibson CM**, editor. Joint utilisation of medications to block platelets optimally [summary]. www.cardiosource.com
355. **Gibson CM**, editor. JUPITER II [summary]. www.cardiosource.com
356. **Gibson CM**, editor. Kuopio Angiogenesis Trial [summary]. www.cardiosource.com
357. **Gibson CM**, editor. KW-3902 in Patients With Acute Decompensated Heart Failure [summary]. www.cardiosource.com
358. **Gibson CM**, editor. Lack of efficacy of clopidogrel pretreatment in the prevention of myocardial damage after elective stent implantation [summary]. www.cardiosource.com
359. **Gibson CM**, editor. Late Thrombosis of Drug-Eluting Stents: A Meta-Analysis [summary]. www.cardiosource.com
360. **Gibson CM**, editor. Lescol Intervention Prevention Study [summary]. www.cardiosource.com
361. **Gibson CM**, editor. Lifestyle Heart Trial [summary]. www.cardiosource.com
362. **Gibson CM**, editor. Late Clinical Events Related to Late Stent Thrombosis After Stopping Clopidogrel (BASKET LATE) [summary]. www.cardiosource.com
363. **Gibson CM**, editor. Limbs International Medical Buflomedil Trial [summary]. www.cardiosource.com
364. **Gibson CM**, editor. Limitation of Myocardial Infarction Following Thrombolysis in Acute [summary]. www.cardiosource.com
365. **Gibson CM**, editor. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of

- Restenosis after Stenting [summary]. www.cardiosource.com
366. **Gibson CM**, editor. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. [summary]. www.cardiosource.com
367. **Gibson CM**, editor. Long-term effect of nifedipine on vasomotion and vessel morphology in patients with coronary artery disease: an intravascular ultrasound-assisted evaluation [summary]. www.cardiosource.com
368. **Gibson CM**, editor. Long-Term Impact of Disease Management in a Large, Diverse Heart Failure Population [summary]. www.cardiosource.com
369. **Gibson CM**, editor. Long-Term Intervention With Pravastatin in Ischemic Disease Trial [summary]. www.cardiosource.com
370. **Gibson CM**, editor. Long-Term Outcomes of Coronary-Artery Bypass Grafting versus Stent Implantation [summary]. www.cardiosource.com
371. **Gibson CM**, editor. Losartan Heart Failure Survival Study [summary]. www.cardiosource.com
372. **Gibson CM**, editor. Losartan Intervention For Endpoint reduction in hypertension (LIFE) study [summary]. www.cardiosource.com
373. **Gibson CM**, editor. Low Blood Pressure and Mortality and Cardiovascular Morbidity in Treated Hypertensive Patients With Coronary Artery Disease [summary]. www.cardiosource.com
374. **Gibson CM**, editor. Low Molecular Weight Heparin (Reviparin) in Preventing Mortality, Reinfarction, and Strokes in Over 15,500 Patients With ST Elevation Acute Myocardial Infarction [summary]. www.cardiosource.com
375. **Gibson CM**, editor. Lower Extremity Arterial Disease Event Reduction Trial [summary]. www.cardiosource.com
376. **Gibson CM**, editor. Lyon Heart Study [summary]. www.cardiosource.com
377. **Gibson CM**, editor. Magnesium in Coronaries [summary]. www.cardiosource.com
378. **Gibson CM**, editor. Maintenance of sinus rhythm with dronedarone in patients with atrial fibrillation or flutter [summary]. www.cardiosource.com
379. **Gibson CM**, editor. Management of Atherothrombosis With Clopidogrel in High-Risk Patients [summary]. www.cardiosource.com
380. **Gibson CM**, editor. Measuring Effects on Intima-Media Thickness: An Evaluation of Rosuvastatin (METEOR) [summary]. www.cardiosource.com
381. **Gibson CM**, editor. Medical Treatment of Myocardial Ischemia in Coronary Artery Disease: effect of Drug Regime and Irregular Dosing in the CAPE II Trial [summary]. www.cardiosource.com
382. **Gibson CM**, editor. Meta-Analysis of Results From Eight Randomized, Placebo-Controlled Trials of the Effect of Cilostazol on Patients With Intermittent Claudication [summary]. www.cardiosource.com
383. **Gibson CM**, editor. Metabolic Efficiency With Ranolazine for Less Ischemia in NSTEMI-ACS (MERLIN TIMI 36) [summary]. www.cardiosource.com
384. **Gibson CM**, editor. Microalbuminuria, Cardiovascular, and Renal Outcomes - Heart Outcomes Prevention Evaluation [summary]. www.cardiosource.com
385. **Gibson CM**, editor. Microalbuminuria Reduction with Valsartan [summary]. www.cardiosource.com
386. **Gibson CM**, editor. Middlesbrough Early Revascularization to Limit Infarction [summary]. www.cardiosource.com
387. **Gibson CM**, editor. Migraine Intervention with STARFlex Technology [summary]. www.cardiosource.com

388. **Gibson CM**, editor. Mode Selection Trial (MOST) in sinus node dysfunction [summary]. www.cardiosource.com
389. **Gibson CM**, editor. Moderate vs. High-Intensity Warfarin for Prevention of Recurrent Thrombosis [summary]. www.cardiosource.com
390. **Gibson CM**, editor. Modification of Diet in Renal Disease Study [summary]. www.cardiosource.com
391. **Gibson CM**, editor. Morbidity and Mortality Following Early Administration of Amiodarone in Myocardial Infarction [summary]. www.cardiosource.com
392. **Gibson CM**, editor. Mortality Assessment in Congestive Heart Failure Trial [summary]. www.cardiosource.com
393. **Gibson CM**, editor. Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction. GUSTO V Randomized Trial [summary]. www.cardiosource.com
394. **Gibson CM**, editor. MRC/BHF Heart Protection Study of Antioxidant Vitamin Supplementation in 20,536 High-risk Individuals: A Randomised Placebo-controlled Trial. [summary]. www.cardiosource.com
395. **Gibson CM**, editor. The Multicenter Aneurysm Screening Study (MASS) into the Effect of Abdominal Aortic Aneurysm Screening on Mortality in Men: A Randomized Controlled Trial [summary]. www.cardiosource.com
396. **Gibson CM**, editor. Multicenter Automatic Defibrillator Implantation Trial II [summary]. www.cardiosource.com
397. **Gibson CM**, editor. Multicenter InSync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation [summary]. www.cardiosource.com
398. **Gibson CM**, editor. Multicenter InSync Randomized Clinical Evaluation [summary]. www.cardiosource.com
399. **Gibson CM**, editor. Multicenter Post-Infarction Program [summary]. www.cardiosource.com
400. **Gibson CM**, editor. Multicenter Prospective Nonrandomized Registry Study for Drug-Eluting Stents in Very Long Coronary Lesions (Cypher vs Taxus) [summary]. www.cardiosource.com
401. **Gibson CM**, editor. Multisite pacing as a supplemental treatment of congestive heart failure: the Medtronic Inc. InSync Study [summary]. www.cardiosource.com
402. **Gibson CM**, editor. Myocardial Perfusion Imaging for Evaluation and Triage of Patients with Suspected Acute Cardiac Ischemia: A Randomized Controlled Trial [summary]. www.cardiosource.com
403. **Gibson CM**, editor. Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand-Alone Procedure in Post-Myocardial Infarction Chronic Heart Failure Patients [summary]. www.cardiosource.com
404. **Gibson CM**, editor. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty [summary]. www.cardiosource.com
405. **Gibson CM**, editor. Na⁺/H⁺ Exchange Inhibition to Prevent Coronary Events in Acute Cardiac Conditions [summary]. www.cardiosource.com
406. **Gibson CM**, editor. Nephrotoxicity in High-Risk Patients Study of IsoOsmolar and Low-Osmolar Non-Ionic Contrast Media Study [summary]. www.cardiosource.com
407. **Gibson CM**, editor. Nordic Diltiazem Study [summary]. www.cardiosource.com
408. **Gibson CM**, editor. North American Vasovagal Pacemaker Study [summary]. www.cardiosource.com
409. **Gibson CM**, editor. Nurse Management for Heart Failure [summary]. www.cardiosource.com
410. **Gibson CM**, editor. Nut and Peanut Butter Consumption and Risk of Type 2 Diabetes in Women

- [summary]. www.cardiosource.com
411. **Gibson CM**, editor. OASIS-6—Glucose-Insulin-Potassium (Oasis-6—GIK) [summary]. www.cardiosource.com
 412. **Gibson CM**, editor. The Occluded Artery Trial [summary]. www.cardiosource.com
 413. **Gibson CM**, editor. oEstrogen in the Prevention of ReInfarction Trial [summary]. www.cardiosource.com
 414. **Gibson CM**, editor. The Olmsted Community Project [summary]. www.cardiosource.com
 415. **Gibson CM**, editor. Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events [summary]. www.cardiosource.com
 416. **Gibson CM**, editor. Omega-3 Fatty Acid Therapy in Patients With Ventricular Tachyarrhythmias [summary]. www.cardiosource.com
 417. **Gibson CM**, editor. Ongoing Tirofiban in Myocardial Infarction Evaluation Trial [summary]. www.cardiosource.com
 418. **Gibson CM**, editor. Ontario Prehospital Advanced Life Support [summary]. www.cardiosource.com
 419. **Gibson CM**, editor. Optimal Coronary Balloon Angioplasty With Provisional Stenting vs. Stent Trial [summary]. www.cardiosource.com
 420. **Gibson CM**, editor. Optimal Pharmacological Therapy in Implantable Cardioverter Defibrillator Patients Trial [summary]. www.cardiosource.com
 421. **Gibson CM**, editor. Oral Rapamycin for Recalcitrant Restenosis [summary]. www.cardiosource.com
 422. **Gibson CM**, editor. Oral Sirolimus to Inhibit Recurrent In-Stent Stenosis [summary]. www.cardiosource.com
 423. **Gibson CM**, editor. Oral Treatment of Restenosis [summary]. www.cardiosource.com
 424. **Gibson CM**, editor. ORBIT [summary]. www.cardiosource.com
 425. **Gibson CM**, editor. Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) [summary]. www.cardiosource.com
 426. **Gibson CM**, editor. Pacemaker Selection in the Elderly [summary]. www.cardiosource.com
 427. **Gibson CM**, editor. The Pacing Therapies for Congestive Heart Failure (PATH-CHF) Study [summary]. www.cardiosource.com
 428. **Gibson CM**, editor. Paclitaxel and sirolimus stents in the real world of interventional cardiology [summary]. www.cardiosource.com
 429. **Gibson CM**, editor. Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent for the Prevention of Restenosis in Diabetic Patients With Coronary Artery Disease [summary]. www.cardiosource.com
 430. **Gibson CM**, editor. Paclitaxel-eluting stents in the treatment of longer lesions. Focus on patients with diabetes [summary]. www.cardiosource.com
 431. **Gibson CM**, editor. Percutaneous Coronary Intervention Among Patients Treated With Enoxaparin Versus Unfractionated Heparin Following Fibrinolytic Administration for ST-Elevation MI (PC1-EXTRACT-TIMI 25) [summary]. www.cardiosource.com
 432. **Gibson CM**, editor. Percutaneous Laser Myocardial Revascularization [summary]. www.cardiosource.com
 433. **Gibson CM**, editor. Percutaneous Transvenous Transplantation of Autologous Myoblasts in the Treatment of Postinfarction Heart Failure [summary]. www.cardiosource.com
 434. **Gibson CM**, editor. Perindopril for Elderly People With Chronic Heart Failure (PEP-CHF) [summary].

www.cardiosource.com

435. **Gibson CM**, editor. Perindopril Protection against Recurrent Stroke Study [summary]. www.cardiosource.com
436. **Gibson CM**, editor. Perindopril Substudy in Coronary Artery Disease and Diabetes: the Diabetic Substudy of EUROPA [summary]. www.cardiosource.com
437. **Gibson CM**, editor. Perindopril, thrombosis, inflammation, endothelial dysfunction, and neurohormonal activation trial, a subanalysis of EUROPA [summary]. www.cardiosource.com
438. **Gibson CM**, editor. Peripheral Arteries Radiation Investigational Study [summary]. www.cardiosource.com
439. **Gibson CM**, editor. Perth Community Stroke Study [summary]. www.cardiosource.com
440. **Gibson CM**, editor. Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft Surgery Study [summary]. www.cardiosource.com
441. **Gibson CM**, editor. Pioglitazone Reduces Neointima Formation After Coronary Stent Implantation [summary]. www.cardiosource.com
442. **Gibson CM**, editor. PLAATO [summary]. www.cardiosource.com
443. **Gibson CM**, editor. Plasminogen Activator-Angioplasty Compatibility Trial [summary]. www.cardiosource.com
444. **Gibson CM**, editor. Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network [summary]. www.cardiosource.com
445. **Gibson CM**, editor. Platelet activity Extinction in non-Q-wave myocardial infarction with Aspirin, Clopidogrel, and Eptifibatide [summary]. www.cardiosource.com
446. **Gibson CM**, editor. Policosanol and Lipid Levels [summary]. www.cardiosource.com
447. **Gibson CM**, editor. Postmenopausal Estrogen/Progestin Interventions [summary]. www.cardiosource.com
448. **Gibson CM**, editor. PRAGUE 2 [summary]. www.cardiosource.com
449. **Gibson CM**, editor. PRAGUE 4 [summary]. www.cardiosource.com
450. **Gibson CM**, editor. PRAGUE 8 [summary]. www.cardiosource.com
451. **Gibson CM**, editor. Pravastatin in Acute Coronary Treatment [summary]. www.cardiosource.com
452. **Gibson CM**, editor. Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 [summary]. www.cardiosource.com
453. **Gibson CM**, editor. Prehospital Thrombolytic Therapy in Patients With Suspected Acute Myocardial Infarction [summary]. www.cardiosource.com
454. **Gibson CM**, editor. PREMIER [summary]. www.cardiosource.com
455. **Gibson CM**, editor. Preprocedural Statin Medication Reduces the Extent of Periprocedural Non-Q-Wave Myocardial Infarction [summary]. www.cardiosource.com
456. **Gibson CM**, editor. Prevention of Events With Angiotensin-Converting Enzyme Inhibition Trial [summary]. www.cardiosource.com
457. **Gibson CM**, editor. Prevention of ischaemic events by early treatment of cerivastatin after acute myocardial infarction [summary]. www.cardiosource.com
458. **Gibson CM**, editor. Prevention of Recurrent Venous Thromboembolism [summary]. www.cardiosource.com
459. **Gibson CM**, editor. Prevention of Renal and Vascular End-stage Disease Intervention Trial [summary].

www.cardiosource.com

460. **Gibson CM**, editor. Prevention of Syncope Trial [summary]. www.cardiosource.com
461. **Gibson CM**, editor. Primary Optimal Percutaneous Coronary Intervention versus Facilitated Intervention in STEMI patients [summary]. www.cardiosource.com
462. **Gibson CM**, editor. PROactive, Prospective Pioglitazone Clinical Trial in Macrovascular Events [summary]. www.cardiosource.com
463. **Gibson CM**, editor. Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health [summary]. www.cardiosource.com
464. **Gibson CM**, editor. PROject of Ex-Vivo vein graft ENGINEering via Transfection (PREVENT IV) [summary]. www.cardiosource.com
465. **Gibson CM**, editor. Propensity Analysis of Long-Term Survival After Surgical or Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease and High-Risk Features [summary]. www.cardiosource.com
466. **Gibson CM**, editor. Prophylactic Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valvular Repair or Replacement [summary]. www.cardiosource.com
467. **Gibson CM**, editor. Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients Trial [summary]. www.cardiosource.com
468. **Gibson CM**, editor. Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure [summary]. www.cardiosource.com
469. **Gibson CM**, editor. PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) [summary]. www.cardiosource.com
470. **Gibson CM**, editor. Prospective Randomized Amlodipine Survival Evaluation-1 [summary]. www.cardiosource.com
471. **Gibson CM**, editor. Prospective Randomized Amlodipine Survival Evaluation-2 [summary]. www.cardiosource.com
472. **Gibson CM**, editor. Prospective Randomized Multi-Center Head-to-Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus) [summary]. www.cardiosource.com
473. **Gibson CM**, editor. Prospective Randomized Trial of Thromboatherectomy With the X-Sizer in Native Coronary Arteries and Saphenous Vein Grafts [summary]. www.cardiosource.com
474. **Gibson CM**, editor. Prospective Study of Pravastatin in the Elderly at Risk [summary]. www.cardiosource.com
475. **Gibson CM**, editor. Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage of Endangered Myocardium Study [summary]. www.cardiosource.com
476. **Gibson CM**, editor. Public Access Defibrillation Trial [summary]. www.cardiosource.com
477. **Gibson CM**, editor. Quinapril Anti-Ischemia and Symptoms of Angina Reduction [summary]. www.cardiosource.com
478. **Gibson CM**, editor. Racial Differences in Benefits of ACE Inhibitors in Hypertension: ALLHAT Substudy [summary]. www.cardiosource.com
479. **Gibson CM**, editor. Radial Artery Patency Study [summary]. www.cardiosource.com
480. **Gibson CM**, editor. Raloxifene Use for The Heart (RUTH) [summary]. www.cardiosource.com
481. **Gibson CM**, editor. Rancho Bernardo Study: Lipid substudy [summary]. www.cardiosource.com

482. **Gibson CM**, editor. Randomized Aldactone Evaluation Study [summary]. www.cardiosource.com
483. **Gibson CM**, editor. Randomized Angioplasty Beta-Blocker Intracoronary Trial II (RABBIT II) [summary]. www.cardiosource.com
484. **Gibson CM**, editor. Randomized Comparison of Off-Pump and On-Pump Multivessel Coronary-Artery Bypass Surgery [summary]. www.cardiosource.com
485. **Gibson CM**, editor. Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary Lesions (LOBG DES II) [summary]. www.cardiosource.com
486. **Gibson CM**, editor. Randomized Comparison of the Endeavor ABT-578 Drug Eluting Stent With a Bare Metal Stent for Coronary Revascularization [summary]. www.cardiosource.com
487. **Gibson CM**, editor. Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAX-AMI) [summary]. www.cardiosource.com
488. **Gibson CM**, editor. Randomized Etanercept North American Strategy to Study Antagonism of Cytokines [summary]. www.cardiosource.com
489. **Gibson CM**, editor. Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [summary]. www.cardiosource.com
490. **Gibson CM**, editor. Randomized Evaluation of Polytetrafluoroethylene-Covered Stent in Saphenous Vein Grafts [summary]. www.cardiosource.com
491. **Gibson CM**, editor. Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot [summary]. www.cardiosource.com
492. **Gibson CM**, editor. Randomized Evaluation of the Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in Primary and Rescue Angioplasty [summary]. www.cardiosource.com
493. **Gibson CM**, editor. Randomized Intravenous Tezosentan Study [summary]. www.cardiosource.com
494. **Gibson CM**, editor. Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention Trial [summary]. www.cardiosource.com
495. **Gibson CM**, editor. Randomized, Placebo-Controlled Trial of Adding Clopidogrel to Aspirin in 46,000 Acute Myocardial Infarction Patients [summary]. www.cardiosource.com
496. **Gibson CM**, editor. Randomized, Placebo-Controlled Trial of Early Metoprolol in 46,000 Acute Myocardial Infarction Patients [summary]. www.cardiosource.com
497. **Gibson CM**, editor. Randomized trial comparing stenting within 24 hours of thrombolysis versus ischemia-guided approach to thrombolysed acute myocardial infarction with ST elevation [summary]. www.cardiosource.com
498. **Gibson CM**, editor. Randomized Trial of 90Sr/90Y beta-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis [summary]. www.cardiosource.com
499. **Gibson CM**, editor. Randomized trial of a conservative treatment strategy versus an interventional treatment strategy in patients with unstable angina [summary]. www.cardiosource.com
500. **Gibson CM**, editor. Randomized Trial of an Education and Support Intervention to Prevent Readmission of Patients with Heart Failure [summary]. www.cardiosource.com
501. **Gibson CM**, editor. Randomized trial of glucose-insulin-potassium infusion on 30 day mortality in patients with acute myocardial infarction treated with primary angioplasty [summary]. www.cardiosource.com
502. **Gibson CM**, editor. Randomized trial of occluded artery angioplasty after acute myocardial infarction [summary]. www.cardiosource.com

503. **Gibson CM**, editor. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis [summary]. www.cardiosource.com
504. **Gibson CM**, editor. Randomized Trial of Telephone Intervention in Chronic Heart Failure [summary]. www.cardiosource.com
505. **Gibson CM**, editor. Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCA Ischemia Among Anti-Platelet and Anti-Thrombotic Agents [summary]. www.cardiosource.com
506. **Gibson CM**, editor. Ranolazine Versus Atenolol for Chronic Angina Pectoris [summary]. www.cardiosource.com
507. **Gibson CM**, editor. Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital Registry [summary]. www.cardiosource.com
508. **Gibson CM**, editor. Rapid Ambulation After Closure [summary]. www.cardiosource.com
509. **Gibson CM**, editor. Rapid Emergency Department Heart Failure Outpatient Trial [summary]. www.cardiosource.com
510. **Gibson CM**, editor. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation [summary]. www.cardiosource.com
511. **Gibson CM**, editor. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation [summary]. www.cardiosource.com
512. **Gibson CM**, editor. Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE 1) [summary]. www.cardiosource.com
513. **Gibson CM**, editor. Reduction in Acute MI After the Implementation of a Comprehensive Smokefree Ordinance [summary]. www.cardiosource.com
514. **Gibson CM**, editor. Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease [summary]. www.cardiosource.com
515. **Gibson CM**, editor. Registry Novoste [summary]. www.cardiosource.com
516. **Gibson CM**, editor. Registry of Clopidogrel Use and Long-Term Clinical Outcomes After Drug-Eluting Stent Implantation [summary]. www.cardiosource.com
517. **Gibson CM**, editor. Relationship Between Baseline White Blood Cell Count and Degree of Coronary Artery Disease and Mortality in Patients with Acute Coronary Syndromes [summary]. www.cardiosource.com
518. **Gibson CM**, editor. ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients with Peripheral Arterial Disease (RIO-Trial) [summary]. www.cardiosource.com
519. **Gibson CM**, editor. Reopro And Primary PTCA Organization and Randomized Trial [summary]. www.cardiosource.com
520. **Gibson CM**, editor. Rescue Angioplasty Versus Conservative Therapy or Repeat Thrombolysis Trial [summary]. www.cardiosource.com
521. **Gibson CM**, editor. Research Into Etanercept Cytokine Antagonism in Ventricular Dysfunction [summary]. www.cardiosource.com
522. **Gibson CM**, editor. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial [summary]. www.cardiosource.com
523. **Gibson CM**, editor. Resynchronization for the HemodyNamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) [summary]. www.cardiosource.com
524. **Gibson CM**, editor. Reversing Atherosclerosis With Aggressive Lipid Lowering [summary].

www.cardiosource.com

- 525. **Gibson CM**, editor. REVIVE II [summary]. www.cardiosource.com
- 526. **Gibson CM**, editor. Rimonabant in Obesity [summary]. www.cardiosource.com
- 527. **Gibson CM**, editor. Rimonabant on Weight Reduction and Weight Maintenance: RIO-NORTH AMERICA [summary]. www.cardiosource.com
- 528. **Gibson CM**, editor. RIO-Diabetes [summary]. www.cardiosource.com
- 529. **Gibson CM**, editor. RIO-Diabetes [summary]. www.cardiosource.com
- 530. **Gibson CM**, editor. Risk Score for Predicting Stroke or Death in New-Onset Atrial Fibrillation Patients: The Framingham Heart Study [summary]. www.cardiosource.com
- 531. **Gibson CM**, editor. Role of Drinking Pattern and Type of Alcohol Consumed in Coronary Heart Disease [summary]. www.cardiosource.com
- 532. **Gibson CM**, editor. ROXithromycin in non-Q wave coronary Syndromes [summary]. www.cardiosource.com
- 533. **Gibson CM**, editor. Safety and Efficacy of Pravastatin 40 mg, 80 mg, and 160 mg per Day [summary]. www.cardiosource.com
- 534. **Gibson CM**, editor. Safety of Concomitant Therapy with Eptifibatide and Enoxaparin in Patients Undergoing Percutaneous Coronary Intervention: Results of the Coronary Revascularization using Integrilin and Single Bolus Enoxaparin Study. [summary]. www.cardiosource.com
- 535. **Gibson CM**, editor. The Saphenous vein graft Angioplasty Free of Emboli Randomized trial [summary]. www.cardiosource.com
- 536. **Gibson CM**, editor. SASTRE [summary]. www.cardiosource.com
- 537. **Gibson CM**, editor. Scandinavian Simvastatin Survival Study Group [summary]. www.cardiosource.com
- 538. **Gibson CM**, editor. SCD-HeFT Cost-Effectiveness Study [summary]. www.cardiosource.com
- 539. **Gibson CM**, editor. Scottish Aortic Stenosis and Lipid Lowering Trial [summary]. www.cardiosource.com
- 540. **Gibson CM**, editor. Scripps Coronary Radiation To Inhibit Proliferation Post Stenting [summary]. www.cardiosource.com
- 541. **Gibson CM**, editor. Scripps Coronary Radiation to Inhibit Proliferation Post Stenting II [summary]. www.cardiosource.com
- 542. **Gibson CM**, editor. Scripps Coronary Radiation to Inhibit Proliferation Post Stenting III [summary]. www.cardiosource.com
- 543. **Gibson CM**, editor. Scripps Coronary Radiation to Inhibit Proliferation Post Stenting IV [summary]. www.cardiosource.com
- 544. **Gibson CM**, editor. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy in Heart Failure [summary]. www.cardiosource.com
- 545. **Gibson CM**, editor. Secondary Prevention Beyond Walls Intervention Trial in Women [summary]. www.cardiosource.com
- 546. **Gibson CM**, editor. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina [summary]. www.cardiosource.com
- 547. **Gibson CM**, editor. Shanghai Trial Of Nifedipine in the Elderly [summary]. www.cardiosource.com
- 548. **Gibson CM**, editor. Shock Inhibition Evaluation With Azimilide [summary]. www.cardiosource.com
- 549. **Gibson CM**, editor. Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions

- [summary]. www.cardiosource.com
550. **Gibson CM**, editor. SIMPLE SVG [summary]. www.cardiosource.com
551. **Gibson CM**, editor. Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction [summary]. www.cardiosource.com
552. **Gibson CM**, editor. Sirolimus-Eluting Stent and a Standard Stent in the Prevention of Restenosis in Small Coronary Arteries [summary]. www.cardiosource.com
553. **Gibson CM**, editor. Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization [summary]. www.cardiosource.com
554. **Gibson CM**, editor. Sirolimus-Eluting Stent in Coronary Lesions [summary]. www.cardiosource.com
555. **Gibson CM**, editor. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease [summary]. www.cardiosource.com
556. **Gibson CM**, editor. Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions [summary]. www.cardiosource.com
557. **Gibson CM**, editor. Sirolimus in De Novo Heart Transplant Recipients [summary]. www.cardiosource.com
558. **Gibson CM**, editor. Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction (SESAMI) [summary]. www.cardiosource.com
559. **Gibson CM**, editor. Smoking Cessation in Smokers Motivated to Quit [summary]. www.cardiosource.com
560. **Gibson CM**, editor. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial [summary]. www.cardiosource.com
561. **Gibson CM**, editor. Sotalol versus propafenone for long-term maintenance of normal sinus rhythm [summary]. www.cardiosource.com
562. **Gibson CM**, editor. Southwest German Interventional Study in Acute Myocardial Infarction [summary]. www.cardiosource.com
563. **Gibson CM**, editor. Specialized Primary and Networked Care in Heart Failure [summary]. www.cardiosource.com
564. **Gibson CM**, editor. SPIRIT [summary]. www.cardiosource.com
565. **Gibson CM**, editor. SPIRIT II [summary]. www.cardiosource.com
566. **Gibson CM**, editor. SPIRIT III [summary]. www.cardiosource.com
567. **Gibson CM**, editor. Sr90 Treatment of Angiographic Restenosis [summary]. www.cardiosource.com
568. **Gibson CM**, editor. St. Francis Heart Study - Natural History [summary]. www.cardiosource.com
569. **Gibson CM**, editor. Statin Administration Before Percutaneous Coronary Intervention [summary]. www.cardiosource.com
570. **Gibson CM**, editor. STEALTH [summary]. www.cardiosource.com
571. **Gibson CM**, editor. Steno 2 Study [summary]. www.cardiosource.com
572. **Gibson CM**, editor. Stent Primary Angioplasty in MI [summary]. www.cardiosource.com
573. **Gibson CM**, editor. Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy [summary]. www.cardiosource.com
574. **Gibson CM**, editor. Stenting of Coronary Arteries in Non Stress/Benestent Disease Trial [summary]. www.cardiosource.com

575. **Gibson CM**, editor. Stent or Angioplasty After Recanalization of Chronic Coronary Occlusions Trial [summary]. www.cardiosource.com
576. **Gibson CM**, editor. Stent or PTCA for Occluded Coronary Arteries in Patients With Acute MI [summary]. www.cardiosource.com
577. **Gibson CM**, editor. Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy (SPACE) [summary]. www.cardiosource.com
578. **Gibson CM**, editor. STents IN Grafts [summary]. www.cardiosource.com
579. **Gibson CM**, editor. Strategies of Treatment of Atrial Fibrillation [summary]. www.cardiosource.com
580. **Gibson CM**, editor. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) [summary]. www.cardiosource.com
581. **Gibson CM**, editor. Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation [summary]. www.cardiosource.com
582. **Gibson CM**, editor. Strong Heart Study [summary]. www.cardiosource.com
583. **Gibson CM**, editor. Study of Cardiovascular Risk Intervention by Pharmacists [summary]. www.cardiosource.com
584. **Gibson CM**, editor. Study of effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure [summary]. www.cardiosource.com
585. **Gibson CM**, editor. Study of Patients Intolerant of Converting Enzyme Inhibitors [summary]. www.cardiosource.com
586. **Gibson CM**, editor. Study to COmpare REstenosis Rate between QueST and QuaDDS-QP2 [summary]. www.cardiosource.com
587. **Gibson CM**, editor. Study TO Prevent Noninsulin Dependent Diabetes Mellitus trial [summary]. www.cardiosource.com
588. **Gibson CM**, editor. Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism [summary]. www.cardiosource.com
589. **Gibson CM**, editor. Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) [summary]. www.cardiosource.com
590. **Gibson CM**, editor. Sudden Cardiac Death in Heart Failure Trial [summary]. www.cardiosource.com
591. **Gibson CM**, editor. Superior Yield of the New strategy of Enoxaparin, Revascularization, and GLYcoprotein IIb/IIIa inhibitors [summary]. www.cardiosource.com
592. **Gibson CM**, editor. Surgical Management of Arterial Revascularization Therapies [summary]. www.cardiosource.com
593. **Gibson CM**, editor. Surgical Treatments for Ischemic Heart Failure [summary]. www.cardiosource.com
594. **Gibson CM**, editor. Survival and Prognosis: Investigation of Crataegus Extract WS 1442 in CHF (SPICE) [summary]. www.cardiosource.com
595. **Gibson CM**, editor. Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE-W) [summary]. www.cardiosource.com
596. **Gibson CM**, editor. SVG WRIST [summary]. www.cardiosource.com
597. **Gibson CM**, editor. Swedish Trial in Old Patients with Hypertension [summary]. www.cardiosource.com
598. **Gibson CM**, editor. Swedish Trial in Old Patients with Hypertension-2 [summary]. www.cardiosource.com

599. **Gibson CM**, editor. Switching from Lovenox to Angiomax in patients with acute coronary syndromes without ST elevation undergoing PCI [summary]. www.cardiosource.com
600. **Gibson CM**, editor. Syncope Evaluation in the Emergency Department Study [summary]. www.cardiosource.com
601. **Gibson CM**, editor. Systolic Hypertension in China Trial [summary]. www.cardiosource.com
602. **Gibson CM**, editor. Systolic Hypertension in Elderly Program [summary]. www.cardiosource.com
603. **Gibson CM**, editor. T-Wave Alternans in Congestive Heart Failure [summary]. www.cardiosource.com
604. **Gibson CM**, editor. T-Wave Alternans in Patients With Heart Failure (ALPHA) [summary]. www.cardiosource.com
605. **Gibson CM**, editor. TAXUS I [summary]. www.cardiosource.com
606. **Gibson CM**, editor. TAXUS II [summary]. www.cardiosource.com
607. **Gibson CM**, editor. TAXUS IV- 2 Year Data [summary]. www.cardiosource.com
608. **Gibson CM**, editor. TAXUS IV Angiographic Study [summary]. www.cardiosource.com
609. **Gibson CM**, editor. TAXUS V [summary]. www.cardiosource.com
610. **Gibson CM**, editor. TAXUS VI [summary]. www.cardiosource.com
611. **Gibson CM**, editor. Telemonitoring for heart failure: Patient characteristics and first results [summary]. www.cardiosource.com
612. **Gibson CM**, editor. Therapeutic Angiogenesis for Patients with Limb Ischaemia by Autologous Transplantation of Bone-Marrow Cells:A Pilot Study and a Randomized Controlled Trial. [summary]. www.cardiosource.com
613. **Gibson CM**, editor. Thrombin Inhibitor in Venous Thromboembolism [summary]. www.cardiosource.com
614. **Gibson CM**, editor. Thrombin Inhibitor in Venous Thromboembolism III [summary]. www.cardiosource.com
615. **Gibson CM**, editor. Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9A Trial [summary]. www.cardiosource.com
616. **Gibson CM**, editor. Thrombolysis in Cardiac Arrest [summary]. www.cardiosource.com
617. **Gibson CM**, editor. Tilarginine Acetate Injection in a Randomized International Study in Unstable MI Patients With Cardiogenic Shock (TRIUMPH) [summary]. www.cardiosource.com
618. **Gibson CM**, editor. Tirofiban Given in the Emergency Room before Primary Angioplasty [summary]. www.cardiosource.com
619. **Gibson CM**, editor. TNK-Tissue Plasminogen Activator Compared With Front-Loaded Tissue Plasminogen Activator in Acute Myocardial Infarction [summary]. www.cardiosource.com
620. **Gibson CM**, editor. Total Ischemic Burden Bisoprolol Study [summary]. www.cardiosource.com
621. **Gibson CM**, editor. Total Occlusion Post-Myocardial Infarction Intervention Study [summary]. www.cardiosource.com
622. **Gibson CM**, editor. Total Occlusion Study of Canada [summary]. www.cardiosource.com
623. **Gibson CM**, editor. Treating to New Targets Study [summary]. www.cardiosource.com
624. **Gibson CM**, editor. Treatment of Enoxaparin and Tirofiban in Acute Myocardial Infarction [summary]. www.cardiosource.com
625. **Gibson CM**, editor. Treatment of Hypertension Based on Home or Office Blood Pressure [summary].

www.cardiosource.com

626. **Gibson CM**, editor. Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons [summary]. www.cardiosource.com
627. **Gibson CM**, editor. Treatment of Mild Hypertension Study [summary]. www.cardiosource.com
628. **Gibson CM**, editor. Trial of Invasive versus Medical Therapy in the Elderly [summary]. www.cardiosource.com
629. **Gibson CM**, editor. Trial of Preventing Hypertension (TROPHY) [summary]. www.cardiosource.com
630. **Gibson CM**, editor. Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated With Angioplasty (TYPHOON) [summary]. www.cardiosource.com
631. **Gibson CM**, editor. United Kingdom Pacing and Cardiovascular Events [summary]. www.cardiosource.com
632. **Gibson CM**, editor. United Kingdom Prospective Diabetes Study [summary]. www.cardiosource.com
633. **Gibson CM**, editor. Urokinasi per via Sistemica nell'Infarto Miocardico [summary]. www.cardiosource.com
634. **Gibson CM**, editor. US Physicians Health Study [summary]. www.cardiosource.com
635. **Gibson CM**, editor. VA Coronary Artery Bypass Surgery Cooperative Study Group [summary]. www.cardiosource.com
636. **Gibson CM**, editor. Valsartan in Acute Myocardial Infarction Trial Investigators [summary]. www.cardiosource.com
637. **Gibson CM**, editor. VALsartan In Diastolic Dysfunction (VALIDD) [summary]. www.cardiosource.com
638. **Gibson CM**, editor. Valsartan Antihypertensive Long-Term Use Evaluation [summary]. www.cardiosource.com
639. **Gibson CM**, editor. Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies [summary]. www.cardiosource.com
640. **Gibson CM**, editor. Varenicline in Smoking Cessation Therapy [summary]. www.cardiosource.com
641. **Gibson CM**, editor. Varenicline vs Placebo on Smoking Cessation [summary]. www.cardiosource.com
642. **Gibson CM**, editor. Vascular Basis for the Treatment of Myocardial Ischemia Study [summary]. www.cardiosource.com
643. **Gibson CM**, editor. Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis [summary]. www.cardiosource.com
644. **Gibson CM**, editor. Vasodilation in the Management of Acute Congestive Heart Failure [summary]. www.cardiosource.com
645. **Gibson CM**, editor. Vasovagal Pacemaker Study II [summary]. www.cardiosource.com
646. **Gibson CM**, editor. Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure [summary]. www.cardiosource.com
647. **Gibson CM**, editor. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial [summary]. www.cardiosource.com
648. **Gibson CM**, editor. Veterans Affairs (VA) Non-Q-Wave Infarction Strategies In-Hospital [summary]. www.cardiosource.com
649. **Gibson CM**, editor. Warfarin Antiplatelet Vascular Evaluation (WAVE) [summary]. www.cardiosource.com

650. **Gibson CM**, editor. Warfarin and Antiplatelet Trial in Chronic Heart Failure [summary]. www.cardiosource.com
651. **Gibson CM**, editor. Warfarin, aspirin, or both after myocardial infarction [summary]. www.cardiosource.com
652. **Gibson CM**, editor. Washington Radiation for In-Stent restenosis Trial [summary]. www.cardiosource.com
653. **Gibson CM**, editor. Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorders [summary]. www.cardiosource.com
654. **Gibson CM**, editor. Western Norway B-Vitamin Intervention Trial (WENBIT) [summary]. www.cardiosource.com
655. **Gibson CM**, editor. Women's Angiographic Vitamin and Estrogen Trial [summary]. www.cardiosource.com
656. **Gibson CM**, editor. Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS) [summary]. www.cardiosource.com
657. **Gibson CM**, editor. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial [summary]. www.cardiosource.com
658. **Gibson CM**, editor. Women's Health Initiative [summary]. www.cardiosource.com
659. **Gibson CM**, editor. Women's Health Study: Low-Dose Aspirin in Primary Prevention [summary]. www.cardiosource.com
660. **Gibson CM**, editor. Women's Health Study: Vitamin E in Primary Prevention [summary]. www.cardiosource.com
661. **Gibson CM**, editor. Women's Initiative for Nonsmoking [summary]. www.cardiosource.com
662. **Gibson CM**, editor. Women's Ischemia Syndrome Evaluation [summary]. www.cardiosource.com
663. **Gibson CM**, editor. WOSCOPS Lipoprotein-Associated Phospholipase Substudy [summary]. www.cardiosource.com
664. **Gibson CM**, editor. X-SIZER in Acute Myocardial Infarction Patients for Negligible Embolization and Optimal ST Resolution [summary]. www.cardiosource.com
665. **Gibson CM**, editor. Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease (ZOMAXX I) [summary]. www.cardiosource.com
666. **Gibson CM**, McCormick I, Smeglin A, Pinto D, Bigelow, BC. "Angulation and Tortuosity." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
667. **Gibson CM**, Anagnostopoulos AM, Leder DM. "Anticoagulation During STEMI and PCI." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
668. **Gibson CM**, Battaglia L, Yang X. "Bifurcation Lesions." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
669. **Gibson CM**, Mafí JN, Harada RK, Tu T, Bigelow BC. "Calcified Plaque." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
670. **Gibson CM**, Yang X, Pinto D, Bigelow BC. "Coronary Artery Perforation." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc.,

New York, NY; (In press) 2010.

671. **Gibson CM**, Choi JC, Chaparro F, Leder DM. "Coronary Vasospasm." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
672. **Gibson CM**, Harada RK. "Chronic Total Occlusions." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
673. **Gibson CM**, Chaparro F, Leder DM, Bigelow BC. "Diabetes Mellitus." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
674. **Gibson CM**, Gheewala NM, Smeglin A. "Left Main Intervention." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
675. **Gibson CM**, Khanna V, Smeglin A, Bigelow BC. "Management of the Thrombotic Lesion." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
676. **Gibson CM**, Gheewala NM, Harada RK, Bigelow BC. "Multivessel Coronary Artery Disease." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
677. **Gibson CM**, Giuseffi J, Leder DM. "No Reflow and Slow Flow." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
678. **Gibson CM**, Leder DM. "Ostial Coronary Lesions." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
679. **Gibson CM**, Zucker A, Leder DM, Bigelow BC. "Renal Failure in Interventional Cardiology." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
680. **Gibson CM**, Nasrallah L, Leder DM, Bigelow BC. "Restenosis." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
681. **Gibson CM**, Choi JC, Yang X. "Saphenous Vein Grafts." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
682. **Gibson CM**, Bello N, Leder DM. "Secondary Prevention of Coronary Artery Disease." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
683. **Gibson CM**, Anagnostopoulos AM, Leder DM, Lorenz D, Bigelow BC. "ST Elevation Myocardial Infarction." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
684. **Gibson CM**, Leder DM, Bigelow BC. "Treatment of Distal Anastomotic Lesions." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.
685. **Gibson CM**, York M, Leder DM. "Unstable Angina: Percutaneous Intervention." In: *Gibson's Treatment Strategies in Interventional Cardiology* [Palm OS and Pocket PC electronic book]. Pocket Medicine Inc., New York, NY; (In press) 2010.

686. Nguyen T, Hu D, Chen SL, **Gibson CM**, et al., editors. *Practical Handbook of Advanced Interventional Cardiology: Tips and Tricks*. 4th edition, Chichester, West Sussex, UK. John Wiley & Sons, Ltd, 2013.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Buros JL, **Gibson CM**, Scirica B, Murphy SA, Stone PH, and Braunwald E. Abstract 1676: Evaluation of continuous Holter monitoring following percutaneous coronary intervention (PCI) as a surrogate for post-PCI myonecrosis: An analysis from the PROTECT-TIMI 30 Trial. AHA 2007 Scientific Sessions, Orlando, FL, USA. 4-7 November 2007.
2. Nguyen MC, Murphy SA, Mega JL, Brieger D, Antman EM, and **Gibson CM**. Abstract 2221: Triple Therapy (TTx): ASA, Thienopyridine and Oral Anticoagulation (OA) Therapy Following ST Elevation Myocardial Infarction (STEMI): Is it Safe? AHA 2007 Scientific Sessions, Orlando, FL, USA. 4-7 November 2007
3. Buros JL, Nguyen MC, Murphy SA, Southard MC, Ciaglo L, Takao ST, Hochberg C, Sabatine MS, Cannon CP, Braunwald E, and **Gibson CM**. Abstract 3006: The Association of Culprit and Non-Culprit Myocardial Perfusion with Clinical Events Following an ST-Elevation MI (STEMI): An Analysis from the CLARITY-TIMI 28 Study. AHA 2007 Scientific Sessions, Orlando, FL, USA. 4-7 November 2007.
4. **Gibson CM**, Pride YB, Buros JL, Murphy SA, Sabatine MS, Cannon CP, and Braunwald E. Abstract 1677: Variable association of hyperemic epicardial flow with adverse outcomes among patients treated with fibrinolytic therapy for ST-segment elevation myocardial infarction: An analysis from CLARITY-TIMI 28. AHA 2007 Scientific Sessions, Orlando, FL, USA. 4-7 November 2007.
5. Nguyen MC, Pinto DS, Hochberg C, Almahameed A, Pride Y, Abraham JE, Frederick PD, Murphy SA, and **Gibson CM**. Abstract 3163: Association of pre-PCI TIMI flow grade (TFG) with subsequent mortality in patients presenting with ST-elevation myocardial infarction (STEMI). AHA 2007 Scientific Sessions, Orlando, FL, USA. 4-7 November 2007.
6. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, **Gibson CM**, Lesser JR, Hanna CA, Udelson JE, Manning WJ, and Maron MS. Evidence that post-contrast delayed enhancement identified by cardiovascular magnetic resonance is an arrhythmogenic substrate in hypertrophic cardiomyopathy. 11th Annual SCMR Scientific Sessions, Los Angeles, CA, USA. 1-3 February 2008.
7. Harrigan CJ, Peters DC, Maron MS, Maron BJ, **Gibson CM**, Manning WJ, and Appelbaum E. Improved detection of myocardial fibrosis using high-resolution, late gadolinium-enhanced cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy. 11th Annual SCMR Scientific Sessions, Los Angeles, CA, USA. 1-3 February 2008.
8. Harrigan CJ, Maron MS, Maron BJ, Peters DC, **Gibson CM**, Manning WJ, and Appelbaum E. Accuracy and reproducibility of quantifying myocardial fibrosis in hypertrophic cardiomyopathy using delayed enhancement cardiovascular magnetic resonance thresholding techniques. 11th Annual SCMR Scientific Sessions, Los Angeles, CA, USA. 1-3 February 2008.
9. Appelbaum E, Harrigan CJ, Kirtane AJ, Clark A, Manning WJ, and **Gibson CM**. TIMI myocardial perfusion grade predicts infarct size, perimeter and border zone following STEMI. 11th Annual SCMR Scientific Sessions, Los Angeles, CA, USA. 1-3 February 2008.
10. Giugliano RP, Giraldez RR, Morrow DA, Antman EM, **Gibson CM**, Mohanavelu S, Murphy SA, McCabe CH, and Braunwald E. The Relative Contribution of Clinical Factors, Treatments, Bleeding, and CV Complications to Mortality in 20,323 Patients Receiving Fibrinolysis for STEMI. ACC 2008 Scientific Sessions, Chicago, IL, USA. 29 March-1 April 2008.
11. Mega JL, Scirica BM, Qin J, **Gibson CM**, and Morrow DA. Chronic Kidney Disease, Cardiovascular Outcomes, and Treatment Disparities following Non-ST Elevation Myocardial Infarction. ACC 2008 Scientific Sessions, Chicago, IL, USA. 29 March-1 April 2008.
12. Buros JL, Pride YB, Alexander JH, Kouchoukos NT, Peterson ED, Ferguson BT, and **Gibson CM**. Relative

contribution of patient characteristics and clinical site characteristics to saphenous vein graft stenosis and adverse cardiac events following coronary artery bypass graft surgery: A PREVENT IV analysis. ACC 2008 Scientific Sessions, Chicago, IL, USA. 29 March-1 April 2008.

13. Shah BR, Peterson ED, Parsons L, Pollack CV, French WJ, Canto JG, **Gibson CM**, and Rogers WJ. Trends in Care Disparities for Patients With Acute Myocardial Infarction in the National Registry of Myocardial Infarction From 1994 to 2006. ACC 2008 Scientific Sessions, Chicago, IL, USA. 29 March-1 April 2008.
14. Appelbaum E, Harrigan C, Manning WJ, Ruberg FL, **Gibson CM**, Skinner M, Tripp KJ, Packman J, and Grogan D. Abstract 694: More extensive left ventricular hypertrophy in transthyretin-type cardiac amyloidosis as compared to primary light-chain cardiac amyloidosis. AHA 2008 Scientific Sessions, New Orleans, LA, USA. 8-12 November 2008.
15. **Gibson CM**, Pride YB, Mohanavelu S, Wiviott SD, Antman EM, and Braunwald E. Abstract 1999: Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndrome Presenting with Isolated Anterior ST-Segment Depressions. AHA 2008 Scientific Sessions, New Orleans, LA, USA. 8-12 November 2008.
16. Ciaglo LN, Karpaliotis D, Kunadian V, Gibson WJ, Buros JL, Zorkun C, Lew ME, Harrington RA, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Marble SJ, Alexander JH, and **Gibson CM**. Abstract 741: Larger saphenous vein grafts in relation to native artery are associated with reduced TIMI grade 3 flow but improved myocardial perfusion at 1 year: A PREVENT IV analysis. AHA 2008 Scientific Sessions, New Orleans, LA, USA. 8-12 November 2008.
17. O'Donoghue M, Morrow DA, Jiang S, Rifai N, Bode C, **Gibson CM**, Gerszten RE, Cannon CP, and Sabatine MS. Serial Inflammatory Biomarkers to Predict Angiographic and Clinical Outcomes in Patients With STEMI Undergoing Fibrinolysis: A CLARITY-TIMI 28 Substudy. ACC 2009 Scientific Sessions, Orlando, FL, USA. 28-31 March 2009.
18. Appelbaum E, Uno H, Verma A, Manning WJ, **Gibson CM**, Desai A, Berglund T, Lukashevick V, Smith BA, Dahlöf B, and Solomon SD. Enhanced Reduction of LV Mass Following Use of Renin-Angiotensin-Aldosterone System Blockade among those with Hypertensive Heart Disease and No Prior Treatment with Angiotensin-Converting Enzyme Inhibition or Angiotensin Receptor Blockade. Oslo, NO. European Meeting on Hypertension 2009. 18-23 Jun 2009.
19. Holmes DR, Foster MT, Kovach RC, and **Gibson CM**. Feasibility Study of an Implantable Device to Monitor ST-Segment Shifts and Alert Patients to Cardiac Ischemia. TCT 2009 Scientific Sessions, San Francisco, CA, USA. 21-25 September 2009.
20. Mega JL, Braunwald E, Lee M, Misselwitz F, Mohanavelu S, Notani R, Peters G, and **Gibson CM**. Abstract 4762: Cessation of Rivaroxaban in Post-ACS Patients is Not Associated With Clinical Evidence of Rebound Hypercoagulability: An ATLAS ACS-TIMI 46 Substudy. AHA 2009 Scientific Sessions, Orlando, FL, USA. 14-18 November 2009.
21. **Gibson CM**, Mega JL, Jennings LK, Mohanavelu S, Misselwitz F, Plotnikov A, Sun X, Zolynas R, and Braunwald E. Abstract 5020: Effect of Rivaroxaban on Markers of Coagulation in Patients With Acute Coronary Syndromes: An ATLAS ACS-TIMI 46 Substudy. AHA 2009 Scientific Sessions, Orlando, FL, USA. 14-18 November 2009.
22. Maron M, Harrigan C, Olivetto I, Appelbaum E, **Gibson CM**, Lesser J, Haas T, Udelson J, Manning W, and Maron B. Abstract 3358: Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. AHA 2009 Scientific Sessions, Orlando, FL, USA. 14-18 November 2009.
23. Tanguay JF, Newby LK, Hochman J, Westerhout CM, Califf RM, **Gibson CM**, Giugliano RP, Harrington RA, Van de Werf F, and Armstrong PW. Sex Differences in High-Risk Acute Coronary Syndromes: Insights From Early-ACS. ACC 2010 Scientific Sessions, Atlanta, GA, USA. 14-16 March 2010.
24. Lopes R, Alexander JH, Mehta RH, Hafley GE, Mack MJ, Allen KB, Peterson ED, Harrington RA, **Gibson CM**, Califf RM, Kouchoukos NT, and Ferguson TB. Vein Graft Failure Following Coronary Artery Bypass

Surgery: Does it Matter? ACC 2010 Scientific Sessions, Atlanta, GA, USA. 14-16 March 2010.

25. Klutstein MW, Westerhout CM, Rao S, Lewis BS, **Gibson CM**, Lutchmedial S, Widimsky P, Steg PG, Dalby A, Zeymer U, Van de Werf F, Harrington RA, Newby K, and Armstrong PW. Abstract 10358: Radial versus Femoral Approach in Non-ST Elevation ACS: Lessons From EARLY. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
26. Podgoreanu MV, Feng S, Hafley G, Donahue M, **Gibson CM**, Schwinn DA, and Alexander JH. Abstract 21392: Genome-wide Association Study of Vein Graft Disease Following Coronary Artery Bypass Surgery. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
27. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Bhatt DL, Stone GW, Lincoff MA, Dauerman HL, **Gibson CM**, White HD, Parick K, Gruberg L, Herrmann HC, McLaurin BT, Goodman S, Harrington RA, and Mahaffey KW. Abstract 14813: Pre-Treatment With Thienopyridines Reduces The Amount of Myonecrosis in Acute Coronary Syndrome Patients Invasively Managed: Insights from the CHAMPION trials. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
28. Lopes RD, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan BS, Brogan GX, **Gibson CM**, and Newby LK. Abstract 12776: Non-ST-segment Elevation Acute Coronary Syndromes Patients without Angiographically Detected Obstructive Coronary Artery Disease are Low-risk but Not No-risk: A Meta-analysis of 8 Trials of 37,101 Patients. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
29. Pinto DS, Kirtane AJ, Frederick PD, Dejam A, Miller DP, Henry TD, and **Gibson CM**. Abstract 13146: The Benefit of Transferring STEMI Patients for PCI Compared with Administration of Onsite Fibrinolytic Declines as Delays Increase. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
30. Piccini JP, White JA, Mehta RH, Al-Khatib SM, Tricoci P, Pollack CV, Montalescot G, Van de Werf F, **Gibson CM**, Harrington RA, and Newby LK. Abstract 13168: Sustained Ventricular Tachycardia and Ventricular Fibrillation are Infrequent Events but are Associated with Increased Arrhythmic and All-cause Death Following Non-ST-Segment Elevation Acute Coronary Syndromes. AHA 2010 Scientific Sessions, Chicago, IL, USA. 13-17 November 2010.
31. Maron MS, Rowin E, Lin D, Appelbaum E, **Gibson CM**, Lesser J, Haas T, Lindberg J, Udelson J, and Manning J. Abstract 914-3: Prevalence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. ACC 2011 Scientific Sessions, New Orleans, LA, USA. 3-5 April 2011.
32. Kunadian V, Zorkun C, James S, Wu J, Muhammad A, Storey R, Steg PG, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, and **Gibson CM**. Abstract 1005-314: Angiographic Outcomes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ACC 2011 Scientific Sessions, New Orleans, LA, USA. 3-5 April 2011.
33. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, **Gibson CM**, Pollack CV, Ornato JP, Lambrew CG, Zalsenski RJ, Penney J, Tiefenbrunn AJ, and Greenland P for the NRMI Investigators. Abstract 1073-36: Risk Factors Ascertained at Presentation and Mortality among Patients with First Myocardial Infarction. ACC 2011 Scientific Sessions, New Orleans, LA, USA. 3-5 April 2011.
34. White HD, Chew DP, Dauerman HL, Mahaffey KW, **Gibson CM**, Harrington RA, and Bhatt DL. Abstract 1139-307: Reduced Immediate Ischemic Events with Cangrelor in PCI Using the Universal Definition of MI: Pooled Analysis of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition Trials. ACC 2011 Scientific Sessions, New Orleans, LA, USA. 3-5 April 2011.
35. Berg DD, Wiviott SD, Sloan S, Kashani A, **Gibson CM**, Cannon CP, Morrow D, Contant CF, Sabatine MS, Braunwald E, and Giugliano RP. Abstract 16393: Causes and Timing of Death in Patients With NSTEMI ACS: An Analysis of the TIMI Trials. AHA 2011 Scientific Sessions, Orlando, FL, USA. 12-16 November 2011.
36. Pride YB, Mohanavelu S, Giugliano RP, Newby LK, Zorkun C, Kunadian V, Braunwald E, Califf RM, Harrington RA, and **Gibson CM**. Abstract 10394: Association Between Angiographic Complications During Percutaneous Coronary Intervention and Clinical Outcomes Among Patients with Acute Coronary Syndrome: An EARLY ACS Angiographic Substudy. AHA 2011 Scientific Sessions, Orlando, FL, USA. 12-16 November

2011.

37. Rowin EJ, Appelbaum E, Hauser TH, Harrigan C, **Gibson CM**, Lesser JR, Haas TS, Udelson JE, Manning J, Maron BJ, and Maron MS. Abstract 10805: Does the 12-lead ECG Have Limitations in Detecting Hypertrophic Cardiomyopathy in the Pre-Participation Screening of Athletes? AHA 2011 Scientific Sessions, Orlando, FL, USA. 12-16 November 2011.
38. Leonardi S, Koehler ML, Truffa A, Tricoci P, White H, **Gibson CM**, Stone GW, Harrington RA, Bhatt DL, and Mahaffey KW. Abstract 10045: A Novel Approach to Define Type 4a Myocardial Infarction in Acute Coronary Syndrome Patients Undergoing Early Invasive Management: Insights From the CHAMPION PLATFORM Trial. AHA 2011 Scientific Sessions, Orlando, FL, USA. 12-16 November 2011.
39. Chan RHM, Hong S, Hass TS, Feeney KM, Lesser J, **Gibson CM**, Manning WJ, Maron BJ, Maron M, and Appelbaum E. Characterization of patients with massive hypertrophic cardiomyopathy using contrast-enhanced magnetic resonance imaging: does contrast provide additional information? 15th Annual SCMR Scientific Sessions 2012, Orlando, FL, USA. 2-5 February 2012.
40. Stone GW, Maehara A, Witzentichler B, Godlewski J, Cristea E, Parise H, Dembrink JH, Ochala A, Wolff S, Chowdhary S, El-Omar M, Neunteuff TD, Metzger DC, and **Gibson CM**. Abstract 304-9: INFUSE-AMI: A 2x2 Factorial, Multicenter, Prospective, Randomized Evaluation of Intracoronary Abciximab and Aspiration Thrombectomy in Patients Undergoing Primary PCI for Anterior STEMI. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
41. Hong-Zohlman SN, Chan RHM, Maron BJ, Olivotto I, Assenza GE, Lesser J, Gruner C, Crean A, Rakowski H, Udelson J, Rowin E, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hauser T, **Gibson CM**, Wanning W, Appelbaum E, and Maron M. Abstract 925-4: Female Gender Is Associated with Major Adverse Cardiovascular Events in Patients with Hypertrophic Cardiomyopathy. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
42. Chan RHM, Maron B, Olivotto I, Assenza G, Hong S, Lesser J, Haas T, Gruner C, Crean A, Rakowski H, Udelson J, Rowin E, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hauser T, **Gibson CM**, Manning W, Appelbaum E, and Maron M. Abstract 925-5: Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: An International Multicenter Study. ACC 2012, Chicago, IL, USA. March 24-27, 2012.
43. Zeymer U, Clare R, Schweiger M, van 't Hof A, Hochman J, James S, White H, Widimsky P, Betriu A, Bode C, Califf RM, Harrington RA, Giugliano R, **Gibson CM**, and Newby LK. Abstract 1169-266/266: Frequency, Clinical and Angiographic Characteristics, and Outcomes of High-risk Non-ST-segment Elevation Acute Coronary Syndromes Patients with Left Circumflex Culprit Lesions. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
44. **Gibson CM**, Guimarães V, John MS, Keenan D, Feitosa A, de Tarso Medeiros P, Piegas L, Krucoff M, and Holmes D. Abstract 1171-353/353: Magnitude And Duration Of Intracardiac ST-Segment Changes For Confirmed Clinical Events: First In-man Experience. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
45. Yu J, Dargas G, Baber U, Vlachojannis G, Clayton T, Pocock S, Feit F, Cox D, Brodie B, Lincoff A, Deliangyris E, Gersh B, **Gibson CM**, Mehran R, and Stone GW. Abstract 2501-10: Impact of Ejection Fraction on Mortality in Patients Undergoing PCI: A Patient-Level Pooled Analysis from the REPLACE-2, ACUITY and HORIZONS-AMI Trials. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
46. Baber U, Colombo A, Weisz G, Chieffo A, **Gibson CM**, Alu M, Barathi P, Sergie Z, Cohen D, Moliterno D, Witzentichler B, Krucoff M, Steg P, and Mehran R. Abstract 2536-628/628: Association of Stent Thrombosis and Patterns of Non-Adherence to Anti-platelet Regimens In Stented Patients: Six Month Results of the PARIS Registry. ACC 2012 Scientific Sessions, Chicago, IL, USA. 24-27 March 2012.
47. Sergie Z, Baber U, Chieffo A, Sartori S, Cohen DJ, **Gibson CM**, Weisz G, Witzentichler B, Colombo A, and Mehran R. Abstract 5247: Predictors of non-adherence to dual antiplatelet therapy after percutaneous coronary intervention in a large multinational registry. ESC 2012 Scientific Sessions, Munich, DE. 25-29 August 2012.

48. Kaya MG, Uyarel H, Akpek M, Eren M, Ergelen M, Kalay N, Elcik D, Sahin O, Oguzhan A, and **Gibson CM**. Abstract P1712: Prognostic value of uric acid in patients with stemi undergoing primary angioplasty: two year follow-up. ESC 2012 Scientific Sessions, Munich, DE. 25-29 August 2012.
49. Kohli P, Chakrabarti A, Bansilal S, Dangas G, Nienaber C, Prats J, and **Gibson CM**. Abstract P2415: Reduction in mortality from thrombin inhibition in CHF patients: results from the premier hospital database. ESC 2012 Scientific Sessions, Munich, DE. 25-29 August 2012.
50. Brener S, Maehara A, Dizon J, Fahy M, Witzenbichler B, Parise H, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, **Gibson CM**, and Stone G. Abstract 57: Angiographic Reperfusion Indices Predict Infarct Size and Mortality: The INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
51. Dambrink JH, Brener S, Maehara A, Chowdhary S, Gershlick A, Koolen J, Mehran R, Fahy M, **Gibson CM**, and Stone G. Abstract 58: Effects of Mechanical Thrombectomy and Intracoronary Abciximab on Coronary Flow and Infarct Size During Primary PCI: Analysis from the INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
52. Maehara A, Mintz G, Brener S, Dambrink JH, El-Omar M, Gershlick A, Fahy M, Mehran R, **Gibson CM**, and Stone G. Abstract 59: Effect of Intracoronary Abciximab and Aspiration Thrombectomy on Microvascular Obstruction in Large Anterior Myocardial Infarction: The INFUSE-AMI MRI Substudy. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
53. Baber U, Mehran R, Brener S, Maehara A, Dudek D, Neunteufl T, Metzger DC, **Gibson CM**, and Stone G. Abstract 149: Impact of Chronic Kidney Disease on Myocardial Infarct Size and Adverse Events in ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
54. Gukathasan N, Mehran R, Brener S, Maehara A, Sergie Z, Metzger DC, Oldroyd K, Parise H, Fahy M, **Gibson CM**, and Stone G. Abstract 366: Impact of gender on adverse cardiac events in patients with large anterior myocardial infarction: Results from the INFUSE-AMI trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
55. Brener S, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Mehran R, Oldroyd K, Parise H, **Gibson CM**, and Stone G. Abstract 467: Clinical Outcomes after Anterior ST-Elevation Myocardial Infarction According to LAD Lesion Location: The INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
56. Palmerini T, Brener S, Dambrink JH, Fahy M, **Gibson CM**, Godlewski J, Maehara A, Ochala A, Parise H, Stone G, and Witzenbichler B. Abstract 486: Relationship Between White Blood Cell Count and Final Infarct Size in Patients with ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Analysis from the INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
57. El-Omar M, Brener S, Maehara A, Scott T, Mehran R, Aengevaeren W, Dudek D, Fahy M, **Gibson CM**, and Stone G. Abstract 509: Low Overall Rates of Angiographically Visible Distal Embolization in INFUSE-AMI: Possible Explanation for Lack of Efficacy of Manual Aspiration Thrombectomy. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
58. Dizon J, Brener S, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Mehran R, **Gibson CM**, and Stone G. Abstract 513: Measures of ST-Segment Resolution Predict Infarct Size: The INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
59. Maehara A, Mintz G, Brener S, Witzenbichler B, Zeymer U, Gershlick A, Fahy M, Mehran R, **Gibson CM**, and Stone G. Abstract 516: Microvascular Obstruction Detected by MRI is a Predictor of Recovery from Myocardial Stunning: The INFUSE-AMI Trial. TCT 2012 Scientific Sessions, Miami Beach, FL, USA. 22-26 October 2012.
60. Chan RH, Maron BJ, Olivetto I, Assenza G, Lesser JR, Haas T, Gruner C, Crean A, Rakowski H, Udelson JE,

- Rowin E, Tomberli B, Spirito P, Formisano F, Biagini E, De Cecco CN, Autore C, Cook EF, Hong SN, **Gibson CM**, Manning WJ, Appelbaum E, and Maron MS. Abstract 13139: Prognostic Utility of Contrast-Enhanced Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy: An International Multicenter Study. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
61. Mega JL, Braunwald E, Wiviott SD, Murphy S, Plotnikov A, Gotcheva N, Ruda M, and **Gibson CM**. Abstract 16014: Evaluation of Cardiac Events in ATLAS ACS 2-TIMI 51. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 62. Chan RH, Afilalo J, Maron BJ, Olivotto I, Assenza G, Lesser JR, Haas T, Gruner C, Crean A, Rakowski H, Udelson JE, Rowin E, Tomberli B, Spirito P, Biagini E, De Cecco CN, Cook EF, Hong SN, **Gibson CM**, Manning WJ, Appelbaum E, and Maron MS. Abstract 17374: Prognostic Utility of Intermediate-Signal-Intensity Late Gadolinium Enhancement in Patients with Hypertrophic Cardiomyopathy. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 63. Gruner C, Chan RH, Rowin EJ, Care M, Litwin FA, Williams W, Appelbaum E, **Gibson CM**, Lesser JR, Haas TS, Udelson JE, Rakowski H, Maron BJ, Crean A, and Maron MS. Abstract 14941: Left Ventricular Apico-Basal Muscle Bundle Identified by Cardiovascular Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: Implications for Diagnosis and Management. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 64. Pride Y, Mohanavelu S, Mega JL, Braunwald E, and **Gibson CM**. Abstract 9944: Temporal Relationship Between Major Hemorrhagic Events and Mortality among Patients with Recent Acute Coronary Syndrome: Insights from ATLAS ACS 2-TIMI 51. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 65. **Gibson CM**, Levitan B, Murphy SA, Yuan Z, Chakrabarti A, Lee M, Mega JL, and Braunwald E. Abstract 13152: A Net Clinical Outcome Analysis Comparing Fatal or Irreversible Ischemic and Bleeding Events in ATLAS ACS 2 – TIMI 51. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 66. Goel K and **Gibson CM**. Abstract 11167: Association of Time to Reperfusion with Left Ventricular Function and Heart Failure in Acute Myocardial Infarction Patients treated with Primary Percutaneous Coronary Intervention - A Systematic review. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 67. **Gibson CM**, Doherty M, Abueg C, Gopalakrishnan L, Kumar V, O'Brian S, Grau-Sepulveda M, Edwards F, Klein L, and Weintraub W. Abstract 16159: Impact of the SYNTAX Score on Revascularization Outcomes for Patients with Multi-Vessel Disease. AHA 2012 Scientific Sessions, Los Angeles, CA, USA. 3-7 November 2012.
 68. Chan RH, Maron B, Olivotto I, Assenza G, Lesser J, Haas T, Gruner C, Creane A, Rakowski H, Udelson J, Rowin E, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook E, Hong S, **Gibson CM**, Manning W, Appelbaum E, and Maron M. Abstract 1121M-142: Does Focal Late Gadolinium Enhancement at the Right Ventricular Insertion Points Matter in Risk Stratification for Sudden Death in Hypertrophic Cardiomyopathy? ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
 69. Kaya M, Akpek M, Celik T, and **Gibson CM**. Abstract 1256-180: Prognostic value of Neutrophil/Lymphocyte Ratio in Patients with STEMI Undergoing Primary Coronary Intervention: Ten-Year Follow-Up Results of Multicenter Experiences. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
 70. Gukathasan N, Witzenbichler B, Weisz G, Henry T, Colombo A, Baber U, Chieffo A, **Gibson CM**, Vadde R, Bharathi P, Sartori S, Kini A, Iakovou A, Krucoff M, Steg P, and Mohran M. Abstract 1199-93: Impact of Gender on Patterns of Dual Antiplatelet Therapy Cessation and Non-Adherence: One-Year Results from the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS), An Observational Single-Arm Study. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
 71. Mega JL, Braunwald E, Murphy S, Plotnikov A, Cook-Burns N, Aylward P, Chopra V, Gao R, Nicolau J, and **Gibson CM**. Abstract 901-6: Rivaroxaban in the Setting of Continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2-TIMI 51 Trial. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.

2013.

72. Bhatt D, Stone G, Maheffy K, **Gibson CM**, Steg P, Hamm C, Price M, Leonardi S, Gallup D, Todd M, Skerjanec S, White H, and Harrington R for the CHAMPION-PHOENIX Investigators. Abstract 301-15: The Main Results of the CHAMPION-PHOENIX Trial. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
73. Chakrabarti A, Grau-Sepulveda M, O'Brein S, Abueg C, Kumar V, Gopalakrishnan L, Doherty ME, Ponirakis A, DeLong E, Peterson E, Garratt K, Edwards F, Weintreib W, and **Gibson CM**. Abstract 2112-251: Angiographic Validation of the American College of Cardiology Foundation's Cardiac Catheterization Database. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
74. Cavender M, Braunwald E, **Gibson CM**, Wiviott S, Murphy S, Amuchastegui M, Ophius AO, van Hesse M, and Mega JL. Abstract 901-5: Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: Findings from the ATLAS ACS 2-TIMI 51 Trial. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
75. Sergie Z, Mehran R, Brener S, Maehara A, Fahy M, Zeymer U, Zaman A, Woehrle J, **Gibson CM**, AND Stone G. Abstract 2101-234: Gender Differences in Cardiac Symptoms 30 Days after Primary PCI for Anterior Myocardial Infarction: Insights from INFUSE-AMI. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
76. Harskamp RE, Alexander K, Schulte P, Jones S, Williams J, Mack M, Peterson E, **Gibson CM**, Califf R, Kouchoukos N, Ferguson T, de Winter R, and Lopes R. Abstract 1283M-73: Extra-Cardiac Vascular Disease Is Associated with Worse Five-Year Clinical Outcomes but Not with Vein Graft Failure after Coronary Artery Bypass Graft Surgery: Insights from the PREVENT-IV Trial. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
77. Stone G, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton T, Cristea E, Wolf S, Brener S, Chowdhary S, El-Omar M, Neunteufl T, Metzger C, Dizon J, Mehran R, and **Gibson CM**. Abstract 2908-5: Intracoronary Abciximab and Aspiration Thrombectomy during Primary PCI for Anterior STEMI: One-Year Results from the Randomized INFUSE-AMI Trial. ACC 2013 Scientific Sessions, San Francisco, CA, USA. 9-11 March 2013.
78. **Gibson CM**, Tricoci P, Abueg C, Feeney K, Huang Z, Smith M, Chen E, and Mahaffey KW. Abstract P240: Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy. ESC 2013 Scientific Sessions, Amsterdam, NL. 31 August-4 September 2013.
79. Oldroyd KG, Brener S, Maehara A, El-Omar M, Witzenbichler B, Xu K, Mehran R, **Gibson CM**, and Stone GW. Abstract 3: Outcomes in STEMI patients treated with clopidogrel or prasugrel: A propensity adjusted analysis from the INFUSE-AMI Trial. TCT 2013 Scientific Sessions, San Francisco, CA, USA. 28 October-1 November 2013.
80. Sanidas E, Brener S, Maehara A, Genereux P, Witzenbichler B, El-Omar M, Xu K, Fahy M, Mehran R, **Gibson CM**, and Stone GW. Abstract 222: Reperfusion Success, Infarct Size and Clinical Outcomes in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Anterior Myocardial Infarction. TCT 2013 Scientific Sessions, San Francisco, CA, USA. 28 October-1 November 2013.
81. Guerchicoff A, Brener S, Fahy M, **Gibson CM**, Maehara A, Mehran R, Stone G, and Witzenbichler B. Abstract 230: Impact of Delay to reperfusion on Infarct Size and Clinical Outcomes in Patients with STEMI: The INFUSE-AMI Trial. TCT 2013 Scientific Sessions, San Francisco, CA, USA. 28 October-1 November 2013.
82. Dohi T, Maehara A, Mintz GS, Genereux P, Brener S, Gershlick A, Mehran R, **Gibson CM**, and Stone G. Abstract 239: Clinical Utility of Peak Creatine Kinase-MB Measurements in Predicting Left Ventricular Dysfunction and Clinical Outcomes After First Anterior Myocardial Infarction: An INFUSE-AMI Sub-study. TCT 2013 Scientific Sessions, San Francisco, CA, USA. 28 October-1 November 2013.
83. Kobayashi N, Maehara A, Mintz GS, Wolff SD, Genereux P, Brener S, Xu K, Mehran R, **Gibson CM**, and

- Stone G. Abstract 263: Left anterior descending artery that wraps around the apex is associated with apical remodeling and subsequent heart failure in patients with anterior ST-Elevation MI: An INFUSE-AMI sub-study. TCT 2013 Scientific Sessions, San Francisco, CA, USA. 28 October-1 November 2013.
84. O'Donoghue ML, Mega JL, Braunwald E, Nicolau JC, Bhatt DL, Murphy SA, **Gibson CM**. Abstract 11382: The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial. AHA 2013 Scientific Sessions, Dallas, TX, USA. 16-20 November 2013.
 85. Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, **Gibson CM**, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB, and Lopes RD. Abstract 14160: Preservation Solutions, Patency, and Outcomes After Coronary Bypass Surgery. AHA 2013 Scientific Sessions, Dallas, TX, USA. 16-20 November 2013.
 86. White HD, Bhatt DL, **Gibson CM**, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, and Harrington RA. Abstract 920-06: Reduced Death, Myocardial Infarction, and Early Stent Thrombosis with Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights from CHAMPION PHOENIX. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 87. Schoos MM, Sartori S, Baber U, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Kini A, Stuckney T, Cohen D, Berger P, Dangas G, Waksman R, Krucoff M, Antoniucci D, Hermiller J, Shawl F, **Gibson CM**, Chieffo A, Moliterno D, Colombo A, Pocock S, Mehran R, and Alu M. Abstract 2105-285: Associations Between Different Modes of DAPT Cessation and Major Adverse Events at 6 Months and Beyond: Insights From the PARIS Registry. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 88. Baber U, Schoos M, Sartori S, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Kini A, Stuckey T, Cohen D, Berger PB, Iakovou I, Dangas G, Waksman R, Krucoff M, Hermiller J, Shawl F, **Gibson CM**, Chieffo A, Alu M, Moliterno D, Colombo A, Pocock S, and Mehran R. Abstract 2105-291: Associations Between Dual Antiplatelet Therapy Cessation and MACE Due to Stopping One or Both Drugs: Insights from the PARIS Registry. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 89. Bansilal S, Baber U, Dangas G, Steg P, Weisz G, Aquino M, Henry T, Kini A, Stuckey T, Cohen D, Berger P, Iakovou I, Waksman R, Antoniucci D, Sartori S, Witzenbichler B, Krucoff M, Hermiller J, Shawl F, **Gibson CM**, Chieffo A, Moliterno D, Alu M, Colombo A, and Mehran R. Abstract 2105-293: Clopidogrel With And Without Proton Pump Inhibitor Use: A Paris Registry Analysis. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 90. Baber U, Schoos M, Sartori S, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Kini A, Stuckey T, Cohen DJ, Berger PB, Dangas G, Waksman R, Antoniucci D, Krucoff M, Hermiller J, Shawl F, **Gibson CM**, Chieffo A, Alu M, Moliterno D, Colombo A, Pocock S, and Mehran R. Abstract 2908-07: Temporal Associations between Time After Percutaneous Coronary Intervention, Dual Antiplatelet Therapy Cessation and Stent Thrombosis in the Contemporary PCI Era: Insights From the PARIS Registry. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 91. Pokorney S, Radder C, Schulte P, Al-Khatib S, Tricoci P, Van de Werf F, James S, Cannon C, Armstrong P, White H, Califf R, **Gibson CM**, Giugliano R, Wallentin L, Mahaffey K, Harrington R, Newby LK, and Piccini J. Abstract 1216-98: High Degree Atrioventricular Block, Asystole, and Electro-Mechanical Dissociation Complicating Non-ST Segment Elevation Myocardial Infarction. ACC 2014 Scientific Sessions, Washington, DC, USA. 29-31 March 2014.
 92. Harskamp RE, Alexander JH, Hager R, Englum B, Schulte PJ, Peterson ED, **Gibson CM**, Califf RM, Ferguson TB, and Lopes RD. Abstract 5940: Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial. ESC 2014 Scientific Sessions, Barcelona, ES. 30 August-3 September 2014.
 93. Mega J, Braunwald E, Murphy S, Fox K, Ruda M, Verheugt F, and **Gibson CM**. Abstract P5518: Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trial. ESC 2014 Scientific Sessions, Barcelona, ES. 30 August-3 September 2014.

94. Bhatt DL, Stone GW, Mahaffey K, **Gibson CM**, Steg PG, Hamm C, Price MJ, Liu T, Deliargyris EN, Skerjanec S, Prats J, White HD, and Harrington R. Abstract 482: Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX. TCT 2014 Scientific Sessions, Washington, DC, USA. 13-17 September 2014.
95. Kumar V, Singh M, Gopalakrishnan L, Kovacs DF, Benatar D, **Gibson CM**, and Khosla S. Abstract 17488: Effect of Cocaine on Coronary Microvasculature. AHA 2014 Scientific Sessions, Chicago, IL, USA. 15-19 November 2014.
96. Mahaffey KW, Bhatt DL, Stone GW, **Gibson CM**, Steg PG, Hamm CW, Wilson MD, Mangum S, Leonardi S, Price MJ, Liu T, Skerjanec S, Prats J, White HD, and Harrington RA. Abstract 18938: Prognostically Important Myocardial Infarctions are Markedly Underreported in Patients Undergoing Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX. AHA 2014 Scientific Sessions, Chicago, IL, USA. 15-19 November 2014.
97. Englum BR, Schulte PJ, Gulack BC, **Gibson CM**, Lopes RD, Mack MJ, Ferguson TB, Harrington RA, Smith PK, and Alexander JH. Abstract 15473: The Use of Coronary Artery Bypass Grafts in Non-significant Lesions: Is There Harm to Patients? AHA 2014 Scientific Sessions, Chicago, IL, USA. 15-19 November 2014.
98. O'Donoghue ML, Bhatt DL, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Prats J, Liu T, Deliargyris E, Mahaffey K, White H, and Harrington R. Abstract 1139-083: The Efficacy, Safety, and Net Clinical Benefit of Cangrelor in Women Undergoing Elective or Urgent PCI: Insights from the CHAMPION-PHOENIX Trial. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
99. Aragon JR, Korjian S, Halaby R, Daaboul Y, Shenoda M, Price S, Bacon J, Beckord B, Miller J, Florea A, Spielman K, Cochet M, Stepanchak M, and **Gibson CM**. Abstract 1139-100: Intracoronary Bivalirudin Administration in STEMI Improves Coronary Flow. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
100. Sherwood M, Lopes R, Sun JL, Harrington R, Wallentin L, Laskowitz DT, James S, Goodman S, Darius H, Lewis B, Liaw D, **Gibson CM**, and Alexander J. Abstract 1209-078: Apixaban Following Acute Coronary Syndromes Among Patients with Prior Stroke: Insights from the APPRAISE-2 Trial. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
101. Cavender M, Bhatt D, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Prats J, Liu T, Deliargyris E, Mahaffey K, White H, and Harrington R. Abstract: 2101-286: Cangrelor in Elderly Patients Undergoing PCI: Findings from CHAMPION-PHOENIX. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
102. Aoi S, Yu J, Sartori S, Baber U, Ariti C, Henry T, Cohen D, Moliterno D, Pocock S, **Gibson CM**, Stuckey T, Berger P, Iakovou I, Waksman R, Hermiller J, and Mehran R. Abstract 2102-279: Impact of Age on the Modes of Dual Antiplatelet Therapy Cessation: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) Registry. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
103. Angiolillo DJ, Bhatt D, Steg P, Stone G, White H, **Gibson CM**, Hamm C, Price M, Prats J, Liu T, Day J, Mahaffey K, and Harrington R. Abstract 2104-275: Impact of Cangrelor Overdosing on Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention: Insights from the CHAMPION Trials. ACC 2015 Scientific Sessions, San Diego, CA, USA. 14-16 March 2015.
104. Storey RF, Bhatt DL, Steg PG, Stone GW, White HD, **Gibson CM**, Hamm CW, Prats J, Mahaffey KW, and Harrington RA. Abstract P1497: Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. ESC 2015 Scientific Sessions, London, UK. 29 August-2 September 2015.
105. Giustino G, Sartori S, Ariti C, Weisz G, Stuckey T, Pocock S, Shawl F, **Gibson CM**, Chieffo A, and Mehran R. Abstract P3342: Predictors of late bleeding after percutaneous coronary intervention: insights from the PARIS registry. ESC 2015 Scientific Sessions, London, UK. 29 August-2 September 2015.
106. Gutierrez JA, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Mahaffey KW,

- White HD, and Bhatt DL. Abstract 4002: The effect of cangrelor and access site on ischemic and bleeding events: insights from CHAMPION-PHOENIX. ESC 2015 Scientific Sessions, London, UK. 29 August-2 September 2015.
107. Abnoui F, Sundaram V, Prats J, Deliargyris EN, Stone GW, Hamm C, Steg PG, **Gibson CM**, White HD, Price MJ, Yong C, Desai M, Harrington R, Bhatt DL, and Mahaffey K. Abstract 75: Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial. TCT 2015 Scientific Sessions, San Francisco, CA, USA. 11-15 October 2015.
 108. Stone GW, Genereux P, White HD, **Gibson CM**, Hamm C, Mahaffey K, Price MJ, Prats J, Harrington R, and Bhatt DL. Abstract 79: Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial. TCT 2015 Scientific Sessions, San Francisco, CA, USA. 11-15 October 2015.
 109. Aoi S, Yu J, Sartori S, Baber U, Ariti C, Henry TD, Cohen D, Moliterno DJ, Pocock SJ, **Gibson CM**, Krucoff M, Dangas G, Steg PG, Weisz G, Witzenbichler B, and Mehran R. Abstract 225: Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry. TCT 2015 Scientific Sessions, San Francisco, CA, USA. 11-15 October 2015.
 110. Giustino G, Brener S, Maehara A, Genereux P, Mehran R, Dudek D, Neunteufl T, Metzger DC, Ozan MO, **Gibson CM**, and Stone GW. Abstract 238: Impact of Smoking on Infarct Size and Adverse Events in Patients With Anterior ST-Elevation Myocardial Infarction: Results From the INFUSE-AMI Trial. TCT 2015 Scientific Sessions, San Francisco, CA, USA. 11-15 October 2015.
 111. Giustino G, Brener S, Maehara A, Mehran R, Genereux P, Dudek D, Neunteufl T, Metzger DC, Ozan MO, **Gibson CM**, and Stone GW. Abstract 265: Impact of Platelet Count on Myocardial Infarct Size and Adverse Events in Anterior ST-Elevation Myocardial Infarction: Results from the INFUSE-AMI Trial. TCT 2015 Scientific Sessions, San Francisco, CA, USA. 11-15 October 2015.
 112. Vaduganathan M, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, and Bhatt DL. Abstract 18632: Variation in Patient Profiles and Outcomes in US and non-US Subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. AHA 2015 Scientific Sessions, Orlando, FL, USA. 7-11 November 2015.
 113. Daaboul Y, Korjian S, Weaver WD, Kloner R, Giugliano R, Carr J, Neal BJ, Chi G, Cochet M, Goodell L, Michalak N, Rusowicz-Orazem L, Alkathery T, Allaham H, Shakil M, Szlosek D, and **Gibson CM**. Abstract 1100-023: The Association Between Left Ventricular Mass and Measures of Infarct Size in Anterior ST-Segment Elevation Myocardial Infarction: Insights From the EMBRACE STEMI Clinical Trial. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
 114. Korjian S, Daaboul Y, Bhatt D, Harrington R, Stone G, Steg P, Hamm C, Price M, Mahaffey K, White H, Prats J, Deliargyris E, and **Gibson CM**. Abstract 1133-016: Efficacy of Cangrelor in Congestive Heart Failure Patients Undergoing PCI: A Subgroup Analysis From the CHAMPION Pooled Database. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
 115. Nicholls SJ, Lincoff A, Barter P, Brewer HB, Fox K, **Gibson CM**, Granger C, Menon V, Montalescot G, Rader D, Tall A, McEneaney E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody G, and Nissen S. Abstract 404-08: Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Events: Results of the ACCELERATE trial. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
 116. Sawlani NN, Harrington R, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Prats J, Deliargyris E, Mahaffey K, White H, and Bhatt DL. Abstract 1174-114: Impact of Prior Cerebrovascular Events on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
 117. Tamez H, Genereux P, Fan W, Kirtane A, Plent S, Deliargyris E, Prats J, Stone G, **Gibson CM**,

- Harrington R, Bhatt D, and Pinto D. Abstract 1174-125: Cost Implications of Procedural Thrombotic Complications in Patients Undergoing Percutaneous Coronary Intervention: Results From the CHAMPION PHOENIX ECONOMICS Study. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
118. Vaduganathan M, Harrington R, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Menozzi A, Prats J, Deliargyris E, Mahaffey K, White H, and Bhatt D. Abstract 1203M-01: The Efficacy and Safety of Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Pooled Analysis of the CHAMPION Trials. ACC 2016 Scientific Sessions, Chicago, IL, USA. 2-4 April 2016.
 119. **Gibson, CM**, Harrington RA, Goldhaber SZ, Hernandez AF, Hull RD, Wiens BL, Gold A, and Cohen AT. Abstract CA02: VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban – A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin. ISTH SCC 2016 Scientific Sessions, Montpellier, FR. 25-28 May 2016.
 120. **Gibson, CM**, Harrington RA, Goldhaber SZ, Hernandez AF, Hull RD, Wiens BL, Gold A, and Cohen AT. Abstract CA02: VTE Prevention in Acutely Ill Medical Patients with Extended Duration Betrixaban – A Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin. ISTH SCC 2016 Scientific Sessions, Montpellier, FR. 25-28 May 2016.
 121. Vaduganathan M, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Deliargyris EN, Prats J, Elkin S, Mahaffey KW, White HD, and Bhatt DL. Abstract P3103: Bleeding events and subsequent 30-day and 1-year mortality after percutaneous coronary intervention: a contemporary pooled patient-level analysis from the CHAMPION trials. ESC 2016 Scientific Sessions, Rome, IT. 27-31 August 2016.
 122. Selvaraj S, Bhatt DL, Stone GW, **Gibson CM**, Steg PG, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, and Harrington RA. Abstract P5648: Off hours versus on hours presentation in ST-segment elevation myocardial infarction: findings from CHAMPION PHOENIX. ESC 2016 Scientific Sessions, Rome, IT. 27-31 August 2016.
 123. Eisen A, Harrington RA, Stone GW, Steg PG, **Gibson CM**, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, and Bhatt DL. Abstract 6045: Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. ESC 2016 Scientific Sessions, Rome, IT. 27-31 August 2016.
 124. Varenhorst CV, Akerblom A, Renlund H, Kunadian V, James SK, Steg PG, Katus HA, Himmelmann A, Aylward P, Maurer G, Storey RF, Armstrong PW, **Gibson CM**, and Wallentin L. Abstract P6231: Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial. ESC 2016 Scientific Sessions, Rome, IT. 27-31 August 2016.
 125. **Gibson CM**, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip G, Cohen M, Husted S, Peterson E, and Fox K. An OPEN-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention PIONEER AF-PCI. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
 126. **Gibson CM**, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein J, Mehran R, D'Andrea D, Merkely B, Zarebinski M, Ophius TO, and Harrington RA. The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
 127. Jain P, Szlosek DA, Korjian S, Daaboul Y, Lopes RD, Goldhaber SZ, Hernandez AF, Hull RD, Harrington RA, Cohen AT, and **Gibson CM**. Abstract 19325: Betrixaban Reduces the Burden of Multiple Symptomatic Venous Thromboembolic Events in the APEX Trial. AHA 2016 Scientific Sessions, New Orleans, LA, USA.

12-16 November 2016.

128. Korjian S, Daaboul Y, Kloner RA, Giugliano RP, Weaver WD, Carr J, Michalak N, Chi G, Villarreal M, Gallo A, Szlosek D, Jain P, Rusowicz-Orazem L, and **Gibson CM**. Abstract 18092: The Relationship Between Patency of the Culprit Artery on Admission and Electrolyte Changes in Anterior STEMI - Analysis From the EMBRACE STEMI Clinical Trial. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
129. Faggioni M, Chandrasekhar J, Baber U, Vogel B, Sartori S, Chieffo A, Aquino M, Witzenbichler B, **Gibson CM**, Colombo A, Kini A, Henry T, Cohen D, Dangas G, Moliterno D, Krucoff M, Steg PG, Pocock S, Weisz G, and Mehran R. Abstract 20373: Influence of Anemia on Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
130. Daaboul Y, Korjian S, Mega JL, Plotnikov AN, Burton P, Braunwald E, and **Gibson CM**. Abstract 18205: Rivaroxaban and Improved Modified Rankin Scale Score Among Patients With Acute Coronary Syndrome who Experience Stroke - Insights From the ATLAS ACS-2-TIMI-51 Clinical Trial. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
131. **Gibson CM**, Chi G, Jain P, Szlosek D, Goldhaber SZ, Hull RD, Hernandez AF, Korjian S, Daaboul Y, Harrington RA, and Cohen AT. Abstract 19875: IMPROVEDD Score: Addition of D-Dimer to the IMPROVE Score Improves Venous Thromboembolism Risk Stratification. An APEX Trial Substudy. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
132. **Gibson CM**, Daaboul Y, Korjian S, Szlosek D, Jain P, Chi G, Hernandez A, Hull R, Goldhaber S, Harrington RA, Wiens BL, Gold A, and Cohen AT. Abstract 19208: Extended Duration Betrixaban Reduces the Risk of Stroke vs Standard Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Substudy. AHA 2016 Scientific Sessions, New Orleans, LA, USA. 12-16 November 2016.
133. Ohman EM, Roe M, Steg P, James S, Povsic T, White J, Rockhold F, Plotnikov A, Mundl H, Bode C, Welsh R, and **Gibson CM**. Abstract 404-10: A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
134. Olivier C, Sundaram V, Ding V, Yang L, Leonardi S, Lopes R, Bhatt D, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, White H, Desai M, Harrington R, Lynch DR, and Mahaffey K. Abstract 1138M-03: One-Year Mortality Increased in Patients With Peri-Procedural Myocardial Infarction: Insights From the CHAMPION Trials. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
135. Vaduganathan M, Harrington R, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Deliargyris EN, Prats J, Mahaffey K, White H, and Bhatt D. Abstract 1166-320: Impact of Periprocedural Myocardial Infarction in Contemporary PCI: Pooled Patient-Level Data From the CHAMPION Trials. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
136. Shah B, Baber U, Krucoff M, Aquino M, Henry T, **Gibson CM**, Moliterno D, Steg PG, Stuckey T, Pocock S, Dangas G, Ariti C, Witzenbichler B, Cohen D, Iakovou I, Sartori S, Chieffo A, Kini A, Colombo A, Weisz G, and Mehran R. Abstract 1166-327: White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
137. Cavender M, Harrington R, Stone G, Deliargyris E, Steg P, **Gibson CM**, Hamm C, Price M, Prats J, Mahaffey K, White H, and Bhatt D. Abstract 1227M-09: Ischemic Events Occur Early in Patients Undergoing PCI and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
138. **Gibson CM**. Abstract 1277-055: Extended Duration Betrixaban Reduces the Risk of Venous Thromboembolism Versus Standard Duration Enoxaparin in the Post Parenteral Period Among Hospitalized Medically Ill Patients. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
139. Vaduganathan M, Harrington R, Stone G, Steg P, **Gibson CM**, Hamm C, Price M, Deliargyris EN, Prats J,

- Mahaffey K, White H, and Bhatt D. Abstract 1284-149: Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin: Insights From CHAMPION PHOENIX. ACC 2017 Scientific Session, Washington, D.C., USA. 17-19 March 2017.
140. Cohen AT, Huang W, Harrington RA, Goldhaber SZ, Hull RD, Hernandez AF, **Gibson CM**, Anderson FA. Abstract OC 12.1: Prevalence of Major Medical Illnesses Associated with Venous Thromboembolism Risk in US Hospitals. ISTH Scientific Sessions, Berlin, HR. 8-13 July 2017.
 141. Cohen AT, Yee M, Arbetter D, Harrington RA, Goldhaber SZ, Hull RD, Hernandez AF, Gold A, **Gibson CM**. Abstract OC 52.3: A landmark analysis of the APEX study comparing extended duration betrixaban with standard duration enoxaparin in hospitalized medically ill patients. ISTH Scientific Sessions, Berlin, HR. 8-13 July 2017.
 142. Yip C, Seneviratna A, Tan SH, Poh SC, Teo ZL, Loh JPY, Yap ES, Richards M, Chan M, **Gibson CM**, Ohman EM. Abstract PB 785: Persistent Thrombin Generation at 24 Months after Acute Coronary Syndrome. ISTH Scientific Sessions, Berlin, HR. 8-13 July 2017.
 143. Menon V, Lincoff AM, Nicholls SJ, Barter PJ, Brewer BH, Fox KAA, **Gibson CM**, Granger C, Montalescot G, Rader D, Tall AR, Ruotolo G, Riesmayer J, St John J, and Nissen SE. Abstract 3911: Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 144. Sorrentino S, Snyder C, Baber U, Sartori S, Cohen DJ, Cono A, **Gibson CM**, Krucoff MW, Moliterno DJ, Chieffo A, Kini A, Witzenbichler B, Steng FG, Pocock S, and Mehran R. Abstract P511: Incidence and patterns of dual antiplatelet therapy cessation among patients with peripheral arterial disease after percutaneous coronary intervention: insights the PARIS registry. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 145. Tortorici MA, Gille A, Liss C, Wright S, D'andrea D, Yee MK, Szachniewicz J, Atar S, Trebacz J, and **Gibson CM**. Abstract P1106: Direct augmentation of cholesterol efflux capacity in AMI atients: a PKPD substudy of AEGIS-I. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 146. **Gibson CM**, Arbetter DF, Jain P, Halaby R, Chi G, Nafee T, Korjian S, Daaboul Y, Harrington RA, Goldhaber SZ, Hull RD, Gold A, and Cohen AT. Abstract P1551: D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely ill medical patients: insights from the APEX trial. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 147. **Gibson CM**, Arbetter DF, Jain P, Halaby R, Chi G, Nafee T, Korjian S, Daaboul Y, Goldhaber SZ, Hull RD, Gold A, Hernandez AF, Cohen AT, and Harrington RA. Abstract P1732: Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 148. **Gibson CM**, Arbetter DF, Jain P, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Peterson E, and Fox KAA. Abstract P3590: Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudy. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 149. Chi G, Nafee T, Korjian S, Daaboul Y, Harrington RA, Goldhaber SZ, Hull RD, Gold A, Cohen AT, and **Gibson CM**. Abstract P4316: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 150. Yee MK, Chi G, Jain P, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Korjian S, Daaboul Y, Lip GYH, Cohen M, Peterson E, Fox KAA, and **Gibson CM**. Abstract P4565: Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 151. Pinto DS, Tamez H, Korjian S, Daaboul Y, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P,

- Eickels M, Lip GYH, Cohen M, Peterson E, Fox KAA, and **Gibson CM**. Abstract P4569: Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
152. Menon V, Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, **Gibson CM**, Granger C, Montalescot G, Rader D, Tall AR, Ruotolo G, St John J, and Nissen SJ. Abstract P5355: Impact of evacetrapib on glyvemic control: results from the accelerate trial. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 153. Chi G, Nafee T, Korjian S, Daaboul Y, Harrington RA, Goldhaber SZ, Hull RD, Gold A, Cohen AT, and **Gibson CM**. Abstract P5599: Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 154. Yee MK, Chi G, Nafee T, Korjian S, Daaboul Y, Harrington RA, Goldhaber SZ, Hull RD, Gold A, Cohen AT, and **Gibson CM**. Abstract P5600: History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 155. Chi G, Korjian S, Daaboul Y, Nafee T, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Eickels M, Lip GYH, Cohen M, Peterson E, Fox KAA, and **Gibson CM**. Abstract P6112: Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial. ESC 2017 Scientific Sessions, Barcelona, ES. 26-30 August 2017.
 156. Sorrentino S, Snyder C, Baber U, Giustino G, Sartori S, Farhan S, Vogel B, Chandrasekhar J, Ge Z, Levine H, Cohen D, Ariti C, **Gibson CM**, Krucoff M, Moliterno D, Chieffo A, Henry T, Iakovou I, Colombo A, Kini A, Witzenbichler B, Steg PG, Pocock S, Mehran R. Abstract 89: Tradeoff between Myocardial Infarction and Bleeding in Relation to Bleeding Risk: insights from PARIS registry. TCT 2017 Scientific Sessions, Denver, CO, USA. 29 October – 2 November 2017.
 157. Kandzari D, Lembo N, Carlson H, **Gibson CM**, Morgan J, Rinehart S, Yehya A, Karmaliotis D. Abstract 259: PERSPECTIVE Trial: Procedural, Clinical and Health Status Outcomes Among Patients Undergoing Chronic Total Occlusion Percutaneous Revascularization. TCT 2017 Scientific Sessions, Denver, CO, USA. 29 October – 2 November 2017.
 158. Kereiakes D, Lepor N, Gerber R, Lee LV, Thompson D, **Gibson CM**. Abstract 586: Alirocumab efficacy and safety in patients with prior coronary revascularization. TCT 2017 Scientific Sessions, Denver, CO, USA. 29 October – 2 November 2017.
 159. Genereux P, Redfors B, Stone G, Steg PG, **Gibson CM**, Hamm C, Price M, Prats J, White H, Bhatt D. Abstract 724: Impact of Coronary Calcification Severity on Clinical Outcomes After Contemporary PCI – Insights From the CHAMPION PHOENIX Trial. TCT 2017 Scientific Sessions, Denver, CO, USA. 29 October – 2 November 2017.
 160. Kotha J, Cardenas JM, Roe MT, Ohman EM, **Gibson CM**, Jennings LK. Abstract M3050: Synergistic Effects of Rivaroxaban With Direct-Acting Anti-Platelet Agents on Platelet Reactivity and Thrombin Generation. AHA 2017 Scientific Sessions, Anaheim, CA, USA. 11-15 November 2017.
 161. Schenone AL, Kalahasti V, Brown K, Shaffer C, **Gibson CM**, D'Andrea DM, Alexander JH, Dey M, Lincoff AM, Mehran R, Kastelein JJP, Menon V. Abstract M5014: The Nature and Number of Unreported Events Identified by the Clinical Event Adjudication Process in the AEGIS-1 Trial. AHA 2017 Scientific Sessions, Anaheim, CA, USA. 11-15 November 2017.
 162. Gille A, Wright SD, Tortorici M, Duffy D, Liss C, Yee MK, Deckelbaum LI, D'Andrea DM, **Gibson CM**. Abstract S2108: CSL112 Restores Cholesterol Efflux in Patients Immediately After Acute Myocardial Infarction. AHA 2017 Scientific Sessions, Anaheim, CA, USA. 11-15 November 2017.
 163. Nafee T, Chi G, Yee MK, Arbetter D, Pinto DS, Mehran R, Bode C, Halperin J, Verheugt FWA, Wildgoose R, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GYH, Cohen M, Peterson ED, Fox KAA,

- Gibson CM.** Abstract S4098: Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation. AHA 2017 Scientific Sessions, Anaheim, CA, USA. 11-15 November 2017.
164. Chi G, Nafee T, Goldhaber SZ, Hernandez AF, Hull RD, Gold A, Korjian S, Daaboul Y, Cohen AT, Harrington RA, **Gibson CM.** Abstract S5173: Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy. AHA 2017 Scientific Sessions, Anaheim, CA, USA. 11-15 November 2017.
 165. Sorrentino S, Baber U, Giustino G, Sartori S, Chandrasekhar J, Snyder C, Farhan S, Vogel B, Zhen G, Cono A, **Gibson CM,** Krucoff M, Moliterno DJ, Chieffo A, Henry T, Weisz G, Iakovou I, Colombo A, Stuckey T, Kini AS, Witzenbichler B, Steg PG, Dangas G, Pocock S, Mehran R. Abstract 1195-237: Incidence, Patterns and Associations Between Dual Antiplatelet Therapy Cessation and Risk for Adverse Events in High-Risk Patients: Insights from the PARIS Registry. ACC 2018 Scientific Session, Orlando, FL, USA. 10-12 March 2018.
 166. **Gibson CM,** Yee M, Daaboul Y, Korjian S, Poyan Mehr A, Kerneis M, Tricoci P, Alexander J, Kastelein J, Mehran R, Bode C, Lewis B, Mehta R, Duffy D, Feaster J, Halabi M, Angiolillo D, Duerschmied D, Oude Ophius T, Merkely B. Abstract 1214-471: The Safety and Tolerability of Multiple Dose Administration of CSL112, an Intravenous Formulation of Plasma-Derived apoA-I, Among Subjects with Moderate Renal Impairment After Acute Myocardial Infarction. ACC 2018 Scientific Session, Orlando, FL, USA. 10-12 March 2018.
 167. Olivier C, Abnoui F, Sundaram V, Yang J, Stone G, Steg P, **Gibson CM,** Hamm C, Price M, Deliargyris E, Prats J, White H, Harrington R, Bhatt D, Mahaffey K, Yong C. Abstract 1316M-03. The Efficacy and Safety of Cangrelor for Patients Undergoing Single Vessel Versus Multi Vessel Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial. ACC 2018 Scientific Session, Orlando, FL, USA. 10-12 March 2018.
 168. Nafee T, **Gibson CM,** Travis R, Kerneis M, Yee MK, Alkhalaf F, Chi G, Kalayci A, Mir M, Alihashemi M, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Abstract 2160: Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
 169. Chi G, **Gibson CM,** Hernandez AF, Hull RD, Kalayci A, Kerneis M, Alkhalaf F, Nafee T, Cohen AT, Harrington RA, Goldhaber SZ. Abstract P1623: Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
 170. Kalayci A, **Gibson CM,** Chi G, Yee M, Korjian S, Datta S, Nafee T, Gurin M, Haroian N, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Abstract P251: Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
 171. Yee MK, **Gibson CM,** Nafee T, Kerneis M, Travis R, Alkhalaf F, Chi G, Datta S, Jafarizade M, Ghaffarpasand E, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Abstract 109: Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
 172. Chi G, **Gibson CM,** Hernandez AF, Hull RD, Cohen AT, Harrington RA, Alkhalaf F, Kalayci A, Kerneis M, Nafee T, Goldhaber SZ. Abstract 4321: Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
 173. Yee MK, Kerneis M, Nafee T, Travis R, Chi G, Mehran R, Wildegoose P, Bode C, Halperin J, Verheugt FW, Lip GYH, Cohen M, Peterson ED, Fox KAA, **Gibson CM.** Abstract 1460: Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29

August 2018.

174. Nafee T, **Gibson CM**, Yee MK, Travis R, Kerneis M, Chi G, Alkhalfan F, Daaboul Y, Korjian S, Bandman O, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Goldhaber SZ. Abstract P6072: Characterization of major and clinically relevant non-major bleeding in the APEX trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
175. Nafee T, Yee MK, Kerneis M, Travis R, Alkhalfan F, Mehran R, Halperin J, Bode C, Wildgoose P, Cohen M, Verheugt FW, Lip GYH, Peterson ED, Fox KAA, **Gibson CM**. Abstract P5139: Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial. ESC 2018 Scientific Sessions, Munich, HR. 25-29 August 2018.
176. Moalem K, Baber U, Chandrasekhar J, Claessen B, Sartori S, Aquino M, Dangas G, Colombo A, Kini A, **Gibson CM**, Krucoff M, Chieffo A, Moliterno D, Witzenbichler B, Pocock S, Mehran R. Abstract 110: Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry. TCT 2018 Scientific Sessions, San Diego, CA, USA. 21-25 September 2018.
177. Sullivan A, Nanna M, Rao S, Cantrell S, **Gibson CM**, Verheugt F, Peterson E, Yee M, Kong D. Abstract 775: A Systematic Review of Randomized and Non-randomized Studies Comparing Dual Therapy with Triple Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. TCT 2018 Scientific Sessions, San Diego, CA, USA. 21-25 September 2018.
178. Pitliya A, **Gibson CM**, Wood MJ, Duran JM, Sharma S, Kaadan I, Ponzini F, Mishra S, Jamil U, Jamil A, Sharfaei S, Walia S, Datta S, Jahansouz M, Jafarizde M, Kahe F, Michalak N, Liu Y, Chi G. Abstract 2012: In-Hospital and Long-Term Clinical Outcomes of Spontaneous Coronary Artery Dissection Managed With Conservative versus Revascularization Strategy: A Meta-Analysis of Current Evidence. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
179. Alkhalfan F, Kerneis M, Nafee T, Yee MK, Chi G, Plotnikov A, Braunwald EU, **Gibson CM**. Abstract 2026: D-Dimer Levels and Clinical Outcomes in Acute Coronary Syndrome Patients: An ATLAS ACS TIMI 46 Trial Substudy. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
180. Chi G, **Gibson CM**, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Liu Y, Walia S, Sharfaei S, Pitliya A, Kazmi HA, Datta S, Kahe F, Ghaffarparasand E, Jafarizde M, Kalayci A, Nafee T, Kerneis M, AlKhalfan F, Yee MK, Travis RS, Goldhaber SZ. Abstract 3257: Hypoalbuminemia and Its Association With Venous Thromboembolism in Acutely Ill Hospitalized Patients: Findings From the APEX Trial. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
181. Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, **Gibson CM**, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue ML. Abstract 2485: Outcomes in Women vs. Men After Non-ST-Elevation Acute Coronary Syndromes: Insights From the TIMI Trials. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
182. Nafee TO, **Gibson CM**, Yee MK, Kerneis M, Travis R, AlKhalfan F, Chi G, Hull RD, Hernandez AF, Cohen AT, Harrington RA, Goldhaber SZ. Abstract 2102: Betrixaban Reduced the Occurrence of Major Adverse Cardiovascular Events Among Acute Medically Ill Patients With a History of Myocardial Infarction or Stroke: Insights From the APEX Trial. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
183. Yee MK, Kerneis M, Nafee T, Mehran R, Lip GYH, Chi G, Travis R, Alkhalfan F, Halperin JL, Bode C, Wildgoose P, Verheugt FWA, Peterson ED, Keith FAA, **Gibson CM**. Abstract 278: Novel Oral Anticoagulant Based versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF PCI Trial. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.
184. Chi G, **Gibson CM**, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Liu Y, Kalayci A, Walia S, Sharfaei S, Pitliya A, Kazmi HA, Datta S, Kahe F, Ghaffarparasand E, Jafarizde M, Yee MK, Travis RS, AlKhalfan F, Nafee T, Kerneis M, Goldhaber SZ. Abstract 135: Prognostic Value of C-Reactive Protein as

Inflammatory Marker for Venous Thromboembolism in Acutely Ill Hospitalized Patients: Analysis From the APEX Trial. AHA 2018 Scientific Sessions, Chicago, IL, USA. 10-12 November 2018.

185. Joyce L, Baber U, Claessen B, Sartori S, Chandrasekhar J, Cohen D, Henry T, Ariti C, Dangas G, Faggioni M, **Gibson CM**, Aquino M, Krucoff M, Vogel B, Moliterno D, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg P, Pocock S, Mehran R. Abstract 1204-054: Dual Antiplatelet Therapy (DAPT) Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) Registry. ACC 2019 Scientific Session, New Orleans, LA, USA. 16-18 March 2019.
186. Bikdeli B, Chatterjee S, Kirtane A, Parikh S, Andreozzi G, **Gibson CM**, Goldhaber S, Eikelboom J, Krumholz HM, Stone G. Abstract 1229-365: Cardiovascular Events in Patients Receiving Sulodexide Versus Control: Systematic Review and Meta-Analysis of Randomized Controlled Trials. ACC 2019 Scientific Session, New Orleans, LA, USA. 16-18 March 2019.
187. Peterson B, Harrington R, Stone G, Steg PG, **Gibson CM**, Hamm C, Price M, Lopes R, Leonardi S, Prats J, Deliargyris E, Mahaffey K, White H, Bhatt DL. Abstract 1255-052: The Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From the CHAMPION Trials. ACC 2019 Scientific Session, New Orleans, LA, USA. 16-18 March 2019.
188. Nafee T, Gibson W, Travis R, Yee M, Kerneis M, Ohman M, **Gibson CM**. Abstract 1330-379: Machine Learning Versus Traditional Risk Stratification Methods in Acute Coronary Syndrome: A Pooled Randomized Clinical Trial Analysis. ACC 2019 Scientific Session, New Orleans, LA, USA. 16-18 March 2019.
189. Karabay AK, **Gibson CM**, Chi G, Alkhalfan F, Pitliya A, Walia SS, Nafee T, Mir M, Kazmi SHA, Qamar I, Hernandez A, Hull R, Cohen A, Harrington R, Goldhaber S. Abstract 1341-491: Paradoxical Protective Effect of Obesity on the Risk of Venous Thromboembolism: Observations From APEX Trial. ACC 2019 Scientific Session, New Orleans, LA, USA. 16-18 March 2019.

Narrative Report

I am an interventional cardiologist, cardiovascular researcher & educator. I am the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. The institutes have led over 1,000 studies, published 3,000 manuscripts in the peer review literature, and have led 60 FDA submissions from their network of 7,000 sites worldwide. . I was named one of the most highly cited researchers in by Thomson Reuters in July 2014 and again in 2018. My work has been cited 75,283 times and I have an h-index of 112.

I obtained his BS, MS, and MD degrees at the University of Chicago where I was a Phi Beta Kappa and AOA graduate. I then went on to do his internship, residency and chief residency at the Brigham and Women's Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School. I have held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine.

In the field of atherosclerosis, I determined that the multiple blockages within a patient progress in their severity at independent rates, and I along with Dr. Bernard Rosner developed and validated the statistical methodology that is used to analyze angiographic data from many atherosclerosis regression trials. Likewise, in the field of interventional cardiology, I demonstrated that when multiple blockages within a patient are dilated, the risk of reblockage or restenosis is independent among all the lesions. This provides the methodological basis for all interventional trials analyzing restenosis data on a per lesion basis rather than on a per patient basis.

I developed the TIMI (Thrombolysis In Myocardial Infarction) frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted as an index of coronary blood flow. This

measure is now the primary endpoint in many angiographic MI trials. I also developed the TIMI myocardial perfusion grade (a measure of microvascular perfusion). In this method, the rate of dye entry and exit from the heart muscle is assessed visually. The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of mortality in acute MI.

I built the TIMI Data Coordinating center and directed it for the first 50 TIMI trials and I continue to manage the data analytic center at Baim that oversees American College of Cardiology registry proposals.

I have led phase 1-4 clinical trials, and cardiology megatrials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack.

For years, I have been chosen as one of Boston's Top Doctors & U.S. News & World Report also lists me as one of America's top doctors.

I founded WikiDoc.org and WikiPatient.org, widely viewed open source textbooks of medicine. I am Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 13 years. I also founded www.clinicaltrialresults.org and has conducted >2,200 TV / video interviews. I have hundreds of thousands of followers on social media where I am a leading influencer.

I am a member of the FDA's cardiorenal panel.